PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
33577917-2	2021	Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral molecule currently used in hepatitis C therapy.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
33318657-0	2021	Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.	SBI-0640756	52-59	eukaryotic translation initiation factor 4E	Homo sapiens	10-15
33318657-4	2021	We compared the mTOR kinase inhibitor (TOR-KI) MLN0128 with SBI-756, a compound targeting eukaryotic translation initiation factor 4G1 (eIF4G1), a scaffolding protein in the eIF4F complex.	SBI-0640756	60-67	eukaryotic translation initiation factor 4E	Homo sapiens	174-179
33318657-6	2021	SBI-756 prevented eIF4E-eIF4G1 association and cap-dependent translation without affecting mTOR substrate phosphorylation.	SBI-0640756	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
33439620-12	2021	Our observations broaden the understanding of thiophosphate biochemistry and enable the rational design of translationally active mRNAs and eIF4E-targeting drugs.	thiophosphoric acid	46-59	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
33605855-5	2021	The role of phosphorylation of eIF4E at Serine 209 on oncogenic transformation has been appreciated for the last 10 years and has been under active investigation as a therapeutic target for cancers including acute myeloid leukemia (AML), but the expression of p-eIF4E in the nucleus and the specific molecular mechanism of action remain largely unresolved.	Serine	40-46	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
33605855-5	2021	The role of phosphorylation of eIF4E at Serine 209 on oncogenic transformation has been appreciated for the last 10 years and has been under active investigation as a therapeutic target for cancers including acute myeloid leukemia (AML), but the expression of p-eIF4E in the nucleus and the specific molecular mechanism of action remain largely unresolved.	Serine	40-46	eukaryotic translation initiation factor 4E	Homo sapiens	262-267
32398685-7	2021	We further showed that osimertinib potently inhibited the MNK kinase activities with IC50 values of 324 nM and 48.6 nM, respectively, against MNK1 and MNK2 kinases; osimertinib (0.3-3 muM) dose-dependently suppressed the phosphorylation of eukaryotic translation initiation factor 4E (eIF4E).	osimertinib	23-34	eukaryotic translation initiation factor 4E	Homo sapiens	240-283
33545678-2	2021	Recent drug repurposing efforts in multiple solid and hematologic malignancies have demonstrated that eIF4E and EZH2 are both pharmacologically inhibited by the FDA-approved antiviral drug ribavirin.	Ribavirin	189-198	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
33545678-10	2021	CONCLUSIONS: The authors demonstrate that ribavirin, a clinically used drug known to inhibit eIF4E and EZH2, has significant antitumor effects in multiple preclinical models of medulloblastoma, including an aggressive group 3 animal model.	Ribavirin	42-51	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
33328636-0	2021	Antidepressant actions of ketamine engage cell-specific translation via eIF4E.	Ketamine	26-34	eukaryotic translation initiation factor 4E	Homo sapiens	72-77
32398685-7	2021	We further showed that osimertinib potently inhibited the MNK kinase activities with IC50 values of 324 nM and 48.6 nM, respectively, against MNK1 and MNK2 kinases; osimertinib (0.3-3 muM) dose-dependently suppressed the phosphorylation of eukaryotic translation initiation factor 4E (eIF4E).	osimertinib	23-34	eukaryotic translation initiation factor 4E	Homo sapiens	285-290
33122085-6	2021	The formation of Y4: P38 hydrogen-bond interaction between the peptide and eIF4E is a rate limiting event in the efficient recognition of the protein since it occurs through the disordered region of the peptide.	Hydrogen	25-33	eukaryotic translation initiation factor 4E	Homo sapiens	75-80
32572959-7	2021	Furthermore, AR-A014418-elicited ERK inactivation inhibited Mnk1-mediated eIF4E phosphorylation, which inhibited MCL1 mRNA translation in U937 cells.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	13-23	eukaryotic translation initiation factor 4E	Homo sapiens	74-79
32572959-11	2021	Collectively, these results indicate that AR-A014418-induced GSK3beta suppression inhibits ERK-Mnk1-eIF4E axis-modulated de novo MCL1 protein synthesis and thereby results in U937 cell apoptosis.	N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea	42-52	eukaryotic translation initiation factor 4E	Homo sapiens	100-105
33189285-2	2021	The mammalian target of rapamycin/eukaryotic initiation factor 4E (mTOR/eIF4E) signaling pathway is involved in fat synthesis.	Sirolimus	24-33	eukaryotic translation initiation factor 4E	Homo sapiens	72-77
33371356-4	2020	Here, we focused on mTOR signaling and investigated how the activities of phospho-ribosomal protein S6 (rps6) and phospho-eukaryotic translation initiation factor 4E (eIF-4E), which act downstream of mTOR signaling in the human placenta, change following treatment of FGR with tadalafil and aimed to elucidate the underlying mechanism of action.	Tadalafil	277-286	eukaryotic translation initiation factor 4E	Homo sapiens	167-173
33371356-8	2020	Levels of phospho-rps6 and phospho-eIF-4E were significantly higher in FGR placenta than in control placenta but decreased to control levels after tadalafil treatment.	Tadalafil	147-156	eukaryotic translation initiation factor 4E	Homo sapiens	35-41
33371356-9	2020	Conclusions: Tadalafil restored the levels of HIF-2alpha, phospho-rps6, and eIF-4E in FGR placenta to those observed in control placenta, suggesting that it could be a promising treatment strategy for FGR.	Tadalafil	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	76-82
33135632-6	2020	p-eIF4E cooperated with mutant KRAS to promote Myc and ISR-dependent glutamine addiction in various CRC cell lines, characterized by increased cell death, transcriptomic heterogeneity and immune suppression upon deprivation.	Glutamine	69-78	eukaryotic translation initiation factor 4E	Homo sapiens	2-7
32981220-4	2020	Overexpression of E6 constructs (HPV-6, HPV-16, HPV-18, and HPV52) showed that E6 oncoproteins increased phosphorylation of the eIF4E protein (Serine-209).	Serine	143-149	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
33116125-8	2020	Moreover, ZJQ-24 inhibited the cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex.	zjq-24	10-16	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
32739551-0	2020	A cell-penetrant lactam-stapled peptide for targeting eIF4E protein-protein interactions.	Lactams	17-23	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
32739551-4	2020	Herein, we describe our continued efforts in this area and report the development and characterization of a cell-penetrant lactam stapled peptide for targeting cellular eIF4E.	Lactams	123-129	eukaryotic translation initiation factor 4E	Homo sapiens	169-174
32941651-6	2020	The 3" UTR of GCH1-mediated translation was resistant to the mTOR inhibitor Torin 1, which inhibits cap-dependent initiation by increasing eIF4E-unbound eIF4G.	Torin 1	76-83	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
32606016-7	2020	Modulation of EZH2, Snail, eIF4E, IMPDH, mTOR, and cyclin D1 were observed in western blots and enzymatic activity assays in response to ribavirin treatment.	Ribavirin	137-146	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
32828276-0	2020	Preclinical evidence that MNK/eIF4E inhibition by cercosporamide enhances the response to antiangiogenic TKI and mTOR inhibitor in renal cell carcinoma.	cercosporamide	50-64	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
32535199-3	2020	The activities of eIF4E are regulated at multiple levels, one of which is through its phosphorylation at Serine 209 by the mitogen-activated protein kinase-interacting kinases (MNKs, including MNK1 and MNK2).	Serine	105-111	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
32606016-10	2020	Our work suggests that NPC responds to ribavirin-mediated EZH2, Snail, eIF4E, IMPDH, and mTOR changes and positions ribavirin for clinical evaluation as a potential addition to our NPC treatment armamentarium.	Ribavirin	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
32736668-0	2020	Inhibition of eIF4E signaling by ribavirin selectively targets lung cancer and angiogenesis.	Ribavirin	33-42	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
32736668-8	2020	The mechanism studies demonstrate that ribavirin acts on lung cancer cells via suppressing eIF4E and mTOR signaling, leading to the subsequent inhibition of eIF4E-mediated protein translation.	Ribavirin	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	91-96
32736668-8	2020	The mechanism studies demonstrate that ribavirin acts on lung cancer cells via suppressing eIF4E and mTOR signaling, leading to the subsequent inhibition of eIF4E-mediated protein translation.	Ribavirin	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	157-162
31512056-0	2020	Positive Correlative over-Expression between eIF4E and Snail in Nasopharyngeal Carcinoma Promotes its Metastasis and Resistance to Cisplatin.	Cisplatin	131-140	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
32278762-8	2020	RESULTS: Curcumol reduced the expression of phosphorylated signal transducer and activator of transcription 3 (p-STAT3) via JAK1, JAK2, and Src pathways and inhibited hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis via mTOR/p70S6K/eIF4E and MAPK pathways.	curcumol	9-17	eukaryotic translation initiation factor 4E	Homo sapiens	246-251
32733883-7	2020	The binding of eIF4E to interacting proteins (4EIPs) that sequester it represents a node that controls many aspects of mRNP fate including localization, stability, poly(A) elongation, deadenylation, and translational activation/repression.	Poly A	164-171	eukaryotic translation initiation factor 4E	Homo sapiens	15-20
32362385-8	2020	These new potential pronucleotides and the expected products of their activation were characterized by biophysical and biochemical methods to determine their affinity towards eIF4E, their ability to inhibit translation in vitro, their susceptibility to enzymatic degradation and their turnover in cell extract.	pronucleotides	20-34	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
31512056-5	2020	In NPC cells, eIF4E knockdown significantly reduced Snail mRNA and protein levels, increased the mRNA level of E-cad (a direct downstream gene of Snail and a negative EMT marker), attenuated the invasive ability of the cells, and sensitized the cells to cisplatin in invasion.	Cisplatin	254-263	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
29334312-0	2020	Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.	Homoharringtonine	30-47	eukaryotic translation initiation factor 4E	Homo sapiens	21-26
32626528-11	2020	In conclusion, the findings of the present study suggest that HIF-1alpha may be a key factor in borneol induced apoptosis of glioma cells, and mTORC1 / eIF4E pathway is involved in the HIF-1alpha regulation by borneol in malignant glioma.	isoborneol	210-217	eukaryotic translation initiation factor 4E	Homo sapiens	152-157
31811670-4	2020	A key feature that emerges as a result of eIF4E phosphorylation is a salt-bridge network between the phosphorylated S209 (pS209) and a specific pair of lysine residues (K159 and K162) within the cap-binding interface on eIF4E.	Lysine	152-158	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
31811670-4	2020	A key feature that emerges as a result of eIF4E phosphorylation is a salt-bridge network between the phosphorylated S209 (pS209) and a specific pair of lysine residues (K159 and K162) within the cap-binding interface on eIF4E.	Lysine	152-158	eukaryotic translation initiation factor 4E	Homo sapiens	220-225
32066877-0	2020	Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer.	Tamoxifen	92-101	eukaryotic translation initiation factor 4E	Homo sapiens	28-33
32066877-6	2020	Furthermore, tamoxifen resistance was conferred by phosphorylation independent eIF4E overexpression.	Tamoxifen	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	79-84
32066877-7	2020	Immunohistochemistry on 134 estrogen receptor (ER+) primary breast cancer samples confirmed that high eIF4E expression was significantly associated with increased ERalpha and FOXM1, and significantly associated with tamoxifen resistance.	Estrogens	28-36	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
32066877-7	2020	Immunohistochemistry on 134 estrogen receptor (ER+) primary breast cancer samples confirmed that high eIF4E expression was significantly associated with increased ERalpha and FOXM1, and significantly associated with tamoxifen resistance.	Tamoxifen	216-225	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
32066877-8	2020	Our study uncovers a novel mechanism whereby phosphorylation independent eIF4E translational reprogramming in governing the protein synthesis of ERalpha and FOXM1 contributes to anti-estrogen insensitivity in ER+ breast cancer.	Estrogens	183-191	eukaryotic translation initiation factor 4E	Homo sapiens	73-78
32066877-9	2020	In eIF4E overexpressing breast cancer, the increased ERalpha protein expression in turn enhances FOXM1 transcription, which together with its increased translation regulated by eIF4E, contributes to tamoxifen resistance.	Tamoxifen	199-208	eukaryotic translation initiation factor 4E	Homo sapiens	3-8
32066877-9	2020	In eIF4E overexpressing breast cancer, the increased ERalpha protein expression in turn enhances FOXM1 transcription, which together with its increased translation regulated by eIF4E, contributes to tamoxifen resistance.	Tamoxifen	199-208	eukaryotic translation initiation factor 4E	Homo sapiens	177-182
32066877-10	2020	Coupled with eIF4E translational regulation, our study highlights an important mechanism conferring tamoxifen resistance via both ERalpha dependent and independent pathways.	Tamoxifen	100-109	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
31921404-0	2020	TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.	Sirolimus	108-117	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
32105459-0	2020	Discovery of Lysine-Targeted eIF4E Inhibitors through Covalent Docking.	Lysine	13-19	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
32105459-2	2020	eIF4E is a notoriously challenging target, and most of the reported inhibitors are negatively charged guanine analogues with negligible cell permeability.	Guanine	102-109	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
32105459-5	2020	Taking advantage of a "make-on-demand" virtual library, we used covalent docking to identify arylsulfonyl fluorides that target a noncatalytic lysine (Lys162) in eIF4E.	arylsulfonyl fluorides	93-115	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
32105459-5	2020	Taking advantage of a "make-on-demand" virtual library, we used covalent docking to identify arylsulfonyl fluorides that target a noncatalytic lysine (Lys162) in eIF4E.	Lysine	143-149	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
32105459-6	2020	Guided by cocrystal structures, we elaborated arylsulfonyl fluoride 2 to 12, which to our knowledge is the first covalent eIF4E inhibitor with cellular activity.	arylsulfonyl fluoride	46-67	eukaryotic translation initiation factor 4E	Homo sapiens	122-127
32105459-7	2020	In addition to providing a new tool for acutely inactivating eIF4E in cells, our computational approach may offer a general strategy for developing selective lysine-targeted covalent ligands.	Lysine	158-164	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
32075852-5	2020	Under hypoxic conditions, TG2 polyaminated eukaryotic translation initiation factor 4E (eIF4E)-bound eukaryotic translation initiation factor 4E-binding proteins (4EBPs) at conserved glutamine residues.	arginyl-glutamine	183-192	eukaryotic translation initiation factor 4E	Homo sapiens	43-86
32075852-5	2020	Under hypoxic conditions, TG2 polyaminated eukaryotic translation initiation factor 4E (eIF4E)-bound eukaryotic translation initiation factor 4E-binding proteins (4EBPs) at conserved glutamine residues.	arginyl-glutamine	183-192	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
32075852-5	2020	Under hypoxic conditions, TG2 polyaminated eukaryotic translation initiation factor 4E (eIF4E)-bound eukaryotic translation initiation factor 4E-binding proteins (4EBPs) at conserved glutamine residues.	arginyl-glutamine	183-192	eukaryotic translation initiation factor 4E	Homo sapiens	101-144
31974652-3	2020	7-Cl-Ph-Ethyl-GMP is an analog of cap and inhibits protein translation by binding and sequestering eIF4E thus blocking eIF4E from binding to the mRNA cap.	2'-guanylic acid	0-17	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
31974652-3	2020	7-Cl-Ph-Ethyl-GMP is an analog of cap and inhibits protein translation by binding and sequestering eIF4E thus blocking eIF4E from binding to the mRNA cap.	2'-guanylic acid	0-17	eukaryotic translation initiation factor 4E	Homo sapiens	119-124
31612523-0	2020	Morphine stimulates angiogenesis through Akt/mTOR/eIF4E activation under serum deprivation or H2 O2 -induced oxidative stress condition.	Morphine	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	50-55
31612523-10	2020	Mechanism analysis indicated that morphine alleviated serum deprivation and H2 O2 -induced angiogenesis inhibition via reducing oxidative stress and damage, and activating Akt/mTOR/eIF4E signaling.	Morphine	34-42	eukaryotic translation initiation factor 4E	Homo sapiens	181-186
31612523-10	2020	Mechanism analysis indicated that morphine alleviated serum deprivation and H2 O2 -induced angiogenesis inhibition via reducing oxidative stress and damage, and activating Akt/mTOR/eIF4E signaling.	Water	76-81	eukaryotic translation initiation factor 4E	Homo sapiens	181-186
31894299-5	2020	This study identified a positive association between FLI1 expression and mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase1 (MKNK1), the immediate upstream regulator of the eIF4E initiation factor.	cholecystokinin C-terminal flanking peptide	125-131	eukaryotic translation initiation factor 4E	Homo sapiens	199-204
31894299-5	2020	This study identified a positive association between FLI1 expression and mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase1 (MKNK1), the immediate upstream regulator of the eIF4E initiation factor.	glycyl-threonine	132-141	eukaryotic translation initiation factor 4E	Homo sapiens	199-204
31782083-3	2020	We provide evidence that eIF4E phosphorylation is regulated by mTORC1 by virtue of its interaction with Raptor through a novel TPTPNPP motif and consequent phosphorylation invitro and in vivo in a Rapamycin-sensitive manner.	Sirolimus	197-206	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
31782083-4	2020	While we show that phosphorylation pattern of eIF4E responds faithfully to Rapamycin inhibition, the prolonged exposure to Rapamycin rescues the loss of eIF4E phosphorylation through Mnk1 activation.	Sirolimus	75-84	eukaryotic translation initiation factor 4E	Homo sapiens	46-51
31782083-4	2020	While we show that phosphorylation pattern of eIF4E responds faithfully to Rapamycin inhibition, the prolonged exposure to Rapamycin rescues the loss of eIF4E phosphorylation through Mnk1 activation.	Sirolimus	123-132	eukaryotic translation initiation factor 4E	Homo sapiens	153-158
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Amino Acids	55-60	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
31782083-5	2020	We also present evidence that eIF4E interacts with the amino terminal domain of S6K1 in a phospho-dependent manner, and this interaction is instrumental in overriding Rapamycin inhibition of S6K1.	Sirolimus	167-176	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
31921404-10	2020	Rapamycin also increased MNK1/2-eIF4E signaling in TSC1-deficient NPCs.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
31740775-3	2019	Asparagine limitation in melanoma and pancreatic cancer cells activates receptor tyrosine kinase-MAPK signalling as part of a feedforward mechanism involving mammalian target of rapamycin complex 1 (mTORC1)-dependent increase in MAPK-interacting kinase 1 (MNK1) and eukaryotic translation initiation factor 4E (eIF4E), resulting in enhanced translation of activating transcription factor 4 (ATF4) mRNA.	tert-butyloxycarbonyl-tryptophyl-leucyl-asparagine	0-10	eukaryotic translation initiation factor 4E	Homo sapiens	266-309
32349518-0	2020	Cinobufagin Triggers Defects in Spindle Formation and Cap-Dependent Translation in Liver Cancer Cells by Inhibiting the AURKA-mTOR-eIF4E Axis.	cinobufagin	0-11	eukaryotic translation initiation factor 4E	Homo sapiens	131-136
32349518-7	2020	Our results suggested that cinobufagin performed an antitumor effects in liver cancer cells by inhibiting the AURKA-mTOR-eIF4E axis.	cinobufagin	27-38	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
31878201-8	2019	In contrast, a PI3K/mTOR inhibitor omipalisib blocked the phosphorylation of Akt and both S6K/S6 and 4E-BP/eIF4E branches, and additively decreased the growth of TSC2-null cells with rapamycin.	omipalisib	35-45	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
31903169-3	2019	Our studies provide evidence that SEL201 suppresses eIF4E phosphorylation on Ser209 in AML cell lines and in primary patient-derived AML cells.	seryl-seryl-seryl-arginine	77-80	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
31578228-6	2019	RESULTS: In vitro ibrutinib treatment of CLL significantly reduced activated NOTCH1/2 and induced dephosphorylation of eIF4E, a NOTCH target in CLL.	ibrutinib	18-27	eukaryotic translation initiation factor 4E	Homo sapiens	119-124
31740775-3	2019	Asparagine limitation in melanoma and pancreatic cancer cells activates receptor tyrosine kinase-MAPK signalling as part of a feedforward mechanism involving mammalian target of rapamycin complex 1 (mTORC1)-dependent increase in MAPK-interacting kinase 1 (MNK1) and eukaryotic translation initiation factor 4E (eIF4E), resulting in enhanced translation of activating transcription factor 4 (ATF4) mRNA.	tert-butyloxycarbonyl-tryptophyl-leucyl-asparagine	0-10	eukaryotic translation initiation factor 4E	Homo sapiens	311-316
31740775-3	2019	Asparagine limitation in melanoma and pancreatic cancer cells activates receptor tyrosine kinase-MAPK signalling as part of a feedforward mechanism involving mammalian target of rapamycin complex 1 (mTORC1)-dependent increase in MAPK-interacting kinase 1 (MNK1) and eukaryotic translation initiation factor 4E (eIF4E), resulting in enhanced translation of activating transcription factor 4 (ATF4) mRNA.	Tyrosine	81-89	eukaryotic translation initiation factor 4E	Homo sapiens	266-309
31740775-3	2019	Asparagine limitation in melanoma and pancreatic cancer cells activates receptor tyrosine kinase-MAPK signalling as part of a feedforward mechanism involving mammalian target of rapamycin complex 1 (mTORC1)-dependent increase in MAPK-interacting kinase 1 (MNK1) and eukaryotic translation initiation factor 4E (eIF4E), resulting in enhanced translation of activating transcription factor 4 (ATF4) mRNA.	Tyrosine	81-89	eukaryotic translation initiation factor 4E	Homo sapiens	311-316
31712417-2	2019	The m7G cap is required for RNAs to bind the eukaryotic translation initiation factor eIF4E and associate with the translation machinery across plant and animal kingdoms.	Guanosine	4-7	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
31439631-1	2019	GIGYF (Grb10-interacting GYF [glycine-tyrosine-phenylalanine domain]) proteins coordinate with 4EHP (eIF4E [eukaryotic initiation factor 4E] homologous protein), the DEAD (Asp-Glu-Ala-Asp)-box helicase Me31B/DDX6, and mRNA-binding proteins to elicit transcript-specific repression.	Glycine	30-37	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
31684984-10	2019	FL3 induced apoptosis of DLBCL cell lines that was associated with inhibition of the ERK-MNK-eIF4E signaling pathway, including aggressive double/triple-hit DLBCL cell lines.	fl3	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
31695627-8	2019	Additionally, translation initiation factor 4E (eIF4E), an important regulator of Akt signaling, was identified to be a target of miR-150, and both eIF4E knockdown and Akt inhibitor GSK690693 inhibited PDGF-BB-induced ASMC proliferation and migration.	GSK690693	182-191	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
31439631-1	2019	GIGYF (Grb10-interacting GYF [glycine-tyrosine-phenylalanine domain]) proteins coordinate with 4EHP (eIF4E [eukaryotic initiation factor 4E] homologous protein), the DEAD (Asp-Glu-Ala-Asp)-box helicase Me31B/DDX6, and mRNA-binding proteins to elicit transcript-specific repression.	Glycine	30-37	eukaryotic translation initiation factor 4E	Homo sapiens	108-139
31439631-1	2019	GIGYF (Grb10-interacting GYF [glycine-tyrosine-phenylalanine domain]) proteins coordinate with 4EHP (eIF4E [eukaryotic initiation factor 4E] homologous protein), the DEAD (Asp-Glu-Ala-Asp)-box helicase Me31B/DDX6, and mRNA-binding proteins to elicit transcript-specific repression.	Tyrosine	38-46	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
31439631-1	2019	GIGYF (Grb10-interacting GYF [glycine-tyrosine-phenylalanine domain]) proteins coordinate with 4EHP (eIF4E [eukaryotic initiation factor 4E] homologous protein), the DEAD (Asp-Glu-Ala-Asp)-box helicase Me31B/DDX6, and mRNA-binding proteins to elicit transcript-specific repression.	Tyrosine	38-46	eukaryotic translation initiation factor 4E	Homo sapiens	108-139
31439631-1	2019	GIGYF (Grb10-interacting GYF [glycine-tyrosine-phenylalanine domain]) proteins coordinate with 4EHP (eIF4E [eukaryotic initiation factor 4E] homologous protein), the DEAD (Asp-Glu-Ala-Asp)-box helicase Me31B/DDX6, and mRNA-binding proteins to elicit transcript-specific repression.	Phenylalanine	47-60	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
31439631-1	2019	GIGYF (Grb10-interacting GYF [glycine-tyrosine-phenylalanine domain]) proteins coordinate with 4EHP (eIF4E [eukaryotic initiation factor 4E] homologous protein), the DEAD (Asp-Glu-Ala-Asp)-box helicase Me31B/DDX6, and mRNA-binding proteins to elicit transcript-specific repression.	Phenylalanine	47-60	eukaryotic translation initiation factor 4E	Homo sapiens	108-139
31483294-7	2019	We show that metformin, an FDA-approved eIF4E inhibitor, suppresses intractable epilepsy.	Metformin	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	40-45
31607311-2	2019	METHODS: Multiple myeloma CD138+ plasma cells were treated with eIF4E inhibitor 4EGI, the changes of autophagy-related factors LC3-II and Beclin1 were detected by fluorescent quantitative PCR and Western blot, the changes of cell proliferation inhibition were detected by MTT assay, and cell apoptosis was detected by flow cytometry.	4-amino-6-methyl-1,3,5-triazine-2-thiol	80-84	eukaryotic translation initiation factor 4E	Homo sapiens	64-69
31215581-0	2019	The role of olefin geometry in the activity of hydrocarbon stapled peptides targeting eukaryotic translation initiation factor 4E (eIF4E).	Alkenes	12-18	eukaryotic translation initiation factor 4E	Homo sapiens	86-129
31327462-6	2019	We found that eIF4E phosphorylation was upregulated in cervical cancer cells and tissues but not normal cervical counterparts, and its phosphorylation at Ser 209 activates Wnt/beta-catenin signaling, promotes growth and migration in cervical cancer, in an MNK-dependent manner.	Serine	154-157	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
31132531-0	2019	Design, synthesis and biological evaluation of bromophenol-thiazolylhydrazone hybrids inhibiting the interaction of translation initiation factors eIF4E/eIF4G as multifunctional agents for cancer treatment.	bromophenol-thiazolylhydrazone	47-77	eukaryotic translation initiation factor 4E	Homo sapiens	147-152
31132531-4	2019	Further mechanism study demonstrated EGPI-1 played an antitumor role in multiple modes of action including regulating the activity of eIF4E by inhibiting the phosphorylation of eIF4E and 4EBP1, disrupting mitochondrial function through the mTOR/4EBP1 signaling pathway, and inducing autophagy, apoptosis and ROS generation.	ros	308-311	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
31074051-1	2019	Eukaryotic initiation factor 4E (eIF4E), a fundamental effector and rate limiting element of protein synthesis, binds the 7-methylguanosine cap at the 5" end of eukaryotic messenger RNA (mRNA) specifically as a constituent of eIF4F translation initiation complex thus facilitating the recruitment of mRNA to the ribosomes.	7-methylguanosine	122-139	eukaryotic translation initiation factor 4E	Homo sapiens	0-31
31074051-1	2019	Eukaryotic initiation factor 4E (eIF4E), a fundamental effector and rate limiting element of protein synthesis, binds the 7-methylguanosine cap at the 5" end of eukaryotic messenger RNA (mRNA) specifically as a constituent of eIF4F translation initiation complex thus facilitating the recruitment of mRNA to the ribosomes.	7-methylguanosine	122-139	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
31074051-1	2019	Eukaryotic initiation factor 4E (eIF4E), a fundamental effector and rate limiting element of protein synthesis, binds the 7-methylguanosine cap at the 5" end of eukaryotic messenger RNA (mRNA) specifically as a constituent of eIF4F translation initiation complex thus facilitating the recruitment of mRNA to the ribosomes.	7-methylguanosine	122-139	eukaryotic translation initiation factor 4E	Homo sapiens	226-231
31431614-2	2019	In this study, we delineate that KRAS-mutant lung cancer cells resistant to pemetrexed (MTA) and anti-MEK drug trametinib acquire an exquisite dependency on endoplasmic reticulum (ER) stress signaling, rendering resistant cancer cells selectively susceptible to blockage of HSP90, the receptor tyrosine kinase AXL, the eukaryotic translation initiation factor 4E (eIF4E), and the unfolded protein response (UPR).	Pemetrexed	76-86	eukaryotic translation initiation factor 4E	Homo sapiens	319-362
31431614-2	2019	In this study, we delineate that KRAS-mutant lung cancer cells resistant to pemetrexed (MTA) and anti-MEK drug trametinib acquire an exquisite dependency on endoplasmic reticulum (ER) stress signaling, rendering resistant cancer cells selectively susceptible to blockage of HSP90, the receptor tyrosine kinase AXL, the eukaryotic translation initiation factor 4E (eIF4E), and the unfolded protein response (UPR).	Pemetrexed	76-86	eukaryotic translation initiation factor 4E	Homo sapiens	364-369
31431614-2	2019	In this study, we delineate that KRAS-mutant lung cancer cells resistant to pemetrexed (MTA) and anti-MEK drug trametinib acquire an exquisite dependency on endoplasmic reticulum (ER) stress signaling, rendering resistant cancer cells selectively susceptible to blockage of HSP90, the receptor tyrosine kinase AXL, the eukaryotic translation initiation factor 4E (eIF4E), and the unfolded protein response (UPR).	trametinib	111-121	eukaryotic translation initiation factor 4E	Homo sapiens	319-362
31431614-2	2019	In this study, we delineate that KRAS-mutant lung cancer cells resistant to pemetrexed (MTA) and anti-MEK drug trametinib acquire an exquisite dependency on endoplasmic reticulum (ER) stress signaling, rendering resistant cancer cells selectively susceptible to blockage of HSP90, the receptor tyrosine kinase AXL, the eukaryotic translation initiation factor 4E (eIF4E), and the unfolded protein response (UPR).	trametinib	111-121	eukaryotic translation initiation factor 4E	Homo sapiens	364-369
31215581-0	2019	The role of olefin geometry in the activity of hydrocarbon stapled peptides targeting eukaryotic translation initiation factor 4E (eIF4E).	Alkenes	12-18	eukaryotic translation initiation factor 4E	Homo sapiens	131-136
31215581-4	2019	By applying this HCS to the disordered peptide eIF4E-binding protein 1 (4E-BP1), we discovered that this type of tethering has a dramatic effect on olefin geometry and activity of the resultant stapled peptides, where the putative trans isomer was found to exhibit enhanced in vitro and cellular inhibitory activity against eIF4E protein-protein interactions.	Alkenes	148-154	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
30801798-5	2019	A pyrene-labeled m7 GTP analogue showed up to eightfold enhanced fluorescence emission upon binding to eukaryotic translation initiation factor 4E (eIF4E) and over 30-fold enhancement upon cleavage by decapping scavenger (DcpS) enzyme.	pyrene	2-8	eukaryotic translation initiation factor 4E	Homo sapiens	103-146
30801798-5	2019	A pyrene-labeled m7 GTP analogue showed up to eightfold enhanced fluorescence emission upon binding to eukaryotic translation initiation factor 4E (eIF4E) and over 30-fold enhancement upon cleavage by decapping scavenger (DcpS) enzyme.	pyrene	2-8	eukaryotic translation initiation factor 4E	Homo sapiens	148-153
30801798-5	2019	A pyrene-labeled m7 GTP analogue showed up to eightfold enhanced fluorescence emission upon binding to eukaryotic translation initiation factor 4E (eIF4E) and over 30-fold enhancement upon cleavage by decapping scavenger (DcpS) enzyme.	7-methylguanosine triphosphate	17-23	eukaryotic translation initiation factor 4E	Homo sapiens	103-146
30801798-5	2019	A pyrene-labeled m7 GTP analogue showed up to eightfold enhanced fluorescence emission upon binding to eukaryotic translation initiation factor 4E (eIF4E) and over 30-fold enhancement upon cleavage by decapping scavenger (DcpS) enzyme.	7-methylguanosine triphosphate	17-23	eukaryotic translation initiation factor 4E	Homo sapiens	148-153
30836163-0	2019	eIF4E is a critical regulator of human papillomavirus (HPV)-immortalized cervical epithelial (H8) cell growth induced by nicotine.	Nicotine	121-129	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
30836163-5	2019	We found that nicotine simultaneously activates AKT/mTOR pathway in HPV-immortalized cervical epithelial (H8) cell line, followed by elevation of 4EBP1/eIF4E axis expression and its translational activity with dose-dependent and time-dependent manners.	Nicotine	14-22	eukaryotic translation initiation factor 4E	Homo sapiens	152-157
30836163-7	2019	We therefore chose to evaluate whether this effect on eIF4E was involved in nicotine-induced proliferation.	Nicotine	76-84	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
30836163-9	2019	What is more, eIF4E knockdown inhibits cellular growth and colony formation after nicotine treatment.	Nicotine	82-90	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
30836163-10	2019	Note as well that eIF4E-specific siRNA could also suppress cell proliferation by decelerating the G0/G1-S transition of H8 cell treated with nicotine.	Nicotine	141-149	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
30836163-12	2019	Furthermore, phosphorylation of 4EBP1 induced by nicotine has been shown to cause dissociation of 4EBP1/eIF4E and eIF4E may serve as a promising determinant of nicotine activity in vitro.	Nicotine	49-57	eukaryotic translation initiation factor 4E	Homo sapiens	104-109
30836163-12	2019	Furthermore, phosphorylation of 4EBP1 induced by nicotine has been shown to cause dissociation of 4EBP1/eIF4E and eIF4E may serve as a promising determinant of nicotine activity in vitro.	Nicotine	49-57	eukaryotic translation initiation factor 4E	Homo sapiens	114-119
30836163-12	2019	Furthermore, phosphorylation of 4EBP1 induced by nicotine has been shown to cause dissociation of 4EBP1/eIF4E and eIF4E may serve as a promising determinant of nicotine activity in vitro.	Nicotine	160-168	eukaryotic translation initiation factor 4E	Homo sapiens	114-119
30973873-8	2019	Moreover, eukaryotic translation initiation factor 4E (EIF4E)-associated protein 1 (Eap1), a target of rapamycin (TOR)-regulated EIF4E binding protein, physically interacts with Dhh1 after nitrogen starvation and facilitates the translation of Atg1 and Atg13.	dhh1	178-182	eukaryotic translation initiation factor 4E	Homo sapiens	10-53
30973873-8	2019	Moreover, eukaryotic translation initiation factor 4E (EIF4E)-associated protein 1 (Eap1), a target of rapamycin (TOR)-regulated EIF4E binding protein, physically interacts with Dhh1 after nitrogen starvation and facilitates the translation of Atg1 and Atg13.	Nitrogen	189-197	eukaryotic translation initiation factor 4E	Homo sapiens	10-53
30677218-9	2019	O-GlcNAcylation of eIF4E at threonine 168 and threonine 177 protected it from degradation through proteasome pathway.	Threonine	28-37	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
30677218-11	2019	High glucose promoted stem-like cell potential of hepatoma cell through OGT-eIF4E axis.	Glucose	5-12	eukaryotic translation initiation factor 4E	Homo sapiens	76-81
30739792-2	2019	In this work, we demonstrate that eIF4E inhibition in ovarian cancer can be achieved by ribavirin, a FDA-approved antiviral drug.	Ribavirin	88-97	eukaryotic translation initiation factor 4E	Homo sapiens	34-39
30739792-4	2019	Mechanistically, ribavirin suppresses Akt/mTOR and eIF4E/p70S6K signaling pathways in ovarian cancer cells.	Ribavirin	17-26	eukaryotic translation initiation factor 4E	Homo sapiens	51-56
30739792-5	2019	We confirm that eIF4E is the critical molecular target of ribavirin, and furthermore that this is dependent on phosphorylation at S209.	Ribavirin	58-67	eukaryotic translation initiation factor 4E	Homo sapiens	16-21
30739792-7	2019	Interestingly, the sensitivity to ribavirin varies among a panel of ovarian cancer cell lines, mostly likely due to their differential expression level of eIF4E and dependency to eIF4E inhibition.	Ribavirin	34-43	eukaryotic translation initiation factor 4E	Homo sapiens	155-160
30739792-7	2019	Interestingly, the sensitivity to ribavirin varies among a panel of ovarian cancer cell lines, mostly likely due to their differential expression level of eIF4E and dependency to eIF4E inhibition.	Ribavirin	34-43	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
30739792-10	2019	Additionally, ribavirin is a useful addition to ovarian cancer treatment, particularly to those with high dependency on eIF4E.	Ribavirin	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	120-125
30735900-0	2019	Synthesis of 7-benzylguanosine cap-analogue conjugates for eIF4E targeted degradation.	7-benzylguanosine	13-30	eukaryotic translation initiation factor 4E	Homo sapiens	59-64
30552925-0	2019	Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin.	Sirolimus	82-91	eukaryotic translation initiation factor 4E	Homo sapiens	0-31
30552925-0	2019	Eukaryotic Initiation Factor 4E (eIF4E) sequestration mediates 4E-BP1 response to rapamycin.	Sirolimus	82-91	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
30552925-1	2019	The cap dependent translation initiation is a tightly controlled process of cooperative ternary complex formation by 4E-BP1, eIF4E and the 5" cap of eukaryotic mRNA in response to environmental cues like glucose, nutrients and growth factor levels.	Glucose	204-211	eukaryotic translation initiation factor 4E	Homo sapiens	125-130
30552925-6	2019	The data presented in this study identifies eIF4E and not Raptor as a cellular factor responsible to regulate rapamycin sensitivity of 4E-BP1 suggesting that the phosphorylation dynamics and rapamycin sensitivity of 4E-BP1 and S6K1 are regulated independently.	Sirolimus	110-119	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
30478448-0	2019	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.	Ribavirin	31-40	eukaryotic translation initiation factor 4E	Homo sapiens	10-15
30591552-2	2019	In this study, we show that synthetic peptides corresponding to the binding interface between Rbm38 and eIF4E, including an 8 amino acid peptide (Pep8) derived from Rbm38, are effective in relieving Rbm38-mediated repression of p53.	amino acid peptide	126-144	eukaryotic translation initiation factor 4E	Homo sapiens	104-109
30591552-3	2019	Molecular simulations showed that Ser-6 in Pep8 forms a hydrogen bond with Asp-202 in eIF4E.	Serine	34-37	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
30591552-3	2019	Molecular simulations showed that Ser-6 in Pep8 forms a hydrogen bond with Asp-202 in eIF4E.	Hydrogen	56-64	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
30591552-3	2019	Molecular simulations showed that Ser-6 in Pep8 forms a hydrogen bond with Asp-202 in eIF4E.	Aspartic Acid	75-78	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
30591552-7	2019	SIGNIFICANCE: Disruption of the Rbm38-eIF4E complex via synthetic peptides induces wild-type p53 expression, suppresses tumor growth and progression, and may serve as a novel cancer therapeutic strategy.	Peptides	66-74	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
30478448-2	2019	Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment.	Ribavirin	135-144	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
30478448-2	2019	Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment.	Ribavirin	135-144	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
30478448-2	2019	Here we discover that EIF4E protein is elevated in most cases of infant ALL and test EIF4E targeting by the repurposed antiviral agent ribavirin, which has anticancer properties through EIF4E inhibition, as a potential treatment.	Ribavirin	135-144	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
30478448-3	2019	We find that ribavirin treatment of actively dividing infant ALL cells on bone marrow stromal cells (BMSCs) at clinically achievable concentrations causes robust proliferation inhibition in proportion with EIF4E expression.	Ribavirin	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	206-211
30478448-4	2019	Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins.	Ribavirin	22-31	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
30478448-4	2019	Further, we find that ribavirin treatment of KMT2A-rearranged (KMT2A-R) infant ALL cells and the KMT2A-AFF1 cell line RS4:11 inhibits EIF4E, leading to decreases in oncogenic EIF4E-regulated cell growth and survival proteins.	Ribavirin	22-31	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
30478448-5	2019	In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5.	Ribavirin	3-12	eukaryotic translation initiation factor 4E	Homo sapiens	66-71
30478448-5	2019	In ribavirin-sensitive KMT2A-R infant ALL cells and RS4:11 cells, EIF4E-regulated proteins with reduced levels of expression following ribavirin treatment include MYC, MCL1, NBN, BCL2 and BIRC5.	Ribavirin	135-144	eukaryotic translation initiation factor 4E	Homo sapiens	66-71
30478448-6	2019	Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
30478448-6	2019	Ribavirin-treated RS4:11 cells exhibit impaired EIF4E-dependent nuclear to cytoplasmic export and/or translation of the corresponding mRNAs, as well as reduced phosphorylation of the p-AKT1, p-EIF4EBP1, p-RPS6 and p-EIF4E signaling proteins.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	193-198
30478448-8	2019	Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
30478448-8	2019	Ribavirin causes nuclear EIF4E to re-localize to the cytoplasm in KMT2A-AFF1 infant ALL and RS4:11 cells, providing further evidence for EIF4E inhibition.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	137-142
30478448-11	2019	This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.	Ribavirin	100-109	eukaryotic translation initiation factor 4E	Homo sapiens	170-175
30478448-11	2019	This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.	Ribavirin	100-109	eukaryotic translation initiation factor 4E	Homo sapiens	170-175
30478448-11	2019	This work establishes that EIF4E is broadly elevated across infant ALL and that clinically relevant ribavirin exposures have preclinical activity and effectively inhibit EIF4E in KMT2A-R cases, suggesting promise in EIF4E targeting using ribavirin as a means of treatment.	Ribavirin	238-247	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
30744688-16	2019	Besides catalyzing serine synthesis to activate AKT pathway, PHGDH was found to interact with the translation initiation factors eIF4A1 and eIF4E and facilitated the assembly of the complex eIF4F on 5" mRNA structure to promote the relevant proteins expression.	Serine	19-25	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
30459229-14	2019	Our work strongly suggests that MNK1-eIF4E signaling drives CIPN and that a drug in human clinical trials, eFT508, may be a new therapeutic for neuropathic pain.	benzonaphthyridone	107-113	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
30881679-0	2019	Structural insights reveal a recognition feature for tailoring hydrocarbon stapled-peptides against the eukaryotic translation initiation factor 4E protein.	Hydrocarbons	63-74	eukaryotic translation initiation factor 4E	Homo sapiens	104-147
30881679-2	2019	We have used a structure-guided approach to rationally develop a set of hydrocarbon stapled-peptides with high binding affinities and residence times against the oncogenic eukaryotic translation initiation factor 4E (eIF4E) protein.	Hydrocarbons	72-83	eukaryotic translation initiation factor 4E	Homo sapiens	172-215
30881679-2	2019	We have used a structure-guided approach to rationally develop a set of hydrocarbon stapled-peptides with high binding affinities and residence times against the oncogenic eukaryotic translation initiation factor 4E (eIF4E) protein.	Hydrocarbons	72-83	eukaryotic translation initiation factor 4E	Homo sapiens	217-222
30881679-5	2019	The interactions were further exploited by designing features in the peptides to attenuate disorder and increase helicity which collectively resulted in the generation of a distinct class of hydrocarbon stapled-peptides targeting eIF4E.	Hydrocarbons	191-202	eukaryotic translation initiation factor 4E	Homo sapiens	230-235
30266538-7	2018	Our results demonstrated that dictamnine reduced HIF-1alpha protein synthesis by downregulating the mTOR/p70S6K/eIF4E and MAPK pathways, and reduced the expression of Slug by inhibiting the GSK-3beta/Slug signaling pathway.	dictamnine	30-40	eukaryotic translation initiation factor 4E	Homo sapiens	112-117
30297804-0	2018	MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.	CGP 57380	15-23	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
30297804-4	2018	We showed that rapamycin and its analog RAD001 (everolimus) exerted only mild inhibition on the viability of Jurkat, CEM and Molt-4 cell lines (for everolimus the maximum inhibition was <40% at 100 nM), but greatly enhanced the phosphorylation of eIF4E, a downstream substrate of MAPK-interacting kinase (MNK) that was involved in promoting cell survival.	Sirolimus	15-24	eukaryotic translation initiation factor 4E	Homo sapiens	250-255
30297804-6	2018	Then we examined the antileukemia effects of CGP57380, a MNK1 inhibitor, and we found that CGP57380 (4-16 muM) dose-dependently suppressed the expression of both phosphor-MNK1 and phosphor-eIF4E, thereby inhibiting downstream targets such as c-Myc and survivin in T-ALL cells.	CGP 57380	91-99	eukaryotic translation initiation factor 4E	Homo sapiens	189-194
30297804-7	2018	Importantly, CGP57380 produced a synergistic growth inhibitory effect with everolimus in T-ALL cells, and treatment with this targeted therapy overcame everolimus-induced eIF4E phosphorylation.	CGP 57380	13-21	eukaryotic translation initiation factor 4E	Homo sapiens	171-176
30297804-7	2018	Importantly, CGP57380 produced a synergistic growth inhibitory effect with everolimus in T-ALL cells, and treatment with this targeted therapy overcame everolimus-induced eIF4E phosphorylation.	Everolimus	152-162	eukaryotic translation initiation factor 4E	Homo sapiens	171-176
30156372-12	2018	Collectively, this study provides novel insights into sigmaA-modulated suppression of LDHA and activation of IDH3B and GDH to activate the mTORC1/eIF4E/HIF-1alpha pathways to upregulate glycolysis and the TCA cycle for virus replication.	Trichloroacetic Acid	205-208	eukaryotic translation initiation factor 4E	Homo sapiens	146-151
29702026-2	2018	In the current study, we extend our previous evidence and demonstrate that a mechanism by which dietary BDPP protects against SD-mediated cognitive impairment is via mechanisms that involve phosphorylation of the mammalian target of rapamycin complex 1 and its direct downstream targets, including the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase beta-1 (p70S6K).	bdpp	104-108	eukaryotic translation initiation factor 4E	Homo sapiens	302-345
30454696-7	2018	We further showed that ribavirin acted on osteosarcoma largely via targeting eIF4E.	Ribavirin	23-32	eukaryotic translation initiation factor 4E	Homo sapiens	77-82
30454696-9	2018	Lastly, we found that eIF4E expression and phosphorylation were elevated in osteosarcoma compared to normal cells, which might explain the selective anti-osteosarcoma activity of ribavirin.	Ribavirin	179-188	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
30454696-10	2018	eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma.	Ribavirin	49-58	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
30454696-10	2018	eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma.	Ribavirin	49-58	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
30454696-10	2018	eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma.	Ribavirin	114-123	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
30454696-10	2018	eIF4E depletion mimics the inhibitory effects of ribavirin, further confirm that eIF4E is the essential target of ribavirin in osteosarcoma.	Ribavirin	114-123	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
29478426-11	2018	In ovo feeding of Arg also enhanced mammalian target of rapamycin, ribosomal protein S6 kinase-1 and eIF4E-bindingprotein-1 messenger RNA expression levels at hatch compared with those of control groups (P<0.05).	Arginine	18-21	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
30221473-0	2018	Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling.	Metformin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	74-79
30221473-8	2018	Repression of protein synthesis by metformin preferentially affects cell cycle-associated proteins, by altering signaling through the mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E axes.	Metformin	35-44	eukaryotic translation initiation factor 4E	Homo sapiens	144-149
31949552-10	2018	CONCLUSION: We conclude that integrin beta1 mediated 5FU chemo resistance in colorectal cancer could be translationally regulated by eIF4E.	Fluorouracil	53-56	eukaryotic translation initiation factor 4E	Homo sapiens	133-138
29981794-9	2018	Mechanism of actions studies suggest that sorafenib inhibited viral translation through dephosphorylation of several key proteins, including eIF4E and p70S6K, leading to a reduction in viral protein production and overall viral replication.	Sorafenib	42-51	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
29959920-3	2018	We show that ribavirin, an anti-viral drug and pharmacological eIF4E inhibitor, effectively inhibits proliferation and decreases viability of paclitaxel-resistant cervical cancer and 5-FU-resistant colon cancer cells while is less toxic to human fibroblast cells.	Ribavirin	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	63-68
29959920-3	2018	We show that ribavirin, an anti-viral drug and pharmacological eIF4E inhibitor, effectively inhibits proliferation and decreases viability of paclitaxel-resistant cervical cancer and 5-FU-resistant colon cancer cells while is less toxic to human fibroblast cells.	Paclitaxel	142-152	eukaryotic translation initiation factor 4E	Homo sapiens	63-68
29959920-6	2018	We further confirm that the mechanism of the action of ribavirin in chemoresistant cancer cells is through suppressing eIF4E function.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	119-124
29959920-7	2018	In addition, specific eIF4E knockdown via two independent siRNA mimics the effects of ribavirin in chemoresistant colon and cervical cancer cells.	Ribavirin	86-95	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
29959920-9	2018	Our work demonstrates that eIF4E inhibition using inhibitor or siRNA, either as single agent or in combination, could sensitize chemoresistant cancer cells to paclitaxel or 5-FU treatment and thereby improving the efficacy of chemodrug.	Paclitaxel	159-169	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
29959920-9	2018	Our work demonstrates that eIF4E inhibition using inhibitor or siRNA, either as single agent or in combination, could sensitize chemoresistant cancer cells to paclitaxel or 5-FU treatment and thereby improving the efficacy of chemodrug.	Fluorouracil	173-177	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
30108651-6	2018	Bufadienolides also inhibit the mammalian target of rapamycin (mTOR) signaling pathway, which is evidenced by the data that bufadienolides inhibit type I insulin-like growth factor- (IGF-1-) activated phosphorylation of mTOR by a concentration- and time-dependent way, as well as phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1).	Bufanolides	0-14	eukaryotic translation initiation factor 4E	Homo sapiens	326-357
30174840-0	2018	Genetic and pharmacological inhibition of eIF4E effectively targets esophageal cancer cells and augments 5-FU"s efficacy.	Fluorouracil	105-109	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
30108651-6	2018	Bufadienolides also inhibit the mammalian target of rapamycin (mTOR) signaling pathway, which is evidenced by the data that bufadienolides inhibit type I insulin-like growth factor- (IGF-1-) activated phosphorylation of mTOR by a concentration- and time-dependent way, as well as phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1).	Bufanolides	124-138	eukaryotic translation initiation factor 4E	Homo sapiens	326-357
30174840-8	2018	Of note, the sensitivity of esophageal cancer cells to ribavirin or eIF4E knockdown correlates well with the expression levels of eIF4E, demonstrating that esophageal cells with higher eIF4E expression are more sensitive to eIF4E inhibition.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
30174840-8	2018	Of note, the sensitivity of esophageal cancer cells to ribavirin or eIF4E knockdown correlates well with the expression levels of eIF4E, demonstrating that esophageal cells with higher eIF4E expression are more sensitive to eIF4E inhibition.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
30174840-8	2018	Of note, the sensitivity of esophageal cancer cells to ribavirin or eIF4E knockdown correlates well with the expression levels of eIF4E, demonstrating that esophageal cells with higher eIF4E expression are more sensitive to eIF4E inhibition.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
30174840-9	2018	We further confirmed that the mechanism of action of ribavirin on esophageal cancer cells was through suppressing the Akt/mTOR/eIF4E and eIF4E-regulated pathways.	Ribavirin	53-62	eukaryotic translation initiation factor 4E	Homo sapiens	127-132
30174840-9	2018	We further confirmed that the mechanism of action of ribavirin on esophageal cancer cells was through suppressing the Akt/mTOR/eIF4E and eIF4E-regulated pathways.	Ribavirin	53-62	eukaryotic translation initiation factor 4E	Homo sapiens	137-142
29538717-9	2018	Sorafenib also inhibited 4E-BP1 phosphorylation, and this effect correlated with decrease of p-eIF4E and total eIF4E.	Sorafenib	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
29717265-5	2018	Targeted phosphoproteomics data demonstrate a significant drop in eIF4G1 Ser-1232 phosphorylation following MET targeting, which is linked to an increased affinity between eIF4G1 and eIF4E.	Serine	73-76	eukaryotic translation initiation factor 4E	Homo sapiens	183-188
29983898-0	2018	Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.	phenazine	51-60	eukaryotic translation initiation factor 4E	Homo sapiens	28-33
29086249-4	2018	We firstly inhibited eIF4E activity by ribavirin in two cell lines (Caki-1 and ACHN) representing RCC metastasis models.	Ribavirin	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	21-26
29086249-6	2018	We further confirmed that the inhibitory effects of ribavirin were attributed to its ability in inhibiting eIF4E-regulated protein translation and activity.	Ribavirin	52-61	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
29086249-7	2018	eIF4E inhibition using siRNA knockdown mimicked ribavirin"s effector in RCC cells.	Ribavirin	48-57	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
29086249-8	2018	Importantly, eIF4E inhibition by both ribavirin and siRNA knockdown significantly sensitized RCC response to chemo- and immunotherapeutic agents in vitro as well as in vivo.	Ribavirin	38-47	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
29795412-3	2018	Methionine starvation caused the most drastic decrease in translation as assessed by polysome formation, ribosome profiling, and a measure of protein synthesis (puromycin-labeled polypeptides) but had no significant effect on eIF2 phosphorylation, 4EBP1 hyperphosphorylation or 4EBP1 binding to eIF4E.	Methionine	0-10	eukaryotic translation initiation factor 4E	Homo sapiens	295-300
29795412-4	2018	Leucine starvation suppressed polysome formation and was the only tested condition that caused a significant decrease in 4EBP1 phosphorylation or increase in 4EBP1 binding to eIF4E, but effects of leucine starvation were not replicated by overexpressing nonphosphorylatable 4EBP1.	Leucine	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
29538717-9	2018	Sorafenib also inhibited 4E-BP1 phosphorylation, and this effect correlated with decrease of p-eIF4E and total eIF4E.	Sorafenib	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
29487419-11	2018	Mass cytometry using mouse and human RMS cell lines validated GSK2126458 specificity at single-cell resolution, decreasing the abundance of phosphorylated Akt as well as decreasing phosphorylation of the downstream mTOR effectors 4ebp1, Eif4e, and S6.	omipalisib	62-72	eukaryotic translation initiation factor 4E	Homo sapiens	237-242
29850566-12	2018	Rapamycin elicited concentration-dependent reductions in the mRNA (P < 0.05) and protein (P < 0.01) expressions of Smad2 and eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	131-137
29323792-1	2018	VNLG-152 is a novel retinamide (NR) shown to suppress growth and progression of genetically diverse prostate cancer cells via inhibition of androgen receptor signaling and eukaryotic initiation factor 4E (eIF4E) translational machinery.	retinamide	20-30	eukaryotic translation initiation factor 4E	Homo sapiens	172-203
28322282-9	2018	The cap-dependent translation initiation gene, EIF4E, is one of the most MIA-dysregulated of all ASD-associated genes and targeted network analyses demonstrate prominent MIA-induced transcriptional dysregulation of mTOR and EIF4E-dependent signaling.	cap	4-7	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
28322282-9	2018	The cap-dependent translation initiation gene, EIF4E, is one of the most MIA-dysregulated of all ASD-associated genes and targeted network analyses demonstrate prominent MIA-induced transcriptional dysregulation of mTOR and EIF4E-dependent signaling.	cap	4-7	eukaryotic translation initiation factor 4E	Homo sapiens	224-229
29323792-1	2018	VNLG-152 is a novel retinamide (NR) shown to suppress growth and progression of genetically diverse prostate cancer cells via inhibition of androgen receptor signaling and eukaryotic initiation factor 4E (eIF4E) translational machinery.	retinamide	20-30	eukaryotic translation initiation factor 4E	Homo sapiens	205-210
29112301-0	2018	Ribavirin augments doxorubicin"s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
29153483-5	2018	What is known is that, on one side, translation initiation factors, such as eIF4E and eIF6, drive tumor growth and regulate metabolism through selective translation of nucleotide biosynthesis, glycolysis and fatty acid synthesis rate-limiting mRNAs, and on the other, that nutrient levels regulate the translational machinery by inducing full activity of translation factors.	Fatty Acids	208-218	eukaryotic translation initiation factor 4E	Homo sapiens	76-81
29212818-7	2018	Treatment of NPCs with the cercosporamide, a MAPK-interacting kinases inhibitor, reduced eIF4E phosphorylation and KDM5A protein expression, increased GFAP levels, and enhanced astrocytogenesis.	cercosporamide	27-41	eukaryotic translation initiation factor 4E	Homo sapiens	89-94
29342273-8	2018	We found that the hypermethylation of cg11037477, located at the promoter of EIF4E, was significantly associated with age at diagnosis and the expression of EIF4E.	cg11037477	38-48	eukaryotic translation initiation factor 4E	Homo sapiens	77-82
29342273-8	2018	We found that the hypermethylation of cg11037477, located at the promoter of EIF4E, was significantly associated with age at diagnosis and the expression of EIF4E.	cg11037477	38-48	eukaryotic translation initiation factor 4E	Homo sapiens	157-162
29487714-5	2018	We provide evidence that ribavirin has a significant impact on AT/RT cell growth and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E and/or EZH2 pathways.	Ribavirin	25-34	eukaryotic translation initiation factor 4E	Homo sapiens	167-172
29112301-0	2018	Ribavirin augments doxorubicin"s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.	Doxorubicin	19-30	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
29112301-0	2018	Ribavirin augments doxorubicin"s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.	Doxorubicin	95-106	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
29112301-2	2018	In this work, we demonstrate that targeting eIF4E by ribavirin sensitizes hepatocellular carcinoma (HCC) cell response to doxorubicin.	Ribavirin	53-62	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
29112301-2	2018	In this work, we demonstrate that targeting eIF4E by ribavirin sensitizes hepatocellular carcinoma (HCC) cell response to doxorubicin.	Doxorubicin	122-133	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
29112301-5	2018	Ribavirin suppresses phosphorylation of molecules involved in Akt/mTOR/eIF4E pathway.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
29112301-6	2018	Overexpression of the phosphomimetic form (S209D) but not the nonphosphorylatable form (S209A) eIF4E significantly reverses the inhibitory effects of ribavirin.	Ribavirin	150-159	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
28573908-0	2018	The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>.	Ribavirin	20-29	eukaryotic translation initiation factor 4E	Homo sapiens	4-9
29042487-5	2018	As ATO has been shown to activate the MAPK-interacting kinase 1 (MNK1)-eukaryotic translation initiation factor 4E (eIF4E) pathway and subsequent mRNA translation in a negative regulatory feedback manner, the mechanistic role of ATO resistance in MES GBM was explored.	Arsenic Trioxide	3-6	eukaryotic translation initiation factor 4E	Homo sapiens	71-114
29042487-5	2018	As ATO has been shown to activate the MAPK-interacting kinase 1 (MNK1)-eukaryotic translation initiation factor 4E (eIF4E) pathway and subsequent mRNA translation in a negative regulatory feedback manner, the mechanistic role of ATO resistance in MES GBM was explored.	Arsenic Trioxide	3-6	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
29112301-7	2018	Interestingly, doxorubicin significantly increases p-eIF4E(S209) level in a dose- and time-dependent manner, suggesting that doxorubicin induces eIF4E activation in HCC cells.	Doxorubicin	15-26	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
29112301-7	2018	Interestingly, doxorubicin significantly increases p-eIF4E(S209) level in a dose- and time-dependent manner, suggesting that doxorubicin induces eIF4E activation in HCC cells.	Doxorubicin	15-26	eukaryotic translation initiation factor 4E	Homo sapiens	145-150
29112301-7	2018	Interestingly, doxorubicin significantly increases p-eIF4E(S209) level in a dose- and time-dependent manner, suggesting that doxorubicin induces eIF4E activation in HCC cells.	Doxorubicin	125-136	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
29112301-7	2018	Interestingly, doxorubicin significantly increases p-eIF4E(S209) level in a dose- and time-dependent manner, suggesting that doxorubicin induces eIF4E activation in HCC cells.	Doxorubicin	125-136	eukaryotic translation initiation factor 4E	Homo sapiens	145-150
29112301-8	2018	In addition, eIF4E activation induced by doxorubicin in HCC cells is inhibited by ribavirin.	Doxorubicin	41-52	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
29112301-8	2018	In addition, eIF4E activation induced by doxorubicin in HCC cells is inhibited by ribavirin.	Ribavirin	82-91	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
28745319-12	2017	Thus, our results demonstrate that while combinations of AR and mTOR inhibitors were effective in suppressing tumor growth by inhibiting both AR-induced transcription and mTOR-induced cap-dependent translation, pre-treatment with AR antagonists including bicalutamide increased eIF4E phosphorylation that induced resistance to combinations of AR and mTOR inhibitors by inducing cap-independent translation.	bicalutamide	255-267	eukaryotic translation initiation factor 4E	Homo sapiens	278-283
29049978-2	2017	In this work, we report that ribavirin, a pharmacologic inhibitor of eIF4E function, effectively targets retinoblastoma and angiogenesis.	Ribavirin	29-38	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
29049978-6	2017	Mechanistically, ribavirin inhibited eIF4E function in retinoblastoma cells as shown by the decreased protein levels of Cyclin D1, c-Myc and VEGF without affecting their mRNA expression.	Ribavirin	17-26	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
29049978-7	2017	Overexpression of the wildtype and phosphormimetic but not the nonphosphorylatable form of eIF4E significantly abolished the inhibitory effects of ribavirin, further demonstrating eIF4E as the target of ribavirin.	Ribavirin	147-156	eukaryotic translation initiation factor 4E	Homo sapiens	180-185
29049978-7	2017	Overexpression of the wildtype and phosphormimetic but not the nonphosphorylatable form of eIF4E significantly abolished the inhibitory effects of ribavirin, further demonstrating eIF4E as the target of ribavirin.	Ribavirin	203-212	eukaryotic translation initiation factor 4E	Homo sapiens	180-185
29049978-8	2017	Genetic knockdown of eIF4E using two independent siRNAs mirrored ribavirin"s effects, confirming the role of eIF4E in retinoblastoma growth, survival and response to chemotherapy.	Ribavirin	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	21-26
28745319-9	2017	Small interfering RNA-mediated knockdown (k/d) of eIF4E-sensitized CRPC cells to RAD001+bicalutamide, whereas eIF4E overexpression induced resistance.	bicalutamide	88-100	eukaryotic translation initiation factor 4E	Homo sapiens	50-55
28745319-10	2017	Inhibition of eIF4E phosphorylation by treatment with CGP57380 (an inhibitor of mitogen-activated protein kinase-interacting serine-threonine kinases MAP kinase-interacting kinase 1 (Mnk1/2), the eIF4E upstream kinase) or inhibitors of extracellular signal-regulated kinase 1/2 (ERK1/2), the upstream kinase-regulating Mnk1/2, also sensitized CRPC cells to RAD001+bicalutamide.	CGP 57380	54-62	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
28745319-10	2017	Inhibition of eIF4E phosphorylation by treatment with CGP57380 (an inhibitor of mitogen-activated protein kinase-interacting serine-threonine kinases MAP kinase-interacting kinase 1 (Mnk1/2), the eIF4E upstream kinase) or inhibitors of extracellular signal-regulated kinase 1/2 (ERK1/2), the upstream kinase-regulating Mnk1/2, also sensitized CRPC cells to RAD001+bicalutamide.	CGP 57380	54-62	eukaryotic translation initiation factor 4E	Homo sapiens	196-201
28745319-10	2017	Inhibition of eIF4E phosphorylation by treatment with CGP57380 (an inhibitor of mitogen-activated protein kinase-interacting serine-threonine kinases MAP kinase-interacting kinase 1 (Mnk1/2), the eIF4E upstream kinase) or inhibitors of extracellular signal-regulated kinase 1/2 (ERK1/2), the upstream kinase-regulating Mnk1/2, also sensitized CRPC cells to RAD001+bicalutamide.	bicalutamide	364-376	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
29269484-0	2017	Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming.	Tamoxifen	58-67	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
29269484-4	2017	Tamoxifen-resistant translational reprogramming is shown to be mediated by increased expression of eIF4E and its increased availability by hyperactive mTOR and to require phosphorylation of eIF4E at Ser209 by increased MNK activity.	Tamoxifen	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
29269484-4	2017	Tamoxifen-resistant translational reprogramming is shown to be mediated by increased expression of eIF4E and its increased availability by hyperactive mTOR and to require phosphorylation of eIF4E at Ser209 by increased MNK activity.	Tamoxifen	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
29269484-5	2017	Resensitization to tamoxifen is restored only by reducing eIF4E expression or mTOR activity and also blocking MNK1 phosphorylation of eIF4E.	Tamoxifen	19-28	eukaryotic translation initiation factor 4E	Homo sapiens	58-63
29269484-5	2017	Resensitization to tamoxifen is restored only by reducing eIF4E expression or mTOR activity and also blocking MNK1 phosphorylation of eIF4E.	Tamoxifen	19-28	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
29269484-8	2017	Tamoxifen-resistant but not tamoxifen-sensitive patient ER+ breast cancer specimens also demonstrate strongly increased MNK phosphorylation of eIF4E.	Tamoxifen	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	143-148
29269484-9	2017	eIF4E levels, availability, and phosphorylation therefore promote tamoxifen resistance in ER+ breast cancer through selective mRNA translational reprogramming.	Tamoxifen	66-75	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
29078784-4	2017	RESULTS: Using a tagged-factor protein capture and RNA-sequencing (RNA-seq) approach, we have assessed how mRNA associations with eIF4E, eIF4G1 and eIF4G2 change globally in response to three defined stresses that each cause a rapid attenuation of protein synthesis: oxidative stress induced by hydrogen peroxide and nutrient stresses caused by amino acid or glucose withdrawal.	Hydrogen Peroxide	295-312	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
29078784-4	2017	RESULTS: Using a tagged-factor protein capture and RNA-sequencing (RNA-seq) approach, we have assessed how mRNA associations with eIF4E, eIF4G1 and eIF4G2 change globally in response to three defined stresses that each cause a rapid attenuation of protein synthesis: oxidative stress induced by hydrogen peroxide and nutrient stresses caused by amino acid or glucose withdrawal.	Glucose	359-366	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
28589219-0	2017	1H, 13C, and 15N backbone chemical shift assignments of 4E-BP144-87 and 4E-BP144-87 bound to eIF4E.	Hydrogen	0-2	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
28589219-0	2017	1H, 13C, and 15N backbone chemical shift assignments of 4E-BP144-87 and 4E-BP144-87 bound to eIF4E.	15n	13-16	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
28577281-0	2017	Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation.	Tamoxifen	9-18	eukaryotic translation initiation factor 4E	Homo sapiens	87-92
29111978-0	2017	The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity.	Hyaluronic Acid	61-71	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
29111978-5	2017	eIF4E stimulates production of enzymes that synthesize the building blocks of HA, UDP-Glucuronic acid and UDP-N-Acetyl-Glucosamine, as well as hyaluronic acid synthase which forms the disaccharide chain.	Uridine Diphosphate Glucuronic Acid	82-101	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
29111978-5	2017	eIF4E stimulates production of enzymes that synthesize the building blocks of HA, UDP-Glucuronic acid and UDP-N-Acetyl-Glucosamine, as well as hyaluronic acid synthase which forms the disaccharide chain.	Uridine Diphosphate N-Acetylglucosamine	106-130	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
29111978-5	2017	eIF4E stimulates production of enzymes that synthesize the building blocks of HA, UDP-Glucuronic acid and UDP-N-Acetyl-Glucosamine, as well as hyaluronic acid synthase which forms the disaccharide chain.	Disaccharides	184-196	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
28699129-6	2017	Within changed pathways, three genes were selected for RT-qPCR analyses as key candidates influencing inflammatory responses: CYBA (component of the superoxide-generating Nox2 enzyme), GSK3B (controller of cell responses after toll-like receptor stimulation), and EIF4E (a key factor of the eukaryotic translation initiation factor 4F complex that regulates abundance of other proteins involved in immune functions).	Superoxides	149-159	eukaryotic translation initiation factor 4E	Homo sapiens	264-269
29100389-0	2017	Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.	phenazine	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	16-21
29100389-8	2017	In order to find a potential inhibitor of Hsp27/eIF4E interaction, BRET assays in combination with molecular simulations identified the phenazine derivative 14 as the compound able to efficiently interfere with this protein/protein interaction, thereby inhibiting cell viability and increasing cell death in chemo- and castration-resistant prostate cancer models in vitro and in vivo.	phenazine	136-145	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
28577281-6	2017	Here, we show that the eIF4F translation pathway was hyperactive in tamoxifen-resistant (TamR) MCF-7L breast cancer cells.	Tamoxifen	68-77	eukaryotic translation initiation factor 4E	Homo sapiens	23-28
28577281-8	2017	Targeting the eIF4E subunit of the eIF4F complex through its degradation using an antisense oligonucleotide (ASO) or via sequestration using a mutant 4E-BP1 inhibited the proliferation and colony formation of TamR cells and partially restored sensitivity to tamoxifen.	Oligonucleotides	92-107	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
28577281-8	2017	Targeting the eIF4E subunit of the eIF4F complex through its degradation using an antisense oligonucleotide (ASO) or via sequestration using a mutant 4E-BP1 inhibited the proliferation and colony formation of TamR cells and partially restored sensitivity to tamoxifen.	Oligonucleotides	92-107	eukaryotic translation initiation factor 4E	Homo sapiens	35-40
28577281-8	2017	Targeting the eIF4E subunit of the eIF4F complex through its degradation using an antisense oligonucleotide (ASO) or via sequestration using a mutant 4E-BP1 inhibited the proliferation and colony formation of TamR cells and partially restored sensitivity to tamoxifen.	Oligonucleotides, Antisense	109-112	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
28577281-8	2017	Targeting the eIF4E subunit of the eIF4F complex through its degradation using an antisense oligonucleotide (ASO) or via sequestration using a mutant 4E-BP1 inhibited the proliferation and colony formation of TamR cells and partially restored sensitivity to tamoxifen.	Oligonucleotides, Antisense	109-112	eukaryotic translation initiation factor 4E	Homo sapiens	35-40
28577281-8	2017	Targeting the eIF4E subunit of the eIF4F complex through its degradation using an antisense oligonucleotide (ASO) or via sequestration using a mutant 4E-BP1 inhibited the proliferation and colony formation of TamR cells and partially restored sensitivity to tamoxifen.	Tamoxifen	258-267	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
28577281-8	2017	Targeting the eIF4E subunit of the eIF4F complex through its degradation using an antisense oligonucleotide (ASO) or via sequestration using a mutant 4E-BP1 inhibited the proliferation and colony formation of TamR cells and partially restored sensitivity to tamoxifen.	Tamoxifen	258-267	eukaryotic translation initiation factor 4E	Homo sapiens	35-40
28577281-11	2017	These results highlight the eIF4F complex as a promising target for patients with acquired resistance to tamoxifen and, potentially, other endocrine therapies.	Tamoxifen	105-114	eukaryotic translation initiation factor 4E	Homo sapiens	28-33
28468879-9	2017	The low dependence on eIF4E suggests that viral mRNAs may engage yet-unknown noncanonical host factors for a cap-dependent initiation mechanism.IMPORTANCE Several members of the Arenaviridae family cause serious hemorrhagic fevers in humans.	cap	109-112	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
28698298-1	2017	The eIF4E homologous protein (4EHP) is thought to repress translation by competing with eIF4E for binding to the 5" cap structure of specific mRNAs to which it is recruited through interactions with various proteins, including the GRB10-interacting GYF (glycine-tyrosine-phenylalanine domain) proteins 1 and 2 (GIGYF1/2).	Glycine	254-261	eukaryotic translation initiation factor 4E	Homo sapiens	4-9
28698298-1	2017	The eIF4E homologous protein (4EHP) is thought to repress translation by competing with eIF4E for binding to the 5" cap structure of specific mRNAs to which it is recruited through interactions with various proteins, including the GRB10-interacting GYF (glycine-tyrosine-phenylalanine domain) proteins 1 and 2 (GIGYF1/2).	Glycine	254-261	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
28698298-1	2017	The eIF4E homologous protein (4EHP) is thought to repress translation by competing with eIF4E for binding to the 5" cap structure of specific mRNAs to which it is recruited through interactions with various proteins, including the GRB10-interacting GYF (glycine-tyrosine-phenylalanine domain) proteins 1 and 2 (GIGYF1/2).	Tyrosine	262-270	eukaryotic translation initiation factor 4E	Homo sapiens	4-9
28698298-1	2017	The eIF4E homologous protein (4EHP) is thought to repress translation by competing with eIF4E for binding to the 5" cap structure of specific mRNAs to which it is recruited through interactions with various proteins, including the GRB10-interacting GYF (glycine-tyrosine-phenylalanine domain) proteins 1 and 2 (GIGYF1/2).	Tyrosine	262-270	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
28698298-1	2017	The eIF4E homologous protein (4EHP) is thought to repress translation by competing with eIF4E for binding to the 5" cap structure of specific mRNAs to which it is recruited through interactions with various proteins, including the GRB10-interacting GYF (glycine-tyrosine-phenylalanine domain) proteins 1 and 2 (GIGYF1/2).	Phenylalanine	271-284	eukaryotic translation initiation factor 4E	Homo sapiens	4-9
28698298-1	2017	The eIF4E homologous protein (4EHP) is thought to repress translation by competing with eIF4E for binding to the 5" cap structure of specific mRNAs to which it is recruited through interactions with various proteins, including the GRB10-interacting GYF (glycine-tyrosine-phenylalanine domain) proteins 1 and 2 (GIGYF1/2).	Phenylalanine	271-284	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
27145354-4	2017	UV crosslinking, followed by gel retardation assays, indicated that Ma5TE interacts in vitro with the complex formed by eIF4E + eIF4G980-1159 (eIF4Fp20 ), but not with each subunit alone or with eIF4E + eIF4G1003-1092 , suggesting binding either through interaction with eIF4E following a conformational change induced by its binding to eIF4G980-1159 , or through a double interaction with eIF4E and eIF4G980-1159 .	ma5te	68-73	eukaryotic translation initiation factor 4E	Homo sapiens	120-125
27145354-4	2017	UV crosslinking, followed by gel retardation assays, indicated that Ma5TE interacts in vitro with the complex formed by eIF4E + eIF4G980-1159 (eIF4Fp20 ), but not with each subunit alone or with eIF4E + eIF4G1003-1092 , suggesting binding either through interaction with eIF4E following a conformational change induced by its binding to eIF4G980-1159 , or through a double interaction with eIF4E and eIF4G980-1159 .	ma5te	68-73	eukaryotic translation initiation factor 4E	Homo sapiens	195-200
27145354-4	2017	UV crosslinking, followed by gel retardation assays, indicated that Ma5TE interacts in vitro with the complex formed by eIF4E + eIF4G980-1159 (eIF4Fp20 ), but not with each subunit alone or with eIF4E + eIF4G1003-1092 , suggesting binding either through interaction with eIF4E following a conformational change induced by its binding to eIF4G980-1159 , or through a double interaction with eIF4E and eIF4G980-1159 .	ma5te	68-73	eukaryotic translation initiation factor 4E	Homo sapiens	195-200
27145354-4	2017	UV crosslinking, followed by gel retardation assays, indicated that Ma5TE interacts in vitro with the complex formed by eIF4E + eIF4G980-1159 (eIF4Fp20 ), but not with each subunit alone or with eIF4E + eIF4G1003-1092 , suggesting binding either through interaction with eIF4E following a conformational change induced by its binding to eIF4G980-1159 , or through a double interaction with eIF4E and eIF4G980-1159 .	ma5te	68-73	eukaryotic translation initiation factor 4E	Homo sapiens	195-200
27145354-5	2017	Critical residues for this interaction reside in an internal bulge of Ma5TE, so that their mutation abolished binding to eIF4E + eIF4G1003-1092 and cap-independent translation.	ma5te	70-75	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
27145354-6	2017	We also developed an in vivo system to test the effect of mutations in eIF4E in Ma5TE-driven cap-independent translation, showing that conserved amino acids in a positively charged RNA-binding motif around amino acid position 228, implicated in eIF4E-eIF4G binding or belonging to the cap-recognition pocket, are essential for cap-independent translation controlled by Ma5TE, and thus for the multiplication of MNSV.	ma5te	80-85	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
27145354-6	2017	We also developed an in vivo system to test the effect of mutations in eIF4E in Ma5TE-driven cap-independent translation, showing that conserved amino acids in a positively charged RNA-binding motif around amino acid position 228, implicated in eIF4E-eIF4G binding or belonging to the cap-recognition pocket, are essential for cap-independent translation controlled by Ma5TE, and thus for the multiplication of MNSV.	ma5te	80-85	eukaryotic translation initiation factor 4E	Homo sapiens	245-250
27145354-6	2017	We also developed an in vivo system to test the effect of mutations in eIF4E in Ma5TE-driven cap-independent translation, showing that conserved amino acids in a positively charged RNA-binding motif around amino acid position 228, implicated in eIF4E-eIF4G binding or belonging to the cap-recognition pocket, are essential for cap-independent translation controlled by Ma5TE, and thus for the multiplication of MNSV.	ma5te	369-374	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
27145354-6	2017	We also developed an in vivo system to test the effect of mutations in eIF4E in Ma5TE-driven cap-independent translation, showing that conserved amino acids in a positively charged RNA-binding motif around amino acid position 228, implicated in eIF4E-eIF4G binding or belonging to the cap-recognition pocket, are essential for cap-independent translation controlled by Ma5TE, and thus for the multiplication of MNSV.	ma5te	369-374	eukaryotic translation initiation factor 4E	Homo sapiens	245-250
28656063-2	2017	The MAP kinase interacting serine/threonine kinase (MNK)-eukaryotic translation initiation factor 4E (eIF4E) axis has been reported to activate Wnt/beta-catenin signaling, and CGP57380, an inhibitor of MNK kinases, inhibits the proliferation of multiple cancers.	CGP 57380	176-184	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
28447756-9	2017	The mRNA expression levels of PCNA and eIF4E were significantly lower in the 240 mg/l matrine-treated group compared with the control.	matrine	86-93	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
27941882-3	2017	Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral molecule currently used in hepatitis C treatment.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
27941882-6	2017	Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways.	Ribavirin	21-30	eukaryotic translation initiation factor 4E	Homo sapiens	160-165
28487484-3	2017	Here we show that the cap-binding eIF4E-homologous protein 4EHP is an integral component of the miRNA-mediated silencing machinery.	cap	22-25	eukaryotic translation initiation factor 4E	Homo sapiens	34-39
27986751-7	2017	Marked reduction in eIF4E and eIF5 expression was seen post BEZ235/everolimus, with extended survival.Conclusions: Translational initiation pathway inhibition could be of clinical utility in MBC patients overexpressing eIF4E and eIF5.	dactolisib	60-66	eukaryotic translation initiation factor 4E	Homo sapiens	20-25
27986751-7	2017	Marked reduction in eIF4E and eIF5 expression was seen post BEZ235/everolimus, with extended survival.Conclusions: Translational initiation pathway inhibition could be of clinical utility in MBC patients overexpressing eIF4E and eIF5.	dactolisib	60-66	eukaryotic translation initiation factor 4E	Homo sapiens	219-224
27986751-7	2017	Marked reduction in eIF4E and eIF5 expression was seen post BEZ235/everolimus, with extended survival.Conclusions: Translational initiation pathway inhibition could be of clinical utility in MBC patients overexpressing eIF4E and eIF5.	Everolimus	67-77	eukaryotic translation initiation factor 4E	Homo sapiens	20-25
28042932-7	2017	Photo-cross-linking of the resulting modified mRNAs with the cap interacting protein eIF4E was successful with aryl azide and diazirine but not benzophenone, reflecting the affinity of the modified 5" caps.	aryl azide	111-121	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
28042932-7	2017	Photo-cross-linking of the resulting modified mRNAs with the cap interacting protein eIF4E was successful with aryl azide and diazirine but not benzophenone, reflecting the affinity of the modified 5" caps.	Diazomethane	126-135	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
28042932-7	2017	Photo-cross-linking of the resulting modified mRNAs with the cap interacting protein eIF4E was successful with aryl azide and diazirine but not benzophenone, reflecting the affinity of the modified 5" caps.	benzophenone	144-156	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
28447756-11	2017	Treatment with 240 mg/l matrine reduced the protein expression levels of PCNA and eIF4E.	matrine	24-31	eukaryotic translation initiation factor 4E	Homo sapiens	82-87
28539821-1	2017	Objectives: 4E-BP1 is a family member of eIF4E binding proteins (4E-BPs) which act as the suppressors of cap-dependent translation of RNA via competitively associating with cap-bound eIF4E.	cap	105-108	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
28539821-1	2017	Objectives: 4E-BP1 is a family member of eIF4E binding proteins (4E-BPs) which act as the suppressors of cap-dependent translation of RNA via competitively associating with cap-bound eIF4E.	cap	105-108	eukaryotic translation initiation factor 4E	Homo sapiens	183-188
28364098-9	2017	Delphinidin inhibited the expression of proteins in mTOR signaling pathway, including AKT, mTOR, eIF4E and p70s6k.	delphinidin	0-11	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
28386346-5	2017	Upregulation of phosphorylated eIF4E (p-eIF4E) levels has also been shown in cisplatin-resistant HeLa cells and has been observed to be a common response of cervical cancer patients undergoing chemotherapy.	Cisplatin	77-86	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
28095120-4	2017	We found that the bent structure of PABP/poly(A) complex is required for PABP"s efficient interaction with eIF4G and eIF4G/eIF4E complex.	Poly A	41-48	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
28095120-6	2017	These results suggest that the bent conformation of PABP, which is induced by the interaction with 3" poly(A) tail, mediates poly(A)-dependent translation by facilitating the interaction with eIF4G and the eIF4G/eIF4E complex.	Poly A	102-109	eukaryotic translation initiation factor 4E	Homo sapiens	212-217
28095120-7	2017	The preferential binding of the eIF4G/eIF4E complex to the bent PABP/poly(A) complex seems to be a mechanism discriminating the mRNA-bound PABPs participating in translation from the idling mRNA-unbound PABPs.	Poly A	69-76	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
27785922-4	2017	Mechanistically, cisplatin increases eIF4E phosphorylation in a dose- and time-dependent manner in ATC cells.	Cisplatin	17-26	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
27785922-5	2017	Mnk inhibitors sensitize the efficacy of cisplatin by inhibiting cisplatin-induced eIF4E phosphorylation.	Cisplatin	41-50	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
27785922-5	2017	Mnk inhibitors sensitize the efficacy of cisplatin by inhibiting cisplatin-induced eIF4E phosphorylation.	Cisplatin	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
28386346-5	2017	Upregulation of phosphorylated eIF4E (p-eIF4E) levels has also been shown in cisplatin-resistant HeLa cells and has been observed to be a common response of cervical cancer patients undergoing chemotherapy.	Cisplatin	77-86	eukaryotic translation initiation factor 4E	Homo sapiens	40-45
28386346-7	2017	Inhibiting eIF4E via siRNA knockdown or Wnt/beta-catenin using the Wnt inhibitor pyrvinium effectively enhanced the anti-proliferative and pro-apoptotic effects of cisplatin in cervical cancer cells both in vitro and in vivo.	pyrvinium	81-90	eukaryotic translation initiation factor 4E	Homo sapiens	11-16
28386346-7	2017	Inhibiting eIF4E via siRNA knockdown or Wnt/beta-catenin using the Wnt inhibitor pyrvinium effectively enhanced the anti-proliferative and pro-apoptotic effects of cisplatin in cervical cancer cells both in vitro and in vivo.	Cisplatin	164-173	eukaryotic translation initiation factor 4E	Homo sapiens	11-16
27879264-1	2017	Small molecules and antisense oligonucleotides that inhibit the translation initiation factors eIF4A1 and eIF4E have been explored as broad-based therapeutic agents for cancer treatment, based on the frequent upregulation of these two subunits of the eIF4F cap-binding complex in many cancer cells.	Oligonucleotides	30-46	eukaryotic translation initiation factor 4E	Homo sapiens	106-111
27879264-1	2017	Small molecules and antisense oligonucleotides that inhibit the translation initiation factors eIF4A1 and eIF4E have been explored as broad-based therapeutic agents for cancer treatment, based on the frequent upregulation of these two subunits of the eIF4F cap-binding complex in many cancer cells.	Oligonucleotides	30-46	eukaryotic translation initiation factor 4E	Homo sapiens	251-256
27900644-3	2017	Deregulation of eukaryotic translation initiation factor 4E (eIF4E) by MAP kinase-interacting kinases (Mnk) on Ser-209 directly or PI3K/mTOR/S6K pathway indirectly has a critical effect on promoting cellular proliferation, malignant transformation and metastasis.	Serine	111-114	eukaryotic translation initiation factor 4E	Homo sapiens	16-59
27900644-3	2017	Deregulation of eukaryotic translation initiation factor 4E (eIF4E) by MAP kinase-interacting kinases (Mnk) on Ser-209 directly or PI3K/mTOR/S6K pathway indirectly has a critical effect on promoting cellular proliferation, malignant transformation and metastasis.	Serine	111-114	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
27932243-0	2017	Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.	Ribavirin	44-53	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
27932243-0	2017	Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma.	Paclitaxel	90-100	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
27932243-3	2017	In this work, we show that ribavirin, an anti-viral drug, effectively augments sensitivity of OTSCC cells to paclitaxel via inhibiting mTOR/eIF4E signaling pathway.	Ribavirin	27-36	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
27932243-3	2017	In this work, we show that ribavirin, an anti-viral drug, effectively augments sensitivity of OTSCC cells to paclitaxel via inhibiting mTOR/eIF4E signaling pathway.	Paclitaxel	109-119	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
27932243-7	2017	Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E.	Ribavirin	17-26	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
27932243-7	2017	Mechanistically, ribavirin significantly decreases mTOR/eIF4E signaling pathway in OTSCC cells via suppressing phosphorylation of Akt, mTOR, 4EBP1 and eIF4E.	Ribavirin	17-26	eukaryotic translation initiation factor 4E	Homo sapiens	151-156
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	216-225	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	216-225	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	216-225	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
27932243-8	2017	Overexpression of the phosphor-mimetic form of eIF4E (eIF4E S209D) but not the nonphosphorylatable form (eIF4E S209A) reverses the effects of ribavirin, confirming that eIF4E inhibition is the mechanism of action of ribavirin in OTSCC cells.	Ribavirin	216-225	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	104-114	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	104-114	eukaryotic translation initiation factor 4E	Homo sapiens	151-156
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	183-193	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
27932243-9	2017	In addition, eIF4E depletion significantly enhances the anti-proliferative and pro-apoptotic effects of paclitaxel, demonstrating the critical role of eIF4E in OTSCC cell response to paclitaxel.	Paclitaxel	183-193	eukaryotic translation initiation factor 4E	Homo sapiens	151-156
27926520-4	2017	We showed that eIF4E is highly phosphorylated at serine 209 in breast cancer patients in response to chemotherapy, which significantly correlated with poorer clinical responses and outcomes.	Serine	49-55	eukaryotic translation initiation factor 4E	Homo sapiens	15-20
32263549-0	2017	Upconversion nanoparticles loaded with eIF4E siRNA and platinum(iv) prodrug to sensitize platinum based chemotherapy for laryngeal cancer and bioimaging.	Platinum	89-97	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
27662474-0	2016	Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.	cercosporamide	65-79	eukaryotic translation initiation factor 4E	Homo sapiens	14-45
27916520-0	2017	Water-Bridge Mediates Recognition of mRNA Cap in eIF4E.	Water	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
27840955-0	2017	miR-141 regulation of EIF4E expression affects docetaxel chemoresistance of non-small cell lung cancer.	Docetaxel	47-56	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
27840955-1	2017	The present study investigated the role of miR-141 regulation of eukaryotic initiation factor-4E (EIF4E) expression in docetaxel chemoresistance of human non-small cell lung cancer (NSCLC).	Docetaxel	119-128	eukaryotic translation initiation factor 4E	Homo sapiens	65-96
27840955-1	2017	The present study investigated the role of miR-141 regulation of eukaryotic initiation factor-4E (EIF4E) expression in docetaxel chemoresistance of human non-small cell lung cancer (NSCLC).	Docetaxel	119-128	eukaryotic translation initiation factor 4E	Homo sapiens	98-103
27840955-3	2017	The expression of EIF4E in docetaxel chemoresistant patients with NSCLCs was markedly lower than those of non-docetaxel chemoresistant patients with NSCLCs.	Docetaxel	27-36	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
27840955-3	2017	The expression of EIF4E in docetaxel chemoresistant patients with NSCLCs was markedly lower than those of non-docetaxel chemoresistant patients with NSCLCs.	Docetaxel	110-119	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
27840955-8	2017	Thus, the present study is the first to show the induction of miR-141/EIF4E expression in an acquired model of docetaxel chemoresistant patients with NSCLCs.	Docetaxel	111-120	eukaryotic translation initiation factor 4E	Homo sapiens	70-75
27840964-0	2017	miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5-fluorouracil by targeting EIF4E.	Fluorouracil	90-104	eukaryotic translation initiation factor 4E	Homo sapiens	118-123
27836976-9	2016	Finally, pharmacological protection of CA1 ischemic neurons with cycloheximide decreased the formation of SGs and restored eIF4E and eIF4B levels in CA1.	Cycloheximide	65-78	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
27662474-6	2016	Cercosporamide blocked the phosphorylation of eIF4E but not Erk or p38 in a dose- and time-dependent manner in HCC and HCC-EC cells, suggesting that suppression of eIF4E phosphorylation was the result of inhibition of Mnk but not Mnk upstream pathways.	cercosporamide	0-14	eukaryotic translation initiation factor 4E	Homo sapiens	46-51
27662474-6	2016	Cercosporamide blocked the phosphorylation of eIF4E but not Erk or p38 in a dose- and time-dependent manner in HCC and HCC-EC cells, suggesting that suppression of eIF4E phosphorylation was the result of inhibition of Mnk but not Mnk upstream pathways.	cercosporamide	0-14	eukaryotic translation initiation factor 4E	Homo sapiens	164-169
27662474-7	2016	Overexpression of constitutively active eIF4E (S209D) but not the nonphosphorylatable eIF4E (S209A) abolished the inhibitory effects of cercosporamide in HepG2 cells.	cercosporamide	136-150	eukaryotic translation initiation factor 4E	Homo sapiens	40-45
27662474-8	2016	Altogether, our work demonstrates that cercosporamide acts as a Mnk inhibitor through blockage of eIF4E phosphorylation and selectively exhibits anti-HCC activities.	cercosporamide	39-53	eukaryotic translation initiation factor 4E	Homo sapiens	98-103
27592390-4	2016	We have used two approaches to design cap-binding inhibitors of eIF4E by modifying the N7-substituent of m7GMP and replacing the phosphate group with isosteres such as squaramides, sulfonamides, and tetrazoles, as well as by structure-based virtual screening aimed at identifying non-nucleotide cap-binding antagonists.	m(7)GMP	105-110	eukaryotic translation initiation factor 4E	Homo sapiens	64-69
27592390-4	2016	We have used two approaches to design cap-binding inhibitors of eIF4E by modifying the N7-substituent of m7GMP and replacing the phosphate group with isosteres such as squaramides, sulfonamides, and tetrazoles, as well as by structure-based virtual screening aimed at identifying non-nucleotide cap-binding antagonists.	Phosphates	129-138	eukaryotic translation initiation factor 4E	Homo sapiens	64-69
27592390-4	2016	We have used two approaches to design cap-binding inhibitors of eIF4E by modifying the N7-substituent of m7GMP and replacing the phosphate group with isosteres such as squaramides, sulfonamides, and tetrazoles, as well as by structure-based virtual screening aimed at identifying non-nucleotide cap-binding antagonists.	squaramide	168-179	eukaryotic translation initiation factor 4E	Homo sapiens	64-69
27592390-4	2016	We have used two approaches to design cap-binding inhibitors of eIF4E by modifying the N7-substituent of m7GMP and replacing the phosphate group with isosteres such as squaramides, sulfonamides, and tetrazoles, as well as by structure-based virtual screening aimed at identifying non-nucleotide cap-binding antagonists.	Tetrazoles	199-209	eukaryotic translation initiation factor 4E	Homo sapiens	64-69
27588477-0	2016	eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.	Cisplatin	63-72	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
27588477-3	2016	We hypothesized that eIF4E promoted ESCC tumorigenesis and facilitated the development of acquired resistance to the cisplatin-based chemotherapy.	Cisplatin	117-126	eukaryotic translation initiation factor 4E	Homo sapiens	21-26
27588477-7	2016	Overexpression of eIF4E decreased the efficacy of cisplatin-induced cell growth inhibition in ESCC cell line and xenograft model (P < 0.05).	Cisplatin	50-59	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
27588477-8	2016	eIF4E knockdown by shRNA increased cisplatin-induced cytotoxicity in ESCC cell lines, and enhanced chemosensitivity to cisplatin in xenograft tumor models.	Cisplatin	35-44	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
27588477-8	2016	eIF4E knockdown by shRNA increased cisplatin-induced cytotoxicity in ESCC cell lines, and enhanced chemosensitivity to cisplatin in xenograft tumor models.	Cisplatin	119-128	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
27588477-9	2016	Furthermore, we found that the PI3K/AKT pathway and Bcl-2/Bax ratio might be responsible for the eIF4E-induced cisplatin resistance in ESCC.	Cisplatin	111-120	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
27194579-2	2016	ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the eIF4E protein.	LY 2275796	0-11	eukaryotic translation initiation factor 4E	Homo sapiens	109-114
27418099-10	2016	EIF4E activity was inhibited by CGP57380 dose-dependently.	CGP 57380	32-40	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
27194579-2	2016	ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the eIF4E protein.	Oligonucleotides	45-60	eukaryotic translation initiation factor 4E	Homo sapiens	109-114
27194579-2	2016	ISIS 183750 is a second-generation antisense oligonucleotide (ASO) designed to inhibit the production of the eIF4E protein.	Oligonucleotides, Antisense	62-65	eukaryotic translation initiation factor 4E	Homo sapiens	109-114
27364770-5	2016	In established and patient-derived cell lines, pharmacologic MNK inhibition using LY2801653 (merestinib) inhibited phosphorylation of the eukaryotic translation initiation factor 4E, a crucial effector for MNK-induced mRNA translation in cancer cells and a marker of transformation.	merestinib	82-91	eukaryotic translation initiation factor 4E	Homo sapiens	138-181
27364770-5	2016	In established and patient-derived cell lines, pharmacologic MNK inhibition using LY2801653 (merestinib) inhibited phosphorylation of the eukaryotic translation initiation factor 4E, a crucial effector for MNK-induced mRNA translation in cancer cells and a marker of transformation.	merestinib	93-103	eukaryotic translation initiation factor 4E	Homo sapiens	138-181
27379616-3	2016	Ribavirin and Indinavir are known inhibitors of eIF4E activity.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
27379616-3	2016	Ribavirin and Indinavir are known inhibitors of eIF4E activity.	Indinavir	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
27527252-1	2016	The eukaryotic translation initiation factor (eIF) 4E, which binds to the 5"-cap of mRNA, undergoes phosphorylation on a single conserved serine, executed by the mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs).	Serine	138-144	eukaryotic translation initiation factor 4E	Homo sapiens	46-53
27520370-0	2016	Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.	Niclosamide	18-29	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
27520370-0	2016	Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.	Dasatinib	92-101	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
27520370-2	2016	Here we show that niclosamide, a FDA-approved anthelmintic drug, enhances the sensitivity of BP-CML cells to dasatinib (2nd generation of BCR-ABL TKI) through inhibiting Erk/Mnk1/eIF4E signaling pathway.	Niclosamide	18-29	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
27520370-2	2016	Here we show that niclosamide, a FDA-approved anthelmintic drug, enhances the sensitivity of BP-CML cells to dasatinib (2nd generation of BCR-ABL TKI) through inhibiting Erk/Mnk1/eIF4E signaling pathway.	Dasatinib	109-118	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
27520370-6	2016	Importantly, niclosamide inhibits phosphorylation of Erk, Mnk1 and eIF4E in CML cells.	Niclosamide	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	67-72
27520370-7	2016	Overexpression of phosphomimetic but not nonphosphorylatable form of eIF4E reverses the inhibitory effects of niclosamide, suggesting that eIF4E inhibition is required for the action of niclosamide in CML.	Niclosamide	110-121	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
27520370-7	2016	Overexpression of phosphomimetic but not nonphosphorylatable form of eIF4E reverses the inhibitory effects of niclosamide, suggesting that eIF4E inhibition is required for the action of niclosamide in CML.	Niclosamide	186-197	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
27520370-8	2016	Compared to NBM, the increased levels of eIF4E and its activity in CML CD34 cells might explain the selective toxicity of niclosamide in CML versus NBM.	Niclosamide	122-133	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
27520370-8	2016	Compared to NBM, the increased levels of eIF4E and its activity in CML CD34 cells might explain the selective toxicity of niclosamide in CML versus NBM.	4-nitrobenzylthioinosine	148-151	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
27520370-9	2016	We further show that dasatinib time-dependently induces eIF4E phosphorylation.	Dasatinib	21-30	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
27520370-10	2016	The combination of eIF4E depletion and dasatinib results in similar effects as the combination of niclosamide and dasatinib, suggesting that niclosamide enhances dasatinib through targeting eIF4E.	Niclosamide	141-152	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
27520370-10	2016	The combination of eIF4E depletion and dasatinib results in similar effects as the combination of niclosamide and dasatinib, suggesting that niclosamide enhances dasatinib through targeting eIF4E.	Niclosamide	141-152	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
26829052-3	2016	mTORC1 is critical to link protein synthesis activity to nutrient and oxygen levels, in part by controlling the 4E-BP1-eIF4E axis.	Oxygen	70-76	eukaryotic translation initiation factor 4E	Homo sapiens	119-124
27289018-2	2016	Here, we report increased MAP kinase-interacting kinase (MNK)-regulated phosphorylation of translation initiation factor 4E (eIF4E) in glioma cells upon temozolomide (TMZ) treatment and in medullary thyroid carcinoma (MTC) cells in response to targeted radionuclide therapy.	Temozolomide	153-165	eukaryotic translation initiation factor 4E	Homo sapiens	125-130
27289018-2	2016	Here, we report increased MAP kinase-interacting kinase (MNK)-regulated phosphorylation of translation initiation factor 4E (eIF4E) in glioma cells upon temozolomide (TMZ) treatment and in medullary thyroid carcinoma (MTC) cells in response to targeted radionuclide therapy.	Temozolomide	167-170	eukaryotic translation initiation factor 4E	Homo sapiens	125-130
27289018-2	2016	Here, we report increased MAP kinase-interacting kinase (MNK)-regulated phosphorylation of translation initiation factor 4E (eIF4E) in glioma cells upon temozolomide (TMZ) treatment and in medullary thyroid carcinoma (MTC) cells in response to targeted radionuclide therapy.	Radioisotopes	253-265	eukaryotic translation initiation factor 4E	Homo sapiens	125-130
27289018-7	2016	Pharmacological inhibition of overexpressed MNK1 by CGP57380 reduced eIF4E phosphorylation and induced association of inactive MNK1 with eIF4G1.	CGP 57380	52-60	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
27632912-8	2016	Similarly, apple extract-induced phosphorylation of the mTOR/p70S6K/S6RP/eIF4B/eIF4E pathway was blocked by pretreatment with PD98059, a specific ERK inhibitor.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	126-133	eukaryotic translation initiation factor 4E	Homo sapiens	79-84
27501049-10	2016	The importance of eIF4E KD to NSCLC phenotype was further corroborated with its inhibitor, ribavirin.	Ribavirin	91-100	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
27501049-12	2016	In summary, targeting eIF4E/eIF4GI reduces migration and EMT, both essential for metastasis, thereby underscoring the potential of TI targeting in NSCLC therapy, especially the already clinically employed agents (ribavirin/4EGI).	Ribavirin	213-222	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
27578149-1	2016	BACKGROUND: Eukaryotic translation initiation factor 4E (eIF4E) plays a pivotal role in the control of cap-dependent translation initiation, modulates the fate of specific mRNAs, occurs in processing bodies (PBs) and is required for formation of stress granules (SGs).	pbs	208-211	eukaryotic translation initiation factor 4E	Homo sapiens	12-55
27578149-1	2016	BACKGROUND: Eukaryotic translation initiation factor 4E (eIF4E) plays a pivotal role in the control of cap-dependent translation initiation, modulates the fate of specific mRNAs, occurs in processing bodies (PBs) and is required for formation of stress granules (SGs).	pbs	208-211	eukaryotic translation initiation factor 4E	Homo sapiens	57-62
27462781-7	2016	We found that Ara-C increased the phosphorylation of Erk1/2, p38 and eIF4E, which correlated with an enhanced level of anti-apoptotic Mcl-1 protein.	Cytarabine	14-19	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
27462781-9	2016	Taken together, our study suggests that MAPK-Mnk-eIF4E pathway plays a critical role in Ara-C-treated MV4-11 cells and targeting Mnk may be a promising therapeutic strategy for sensitizing leukemic cells to Ara-C therapy.	Cytarabine	88-93	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
27462781-9	2016	Taken together, our study suggests that MAPK-Mnk-eIF4E pathway plays a critical role in Ara-C-treated MV4-11 cells and targeting Mnk may be a promising therapeutic strategy for sensitizing leukemic cells to Ara-C therapy.	Cytarabine	207-212	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
27413184-6	2016	Our data suggest a physiological role for MNK1a-Ser(353) phosphorylation in regulation of the MNK1a kinase, which correlates with increased eIF4E phosphorylation in vitro and in vivo.	Serine	48-51	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
27431506-5	2016	We applied this method to functionalize oligonucleotides with biotin and an orthosteric inhibitor of the eukaryotic initiation factor 4E (eIF4E), an enzyme involved in mRNA recognition.	Oligonucleotides	40-56	eukaryotic translation initiation factor 4E	Homo sapiens	105-136
27431506-5	2016	We applied this method to functionalize oligonucleotides with biotin and an orthosteric inhibitor of the eukaryotic initiation factor 4E (eIF4E), an enzyme involved in mRNA recognition.	Oligonucleotides	40-56	eukaryotic translation initiation factor 4E	Homo sapiens	138-143
28090419-5	2016	The common biochemical thread for these activities is the ability of eIF4E to bind the 7-methylguanosine cap on the 5" end of mRNAs.	7-methylguanosine	87-104	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
27307295-4	2016	Our studies show that merestinib effectively blocks eIF4E phosphorylation in AML cells and suppresses primitive leukemic progenitors from AML patients in vitro and in an AML xenograft model in vivo.	merestinib	22-32	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
28881582-3	2017	Here, we investigate whether metformin-induced apoptosis in HCC is mediated by the downstream mTORC1 effectors eukaryotic initiation factor 4E and (eIF4E)-binding proteins (4E-BPs).	Metformin	29-38	eukaryotic translation initiation factor 4E	Homo sapiens	111-142
27313212-3	2016	This step is initiated by eukaryotic initiation factor 4E (eIF4E) (the m7GTP cap-binding protein), whose binding to eIF4G (a scaffolding subunit) and eIF4A (an ATP-dependent RNA helicase) leads to assembly of active eIF4F complex.	Adenosine Triphosphate	160-163	eukaryotic translation initiation factor 4E	Homo sapiens	26-57
27313212-3	2016	This step is initiated by eukaryotic initiation factor 4E (eIF4E) (the m7GTP cap-binding protein), whose binding to eIF4G (a scaffolding subunit) and eIF4A (an ATP-dependent RNA helicase) leads to assembly of active eIF4F complex.	Adenosine Triphosphate	160-163	eukaryotic translation initiation factor 4E	Homo sapiens	59-64
30258883-0	2016	The estrogen metabolite 2-methoxyestradiol regulates eukaryotic initiation factor 4E (eIF4E) and inhibits protein synthesis in MG63 osteosarcoma cells.	2-Methoxyestradiol	24-42	eukaryotic translation initiation factor 4E	Homo sapiens	53-84
27196780-5	2016	Platinum resistance is shown to be associated with activating phosphorylation of AKT and CHK1, inactivating phosphorylation of 4E-BP1, the negative regulator of eIF4E, which promotes increased cap-dependent mRNA translation and increased levels of CHK1 and BRCA1 proteins.	Platinum	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
27053525-8	2016	At this same time point, phosphorylation of eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) at Thr(37/46) was unaffected by supplementation, while that of Thr(46) alone exhibited a pattern similar to that of S6K1, being 18% higher with EAA than BCAA.	Threonine	126-129	eukaryotic translation initiation factor 4E	Homo sapiens	44-87
27245614-5	2016	Furthermore, rapamycin disrupted eIF4E function selectively in lymphocytes, which was due to the increased abundance of 4E-BP2 relative to that of 4E-BP1 in these cells and the greater sensitivity of 4E-BP2 to rapamycin.	Sirolimus	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
26945967-6	2016	Furthermore, we identified activated eIF4E, which is phosphorylated by MNK1, as a regulator of Sox2 expression after irradiation, and pharmacologic inhibition of eIF4E with CGP57380 and Ribavirin significantly weakened Sox2-mediated tumor cell repopulation.	CGP 57380	173-181	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
26945967-6	2016	Furthermore, we identified activated eIF4E, which is phosphorylated by MNK1, as a regulator of Sox2 expression after irradiation, and pharmacologic inhibition of eIF4E with CGP57380 and Ribavirin significantly weakened Sox2-mediated tumor cell repopulation.	Ribavirin	186-195	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
27105488-4	2016	We found that sorafenib downregulated AIB1 protein expression by inhibiting AIB1 mRNA translation through simultaneously blocking eIF4E and mTOR/p70S6K/RP-S6 signaling.	Sorafenib	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
27002144-2	2016	Under conditions of extreme oxygen depletion (hypoxia), human cells repress eIF4E and switch to an alternative cap-dependent translation mediated by a homolog of eIF4E, eIF4E2.	Oxygen	28-34	eukaryotic translation initiation factor 4E	Homo sapiens	76-81
27002144-2	2016	Under conditions of extreme oxygen depletion (hypoxia), human cells repress eIF4E and switch to an alternative cap-dependent translation mediated by a homolog of eIF4E, eIF4E2.	Oxygen	28-34	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
27002144-2	2016	Under conditions of extreme oxygen depletion (hypoxia), human cells repress eIF4E and switch to an alternative cap-dependent translation mediated by a homolog of eIF4E, eIF4E2.	cap	111-114	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
27002144-4	2016	This complex mediates cap-dependent translation under cell culture conditions of 1% oxygen (to mimic tumor microenvironments), whereas eIF4E mediates cap-dependent translation at 21% oxygen (ambient air).	Oxygen	183-189	eukaryotic translation initiation factor 4E	Homo sapiens	135-140
27002144-8	2016	The oxygen-dependent activities of eIF4E and eIF4E2 are elucidated by observing their polysome association and the status of mammalian target of rapamycin complex 1 (eIF4E-dependent) or hypoxia-inducible factor 2alpha expression (eIF4E2-dependent).	Oxygen	4-10	eukaryotic translation initiation factor 4E	Homo sapiens	35-40
27002144-8	2016	The oxygen-dependent activities of eIF4E and eIF4E2 are elucidated by observing their polysome association and the status of mammalian target of rapamycin complex 1 (eIF4E-dependent) or hypoxia-inducible factor 2alpha expression (eIF4E2-dependent).	Oxygen	4-10	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
27002144-9	2016	We have identified oxygen conditions where eIF4E is the dominant cap-binding protein (21% normoxia or standard cell culture conditions), where eIF4E2 is the dominant cap-binding protein (1% hypoxia or ischemic diseases and cancerous tumors), and where both cap-binding proteins act simultaneously to initiate the translation of distinct mRNAs (1-11% physioxia or during development and stem cell differentiation).	Oxygen	19-25	eukaryotic translation initiation factor 4E	Homo sapiens	43-48
27050281-0	2016	CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.	CGP 57380	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	129-134
27050281-3	2016	Rapamycin induces eIF4E phosphorylation by activating MAPK-interacting kinases (Mnks), and therefore targeting Mnk/eIF4E pathway represents a potential therapeutic strategy for the treatment of NSCLC.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
27050281-3	2016	Rapamycin induces eIF4E phosphorylation by activating MAPK-interacting kinases (Mnks), and therefore targeting Mnk/eIF4E pathway represents a potential therapeutic strategy for the treatment of NSCLC.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
27050281-5	2016	Meanwhile, inhibiting Mnk1 expression by Mnk inhibitor (CGP57380) could abrogate rapalogs (RAD001)-induced eIF4E phosphorylation and Akt activation.	CGP 57380	56-64	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
27114554-12	2016	Cap-dependent changes to the structure of eIF4E underpin this selectivity.	cap	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
27114554-4	2016	Typically, eIF4E is localized to both the nucleus and cytoplasm, where it acts in export and translation of specific methyl 7-guanosine (m(7)G)-capped mRNAs, respectively.	7-guanosine	124-135	eukaryotic translation initiation factor 4E	Homo sapiens	11-16
27114554-7	2016	During clinical responses to the m(7)G-cap competitor ribavirin, eIF4E is mainly cytoplasmic.	Ribavirin	54-63	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
27114554-13	2016	Indeed, m(7)G cap analogs or ribavirin prevents nuclear entry of eIF4E, which mirrors the trafficking phenotypes observed in patients with AML.	Ribavirin	29-38	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
30258883-0	2016	The estrogen metabolite 2-methoxyestradiol regulates eukaryotic initiation factor 4E (eIF4E) and inhibits protein synthesis in MG63 osteosarcoma cells.	2-Methoxyestradiol	24-42	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
30258883-4	2016	Our results show that 2-ME treatment increases the association of eIF4E with 4E-BP1 in osteosarcoma cells.	2-Methoxyestradiol	22-26	eukaryotic translation initiation factor 4E	Homo sapiens	66-71
30258883-5	2016	Also, 2-ME decreases the binding of eIF4E protein to 7-methyl-guanosine cap structure, indicating that 2-ME treatment results in the inhibition of translational initiation.	2-Methoxyestradiol	6-10	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
30258883-5	2016	Also, 2-ME decreases the binding of eIF4E protein to 7-methyl-guanosine cap structure, indicating that 2-ME treatment results in the inhibition of translational initiation.	7-methylguanosine	53-71	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
30258883-5	2016	Also, 2-ME decreases the binding of eIF4E protein to 7-methyl-guanosine cap structure, indicating that 2-ME treatment results in the inhibition of translational initiation.	2-Methoxyestradiol	103-107	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
26944016-7	2016	Depletion of eIF4E abolishes the inhibitory effects of rifabutin on beta-catenin activities and overexpression of beta-catenin reverses the inhibitory effects of rifabutin on cell growth and survival, further confirming that rifabutin acts on lung cancer cells via targeting eIF4E- beta-catenin axis.	Rifabutin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
26939700-6	2016	Using a tet-on-inducible eIF4E-knockdown system, eIF4E downregulation blocks multiple myeloma tumor growth in vivo, correlating with decreased eIF4E expression.	tetramethylenedisulfotetramine	8-11	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
26939700-6	2016	Using a tet-on-inducible eIF4E-knockdown system, eIF4E downregulation blocks multiple myeloma tumor growth in vivo, correlating with decreased eIF4E expression.	tetramethylenedisulfotetramine	8-11	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
26939700-6	2016	Using a tet-on-inducible eIF4E-knockdown system, eIF4E downregulation blocks multiple myeloma tumor growth in vivo, correlating with decreased eIF4E expression.	tetramethylenedisulfotetramine	8-11	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
26668315-7	2016	Analysis of proteins bound to m(7)GTP-Sepharose reveals that both CGP and eIF4G(1357-1600) decrease binding of eIF4E to eIF4G.	(7)gtp	31-37	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
27025252-3	2016	Se inhibits translation initiation by altering the cap-binding activity of eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4EBP1).	Selenious Acid	0-2	eukaryotic translation initiation factor 4E	Homo sapiens	75-118
27025252-8	2016	Selenite induces a block in translation and leads to stress granule assembly through the sequestration of eIF4E by binding hypophosphorylated 4EBP1.	Selenious Acid	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	106-111
26603836-7	2016	Indeed, eIF4E inhibition induces tumor regression in cell line and patient-derived tumorgrafts of TH-DLBCL, even in the presence of elevated Hsp90 activity.	th-dlbcl	98-106	eukaryotic translation initiation factor 4E	Homo sapiens	8-13
26882068-0	2016	Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma.	Serine	25-31	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
26668315-7	2016	Analysis of proteins bound to m(7)GTP-Sepharose reveals that both CGP and eIF4G(1357-1600) decrease binding of eIF4E to eIF4G.	Sepharose	38-47	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
26811205-5	2016	Immunoprecipitation assays using anti-eIF4E antibodies revealed that the binding affinity of eIF4E to the cap structure of mRNA in the PIC was sensitive to the number of charged aminoethylene repeats in the polyamine side chain and was strongly correlated with their translational efficiency.	aziridine	178-191	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
26811205-5	2016	Immunoprecipitation assays using anti-eIF4E antibodies revealed that the binding affinity of eIF4E to the cap structure of mRNA in the PIC was sensitive to the number of charged aminoethylene repeats in the polyamine side chain and was strongly correlated with their translational efficiency.	aziridine	178-191	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
26811205-5	2016	Immunoprecipitation assays using anti-eIF4E antibodies revealed that the binding affinity of eIF4E to the cap structure of mRNA in the PIC was sensitive to the number of charged aminoethylene repeats in the polyamine side chain and was strongly correlated with their translational efficiency.	Polyamines	207-216	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
26811205-5	2016	Immunoprecipitation assays using anti-eIF4E antibodies revealed that the binding affinity of eIF4E to the cap structure of mRNA in the PIC was sensitive to the number of charged aminoethylene repeats in the polyamine side chain and was strongly correlated with their translational efficiency.	Polyamines	207-216	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
26861281-0	2016	Isolation of Flavonoids from Deguelia duckeana and Their Effect on Cellular Viability, AMPK, eEF2, eIF2 and eIF4E.	Flavonoids	13-23	eukaryotic translation initiation factor 4E	Homo sapiens	108-113
26542945-3	2015	RESULTS: We show that FK866 induces a translational arrest in leukemia cells through inhibition of MTOR/4EBP1 signaling and of the initiation factors EIF4E and EIF2A.	N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide	22-27	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
27941351-2	2016	The small molecule 4EG-I, a potent inhibitor of translation initiation through disrupting eIF4E/eIF4G interaction, has been shown to exert anticancer effects in animal models of human cancers.	4eg-i	19-24	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
26498997-0	2015	Knockdown of eIF4E suppresses cell proliferation, invasion and enhances cisplatin cytotoxicity in human ovarian cancer cells.	Cisplatin	72-81	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
26498997-4	2015	First the activation of eIF4E protein was detected with m7-GTP cap binding assays in ovarian cancer and control cells.	7-methylguanosine triphosphate	56-62	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
26498997-8	2015	Finally, we investigated the effect of knockdown of eIF4E on the chemosensitivity of ovarian cancer cells to cisplatin in vitro.	Cisplatin	109-118	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
26498997-10	2015	The results of BrdU incorporation and FCM assay indicate that knockdown of eIF4E efficiently suppressed cell growth and induce cell cycle arrest in G1 phase and subsequent apoptosis in ovarian cancer cells.	Fosfomycin	38-41	eukaryotic translation initiation factor 4E	Homo sapiens	75-80
26498997-12	2015	We also confirmed that knockdown eIF4E could synergistically enhance the cytotoxicity effects of cisplatin to cancer cells and sensitized cisplatin-resistant C200 cells in vitro.	Cisplatin	97-106	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
26498997-12	2015	We also confirmed that knockdown eIF4E could synergistically enhance the cytotoxicity effects of cisplatin to cancer cells and sensitized cisplatin-resistant C200 cells in vitro.	Cisplatin	138-147	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
26498997-13	2015	This study demonstrates that the activation of eIF4E gene is an essential component of the malignant phenotype in ovarian cancer, and aberration of eIF4E expression is associated with proliferation, migration, invasion and chemosensitivity to cisplatin in ovarian cancer cells.	Cisplatin	243-252	eukaryotic translation initiation factor 4E	Homo sapiens	148-153
26427906-0	2015	Gating by tryptophan 73 exposes a cryptic pocket at the protein-binding interface of the oncogenic eIF4E protein.	Tryptophan	10-20	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
26427906-3	2015	We report here the presence of a cryptic pocket at the protein-binding interface of eIF4E, which opens transiently during molecular dynamics simulations of the protein in solvent water and is observed to be stable when solvent water is mixed with benzene molecules.	Water	179-184	eukaryotic translation initiation factor 4E	Homo sapiens	84-89
26427906-3	2015	We report here the presence of a cryptic pocket at the protein-binding interface of eIF4E, which opens transiently during molecular dynamics simulations of the protein in solvent water and is observed to be stable when solvent water is mixed with benzene molecules.	Water	227-232	eukaryotic translation initiation factor 4E	Homo sapiens	84-89
26427906-3	2015	We report here the presence of a cryptic pocket at the protein-binding interface of eIF4E, which opens transiently during molecular dynamics simulations of the protein in solvent water and is observed to be stable when solvent water is mixed with benzene molecules.	Benzene	247-254	eukaryotic translation initiation factor 4E	Homo sapiens	84-89
26078354-0	2015	Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.	Arginine	18-26	eukaryotic translation initiation factor 4E	Homo sapiens	119-124
26078354-11	2015	Collectively, our findings provide new evidence that PRMT5 plays an important role in CRC pathogenesis through epigenetically regulating arginine methylation of oncogenes such as eIF4E and FGFR3.	Arginine	137-145	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
26317515-0	2015	Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	40-45
26317515-0	2015	Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
26317515-2	2015	Previous studies reported that ribavirin could suppress eIF4E-controlled translation and reduce the synthesis of onco-proteins.	Ribavirin	31-40	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
26317515-5	2015	7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly.	7-methylguanosine	0-18	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
26317515-5	2015	7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly.	7-methylguanosine	0-18	eukaryotic translation initiation factor 4E	Homo sapiens	155-160
26317515-5	2015	7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly.	7-methylguanosine	0-18	eukaryotic translation initiation factor 4E	Homo sapiens	221-226
26317515-5	2015	7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly.	Ribavirin	64-73	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
26317515-5	2015	7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly.	Ribavirin	64-73	eukaryotic translation initiation factor 4E	Homo sapiens	155-160
26317515-5	2015	7-Methyl-guanosine cap affinity assay further demonstrated that ribavirin remarkably increased the eIF4E binding to 4EBP1 and decreased the combination of eIF4E with eIF4G, consequently resulting in a major inhibition of eIF4F complex assembly.	Ribavirin	64-73	eukaryotic translation initiation factor 4E	Homo sapiens	221-226
26044548-8	2015	However, MNKI-85, a first-in-class inhibitor of Mnk2, can be used as a powerful pharmacologic tool in studying the Mnk2/eIF4E-mediated tumorigenic mechanism.	4-((4-fluoro-2-isopropoxyphenyl)amino)-N-(2-methoxyethyl)-5-methylthieno(2,3-d)pyrimidine-6-carboxamide	9-16	eukaryotic translation initiation factor 4E	Homo sapiens	120-125
25982998-10	2015	More importantly, after treated with eIF4E siRNA, cellular migratory capacity on fibronectin of HT-29 and beta6-transfected SW480 as well as their survival to 5-FU was decreased distinctly.	Fluorouracil	159-163	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
26002467-7	2015	In addition, depletion of eIF4E attenuated thioacetamide (TAA)-induced liver fibrosis in vivo.	Thioacetamide	43-56	eukaryotic translation initiation factor 4E	Homo sapiens	26-31
26095252-5	2015	In particular, we demonstrate that the dose of eIF4E is essential for translating mRNAs that regulate reactive oxygen species, fueling transformation and cancer cell survival in vivo.	Reactive Oxygen Species	102-125	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
25850883-0	2015	Dehydrocostus lactone suppressed the proliferation, migration, and invasion of colorectal carcinoma through the downregulation of eIF4E expression.	Lactones	14-21	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
25850883-7	2015	The expression of eukaryotic translation initiation factor 4E (eIF4E), which was originally highly expressed in both cells, was significantly decreased by DHC.	dehydrocostus lactone	155-158	eukaryotic translation initiation factor 4E	Homo sapiens	18-61
25850883-7	2015	The expression of eukaryotic translation initiation factor 4E (eIF4E), which was originally highly expressed in both cells, was significantly decreased by DHC.	dehydrocostus lactone	155-158	eukaryotic translation initiation factor 4E	Homo sapiens	63-68
25850883-9	2015	To the best of our knowledge, this is the first time it has been shown that DHC suppressed the proliferation, cell cycle progression, antiapoptosis, and migration and invasion capabilities of CRC cells by the downregulation of eIF4E expression.	dehydrocostus lactone	76-79	eukaryotic translation initiation factor 4E	Homo sapiens	227-232
25850883-10	2015	In terms of the overexpression of eIF4E in many cancers, it was speculated that DHC might also play an anticancerous role by suppressing eIF4E expression.	dehydrocostus lactone	80-83	eukaryotic translation initiation factor 4E	Homo sapiens	34-39
25850883-10	2015	In terms of the overexpression of eIF4E in many cancers, it was speculated that DHC might also play an anticancerous role by suppressing eIF4E expression.	dehydrocostus lactone	80-83	eukaryotic translation initiation factor 4E	Homo sapiens	137-142
25915158-0	2015	Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue.	Serine	103-109	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
25915158-2	2015	Here we identify a small molecule, homoharringtonine (HHT), that antagonizes p-eIF4E function and eradicates acute myeloid leukemia (AML) expressing high level of p-eIF4E in vitro and in vivo.	Homoharringtonine	35-52	eukaryotic translation initiation factor 4E	Homo sapiens	79-84
25915158-2	2015	Here we identify a small molecule, homoharringtonine (HHT), that antagonizes p-eIF4E function and eradicates acute myeloid leukemia (AML) expressing high level of p-eIF4E in vitro and in vivo.	Homoharringtonine	35-52	eukaryotic translation initiation factor 4E	Homo sapiens	165-170
25915158-4	2015	HHT targets the phosphorylated serine 209 residue of p-eIF4E and induces p-eIF4E oligomerization, which enhances its interaction with the small ubiquitin-like protein modifier (SUMO)-conjugating enzyme UBC9, resulting in proteasome-dependent degradation of p-eIF4E via SUMO2/3-mediated SUMOylation.	Serine	31-37	eukaryotic translation initiation factor 4E	Homo sapiens	55-60
25915158-5	2015	These results suggest that the phosphorylated serine 209 residue of p-eIF4E might be a potential target for developing small molecule-based new therapies for leukemia.	Serine	46-52	eukaryotic translation initiation factor 4E	Homo sapiens	70-75
25615552-0	2015	The role of eIF4E in response and acquired resistance to vemurafenib in melanoma.	Vemurafenib	57-68	eukaryotic translation initiation factor 4E	Homo sapiens	12-17
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	236-241
25659819-4	2015	Rapamycin inhibits the phosphorylation of S6K at nano-molar concentrations in MDA-MB-231 cells; however, micro-molar concentrations of rapamycin are required to inhibit phosphorylation of 4E-BP1 - the phosphorylation of which liberates eIF4E to initiate translation.	Sirolimus	135-144	eukaryotic translation initiation factor 4E	Homo sapiens	236-241
25615552-3	2015	We hypothesized that eIF4E promotes melanoma cell proliferation and facilitates the development of acquired resistance to the BRAF inhibitor vemurafenib.	Vemurafenib	141-152	eukaryotic translation initiation factor 4E	Homo sapiens	21-26
25615552-6	2015	Moreover, in BRAF(V600E) melanoma cell lines, vemurafenib inhibits 4E-BP1 phosphorylation, thus promoting its binding to eIF4E.	Vemurafenib	46-57	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
25615552-7	2015	Cap-binding and polysome profiling analysis confirmed that vemurafenib stabilizes the eIF4E-4E-BP1 association and blocks mRNA translation, respectively.	Vemurafenib	59-70	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
25615552-8	2015	Conversely, in cells with acquired resistance to vemurafenib, there is an increased dependence on eIF4E for survival; 4E-BP1 is highly phosphorylated and thus eIF4E-4E-BP1 associations are impeded.	Vemurafenib	49-60	eukaryotic translation initiation factor 4E	Homo sapiens	98-103
25615552-8	2015	Conversely, in cells with acquired resistance to vemurafenib, there is an increased dependence on eIF4E for survival; 4E-BP1 is highly phosphorylated and thus eIF4E-4E-BP1 associations are impeded.	Vemurafenib	49-60	eukaryotic translation initiation factor 4E	Homo sapiens	159-164
25615552-9	2015	Moreover, increasing eIF4E activity by silencing 4E-BP1/2 renders vemurafenib-responsive cells more resistant to BRAF inhibition.	Vemurafenib	66-77	eukaryotic translation initiation factor 4E	Homo sapiens	21-26
25615552-10	2015	In conclusion, these data suggest that therapeutically targeting eIF4E may be a viable means of inhibiting melanoma cell proliferation and overcoming vemurafenib resistance.	Vemurafenib	150-161	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
25738706-1	2015	The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5"-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2).	Ribavirin	53-62	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
25738706-6	2015	Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	112-117
25813250-0	2015	miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression.	Docetaxel	16-25	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
25813250-8	2015	This serves as a mechanism of acquired docetaxel resistance in BC cells, possibly through direct interactions with EIF4E, therefore presenting a potential therapeutic target for the treatment of docetaxel resistant BC.	Docetaxel	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
25813250-8	2015	This serves as a mechanism of acquired docetaxel resistance in BC cells, possibly through direct interactions with EIF4E, therefore presenting a potential therapeutic target for the treatment of docetaxel resistant BC.	Docetaxel	195-204	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
25839159-2	2015	We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state.	cap	29-32	eukaryotic translation initiation factor 4E	Homo sapiens	96-101
25816092-6	2015	The compounds can also serve as reporter ligands for protein binding studies, as exemplified by studying interaction of fluorophosphate mRNA cap analogues with eukaryotic translation initiation factor (eIF4E).	fluorophosphate	120-135	eukaryotic translation initiation factor 4E	Homo sapiens	202-207
25884680-8	2015	High expression levels of eukaryotic translation initiation factor 4E (eIF4E) were observed in 5 everolimus-resistant SCLC cells and SBC5 R10 cells by Western blotting.	Everolimus	97-107	eukaryotic translation initiation factor 4E	Homo sapiens	26-69
25884680-8	2015	High expression levels of eukaryotic translation initiation factor 4E (eIF4E) were observed in 5 everolimus-resistant SCLC cells and SBC5 R10 cells by Western blotting.	Everolimus	97-107	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
25884680-10	2015	Importantly, after reduction of MYC or eIF4E by siRNAs, the SBC5 parent and two SBC5-resistant cells displayed increased sensitivity to everolimus relative to the siRNA controls.	Everolimus	136-146	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
25884680-11	2015	CONCLUSION: These findings suggest that eIF4E has been shown to be an important factor in the resistance to everolimus in SCLC cells.	Everolimus	108-118	eukaryotic translation initiation factor 4E	Homo sapiens	40-45
25884680-12	2015	Furthermore, a link between MYC and mTOR-independent eIF4E contribute to the resistance to everolimus in SCLC cells.	Everolimus	91-101	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
25535978-5	2015	The assembly of the eIF4F translation initiation complex was examined using a 7-methyl-guanosine cap affinity assay.	7-methylguanosine	78-96	eukaryotic translation initiation factor 4E	Homo sapiens	20-25
25535978-7	2015	The phosphorylation levels of eIF4E (p-eIF4E) at Ser209 influence the antileukemia roles of PP242.	PP242	92-97	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
25535978-7	2015	The phosphorylation levels of eIF4E (p-eIF4E) at Ser209 influence the antileukemia roles of PP242.	PP242	92-97	eukaryotic translation initiation factor 4E	Homo sapiens	37-44
25535978-9	2015	Surprisingly, the effects of PP242 in leukemia cells with high p-eIF4E expression, such as the acute myelomonocytic leukemia THP-1 cell line and M4-M5 primary blasts, were also weak.	PP242	29-34	eukaryotic translation initiation factor 4E	Homo sapiens	63-70
25535978-10	2015	In contrast, PP242 exerted a significant antiproliferative effect in the Ph+ acute lymphoblastic leukemia SUP-B15 cell line and the mantle cell lymphoma JEKO-1 cell line, which had intermediate p-eIF4E levels.	PP242	13-18	eukaryotic translation initiation factor 4E	Homo sapiens	194-201
25535978-11	2015	PP242 inhibited the translation of the antiapoptotic protein Mcl-1 by downregulating the Akt/mTORC1/eIF4E signaling pathway.	PP242	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	100-105
24047601-7	2015	U0126 abolished ODP consolidation and reduced both phosphorylation of eukaryotic initiation factor 4E (eIF4E) and levels of the synaptic marker PSD-95.	U 0126	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	70-101
25624349-6	2015	Accumulated ARIH1 associated with 4EHP, and in turn, this competitive inhibitor of the eukaryotic translation initiation factor 4E (eIF4E) underwent increased nondegradative ubiquitination upon DNA damage.	4ehp	34-38	eukaryotic translation initiation factor 4E	Homo sapiens	87-130
25624349-6	2015	Accumulated ARIH1 associated with 4EHP, and in turn, this competitive inhibitor of the eukaryotic translation initiation factor 4E (eIF4E) underwent increased nondegradative ubiquitination upon DNA damage.	4ehp	34-38	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
25608710-2	2015	In this article, we report that a pharmacologic inhibitor of eIF4E function, ribavirin, safely and potently suppresses breast tumor formation.	Ribavirin	77-86	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
25608710-6	2015	Our findings offer a preclinical rationale to explore broadening the clinical evaluation of ribavirin, currently being tested in patients with eIF4E-overexpressing leukemia, as a strategy to treat solid tumors such as metastatic breast cancer.	Ribavirin	92-101	eukaryotic translation initiation factor 4E	Homo sapiens	143-148
25634130-1	2015	The synthesis and in vitro and in vivo antibreast and antiprostate cancers activities of novel C-4 heteroaryl 13-cis-retinamides that modulate Mnk-eIF4E and AR signaling are discussed.	13-cis-retinamides	110-128	eukaryotic translation initiation factor 4E	Homo sapiens	147-152
24047601-7	2015	U0126 abolished ODP consolidation and reduced both phosphorylation of eukaryotic initiation factor 4E (eIF4E) and levels of the synaptic marker PSD-95.	U 0126	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	103-108
25742094-5	2015	Furthermore, pull-down assays with 7-methyl- GTP Sepharose 4B beads indicate that Ligustrazine reduces the available eIF4E for translation initiation.	7-methylguanosine triphosphate	35-48	eukaryotic translation initiation factor 4E	Homo sapiens	117-122
25422161-5	2015	eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins.	Ribavirin	123-132	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
25422161-5	2015	eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins.	Ribavirin	123-132	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
25422161-5	2015	eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins.	Ribavirin	134-137	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
25422161-5	2015	eIF4E inhibition in MM cells [bone marrow (BM), lines] by siRNA and/or the anti-viral drug and competitive eIF4E inhibitor ribavirin (RBV) deleteriously affected MM cells in a similar manner to the overexpression of tetraspanins.	Ribavirin	134-137	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
25422161-7	2015	Our results demonstrate that breach of proteostasis via eIF4E inhibition is an attractive therapeutic approach that may be relatively easily achieved by employing RBV, making this strategy readily translatable into the clinic.	Ribavirin	163-166	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
25742094-5	2015	Furthermore, pull-down assays with 7-methyl- GTP Sepharose 4B beads indicate that Ligustrazine reduces the available eIF4E for translation initiation.	Sepharose	49-61	eukaryotic translation initiation factor 4E	Homo sapiens	117-122
25742094-5	2015	Furthermore, pull-down assays with 7-methyl- GTP Sepharose 4B beads indicate that Ligustrazine reduces the available eIF4E for translation initiation.	tetramethylpyrazine	82-94	eukaryotic translation initiation factor 4E	Homo sapiens	117-122
25742094-7	2015	In addition, the transient overexpression of eIF4E or MNK1 prevents the Ligustrazine-induced inhibition of proliferation and confers significant protection against Ligustrazine-induced apoptosis.	tetramethylpyrazine	72-84	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
25742094-7	2015	In addition, the transient overexpression of eIF4E or MNK1 prevents the Ligustrazine-induced inhibition of proliferation and confers significant protection against Ligustrazine-induced apoptosis.	tetramethylpyrazine	164-176	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
25742094-8	2015	Therefore, the present study provides evidences that Ligustrazine may be a candidate for therapeutic reagent for the treatment of HRPC and certifies that Ligustrazine modulates the availability of eIF4E mainly through the mTOR and MEK/ERK signaling pathways to inhibit cap-dependent translation.	tetramethylpyrazine	53-65	eukaryotic translation initiation factor 4E	Homo sapiens	197-202
25742094-8	2015	Therefore, the present study provides evidences that Ligustrazine may be a candidate for therapeutic reagent for the treatment of HRPC and certifies that Ligustrazine modulates the availability of eIF4E mainly through the mTOR and MEK/ERK signaling pathways to inhibit cap-dependent translation.	tetramethylpyrazine	154-166	eukaryotic translation initiation factor 4E	Homo sapiens	197-202
25743822-5	2015	Three key proteins (GAPDH, HSPB1 and EIF4E) changed in pemetrexed treated A549 cells were validated by Western blotting.	Pemetrexed	55-65	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
25425688-0	2015	A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.	Ribavirin	19-28	eukaryotic translation initiation factor 4E	Homo sapiens	135-140
25425688-0	2015	A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.	Cytarabine	42-52	eukaryotic translation initiation factor 4E	Homo sapiens	135-140
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	28-37	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
25510279-7	2015	Finally, recent clinical work targeting eIF4E in acute myeloid leukemia patients with ribavirin is discussed.	Ribavirin	86-95	eukaryotic translation initiation factor 4E	Homo sapiens	40-45
25439783-7	2015	TE2 cells are sensitized to rapamycin treatment after overexpression of 4E-BP1 or knockdown of eIF4E; TE1 cells become resistant to rapamycin after knockdown of 4E-BP1 or overexpression of eIF4E.	Sirolimus	28-37	eukaryotic translation initiation factor 4E	Homo sapiens	189-194
25439783-8	2015	These data suggest that the 4E-BP1/eIF4E ratio is a determinant for the response of TE1 and TE2 cells to rapamycin treatment.	Sirolimus	105-114	eukaryotic translation initiation factor 4E	Homo sapiens	35-40
25439783-12	2015	Thus, the 4E-BP1/eIF4E ratio may represent a therapeutic index for the prediction of clinical outcome of rapamycin treatment in patients with esophageal squamous cell carcinoma.	Sirolimus	105-114	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
25514650-5	2014	When transfected into cells, eIF4e aptamers cause a dramatic loss of cell proliferation in tumor cells as seen with eIF4e knockdown with antisense oligonucleotides, shRNAs, and siRNAs, hinting at therapeutic possibilities.	Oligonucleotides	147-163	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
25514650-5	2014	When transfected into cells, eIF4e aptamers cause a dramatic loss of cell proliferation in tumor cells as seen with eIF4e knockdown with antisense oligonucleotides, shRNAs, and siRNAs, hinting at therapeutic possibilities.	Oligonucleotides	147-163	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
25477336-5	2014	This form was discovered while developing means to target a specific oncogene, the eukaryotic translation initiation factor 4E (eIF4E), with its inhibitor ribavirin.	Ribavirin	155-164	eukaryotic translation initiation factor 4E	Homo sapiens	83-126
25477336-5	2014	This form was discovered while developing means to target a specific oncogene, the eukaryotic translation initiation factor 4E (eIF4E), with its inhibitor ribavirin.	Ribavirin	155-164	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
25356869-1	2014	The eukaryotic initiation factor eIF4E is essential for cap-dependent initiation of translation in eukaryotes.	cap	56-59	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
25403230-1	2014	The phosphorylation of eIF4E1 at serine 209 by MNK1 or MNK2 has been shown to initiate oncogenic mRNA translation, a process that favours cancer development and maintenance.	Serine	33-39	eukaryotic translation initiation factor 4E	Homo sapiens	23-29
25100829-7	2014	Furthermore, by knocking down 4EBP1 in combination with the new mTOR inhibitor INK-128 treatment, we discovered that LMP2A expression activates the 4EBP1-eIF4E axis and increases the expression of MTA1 at the translational level partially independent of c-myc.	INK128	79-86	eukaryotic translation initiation factor 4E	Homo sapiens	154-159
24711125-3	2014	Mesothelioma cells were treated with 4Ei-1, a membrane permeable prodrug that when converted to the active drug, 7-benzyl guanosine monophosphate (7Bn-GMP) displaces capped mRNAs from the eIF4F complex.	SCHEMBL5367406	113-145	eukaryotic translation initiation factor 4E	Homo sapiens	188-193
25193863-3	2014	We provide evidence that mTORC1 inhibition by rapamycin results in engagement of a negative feedback regulatory loop in malignant medulloblastoma cells, involving phosphorylation of the eukaryotic translation-initiation factor eIF4E.	Sirolimus	46-55	eukaryotic translation initiation factor 4E	Homo sapiens	227-232
25197055-0	2014	Translation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma.	Dexamethasone	49-62	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
25197055-5	2014	We find that suppression of all three subunits of the eIF4F cap-binding complex synergizes with DEX in MM to induce cell death.	Dexamethasone	96-99	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
25197055-6	2014	Using a suite of small molecules that target various activities of eIF4F, we observed that cell survival and DEX resistance are attenuated upon eIF4F inhibition in MM cell lines and primary human samples.	Dexamethasone	109-112	eukaryotic translation initiation factor 4E	Homo sapiens	67-72
25197055-6	2014	Using a suite of small molecules that target various activities of eIF4F, we observed that cell survival and DEX resistance are attenuated upon eIF4F inhibition in MM cell lines and primary human samples.	Dexamethasone	109-112	eukaryotic translation initiation factor 4E	Homo sapiens	144-149
25197055-7	2014	Levels of MYC and myeloid cell leukemia 1, two known eIF4F-responsive transcripts and key survival factors in MM, were reduced upon eIF4F inhibition, and their independent suppression also synergized with DEX.	Dexamethasone	205-208	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
24894874-3	2014	Recruitment of NS5A and eIF4E to 40S ribosome was confirmed by polysome fractionation, subcellular fractionation and high-salt-wash immunoprecipitation.	Salts	122-126	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
25115391-4	2014	Here we report that 4EGI-1, an inhibitor of the interaction between translation initiation factors eIF4E1 and eIF4G1 effectively inhibits breast CSCs through selectively reducing translation persistent in breast CSCs.	4egi-1	20-26	eukaryotic translation initiation factor 4E	Homo sapiens	99-105
24711125-3	2014	Mesothelioma cells were treated with 4Ei-1, a membrane permeable prodrug that when converted to the active drug, 7-benzyl guanosine monophosphate (7Bn-GMP) displaces capped mRNAs from the eIF4F complex.	7bn-gmp	147-154	eukaryotic translation initiation factor 4E	Homo sapiens	188-193
24763507-4	2014	The effect of the 6-thioguanosine moiety on binding to the translation factor eIF4E and the efficiency of mRNA translation was determined.	6-thioguanosine	18-33	eukaryotic translation initiation factor 4E	Homo sapiens	78-83
24970821-6	2014	These effects on expression of eIF4E-dependent proteins and ribosome assembly were mimicked by 2-24 h treatment with the pan-HDACi, trichostatin A (TSA), which induced acetylation of 15 different polysome-associated proteins including RPL24.	trichostatin A	132-146	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
24970821-6	2014	These effects on expression of eIF4E-dependent proteins and ribosome assembly were mimicked by 2-24 h treatment with the pan-HDACi, trichostatin A (TSA), which induced acetylation of 15 different polysome-associated proteins including RPL24.	trichostatin A	148-151	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
24345331-7	2014	The association between Ouabain and eIF4E not only raises the hope of using cardiac glycosides for cancer therapeutics more rational, but also offers a pharmacologic means for developing novel anti-cancer HIF-1alpha antagonists.	Glycosides	84-94	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
24870236-3	2014	Therapies are under development to improve outcomes and include targeting the eukaryotic translation initiation factor (eIF4E) with its inhibitor ribavirin.	Ribavirin	146-155	eukaryotic translation initiation factor 4E	Homo sapiens	120-125
24859482-0	2014	Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells.	celastrol	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	eukaryotic translation initiation factor 4E	Homo sapiens	217-248
24859482-8	2014	Markedly, we found that suppression of HIF-1alpha accumulation by celastrol correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors, ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E (eIF4E) and extracellular signal-regulated kinase (ERK), pathways known to regulate HIF-1alpha expression at the translational level.	celastrol	66-75	eukaryotic translation initiation factor 4E	Homo sapiens	250-255
24675136-2	2014	4EGI-1, (E/Z)-2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid, is a hit compound discovered in a screening campaign of small molecule libraries as an inhibitor of translation initiation factors eIF4E and eIF4G protein-protein interaction; it inhibits translation initiation in vitro and in vivo.	4-amino-6-methyl-1,3,5-triazine-2-thiol	0-4	eukaryotic translation initiation factor 4E	Homo sapiens	230-235
24675136-2	2014	4EGI-1, (E/Z)-2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid, is a hit compound discovered in a screening campaign of small molecule libraries as an inhibitor of translation initiation factors eIF4E and eIF4G protein-protein interaction; it inhibits translation initiation in vitro and in vivo.	4EGI-1 compound	12-97	eukaryotic translation initiation factor 4E	Homo sapiens	230-235
24675136-3	2014	A series of 4EGI-1-derived thiazol-2-yl hydrazones have been designed and synthesized in order to delineate the structural latitude and improve its binding affinity to eIF4E, and increase its potency in inhibiting the eIF4E/eIF4G interaction.	4egi-1-derived thiazol-2-yl hydrazones	12-50	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
24675136-3	2014	A series of 4EGI-1-derived thiazol-2-yl hydrazones have been designed and synthesized in order to delineate the structural latitude and improve its binding affinity to eIF4E, and increase its potency in inhibiting the eIF4E/eIF4G interaction.	4egi-1-derived thiazol-2-yl hydrazones	12-50	eukaryotic translation initiation factor 4E	Homo sapiens	218-223
23624914-3	2014	Our recent study showed that both ERK and AKT signaling are required to activate eukaryotic translation initiation factor 4E (eIF4E)-initiated cap-dependent translation via convergent regulation of the translational repressor 4E-binding protein 1 (4E-BP1) for maintaining CRC transformation.	cap	143-146	eukaryotic translation initiation factor 4E	Homo sapiens	81-124
23624914-3	2014	Our recent study showed that both ERK and AKT signaling are required to activate eukaryotic translation initiation factor 4E (eIF4E)-initiated cap-dependent translation via convergent regulation of the translational repressor 4E-binding protein 1 (4E-BP1) for maintaining CRC transformation.	cap	143-146	eukaryotic translation initiation factor 4E	Homo sapiens	126-131
24363449-6	2014	RNAi-mediated knockdown of eIF4E reversed acquired resistance to AZD8055 in SW620:8055R cells; furthermore, increased expression of eIF4E was sufficient to reduce sensitivity to AZD8055 in a heterologous cell system.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	65-72	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
23325513-3	2014	The eukaryotic translation initiation factor 4G (eIF4G) plays an important role in the formation of the translation initiation complex eIF4F consisting of eIF4G, the ATP dependent RNA helicase eIF4A and the cap binding protein eIF4E.	Adenosine Triphosphate	166-169	eukaryotic translation initiation factor 4E	Homo sapiens	135-140
23325513-3	2014	The eukaryotic translation initiation factor 4G (eIF4G) plays an important role in the formation of the translation initiation complex eIF4F consisting of eIF4G, the ATP dependent RNA helicase eIF4A and the cap binding protein eIF4E.	Adenosine Triphosphate	166-169	eukaryotic translation initiation factor 4E	Homo sapiens	227-232
24458973-0	2014	3-substituted indazoles as configurationally locked 4EGI-1 mimetics and inhibitors of the eIF4E/eIF4G interaction.	3-substituted indazoles	0-23	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
24458973-5	2014	In a structure-activity relationship study directed towards probing the structural latitude of this new chemotype as an inhibitor of eIF4E/eIF4G interaction and translation initiation we identified 1 d, an indazole-based 4EGI-1 mimetic, as a new and improved lead inhibitor of eIF4E/eIF4G interaction and a promising molecular probe candidate for elucidation of the role of cap-dependent translation initiation in a host of pathophysiological states.	Indazoles	206-214	eukaryotic translation initiation factor 4E	Homo sapiens	133-138
24363449-6	2014	RNAi-mediated knockdown of eIF4E reversed acquired resistance to AZD8055 in SW620:8055R cells; furthermore, increased expression of eIF4E was sufficient to reduce sensitivity to AZD8055 in a heterologous cell system.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	178-185	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
24363449-6	2014	RNAi-mediated knockdown of eIF4E reversed acquired resistance to AZD8055 in SW620:8055R cells; furthermore, increased expression of eIF4E was sufficient to reduce sensitivity to AZD8055 in a heterologous cell system.	(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol	178-185	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
24551240-2	2014	The phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) by MAP kinase-interacting kinases (Mnk) on Ser-209 promotes cellular proliferation, survival, malignant transformation and metastasis.	Serine	118-121	eukaryotic translation initiation factor 4E	Homo sapiens	23-66
24551240-2	2014	The phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) by MAP kinase-interacting kinases (Mnk) on Ser-209 promotes cellular proliferation, survival, malignant transformation and metastasis.	Serine	118-121	eukaryotic translation initiation factor 4E	Homo sapiens	68-73
25150148-4	2014	The BH3-analogs were tested as substrates and binding partners for two major cytoplasmic cap-binding proteins, DcpS, a decapping pyrophosphatase, and eIF4E, a translation initiation factor.	BH 3	4-7	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
24504069-5	2014	The oncogenic potential of eIF4E is strictly dependent on serine209 phosphorylation by upstream MAPK-interacting kinases (Mnks).	serine209	58-67	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
24052408-0	2014	Superoxide activates mTOR-eIF4E-Bax route to induce enhanced apoptosis in leukemic cells.	Superoxides	0-10	eukaryotic translation initiation factor 4E	Homo sapiens	26-31
26097864-5	2014	We have recently reported that selective inhibition of mTORC1 by rapamycin or its analogs in medulloblastoma cells results in phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) on serine-209, an event known to be associated with induction of protein translation and cell transformation.	Sirolimus	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	145-188
26097864-5	2014	We have recently reported that selective inhibition of mTORC1 by rapamycin or its analogs in medulloblastoma cells results in phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) on serine-209, an event known to be associated with induction of protein translation and cell transformation.	Sirolimus	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
26097864-5	2014	We have recently reported that selective inhibition of mTORC1 by rapamycin or its analogs in medulloblastoma cells results in phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) on serine-209, an event known to be associated with induction of protein translation and cell transformation.	Serine	200-206	eukaryotic translation initiation factor 4E	Homo sapiens	145-188
26097864-5	2014	We have recently reported that selective inhibition of mTORC1 by rapamycin or its analogs in medulloblastoma cells results in phosphorylation of eukaryotic translation initiation factor 4E (eIF4E) on serine-209, an event known to be associated with induction of protein translation and cell transformation.	Serine	200-206	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
25150148-6	2014	Depending on its placement, the boranophosphate group weakened the interaction with DcpS but stabilized the interaction with eIF4E.	boranophosphate	32-47	eukaryotic translation initiation factor 4E	Homo sapiens	125-130
23934262-9	2013	RESULTS: Two compounds, 1,4-O-diferuloylsecoisolariciresinol (IM-1) and Pierreione B (IM-2), were identified which induced significant nuclear translocation of eIF4E in a panel of cancer cells.	1,4-O-diferuloylsecoisolariciresinol	24-60	eukaryotic translation initiation factor 4E	Homo sapiens	160-165
24260583-0	2013	Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.	Oligonucleotides	88-103	eukaryotic translation initiation factor 4E	Homo sapiens	63-68
24260583-2	2013	In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma.	Oligonucleotides	92-107	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
24260583-2	2013	In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma.	Oligonucleotides	92-107	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
24260583-2	2013	In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma.	Oligonucleotides	92-107	eukaryotic translation initiation factor 4E	Homo sapiens	67-72
24260583-2	2013	In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma.	4easo	109-114	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
24260583-2	2013	In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma.	4easo	109-114	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
24260583-2	2013	In this study, disabling the eIF4F complex by targeting eIF4E with eIF4E-specific antisense oligonucleotide (4EASO) is assessed as a therapy for mesothelioma.	4easo	109-114	eukaryotic translation initiation factor 4E	Homo sapiens	67-72
24260583-8	2013	4EASO treatment resulted in dose dependent decrease in eIF4E levels, which corresponded to cytotoxicity of mesothelioma cells.	4easo	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	55-60
24260583-9	2013	4EASO resulted in decreased levels of eIF4E in non-malignant LP9 cells, but this did not correspond to increased cytotoxicity.	4easo	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
24219888-7	2013	RESULTS: Our results demonstrate that transient inhibition of eIF4E protects against cyclophosphamide-induced alopecia at the organismal level.	Cyclophosphamide	85-101	eukaryotic translation initiation factor 4E	Homo sapiens	62-67
23934262-9	2013	RESULTS: Two compounds, 1,4-O-diferuloylsecoisolariciresinol (IM-1) and Pierreione B (IM-2), were identified which induced significant nuclear translocation of eIF4E in a panel of cancer cells.	pierreione B	72-84	eukaryotic translation initiation factor 4E	Homo sapiens	160-165
23601822-10	2013	Finally, the nucleoproteins of JUNV, TCRV and PICV were able to interact with 7 methyl-guanosine (cap), suggesting that the independence of JUNV multiplication on eIF4E, the cap-binding protein, may be due to the replacement of this factor by N protein.	7-methylguanosine	78-96	eukaryotic translation initiation factor 4E	Homo sapiens	163-168
23831578-0	2013	Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
24086504-8	2013	For instance, our results indicate that the N7-methyl group of the classical N7-methyl guanosine cap is not always indispensable for binding to eIF4E and subsequently for translation when compensatory modifications are present on the capped residue.	Guanosine	87-96	eukaryotic translation initiation factor 4E	Homo sapiens	144-149
23829765-10	2013	The bis-MTX-ASO was shown to undergo endosomal escape resulting in the knock down of eIF4E with at least the same efficiency as ASO delivered by oligofectamine.	bis-mtx-aso	4-15	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
23831578-3	2013	Rapamycin increases eIF4E phosphorylation in cancer cells, potentially limiting their anti-cancer effects.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	20-25
23831578-4	2013	Here we show that the rapamycin-induced increase in eIF4E phosphorylation reflects increased activity of Mnk2 but not Mnk1.	Sirolimus	22-31	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
23901100-8	2013	Finally, we have successfully separated the two functions of eIF4E to show that its helicase promoting activity increases the rate of translation by a mechanism that is distinct from its cap-binding function.	cap	187-190	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
23974830-0	2013	Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.	Anthracyclines	140-153	eukaryotic translation initiation factor 4E	Homo sapiens	0-43
23974830-0	2013	Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.	Anthracyclines	140-153	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
22797067-0	2013	Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.	gemcitabine	0-11	eukaryotic translation initiation factor 4E	Homo sapiens	103-108
23883783-9	2013	Erlotinib inhibits EGFR phosphorylation in EGFR-TKI resistant cells, however, results in activation of downstream signaling molecules including Akt and extracellular regulated kinase, ERK 1/2, resulting in maintenance of eukaryotic initiation factor 4F (eIF4F) activation.	Erlotinib Hydrochloride	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	221-252
23883783-9	2013	Erlotinib inhibits EGFR phosphorylation in EGFR-TKI resistant cells, however, results in activation of downstream signaling molecules including Akt and extracellular regulated kinase, ERK 1/2, resulting in maintenance of eukaryotic initiation factor 4F (eIF4F) activation.	Erlotinib Hydrochloride	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	254-259
23883783-10	2013	eIF4F cap-complex formation is maintained in erlotinib-resistant cells, but not in erlotinib-sensitive cells.	Erlotinib Hydrochloride	45-54	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
23883783-11	2013	Finally, using an antisense oligonucleotide against eukaryotic translation initiation factor 4E and a small-molecule inhibitor to disrupt eIF4F formation, we show that cap-dependent translation inhibition can enhance sensitivity to erlotinib.	Oligonucleotides	28-43	eukaryotic translation initiation factor 4E	Homo sapiens	52-95
23883783-11	2013	Finally, using an antisense oligonucleotide against eukaryotic translation initiation factor 4E and a small-molecule inhibitor to disrupt eIF4F formation, we show that cap-dependent translation inhibition can enhance sensitivity to erlotinib.	Erlotinib Hydrochloride	232-241	eukaryotic translation initiation factor 4E	Homo sapiens	52-95
23883783-11	2013	Finally, using an antisense oligonucleotide against eukaryotic translation initiation factor 4E and a small-molecule inhibitor to disrupt eIF4F formation, we show that cap-dependent translation inhibition can enhance sensitivity to erlotinib.	Erlotinib Hydrochloride	232-241	eukaryotic translation initiation factor 4E	Homo sapiens	138-143
23872707-4	2013	We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Emu-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness.	hippuristanol	20-33	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
23872707-4	2013	We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Emu-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness.	hippuristanol	20-33	eukaryotic translation initiation factor 4E	Homo sapiens	230-235
23872707-4	2013	We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Emu-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness.	hippuristanol	35-39	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
23872707-4	2013	We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Emu-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness.	hippuristanol	35-39	eukaryotic translation initiation factor 4E	Homo sapiens	230-235
23872707-4	2013	We report here that hippuristanol (Hipp), a translation initiation inhibitor that selectively inhibits the eIF4F RNA helicase subunit, eIF4A, resensitizes Emu-Myc lymphomas to DNA damaging agents, including those that overexpress eIF4E-a modifier of rapamycin responsiveness.	Sirolimus	250-259	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
23359369-0	2013	TGFbeta-induced PI 3 kinase-dependent Mnk-1 activation is necessary for Ser-209 phosphorylation of eIF4E and mesangial cell hypertrophy.	Serine	72-75	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
23359369-2	2013	TGFbeta time-dependently stimulated eIF4E phosphorylation at Ser-209 concomitant with enhanced phosphorylation of Erk1/2 (extracellular signal regulated kinase1/2) and MEK (mitogen-activated and extracellular signal-regulated kinase kinase) in mesangial cells.	Serine	61-64	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
23359369-5	2013	Pharmacological or dominant negative inhibition of phosphatidylinositol (PI) 3 kinase decreased MEK/Erk1/2 phosphorylation leading to suppression of eIF4E phosphorylation.	Phosphatidylinositols	51-71	eukaryotic translation initiation factor 4E	Homo sapiens	149-154
23359369-6	2013	Inducible phosphorylation of eIF4E at Ser-209 is mediated by Mnk-1 (mitogen-activated protein kinase signal-integrating kinase-1).	Serine	38-41	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
23359369-13	2013	Moreover, we conclude that TGFbeta-induced noncanonical signaling circuit involving PI 3 kinase-dependent Mnk-1-mediated phosphorylation of eIF4E at Ser-209 is required to facilitate mesangial cell hypertrophy.	Serine	149-152	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
23667251-0	2013	Hypoxia-inducible factor-1alpha (HIF-1alpha) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions.	cap	54-57	eukaryotic translation initiation factor 4E	Homo sapiens	139-145
23737503-4	2013	Here, we show that the MAP kinase interacting serine/threonine kinase (MNK)-eukaryotic translation initiation factor 4E (eIF4E) axis is overexpressed in BC GMPs but not normal HSCs, and that MNK kinase-dependent eIF4E phosphorylation at serine 209 activates beta-catenin signaling in BC GMPs.	Serine	46-52	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
23737503-4	2013	Here, we show that the MAP kinase interacting serine/threonine kinase (MNK)-eukaryotic translation initiation factor 4E (eIF4E) axis is overexpressed in BC GMPs but not normal HSCs, and that MNK kinase-dependent eIF4E phosphorylation at serine 209 activates beta-catenin signaling in BC GMPs.	Serine	46-52	eukaryotic translation initiation factor 4E	Homo sapiens	212-217
23376634-3	2013	This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E.	Sirolimus	58-67	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
23376634-3	2013	This was indicated by treatment with the mTORC1 inhibitor rapamycin, which suppressed both S6 kinase and 4E-BP1 phosphorylation (dephosphorylated 4E-BP1 binds and inactivates eIF4E), or by knockdown of eIF4E.	Sirolimus	58-67	eukaryotic translation initiation factor 4E	Homo sapiens	202-207
23376634-9	2013	These data indicate that the cytostatic effect of rapamycin is suppression of both S6 kinase and eIF4E, while the cytotoxic effects are due suppression of eIF4E in the absence of S6 kinase-dependent activation of TGF-beta signals.	Sirolimus	50-59	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
22797067-9	2013	Silencing of SRSF1 by RNAi abolished this splicing event and recapitulated the effects of MNK pharmacological or genetic inhibition on eIF4E phosphorylation and apoptosis in gemcitabine-treated cells.	gemcitabine	174-185	eukaryotic translation initiation factor 4E	Homo sapiens	135-140
22797067-10	2013	Our results highlight a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which leads to MNK2-dependent phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway represents an escape route utilized by PDAC cells to withstand chemotherapeutic treatments.	gemcitabine	64-75	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
22797067-10	2013	Our results highlight a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which leads to MNK2-dependent phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway represents an escape route utilized by PDAC cells to withstand chemotherapeutic treatments.	gemcitabine	64-75	eukaryotic translation initiation factor 4E	Homo sapiens	171-176
23547259-5	2013	Here, we report a novel role of the mTORC1-eukaryotic translation initiation factor 4E (eIF4E) pathway, a key regulator of cap-dependent translation initiation of oncogenic factors, in SG formation.	cap	123-126	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
23588929-0	2013	Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.	perifosine	117-127	eukaryotic translation initiation factor 4E	Homo sapiens	108-113
23588929-12	2013	Perifosine downregulated the T-eIF4E and p-eIF4E levels in a dose- and time-dependent manner; it also inhibited the growth of gastric cancer cells.	perifosine	0-10	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
23588929-12	2013	Perifosine downregulated the T-eIF4E and p-eIF4E levels in a dose- and time-dependent manner; it also inhibited the growth of gastric cancer cells.	perifosine	0-10	eukaryotic translation initiation factor 4E	Homo sapiens	43-48
23462168-4	2013	Cellular abundance of the mTORC1 components mTOR and (phosphorylated) mTOR(Ser2448) increased, as did complex eukaryotic initiation factor 4E:eukaryotic initiation factor 4E binding protein 1 (eIF4E:4EBP1), whereas no change was observed for mTORC1-downstream targets 4EBP1, 4EBP1(Ser65), p70/p85(S6K) and p70(S6K)Thre389/p85(S6K)Thre412.	thre389	314-321	eukaryotic translation initiation factor 4E	Homo sapiens	193-198
23583375-0	2013	Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.	ribavirin 5'-triphosphate	121-143	eukaryotic translation initiation factor 4E	Homo sapiens	79-84
23583375-2	2013	A potential anticancer agent, ribavirin, targets eIF4E activity in AML patients corresponding to clinical responses.	Ribavirin	30-39	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
23583375-3	2013	To date, ribavirin is the only direct inhibitor of eIF4E to reach clinical trials.	Ribavirin	9-18	eukaryotic translation initiation factor 4E	Homo sapiens	51-56
23583375-4	2013	We showed that ribavirin acts as a competitive inhibitor of the methyl 7-guanosine (m(7)G) cap, the natural ligand of eIF4E.	Ribavirin	15-24	eukaryotic translation initiation factor 4E	Homo sapiens	118-123
23583375-4	2013	We showed that ribavirin acts as a competitive inhibitor of the methyl 7-guanosine (m(7)G) cap, the natural ligand of eIF4E.	methyl 7-guanosine	64-82	eukaryotic translation initiation factor 4E	Homo sapiens	118-123
23583375-5	2013	Here we examine the conformational changes occurring in human eIF4E upon binding the active metabolite of ribavirin, ribavirin triphosphate (RTP).	Ribavirin	106-115	eukaryotic translation initiation factor 4E	Homo sapiens	62-67
23583375-5	2013	Here we examine the conformational changes occurring in human eIF4E upon binding the active metabolite of ribavirin, ribavirin triphosphate (RTP).	ribavirin 5'-triphosphate	117-139	eukaryotic translation initiation factor 4E	Homo sapiens	62-67
23583375-5	2013	Here we examine the conformational changes occurring in human eIF4E upon binding the active metabolite of ribavirin, ribavirin triphosphate (RTP).	ribavirin 5'-triphosphate	141-144	eukaryotic translation initiation factor 4E	Homo sapiens	62-67
23509154-4	2013	Treatment of AML cells with cercosporamide resulted in a dose-dependent suppression of eIF4E phosphorylation.	cercosporamide	28-42	eukaryotic translation initiation factor 4E	Homo sapiens	87-92
23509154-5	2013	Such suppression of Mnk kinase activity and eIF4E phosphorylation by cercosporamide resulted in dose-dependent suppressive effects on primitive leukemic progenitors (CFU-L) from AML patients and enhanced the antileukemic properties of cytarabine (Ara-C) or mammalian target of rapamycin (mTOR) complex 1 inhibition.	cercosporamide	69-83	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
23509154-5	2013	Such suppression of Mnk kinase activity and eIF4E phosphorylation by cercosporamide resulted in dose-dependent suppressive effects on primitive leukemic progenitors (CFU-L) from AML patients and enhanced the antileukemic properties of cytarabine (Ara-C) or mammalian target of rapamycin (mTOR) complex 1 inhibition.	Cytarabine	235-245	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
23509154-7	2013	Altogether, this work demonstrates that the unique Mnk inhibitor cercosporamide suppresses phosphorylation of eIF4E and exhibits antileukemic effects, in support of future clinical-translational efforts involving combinations of Mnk inhibitors with cytarabine and/or mTOR inhibitors for the treatment of AML.	cercosporamide	65-79	eukaryotic translation initiation factor 4E	Homo sapiens	110-115
23462168-4	2013	Cellular abundance of the mTORC1 components mTOR and (phosphorylated) mTOR(Ser2448) increased, as did complex eukaryotic initiation factor 4E:eukaryotic initiation factor 4E binding protein 1 (eIF4E:4EBP1), whereas no change was observed for mTORC1-downstream targets 4EBP1, 4EBP1(Ser65), p70/p85(S6K) and p70(S6K)Thre389/p85(S6K)Thre412.	thre412	330-337	eukaryotic translation initiation factor 4E	Homo sapiens	193-198
23471078-8	2013	Western blot experiments showed that the eukaryotic translation initiation factor eIF4E is retained in the nucleus after LMB treatment.	leptomycin B	121-124	eukaryotic translation initiation factor 4E	Homo sapiens	82-87
23471078-9	2013	Blockade of eIF4E by ribavirin or overexpression of the promyelocytic leukemia protein (PML) decreased iNOS expression due to reduced iNOS mRNA export from the nucleus.	Ribavirin	21-30	eukaryotic translation initiation factor 4E	Homo sapiens	12-17
23628019-2	2013	SYBR Green I RT-PCR was used to assay the expression level of eIF4E mRNA extracted from bone marrow mononuclear cells in 30 patients with AML (6 in M2, 5 in M3, 8 in M4, 10 in M5, 1 in M6) and 20 patients with non-malignant hematologic diseases.	sybr	0-4	eukaryotic translation initiation factor 4E	Homo sapiens	62-67
23219983-4	2013	The structure of eIF4E bound to the cap mimic 7-methyl-GDP revealed that two tryptophans from different loops in eIF4E sandwiched the 7-methylguanine group between them.	7-methylguanosine 5'-diphosphate	46-58	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
23219983-4	2013	The structure of eIF4E bound to the cap mimic 7-methyl-GDP revealed that two tryptophans from different loops in eIF4E sandwiched the 7-methylguanine group between them.	7-methylguanosine 5'-diphosphate	46-58	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
23219983-4	2013	The structure of eIF4E bound to the cap mimic 7-methyl-GDP revealed that two tryptophans from different loops in eIF4E sandwiched the 7-methylguanine group between them.	Tryptophan	77-88	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
23219983-4	2013	The structure of eIF4E bound to the cap mimic 7-methyl-GDP revealed that two tryptophans from different loops in eIF4E sandwiched the 7-methylguanine group between them.	Tryptophan	77-88	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
23219983-4	2013	The structure of eIF4E bound to the cap mimic 7-methyl-GDP revealed that two tryptophans from different loops in eIF4E sandwiched the 7-methylguanine group between them.	7-methylguanine	134-149	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
23219983-4	2013	The structure of eIF4E bound to the cap mimic 7-methyl-GDP revealed that two tryptophans from different loops in eIF4E sandwiched the 7-methylguanine group between them.	7-methylguanine	134-149	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
23840271-8	2013	In addition, butein concentration-dependently repressed the phosphorylation of Akt, mTOR, and the major downstream effectors, p70S6K, 4E-BP1, and eIF4E in EPCs.	butein	13-19	eukaryotic translation initiation factor 4E	Homo sapiens	146-151
23289910-0	2013	Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.	n-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide	49-124	eukaryotic translation initiation factor 4E	Homo sapiens	190-195
23289910-2	2013	Binding protein eIF4E to N(7)-methylated guanosine capped mRNA has been found to be the rate-limiting step governing translation initiation, and therefore represents an attractive target for drug discovery.	4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride	25-29	eukaryotic translation initiation factor 4E	Homo sapiens	16-21
23289910-3	2013	Our group has found that 7-benzyl guanosine monophosphate (7Bn-GMP) is a potent antagonist of eIF4E cap binding (K(d) = 0.8 muM).	SCHEMBL5367406	25-57	eukaryotic translation initiation factor 4E	Homo sapiens	94-99
23289910-6	2013	Recently, we have prepared a tryptamine phosphoramidate prodrug of 7Bn-GMP, 4Ei-1, and shown that it is a substrate for human histidine triad nucleotide binding protein (hHINT1) and inhibits eIF4E initiated epithelial-mesenchymal transition (EMT) by Zebra fish embryo cells.	tryptamine phosphoramidate	29-55	eukaryotic translation initiation factor 4E	Homo sapiens	191-196
23085065-3	2012	Here, we show that translation of the mRNA with the Apaf-1 5" UTR is relatively resistant to apoptosis induced by etoposide when eIF4E is sequestered by 4E-BP and eIF4G is partially cleaved.	Etoposide	114-123	eukaryotic translation initiation factor 4E	Homo sapiens	129-134
22767218-8	2012	Moreover, direct targeting of eIF4F with constitutively active 4E-BP1 is significantly more potent in collaboration with bortezomib than rapamycin.	Bortezomib	121-131	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
22968905-7	2012	Detailed protein interaction studies with immobilized anti-eIF4E and m(7) GTP-Sepharose showed a differential binding of the 4E-BP2 isoforms to the eIF4E variants and to the cap structure.	(7) gtp-sepharose	70-87	eukaryotic translation initiation factor 4E	Homo sapiens	148-153
22929805-10	2012	Moreover, the phosphorylation levels of mTOR, extracellular signal-regulated kinase (ERK), p70S6K, RP-S6, 4E-BP1, and eIF4E were significantly suppressed by sorafenib.	Sorafenib	157-166	eukaryotic translation initiation factor 4E	Homo sapiens	118-123
22985415-7	2012	Our data have important implications for the regulatory role of m(7)GDP in mRNA metabolic pathways due to its possible interactions with different cap-binding proteins, such as DcpS or eIF4E.	Guanosine Diphosphate	68-71	eukaryotic translation initiation factor 4E	Homo sapiens	185-190
22217516-5	2012	Similarly, soy peptide-induced phosphorylation of the ERK/mTOR/S6RP/eIF4E pathway was blocked in response to pretreatment with PD98059, a specific ERK inhibitor.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	127-134	eukaryotic translation initiation factor 4E	Homo sapiens	68-73
22217516-6	2012	Moreover, inhibition of TGF-beta1 through PD98059 pretreatment and a consecutive decrease in ADSC proliferation revealed that TGF-beta1 induces the phosphorylation of mTOR/S6RP/eIF4E.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	42-49	eukaryotic translation initiation factor 4E	Homo sapiens	177-182
22827930-4	2012	Treatment with LH/hCG increased the expression of downstream targets of mTORC1, ribosomal protein S6 kinase 1, and eukaryotic initiation factor 4E as well as steroidogenic enzymes.	Luteinizing Hormone	15-17	eukaryotic translation initiation factor 4E	Homo sapiens	80-146
22767218-8	2012	Moreover, direct targeting of eIF4F with constitutively active 4E-BP1 is significantly more potent in collaboration with bortezomib than rapamycin.	Sirolimus	137-146	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
22614784-0	2012	Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E.	cryptotanshinone	0-16	eukaryotic translation initiation factor 4E	Homo sapiens	147-178
22748716-7	2012	OBJECTIVE: Analyze eIF4E involvement in EVT differentiation and function.	EVT	40-43	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
22748716-14	2012	CONCLUSIONS: Our results suggest that eIF4E prevents final EVT differentiation and supports placental cell proliferation and survival.	EVT	59-62	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
23259313-1	2012	OBJECTIVE: To study the expression of eIF4E, p-eIF4E (Ser 209) and Mcl-1 gene in the pathological scars and to investigate its role and its probable mechanism in the pathogenesis of abnormal scar.	Serine	54-57	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
22556409-10	2012	Furthermore, ectopic expression of eIF-4E blunted pp242-induced ERK phosphorylation.	PP242	50-55	eukaryotic translation initiation factor 4E	Homo sapiens	35-41
22705549-7	2012	Moreover, H(2)O(2)-induced SGs are compositionally distinct from canonical SGs, and targeted knockdown of eIF4E, a protein required for canonical translation initiation, inhibits H(2)O(2)-induced SG assembly.	Hydrogen Peroxide	179-187	eukaryotic translation initiation factor 4E	Homo sapiens	106-111
22495651-0	2012	Cap-dependent translation initiation factor eIF4E: an emerging anticancer drug target.	cap	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	6-11	eukaryotic translation initiation factor 4E	Homo sapiens	70-76
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	Sirolimus	33-42	eukaryotic translation initiation factor 4E	Homo sapiens	70-76
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	180-185	eukaryotic translation initiation factor 4E	Homo sapiens	70-76
22556409-11	2012	Since pp242 was more potent than rapamycin in causing sequestering of eIF-4E, a TORC1/4E-BP1/eIF-4E-mediated mechanism of ERK activation could explain the greater effectiveness of pp242.	PP242	180-185	eukaryotic translation initiation factor 4E	Homo sapiens	93-99
22231280-5	2012	Here we show that single-agent bortezomib treatment of MCL cell lines leads to G2/M arrest and induction of apoptosis accompanied by downregulation of EIF4E and CCND1 mRNA but upregulation of p15(INK4B) and p21 mRNA.	Bortezomib	31-41	eukaryotic translation initiation factor 4E	Homo sapiens	151-156
22392810-5	2012	Targeting the cap-binding pocket of eIF4E should represent a way to inhibit all the eIF4E cellular functions.	cap	14-17	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
22392810-5	2012	Targeting the cap-binding pocket of eIF4E should represent a way to inhibit all the eIF4E cellular functions.	cap	14-17	eukaryotic translation initiation factor 4E	Homo sapiens	84-89
22678294-2	2012	The initial step of protein synthesis is the binding of the eukaryotic translation initiation factor 4E (eIF4E) to the 7-methylguanosine (m(7)-GpppG) 5" cap of messenger RNAs.	7-methylguanosine	119-136	eukaryotic translation initiation factor 4E	Homo sapiens	60-103
22678294-2	2012	The initial step of protein synthesis is the binding of the eukaryotic translation initiation factor 4E (eIF4E) to the 7-methylguanosine (m(7)-GpppG) 5" cap of messenger RNAs.	7-methylguanosine	119-136	eukaryotic translation initiation factor 4E	Homo sapiens	105-110
22678294-2	2012	The initial step of protein synthesis is the binding of the eukaryotic translation initiation factor 4E (eIF4E) to the 7-methylguanosine (m(7)-GpppG) 5" cap of messenger RNAs.	7-methyl-diguanosine triphosphate	138-148	eukaryotic translation initiation factor 4E	Homo sapiens	60-103
22678294-2	2012	The initial step of protein synthesis is the binding of the eukaryotic translation initiation factor 4E (eIF4E) to the 7-methylguanosine (m(7)-GpppG) 5" cap of messenger RNAs.	7-methyl-diguanosine triphosphate	138-148	eukaryotic translation initiation factor 4E	Homo sapiens	105-110
22678294-3	2012	Low oxygen tension (hypoxia) represses cap-mediated translation by sequestering eIF4E through mammalian target of rapamycin (mTOR)-dependent mechanisms.	Oxygen	4-10	eukaryotic translation initiation factor 4E	Homo sapiens	80-85
22678294-7	2012	We show that hypoxia stimulates the formation of a complex that includes the oxygen-regulated hypoxia-inducible factor 2alpha (HIF-2alpha), the RNA-binding protein RBM4 and the cap-binding eIF4E2, an eIF4E homologue.	Oxygen	77-83	eukaryotic translation initiation factor 4E	Homo sapiens	189-194
22397984-4	2012	Similarly, pharmacologic inhibition of eIF4E with ribavirin also enhanced tumor cell radiosensitivity.	Ribavirin	50-59	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
21618507-7	2012	Treatment of cells with fisetin caused decrease in the protein expression of PI3K (p85 and p110), inhibition of phosphorylation of Akt, mTOR, p70S6K1, eIF-4E and 4E-BP1.	fisetin	24-31	eukaryotic translation initiation factor 4E	Homo sapiens	151-168
21876152-3	2011	Using genetically defined human mammary epithelial cells, we evolved resistance to the PI3K/mammalian target of rapamycin (mTOR) inhibitor BEZ235, and by genome-wide copy number analyses, we identified MYC and eIF4E amplification within the resistant cells.	dactolisib	139-145	eukaryotic translation initiation factor 4E	Homo sapiens	210-215
22236867-0	2012	Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer.	Erlotinib Hydrochloride	137-146	eukaryotic translation initiation factor 4E	Homo sapiens	23-66
22236867-8	2012	By proteomics, we found that eIF4E levels were elevated in erlotinib-resistant cell lines compared with the sensitive parental cell line.	Erlotinib Hydrochloride	59-68	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
22236867-9	2012	In agreement, assembly of the eIF4F cap complex and several oncogenic proteins regulated by the cap-dependent translation mechanism, were also increased in erlotinib-resistant cells.	Erlotinib Hydrochloride	156-165	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
22236867-10	2012	Thus, erlotinib-resistant cells exhibit elevated eIF4E expression and cap-dependent translation.	Erlotinib Hydrochloride	6-15	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
22236867-11	2012	Inhibition of eIF4F with different means (e.g., gene knockdown) downregulated c-Met expression and partially restored cell sensitivity to erlotinib, suggesting that elevated eIF4E contributes to development of erlotinib resistance, likely through positive regulation of c-Met expression.	Erlotinib Hydrochloride	138-147	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
22236867-11	2012	Inhibition of eIF4F with different means (e.g., gene knockdown) downregulated c-Met expression and partially restored cell sensitivity to erlotinib, suggesting that elevated eIF4E contributes to development of erlotinib resistance, likely through positive regulation of c-Met expression.	Erlotinib Hydrochloride	210-219	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
22236867-11	2012	Inhibition of eIF4F with different means (e.g., gene knockdown) downregulated c-Met expression and partially restored cell sensitivity to erlotinib, suggesting that elevated eIF4E contributes to development of erlotinib resistance, likely through positive regulation of c-Met expression.	Erlotinib Hydrochloride	210-219	eukaryotic translation initiation factor 4E	Homo sapiens	174-179
22236867-12	2012	Taken together, we suggest that elevated eIF4E in NSCLC cells is associated with proliferation, invasion and acquired erlotinib resistance.	Erlotinib Hydrochloride	118-127	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
22392765-4	2012	The function of eIF4E is modulated through phosphorylation of a conserved serine (Ser209) by Mnk1 and Mnk2 downstream of ERK.	Serine	74-80	eukaryotic translation initiation factor 4E	Homo sapiens	16-21
21913890-6	2012	Molecular dynamics simulation suggested that the conserved PGVTS/T region functions as a kind of paste, adhering the root of both the eIF4E N-terminal and 4E-BP C-terminal flexible regions through a hydrophobic interaction, where valine is located at the crossing position of both flexible regions.	Valine	230-236	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
21796793-6	2012	Recently, specific targeting of the eIF4E-dependent mRNA export pathway in a phase II proof-of-principle trial with ribavirin led to impaired eIF4E-dependent mRNA export correlating with clinical responses including remissions in leukemia patients.	Ribavirin	116-125	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
21796793-6	2012	Recently, specific targeting of the eIF4E-dependent mRNA export pathway in a phase II proof-of-principle trial with ribavirin led to impaired eIF4E-dependent mRNA export correlating with clinical responses including remissions in leukemia patients.	Ribavirin	116-125	eukaryotic translation initiation factor 4E	Homo sapiens	142-147
22129918-3	2011	The role of eIF4E in oncogenic transformation and the development of a means to directly target its activity with ribavirin are discussed here.	Ribavirin	114-123	eukaryotic translation initiation factor 4E	Homo sapiens	12-17
20652449-4	2011	Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay.	Cisplatin	104-113	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
20652449-4	2011	Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay.	Doxorubicin	115-125	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
20652449-4	2011	Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay.	Paclitaxel	127-137	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
20652449-4	2011	Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay.	Docetaxel	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
20652449-4	2011	Importantly, we showed that silencing of eIF4E sensitized MDA-MB-231 cells to chemotherapeutic drugs of cisplatin, adriamycin, paclitaxel and docetaxel as assessed by MTT assay.	monooxyethylene trimethylolpropane tristearate	167-170	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
22071574-5	2011	We report here that the apoptotic effects of high-dose rapamycin treatment correlate with suppressing phosphorylation of the mTOR complex 1 substrate, eukaryotic initiation factor 4E (eIF4E) binding protein-1 (4E-BP1).	Sirolimus	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	151-182
22071574-10	2011	This study reveals that the apoptotic effect of rapamycin requires doses that completely dissociate Raptor from mTORC1 and suppress that phosphorylation of 4E-BP1 and inhibit eIF4E.	Sirolimus	48-57	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
21750861-8	2011	After treatment with CGP57380, the MAP kinase-interacting kinase (MNK) inhibitor, downregulation of p-eIF4E levels was associated with an increase of E-cadherin and beta-catenin protein expression.	CGP 57380	21-29	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
21965542-4	2011	These structures and Nuclear Magnetic Resonance (NMR) data indicate that the nematode Ascaris suum eIF4E binds the two different caps in a similar manner except for the loss of a single hydrogen bond on binding the m(2,2,7)G-cap.	Hydrogen	186-194	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
21831956-0	2011	A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.	Oligonucleotides	95-110	eukaryotic translation initiation factor 4E	Homo sapiens	78-84
21831956-0	2011	A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer.	LY 2275796	111-120	eukaryotic translation initiation factor 4E	Homo sapiens	78-84
21831956-1	2011	PURPOSE: The antisense oligonucleotide LY2275796 blocks expression of cap-binding protein eukaryotic initiation factor 4E (eIF-4E), an mRNA translation regulator upregulated in tumors.	Oligonucleotides	23-38	eukaryotic translation initiation factor 4E	Homo sapiens	123-129
21831956-1	2011	PURPOSE: The antisense oligonucleotide LY2275796 blocks expression of cap-binding protein eukaryotic initiation factor 4E (eIF-4E), an mRNA translation regulator upregulated in tumors.	LY 2275796	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	123-129
21834756-7	2011	Sorafenib inhibited p-eIF4E Ser209, p-p38 Thr180/Tyr182 and reduced survivin expression.	Sorafenib	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
21661078-1	2011	To clarify the higher eukaryotic initiation factor 4E (eIF4E) binding selectivity of 4E-binding protein 2 (4E-BP2) than of 4E-BP1, as determined by Trp fluorescence analysis, the crystal structure of the eIF4E binding region of 4E-BP2 in complex with m(7) GTP-bound human eIF4E has been determined by X-ray diffraction analysis and compared with that of 4E-BP1.	(7) gtp	252-259	eukaryotic translation initiation factor 4E	Homo sapiens	55-60
21661078-2	2011	The crystal structure revealed that the Pro47-Ser65 moiety of 4E-BP2 adopts a L-shaped conformation involving extended and alpha-helical structures and extends over the N-terminal loop and two different helix regions of eIF4E through hydrogen bonds, and electrostatic and hydrophobic interactions; these features were similarly observed for 4E-BP1.	Hydrogen	234-242	eukaryotic translation initiation factor 4E	Homo sapiens	220-225
21635931-7	2011	Levels of eIF4E phosphorylated at serine 209 (p-eIF4E-Ser209) and eIF4B phosphorylated at serine 504 (p-eIF4B-Ser504) were also examined.	Serine	34-40	eukaryotic translation initiation factor 4E	Homo sapiens	10-15
21717584-6	2011	Mammalian target of rapamycin complex 1 (mTORC1), which is negatively regulated by AMPK and plays a central role in cell growth and proliferation, was inhibited by metformin, as manifested by dephosphorylation of its downstream targets 40S ribosomal S6 kinase 1 (S6K1) (T389), the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) (T37/46) and S6 (S235/236) in C666-1 cells.	Metformin	164-173	eukaryotic translation initiation factor 4E	Homo sapiens	281-324
21455212-0	2011	Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.	Ribavirin	25-34	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
21576371-6	2011	Using small interfering RNA (siRNA), we find that knockdown of raptor relieves autophagy and the eIF4E effector pathway from rapamycin resistance.	Sirolimus	125-134	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
21645857-4	2011	To understand how this uncapped RNA is bound tightly by eIF4E, we employ SHAPE probing, phylogenetic comparisons with new PTEs discovered in panico- and carmoviruses, footprinting of the eIF4E binding site, and 3D RNA modeling using NAST, MC-Fold, and MC-Sym to predict a compact, 3D structure of the RNA.	Methylcholanthrene	239-241	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
21645857-4	2011	To understand how this uncapped RNA is bound tightly by eIF4E, we employ SHAPE probing, phylogenetic comparisons with new PTEs discovered in panico- and carmoviruses, footprinting of the eIF4E binding site, and 3D RNA modeling using NAST, MC-Fold, and MC-Sym to predict a compact, 3D structure of the RNA.	Methylcholanthrene	252-254	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
21645857-5	2011	We propose that the cap-binding pocket of eIF4E clamps around a pseudoknot, placing a highly SHAPE-reactive guanosine in the pocket in place of the normal m7GpppN cap.	Guanosine	108-117	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
21389327-9	2011	Furthermore, inhibition of the eIF4E-C/EBPbeta axis by IMiD compounds was not observed in IMiD-resistant MM cells.	imid	55-59	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
21364523-5	2011	The first inhibitors of translation, drugs designed to target eIF4E, have been trialed in hematologic malignancies, while antisense oligonucleotides against eIF4E are also due to enter clinical trials.	Oligonucleotides	132-148	eukaryotic translation initiation factor 4E	Homo sapiens	157-162
21415224-0	2011	Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
21415224-3	2011	EXPERIMENTAL DESIGN: Breast cancer cells were treated with ribavirin, an inhibitor of eIF4E, and effects on cell proliferation and on known mRNA targets of eIF4E were determined.	Ribavirin	59-68	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
21415224-3	2011	EXPERIMENTAL DESIGN: Breast cancer cells were treated with ribavirin, an inhibitor of eIF4E, and effects on cell proliferation and on known mRNA targets of eIF4E were determined.	Ribavirin	59-68	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
21415224-6	2011	RESULTS: At clinically relevant concentrations, ribavirin reduced cell proliferation and suppressed clonogenic potential, correlating with reduced mRNA export and protein expression of important eIF4E targets.	Ribavirin	48-57	eukaryotic translation initiation factor 4E	Homo sapiens	195-200
21406405-4	2011	Inhibition of MNK1 activity in GBM cells by the small molecule CGP57380 suppressed eIF4E phosphorylation, proliferation, and colony formation whereas concomitant treatment with CGP57380 and the mTOR inhibitor rapamycin accentuated growth inhibition and cell-cycle arrest.	CGP 57380	63-71	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
21233335-4	2011	eIF4E can then be phosphorylated at serine 209 by the MAPK-interacting kinases (Mnk), which also interact with eIF4G.	Serine	36-42	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
20499137-8	2011	Our data suggest that in PCNSL cells eIF4E phosphorylation plays an important role in proliferation and our results identify inhibition of the MNK1/eIF4E pathway as a potential therapeutic target in patients with PCNSL.	pcnsl	25-30	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
21149447-4	2011	Our data demonstrate that IFNgamma treatment of sensitive cells results in engagement of Mnk1, activation of its kinase domain, and downstream phosphorylation of the cap-binding protein eIF4E on Ser-209.	Serine	195-198	eukaryotic translation initiation factor 4E	Homo sapiens	186-191
20706274-6	2011	Investigation of the molecular mechanism of Roc-mediated downregulation of c-FLIP revealed that it inhibits phosphorylation of the translation initiation factor 4E (eIF4E), a key factor that controls the rate-limiting step of translation, through inhibition of the MEK-ERK-MNK1 signaling pathway.	rocaglamide	44-47	eukaryotic translation initiation factor 4E	Homo sapiens	165-170
21283665-3	2011	METHODOLOGY/PRINCIPAL FINDINGS: To study structure-function relationships between pea eIF4E and PSbMV VPg, we obtained an X-ray structure for eIF4E(S) bound to m(7)GTP.	(7)gtp	161-167	eukaryotic translation initiation factor 4E	Homo sapiens	142-147
21283665-7	2011	The data showed that essential resistance determinants in eIF4E differed for different viruses although the critical region involved (possibly in VPg-binding) was conserved and partially overlapped with the m(7)GTP-binding region.	Guanosine Triphosphate	211-214	eukaryotic translation initiation factor 4E	Homo sapiens	58-63
21094167-4	2011	A novel peptide based on the eIF4E-binding peptide eIF4G1, where the alpha-helix was stabilized by the inclusion of alpha-helix inducers as shown by CD measurements, was synthesized.	Cadmium	149-151	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
21075852-4	2011	IFNlambda-inducible phosphorylation/activation of RSK1 results in its dissociation from 4E-BP1 at the same time that 4E-BP1 dissociates from eIF4E to allow formation of eIF4F and initiation of cap-dependent translation.	ifnlambda	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
21075852-4	2011	IFNlambda-inducible phosphorylation/activation of RSK1 results in its dissociation from 4E-BP1 at the same time that 4E-BP1 dissociates from eIF4E to allow formation of eIF4F and initiation of cap-dependent translation.	ifnlambda	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	169-174
21949767-12	2011	MNK kinase mediated the eIF4E phosphorylation and inhibition or depletion of MNK markedly suppressed proliferation of the CTCL cells when combined with the rapamycin-mediated inhibition of mTORC1.	Sirolimus	156-165	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
20854261-7	2010	Steroid replacements indicated that progesterone in combination with 17beta-oestradiol induced the formation of the 23 kDa eIF4E.	Steroids	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
20854261-7	2010	Steroid replacements indicated that progesterone in combination with 17beta-oestradiol induced the formation of the 23 kDa eIF4E.	Progesterone	36-48	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
20854261-7	2010	Steroid replacements indicated that progesterone in combination with 17beta-oestradiol induced the formation of the 23 kDa eIF4E.	Estradiol	69-86	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
21799944-8	2010	The antitumor activity of CDDO-Me was associated with the inhibition of prosurvival p-Akt, NF-kappaB and mammalian target of rapamycin (mTOR) signaling proteins and the downstream targets of Akt and mTOR, such as p-Foxo3a (Akt) and p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR).	bardoxolone methyl	26-33	eukaryotic translation initiation factor 4E	Homo sapiens	242-248
20971826-6	2010	Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels.	enzastaurin	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	59-64
20971826-6	2010	Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels.	enzastaurin	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	110-115
20971826-6	2010	Accordingly, enzastaurin treatment increases the amount of eIF4E bound to 4E-BP1 and decreases association of eIF4E with eIF4G, thereby reducing eIF4F translation initiation complex levels.	enzastaurin	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	145-150
20971826-9	2010	Furthermore, eIF4E expression was increased and 4E-BP1 expression was decreased in cancer cells selected for reduced sensitivity to enzastaurin-induced apoptosis.	enzastaurin	132-143	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
20971826-10	2010	These data highlight the importance of modulating 4E-BP1 function, and eIF4F complex levels, in the direct antitumor effect of enzastaurin and suggest that 4E-BP1 function may serve as a promising determinant of enzastaurin activity.	enzastaurin	127-138	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
20686366-3	2010	MNKs phosphorylate eIF4E on serine 209, a modification that can be required for eIF4E-dependent cell transformation.	Serine	28-34	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
20736160-10	2010	Thr(69) phosphorylation alone allows binding to eIF4E, and subsequent Thr(36)/Thr(45) phosphorylation was sufficient to dissociate 4E-BP1 from eIF4E, which led to eIF4E-4G interaction.	Threonine	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
20686366-3	2010	MNKs phosphorylate eIF4E on serine 209, a modification that can be required for eIF4E-dependent cell transformation.	Serine	28-34	eukaryotic translation initiation factor 4E	Homo sapiens	80-85
20616046-4	2010	Furthermore, we reveal that LIMD1, Ajuba, and WTIP bind to Ago1/2, RCK, Dcp2, and eIF4E in vivo, that they are required for miRNA-mediated, but not siRNA-mediated gene silencing and that all three proteins bind to the mRNA 5" m(7)GTP cap-protein complex.	(7)gtp	227-233	eukaryotic translation initiation factor 4E	Homo sapiens	82-87
20629523-3	2010	In this case, ribavirin targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers including many leukemias and lymphomas.	Ribavirin	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
20629523-4	2010	Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E.	Ribavirin	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
20629523-4	2010	Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E.	Ribavirin	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
19826913-4	2010	The objective of this study was to exam the curcumin cytotoxic effect and modulation of two major rate-limiting translation initiation factors, including eIF2alpha and eIF4E protein expression levels in lung adenocarcinoma epithelial cell line A549.	Curcumin	44-52	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
19826913-9	2010	These findings suggest that curcumin could reduce cell viability through prohibiting the initiation of protein synthesis by modulating eIF2alpha and eIF4E.	Curcumin	28-36	eukaryotic translation initiation factor 4E	Homo sapiens	149-154
20664001-4	2010	Cytarabine induced phosphorylation/activation of Mnk and Mnk-mediated phosphorylation of eIF4E on Ser209, as evidenced by studies involving pharmacological inhibition of Mnk or experiments using cells with targeted disruption of Mnk1 and Mnk2 genes.	Cytarabine	0-10	eukaryotic translation initiation factor 4E	Homo sapiens	89-94
20664001-7	2010	It is noteworthy that the mammalian target of rapamycin (mTOR) inhibitor rapamycin also induced phosphorylation of eIF4E in a Mnk-dependent manner, whereas inhibition strongly enhanced its antileukemic effects.	Sirolimus	46-55	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
20927323-6	2010	Inhibition of PP2A using either okadaic acid or PP2A small interfering RNA (siRNA) increased eIF4E phosphorylation, which could be abolished by the presence of the Mnk inhibitor CGP57380 or deficiency of Mnk genes.	Okadaic Acid	32-44	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
20927323-9	2010	m(7)GTP pull-down assay detected more eIF4G and phospho-eIF4E and less 4EBP-1 in PP2A siRNA-transfected cells than in control siRNA-transfected cells, indicating an increased cap binding of eIF4F complex.	(7)gtp	1-7	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
20818934-6	2010	Ex vivo incubation of adult muscles with hydrogen peroxide mimicked the age-related decreases seen in eIF4E and 4EBP1 phosphorylation, whereas the inclusion of acetaminophen in the muscle bath attenuated this effect.	Hydrogen Peroxide	41-58	eukaryotic translation initiation factor 4E	Homo sapiens	102-117
20722422-1	2010	Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate the oncogene eIF4E on serine 209.	Serine	113-119	eukaryotic translation initiation factor 4E	Homo sapiens	104-109
20557982-0	2010	Synthesis and evaluation of quinazolinone derivatives as inhibitors of NF-kappaB, AP-1 mediated transcription and eIF-4E mediated translational activation: inhibitors of multi-pathways involve in cancer.	Quinazolinones	28-41	eukaryotic translation initiation factor 4E	Homo sapiens	114-120
20359850-5	2010	We demonstrated that transfection with PDCD4 or inhibition of JNK by SP600125 alters the expression and phosphorylation of eIF4E in the presence of H(2)O(2).	pyrazolanthrone	69-77	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	124-129
20177775-5	2010	Rapamycin and its analogues are known to inhibit mTOR pathway; however, they also show simultaneous upregulation of Akt and eIF4E survival pathways on inhibition of mTOR, rendering cells more resistant to rapamycin treatment.	Sirolimus	205-214	eukaryotic translation initiation factor 4E	Homo sapiens	124-129
20177775-6	2010	In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells.	Sirolimus	69-78	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
20177775-6	2010	In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells.	Isoflavones	84-95	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
20177775-6	2010	In this study we investigated the effect of combination treatment of rapamycin with isoflavones such as genistein and biochanin A on mTOR pathway and activation of Akt and eIF4E in human glioblastoma (U87) cells.	Genistein	104-113	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
20177775-7	2010	Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 muM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone.	Sirolimus	47-56	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
20177775-7	2010	Our results show that combination treatment of rapamycin with isoflavones, especially biochanin A at 50 muM, decreased the phosphorylation of Akt and eIF4E proteins and rendered U87 cells more sensitive to rapamycin treatment when compared to cells treated with rapamycin alone.	Isoflavones	62-73	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
20616046-5	2010	Mechanistically, we propose the Ajuba LIM proteins interact with the m(7)GTP cap structure via a specific interaction with eIF4E that prevents 4EBP1 and eIF4G interaction.	(7)gtp	70-76	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
20142804-3	2010	Here, we show that hydrogen peroxide (H(2)O(2)), a major oxidant generated when oxidative stress occurs, induced apoptosis of neuronal cells (PC12 cells and primary murine neurons), by inhibiting the mammalian target of rapamycin (mTOR)-mediated phosphorylation of ribosomal p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1).	Hydrogen Peroxide	19-36	eukaryotic translation initiation factor 4E	Homo sapiens	300-331
20142804-3	2010	Here, we show that hydrogen peroxide (H(2)O(2)), a major oxidant generated when oxidative stress occurs, induced apoptosis of neuronal cells (PC12 cells and primary murine neurons), by inhibiting the mammalian target of rapamycin (mTOR)-mediated phosphorylation of ribosomal p70 S6 kinase (S6K1) and eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1).	Hydrogen Peroxide	38-46	eukaryotic translation initiation factor 4E	Homo sapiens	300-331
20354178-5	2010	The inhibition in translation caused by sertraline is associated with decreased levels of the eukaryotic initiation factor (eIF) 4F complex, altered localization of eIF4E, and increased eIF2alpha phosphorylation.	Sertraline	40-50	eukaryotic translation initiation factor 4E	Homo sapiens	165-170
19220580-5	2009	Sorafenib-induced growth suppression and apoptosis were associated with inhibition of angiogenesis, down-regulation of phospho-platelet-derived growth factor receptor beta Tyr1021, phospho-eIF4E Ser209, phospho-c-Raf Ser259, c-Raf, Mcl-1, Bcl-2, Bcl-x and positive cell cycle regulators, up-regulation of apoptosis signalling kinase-1, p27 and p21.	Sorafenib	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	189-194
20060622-2	2010	Association of the cap-binding protein eIF4E with N(7)-methylated guanosine capped mRNA is the rate limiting step governing translation initiation; and therefore represents an attractive process for cancer drug discovery.	4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride	50-54	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
20060622-2	2010	Association of the cap-binding protein eIF4E with N(7)-methylated guanosine capped mRNA is the rate limiting step governing translation initiation; and therefore represents an attractive process for cancer drug discovery.	Guanosine	66-75	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
20060622-3	2010	Previously, replacement of the 7-Me group of the Me(7)-guanosine monophosphate with a benzyl group has been found to increase binding affinity to eIF4E.	7-me	31-35	eukaryotic translation initiation factor 4E	Homo sapiens	146-151
20060622-3	2010	Previously, replacement of the 7-Me group of the Me(7)-guanosine monophosphate with a benzyl group has been found to increase binding affinity to eIF4E.	me(7)-guanosine monophosphate	49-78	eukaryotic translation initiation factor 4E	Homo sapiens	146-151
20060622-5	2010	To explore the structure-activity relationships governing the affinity of N(7)-benzylated guanosine monophosphate (Bn(7)-GMP) for eIF4E, we virtually screened a library of 80 Bn(7)-GMP analogs utilizing CombiGlide as implemented in Schrodinger.	4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride	74-78	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
20060622-5	2010	To explore the structure-activity relationships governing the affinity of N(7)-benzylated guanosine monophosphate (Bn(7)-GMP) for eIF4E, we virtually screened a library of 80 Bn(7)-GMP analogs utilizing CombiGlide as implemented in Schrodinger.	Guanosine Monophosphate	90-113	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
20060622-5	2010	To explore the structure-activity relationships governing the affinity of N(7)-benzylated guanosine monophosphate (Bn(7)-GMP) for eIF4E, we virtually screened a library of 80 Bn(7)-GMP analogs utilizing CombiGlide as implemented in Schrodinger.	6-bromo-2-naphthyl sulfate	115-117	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
20154140-0	2010	The nematode eukaryotic translation initiation factor 4E/G complex works with a trans-spliced leader stem-loop to enable efficient translation of trimethylguanosine-capped RNAs.	trimethylguanosine	146-164	eukaryotic translation initiation factor 4E	Homo sapiens	13-56
20101233-12	2010	Forced overexpression of eIF4E induces resistance to androgen-withdrawal and paclitaxel treatment in the prostate LNCaP cells in vitro.	Paclitaxel	77-87	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
20227039-2	2010	While phosphorylation of rpS6 is dispensable for cancer formation, 4EBP-eIF4E exerts significant control over cap-dependent translation, cell growth, cancer initiation, and progression.	cap	110-113	eukaryotic translation initiation factor 4E	Homo sapiens	72-77
20227039-5	2010	The therapeutic benefit of PP242 is mediated through inhibition of mTORC1-dependent 4EBP-eIF4E hyperactivation.	PP242	27-32	eukaryotic translation initiation factor 4E	Homo sapiens	89-94
20145189-7	2010	In the immortalized, leukoplakia, and cancer cells, curcumin inhibited cap-dependent translation by suppressing the phosphorylation of 4E-BP1, eIF4G, eIF4B, and Mnk1, and also reduced the total levels of eIF4E and Mnk1.	Curcumin	52-60	eukaryotic translation initiation factor 4E	Homo sapiens	204-209
19765649-6	2010	Resveratrol inhibited high glucose-induced changes in association of eIF4E with eIF4G, phosphorylation of eIF4E, eEF2, eEF2 kinase and, p70S6 kinase, indicating that it affects important events in both initiation and elongation phases of mRNA translation.	Resveratrol	0-11	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
19765649-6	2010	Resveratrol inhibited high glucose-induced changes in association of eIF4E with eIF4G, phosphorylation of eIF4E, eEF2, eEF2 kinase and, p70S6 kinase, indicating that it affects important events in both initiation and elongation phases of mRNA translation.	Resveratrol	0-11	eukaryotic translation initiation factor 4E	Homo sapiens	106-111
19765649-6	2010	Resveratrol inhibited high glucose-induced changes in association of eIF4E with eIF4G, phosphorylation of eIF4E, eEF2, eEF2 kinase and, p70S6 kinase, indicating that it affects important events in both initiation and elongation phases of mRNA translation.	Glucose	27-34	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
19765649-6	2010	Resveratrol inhibited high glucose-induced changes in association of eIF4E with eIF4G, phosphorylation of eIF4E, eEF2, eEF2 kinase and, p70S6 kinase, indicating that it affects important events in both initiation and elongation phases of mRNA translation.	Glucose	27-34	eukaryotic translation initiation factor 4E	Homo sapiens	106-111
19934253-5	2010	Here we show that anisomycin-induced CHOP expression depends on phosphorylated eIF4E/S209 and eIF2alpha/S51.	Anisomycin	18-28	eukaryotic translation initiation factor 4E	Homo sapiens	79-84
19934253-8	2010	We also demonstrated that anisomycin-induced translation is tightly regulated by partner binding preference of eIF4E.	Anisomycin	26-36	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
19934253-9	2010	Furthermore, mutating the uORF sequence abolished the anisomycin-induced association of chop mRNA with phospho-eIF4E and polysomes, thus demonstrating the significance of this cis-regulatory element in conferring on the transcript a stress-responsive translational inducibility.	Anisomycin	54-64	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
19924990-3	2009	Biophysical studies of the association between eIF4E and various cap analogs have demonstrated that m(7)GTP binds to the protein ca.	(7)gtp	101-107	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
19924990-6	2009	To address the role of the 7-methyl group in the eIF4E/m7GpppX cap interaction, binding free energies have been computed for m(7)GTP, GTP, protonated GTP at N(7), the 7-methyldeazaguanosine 5"-triphosphate (m(7)DTP), and 7-deazaguanosine 5"-triphosphate (DTP) cap analogs.	(7)gtp	126-132	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
19850929-0	2009	The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G.	geldanamycin	20-32	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
19850929-0	2009	The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G.	geldanamycin	20-32	eukaryotic translation initiation factor 4E	Homo sapiens	71-76
19850929-6	2009	Furthermore, the amount of eIF4G that is associated with the cap via eIF4E is reduced by geldanamycin treatment.	geldanamycin	89-101	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
19858189-0	2009	Kinetic mechanism for the binding of eIF4F and tobacco Etch virus internal ribosome entry site rna: effects of eIF4B and poly(A)-binding protein.	Poly A	121-128	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
19858189-10	2009	Poly(A)-binding protein and eIF4B mainly affect the eIF4F/TEV association rate.	Poly A	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
19710013-7	2009	The structure suggests an alternate orientation of a conserved, key Glu-90 in the cap-binding pocket that may contribute to dual binding specificity and a position for mRNA bound to eIF4E consistent with biochemical data.	Glutamic Acid	68-71	eukaryotic translation initiation factor 4E	Homo sapiens	182-187
19708031-0	2009	Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.	Methotrexate	187-199	eukaryotic translation initiation factor 4E	Homo sapiens	14-45
19708031-0	2009	Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.	Cytarabine	205-215	eukaryotic translation initiation factor 4E	Homo sapiens	14-45
19641186-4	2009	Subsequent investigations revealed that rapamycin also activated eIF4E and the mTORC2 target Akt, suggesting a potential mechanism of rapamycin resistance.	Sirolimus	40-49	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
19714237-5	2009	Nevertheless, eIF4F components are indispensable for ASFV protein synthesis and virus spread, since eIF4E or eIF4G depletion in COS-7 or Vero cells strongly prevents accumulation of viral proteins and decreases virus titre.	carbonyl sulfide	128-131	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
19714237-5	2009	Nevertheless, eIF4F components are indispensable for ASFV protein synthesis and virus spread, since eIF4E or eIF4G depletion in COS-7 or Vero cells strongly prevents accumulation of viral proteins and decreases virus titre.	carbonyl sulfide	128-131	eukaryotic translation initiation factor 4E	Homo sapiens	100-105
19628077-3	2009	High eukaryotic Initiation Factor 4E (eIF4E) overexpression in tumor specimens is an independent predictor for relapse in breast cancer, perhaps secondary to tousled-like kinase 1B upregulation and subsequent doxorubicin resistance.	Doxorubicin	209-220	eukaryotic translation initiation factor 4E	Homo sapiens	5-36
19628077-3	2009	High eukaryotic Initiation Factor 4E (eIF4E) overexpression in tumor specimens is an independent predictor for relapse in breast cancer, perhaps secondary to tousled-like kinase 1B upregulation and subsequent doxorubicin resistance.	Doxorubicin	209-220	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
19433856-0	2009	Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.	Ribavirin	116-125	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
19440045-0	2009	Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site.	Glycerol	59-67	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
19440045-2	2009	One of these complexes has m(7)GTP bound in a conformation which has been observed in several eIF4E crystal structures, whilst the other complex is free of m(7)GTP and contains a unique glycerol.	(7)gtp	28-34	eukaryotic translation initiation factor 4E	Homo sapiens	94-99
19440045-2	2009	One of these complexes has m(7)GTP bound in a conformation which has been observed in several eIF4E crystal structures, whilst the other complex is free of m(7)GTP and contains a unique glycerol.	Glycerol	186-194	eukaryotic translation initiation factor 4E	Homo sapiens	94-99
19440045-7	2009	This novel conformation of eIF4E with glycerol bound is hypothesized to be an intermediate state between the apo and m(7)GTP bound forms of eIF4E.	Glycerol	38-46	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
19440045-7	2009	This novel conformation of eIF4E with glycerol bound is hypothesized to be an intermediate state between the apo and m(7)GTP bound forms of eIF4E.	Glycerol	38-46	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
19440045-7	2009	This novel conformation of eIF4E with glycerol bound is hypothesized to be an intermediate state between the apo and m(7)GTP bound forms of eIF4E.	(7)gtp	118-124	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
19440045-7	2009	This novel conformation of eIF4E with glycerol bound is hypothesized to be an intermediate state between the apo and m(7)GTP bound forms of eIF4E.	(7)gtp	118-124	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
19189297-5	2009	The antitumor activity of CDDO-Me was associated with the inhibition of p-Akt, mammalian target of rapamycin (mTOR), and nuclear factor kappa B (NF-kappaB) signaling proteins and their downstream targets such as p-Bad and p-Foxo3a (Akt); p-S6K1, p-eIF-4E and p-4E-BP1 (mTOR); and COX-2, VEGF and cyclin D1(NF-kappaB).	bardoxolone methyl	26-33	eukaryotic translation initiation factor 4E	Homo sapiens	248-254
19383915-7	2009	In these prostate cancer cells, reducing eIF4E expression with an eIF4E-specific antisense oligonucleotide currently in phase I clinical trials robustly induces apoptosis, regardless of cell cycle phase, and reduces expression of the eIF4E-regulated proteins BCL-2 and c-myc.	Oligonucleotides	91-106	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
19383915-7	2009	In these prostate cancer cells, reducing eIF4E expression with an eIF4E-specific antisense oligonucleotide currently in phase I clinical trials robustly induces apoptosis, regardless of cell cycle phase, and reduces expression of the eIF4E-regulated proteins BCL-2 and c-myc.	Oligonucleotides	91-106	eukaryotic translation initiation factor 4E	Homo sapiens	66-71
19383915-7	2009	In these prostate cancer cells, reducing eIF4E expression with an eIF4E-specific antisense oligonucleotide currently in phase I clinical trials robustly induces apoptosis, regardless of cell cycle phase, and reduces expression of the eIF4E-regulated proteins BCL-2 and c-myc.	Oligonucleotides	91-106	eukaryotic translation initiation factor 4E	Homo sapiens	66-71
19433856-2	2009	The oncogenic potential of eIF4E arises from its ability to bind the 7-methyl guanosine (m(7)G) cap on mRNAs, thereby selectively enhancing eIF4E-dependent nuclear mRNA export and translation.	7-methylguanosine	69-87	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
19433856-3	2009	We tested the clinical efficacy of targeting eIF4E in M4/M5 AML patients with a physical mimic of the m(7)G cap, ribavirin.	Ribavirin	113-122	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
19433856-5	2009	Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and reduction of eIF4E levels were associated with clinical response.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	44-49
19433856-5	2009	Ribavirin-induced relocalization of nuclear eIF4E to the cytoplasm and reduction of eIF4E levels were associated with clinical response.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	84-89
19159466-3	2009	1 describes an MC sequence region identified in Ago2 that displays similarity to the cap-binding motif in translation initiation factor 4E (eIF4E).	cap	85-88	eukaryotic translation initiation factor 4E	Homo sapiens	140-145
19122207-3	2009	Surprisingly, the effect of m(7)GTP on both the rate constants and equilibrium binding constants for the interactions of VPg differed for the four eIF4E orthologues.	7-methylguanosine triphosphate	28-35	eukaryotic translation initiation factor 4E	Homo sapiens	147-152
18327707-0	2009	Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.	Cisplatin	92-101	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
18327707-16	2009	Furthermore, we also testified that eIF4E-shRNA could synergistically enhance the cytotoxicity effects of cisplatin to MCF-7 cells both in vitro and in vivo.	Cisplatin	106-115	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
18327707-18	2009	Thus, eIF4E might play an important role in chemosensitivity to cisplatin, and survivin promoter-driven RNAi targeting eIF4E can be used as adjuvant therapy for human breast carcinomas with tumor specificity and high efficacy.	Cisplatin	64-73	eukaryotic translation initiation factor 4E	Homo sapiens	6-11
19176385-3	2009	Recently, we have shown that curcumin inhibits phosphorylation of p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), two downstream effector molecules of the mammalian target of rapamycin complex 1 (mTORC1) in numerous cancer cell lines.	Curcumin	29-37	eukaryotic translation initiation factor 4E	Homo sapiens	93-124
19159466-4	2009	In a cap-bound eIF4E structure, two important aromatic residues of the motif stack on either side of a 7-methylguanosine 5"-triphosphate (m7Gppp) base.	7-methylguanosine triphosphate	103-136	eukaryotic translation initiation factor 4E	Homo sapiens	15-20
19159466-4	2009	In a cap-bound eIF4E structure, two important aromatic residues of the motif stack on either side of a 7-methylguanosine 5"-triphosphate (m7Gppp) base.	m7gppp	138-144	eukaryotic translation initiation factor 4E	Homo sapiens	15-20
19159466-7	2009	RESULTS: A number of sequence-based and structure-based bioinformatics methods reveal the reported similarity between the Ago2 MC sequence region and the eIF4E cap-binding motif to be spurious.	Methylcholanthrene	127-129	eukaryotic translation initiation factor 4E	Homo sapiens	154-159
19134194-6	2009	In the TMAs, eIF4E levels correlated strongly with c-Myc, cyclin D1, TLK1B, VEGF, and ODC.	4,4-dimethylcholesta-8,14-dien-3-ol	7-11	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
19159466-12	2009	Mapping of the MC sequence to the mid domain structure reveals Ago2 aromatics that are incompatible with eIF4E-like mRNA cap-binding, yet display some limited local structure similarities that cause the chance sequence match to eIF4E.	Methylcholanthrene	15-17	eukaryotic translation initiation factor 4E	Homo sapiens	105-110
19159466-12	2009	Mapping of the MC sequence to the mid domain structure reveals Ago2 aromatics that are incompatible with eIF4E-like mRNA cap-binding, yet display some limited local structure similarities that cause the chance sequence match to eIF4E.	Methylcholanthrene	15-17	eukaryotic translation initiation factor 4E	Homo sapiens	228-233
20049173-4	2009	We describe several strategies that have been suggested for eIF4E targeting in the clinic: the use of a small molecule antagonist of eIF4E (ribavirin), siRNA or antisense oligonucleotide strategies, suicide gene therapy, and the use of a tissue-targeting 4EBP fusion peptide.	Ribavirin	140-149	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
20049173-4	2009	We describe several strategies that have been suggested for eIF4E targeting in the clinic: the use of a small molecule antagonist of eIF4E (ribavirin), siRNA or antisense oligonucleotide strategies, suicide gene therapy, and the use of a tissue-targeting 4EBP fusion peptide.	Oligonucleotides	171-186	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
20049173-5	2009	The first clinical trial targeting eIF4E indicates that ribavirin effectively targets eIF4E in poor prognosis leukemia patients and more importantly leads to striking clinical responses including complete and partial remissions.	Ribavirin	56-65	eukaryotic translation initiation factor 4E	Homo sapiens	35-40
20049173-5	2009	The first clinical trial targeting eIF4E indicates that ribavirin effectively targets eIF4E in poor prognosis leukemia patients and more importantly leads to striking clinical responses including complete and partial remissions.	Ribavirin	56-65	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
18639543-9	2008	Our data suggested that TCN may exhibit anticancer activity by inhibiting HIF-1alpha translation through the inhibition of eIF4E phosphorylation pathway and thus provide a novel mechanism for the anticancer activity of quassinoids.	6 alpha-tigloyloxychaparrinone	24-27	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
18809972-4	2008	In contrast, eIF4E phosphorylation is low in PC3 and LNCaP cells with mutated PTEN and constitutively active AKT/mTOR pathway, but it can be strongly induced through inhibition of mTOR activity by rapamycin or serum depletion.	Sirolimus	197-206	eukaryotic translation initiation factor 4E	Homo sapiens	13-18
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Erlotinib Hydrochloride	26-35	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Erlotinib Hydrochloride	26-35	eukaryotic translation initiation factor 4E	Homo sapiens	255-260
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Sirolimus	47-56	eukaryotic translation initiation factor 4E	Homo sapiens	255-260
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Erlotinib Hydrochloride	126-135	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
18981735-9	2008	Moreover, the presence of erlotinib suppressed rapamycin-induced phosphorylation of Akt, ERK and eIF4E as well, implying that erlotinib can suppress mTOR inhibition-induced feedback activation of several survival signaling pathways including Akt, ERK and eIF4E.	Erlotinib Hydrochloride	126-135	eukaryotic translation initiation factor 4E	Homo sapiens	255-260
18386287-4	2008	EIF4E binding to mRNA and to other initiation factors is regulated on several levels, including its phosphorylation on Ser-209, and association with its regulatory protein 4E-binding protein (4E-BP1).	Serine	119-122	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
18361417-5	2008	Rapamycin was found to prevent dissociation of 4E-BP from the initiation factor eIF4E and to suppress correlatively a burst of global protein synthesis occurring at the G2/M transition.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	80-85
18706892-0	2008	Ribavirin targets eIF4E dependent Akt survival signaling.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
18706892-4	2008	We demonstrate that a physical mimic of the m(7)G cap, ribavirin, inhibits eIF4E dependent Akt survival signaling.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	75-80
18706892-5	2008	Specifically, ribavirin impairs eIF4E mediated Akt activation via inhibiting the production of an upstream activator of Akt, NBS1.	Ribavirin	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
18706892-6	2008	Consequently, ribavirin impairs eIF4E dependent apoptotic rescue.	Ribavirin	14-23	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
18706892-8	2008	Ribavirin represents a first-in-class strategy to inhibit eIF4E dependent cancers, through competition for m(7)G cap binding.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	58-63
18706892-9	2008	Thus, ribavirin coordinately impairs eIF4E dependent pathways and thereby, potently inhibits its biological effects.	Ribavirin	6-15	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
18639543-10	2008	TCN could be a new HIF-1-targeted anticancer agent and be effective on mammalian target of rapamycin (mTOR)-targeted cancer therapy, in which mTOR inhibition increases eIF4E phosphorylation.	6 alpha-tigloyloxychaparrinone	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
18701474-6	2008	Expression of wild-type eIF4E in rapamycin-treated E6/E7/hTert/HRas(V12) and U373 cells failed to rescue colony formation, although expression of wild-type S6K1 or rapamycin-resistant S6K1 in rapamycin-treated U373 and U251 provided partial rescue.	Sirolimus	33-42	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
18644990-3	2008	Rapamycin inhibits translation initiation by decreasing the phosphorylation of 4E-BP1, increasing eIF4E/4E-BP1 interaction.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	98-103
18628479-6	2008	In addition, fluvastatin blocks the mTOR-dependent phosphorylation/deactivation of the translational repressor eukaryotic initiation factor 4E (eIF4E)-binding protein, leading to the formation of eIF4E-binding protein-eIF4E complexes that suppress initiation of cap-dependent mRNA translation.	Fluvastatin	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	111-142
18628479-6	2008	In addition, fluvastatin blocks the mTOR-dependent phosphorylation/deactivation of the translational repressor eukaryotic initiation factor 4E (eIF4E)-binding protein, leading to the formation of eIF4E-binding protein-eIF4E complexes that suppress initiation of cap-dependent mRNA translation.	Fluvastatin	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	144-149
18628479-6	2008	In addition, fluvastatin blocks the mTOR-dependent phosphorylation/deactivation of the translational repressor eukaryotic initiation factor 4E (eIF4E)-binding protein, leading to the formation of eIF4E-binding protein-eIF4E complexes that suppress initiation of cap-dependent mRNA translation.	Fluvastatin	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	196-201
18628479-6	2008	In addition, fluvastatin blocks the mTOR-dependent phosphorylation/deactivation of the translational repressor eukaryotic initiation factor 4E (eIF4E)-binding protein, leading to the formation of eIF4E-binding protein-eIF4E complexes that suppress initiation of cap-dependent mRNA translation.	Fluvastatin	13-24	eukaryotic translation initiation factor 4E	Homo sapiens	196-201
18625073-8	2008	During the 8 hour period following NAC, loratadine and the CBP both reduced NSS compared with placebo (P = 0.034 and P = 0.029, respectively).	nac	35-38	eukaryotic translation initiation factor 4E	Homo sapiens	59-62
18625073-9	2008	Analysis of nasal lavage fluid demonstrated that the CBP prevented the increase in prostaglandin D2 release following NAC, while neither loratadine nor placebo had this effect.	Prostaglandin D2	83-99	eukaryotic translation initiation factor 4E	Homo sapiens	53-56
18625073-9	2008	Analysis of nasal lavage fluid demonstrated that the CBP prevented the increase in prostaglandin D2 release following NAC, while neither loratadine nor placebo had this effect.	nac	118-121	eukaryotic translation initiation factor 4E	Homo sapiens	53-56
18625073-11	2008	CONCLUSION: The CBP significantly reduced NSS during the 8 hours following NAC and marginally inhibited the release of prostaglandin D2 into nasal lavage fluid, suggesting potential clinical utility in patients with allergic rhinitis.	nac	75-78	eukaryotic translation initiation factor 4E	Homo sapiens	16-19
18625073-11	2008	CONCLUSION: The CBP significantly reduced NSS during the 8 hours following NAC and marginally inhibited the release of prostaglandin D2 into nasal lavage fluid, suggesting potential clinical utility in patients with allergic rhinitis.	Prostaglandin D2	119-135	eukaryotic translation initiation factor 4E	Homo sapiens	16-19
18644990-8	2008	eIF4E knockdown inhibited the growth of cells with varying total and phosphorylated 4E-BP1 levels and inhibited rapamycin-insensitive as well as rapamycin-sensitive cell lines.	Sirolimus	112-121	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
18644990-8	2008	eIF4E knockdown inhibited the growth of cells with varying total and phosphorylated 4E-BP1 levels and inhibited rapamycin-insensitive as well as rapamycin-sensitive cell lines.	Sirolimus	145-154	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
18081851-3	2008	In this study, we demonstrate that in cultured normal human keratinocytes Mnk1 and its downstream target eukaryotic initiation factor 4E (eIF4E) are phosphorylated in a time-dependent manner in response to stimulation with anisomycin or interleukin (IL)-1beta.	Anisomycin	223-233	eukaryotic translation initiation factor 4E	Homo sapiens	105-136
18460902-3	2008	A speculative extension of the above finding is that the cap contributes to encapsidation via its interaction with the poly(A) tail, possibly involving eIF4E-eIF4G-PABP interaction.	Poly A	119-126	eukaryotic translation initiation factor 4E	Homo sapiens	152-157
18081851-3	2008	In this study, we demonstrate that in cultured normal human keratinocytes Mnk1 and its downstream target eukaryotic initiation factor 4E (eIF4E) are phosphorylated in a time-dependent manner in response to stimulation with anisomycin or interleukin (IL)-1beta.	Anisomycin	223-233	eukaryotic translation initiation factor 4E	Homo sapiens	138-143
18081851-5	2008	Furthermore, we show that the Mnk inhibitor CGP57380 is capable of inhibiting the phosphorylation of eIF4E in keratinocytes, and that the abolishment of eIF4E phosphorylation dramatically decreases the anisomycin-induced protein release of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), IL-1beta and IL-6 as well as the IL-1beta-induced protein release of TNF-alpha.	CGP 57380	44-52	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
18081851-5	2008	Furthermore, we show that the Mnk inhibitor CGP57380 is capable of inhibiting the phosphorylation of eIF4E in keratinocytes, and that the abolishment of eIF4E phosphorylation dramatically decreases the anisomycin-induced protein release of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha), IL-1beta and IL-6 as well as the IL-1beta-induced protein release of TNF-alpha.	Anisomycin	202-212	eukaryotic translation initiation factor 4E	Homo sapiens	153-158
18430890-0	2008	Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS.	Parathion	62-78	eukaryotic translation initiation factor 4E	Homo sapiens	114-119
18430890-7	2008	We found that phosphorothioate modifications generally stabilized the complex between eIF4E and the cap analog.	Parathion	14-30	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
18343217-4	2008	Here, we show that overexpression of eIF4E-T preferentially inhibits cap-dependent steady-state translation, but not the pioneer round of translation.	cap	69-72	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
18377870-6	2008	Expression of a constitutively active form of the mTOR target ribosomal protein S6 kinase (S6K) or of translation factor eIF4E reduced apoptosis by glucose limitation, and co-expression of S6K and eIF4E protected beta cells to the same extent as active Akt.	Glucose	148-155	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
18215131-7	2008	Treatments with NMDA or NO promoted calpain-dependent eIF4G cleavage and 4E-BP1 (eIF4E-binding protein 1) dephosphorylation and also abolished the formation of eIF4E-eIF4G complexes; however, they did not induce eIF2alpha phosphorylation.	N-Methylaspartate	16-20	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
18215131-9	2008	NOS inhibitors also prevented NMDA-induced eIF4G degradation, 4E-BP1 dephosphorylation, decreased eIF4E-eIF4G-binding and cell death.	N-Methylaspartate	30-34	eukaryotic translation initiation factor 4E	Homo sapiens	98-103
18220364-4	2008	We have investigated conformational changes of eIF4E induced by interaction with two cap analogues, 7-methyl-GTP and N (2), N (2),7-trimethyl-GTP.	7-methylguanosine triphosphate	100-112	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
18367715-2	2008	eIF4F is a heterotrimeric complex composed of three subunits: eIF4E, a 7-methyl guanosine cap binding protein; eIF4A, a DEAD-box RNA helicase; and eIF4G.	Guanosine	80-89	eukaryotic translation initiation factor 4E	Homo sapiens	62-67
18367715-4	2008	These studies have led to a model whereby eIF4E interacts with the 7-methyl guanosine cap structure in an ATP-independent manner, followed by an ATP-dependent interaction of eIF4A and eIF4B.	7-methylguanosine	67-85	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
18367715-4	2008	These studies have led to a model whereby eIF4E interacts with the 7-methyl guanosine cap structure in an ATP-independent manner, followed by an ATP-dependent interaction of eIF4A and eIF4B.	Adenosine Triphosphate	106-109	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
18367715-4	2008	These studies have led to a model whereby eIF4E interacts with the 7-methyl guanosine cap structure in an ATP-independent manner, followed by an ATP-dependent interaction of eIF4A and eIF4B.	Adenosine Triphosphate	145-148	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
18280804-3	2008	We now demonstrate that treatment of acute promyelocytic leukemia (APL)-derived NB4 cells with ATRA results in dissociation of the translational repressor 4E-BP1 from the eukaryotic initiation factor eIF4E, and subsequent formation of eIF4G-eIF4E complexes.	Tretinoin	95-99	eukaryotic translation initiation factor 4E	Homo sapiens	200-205
18280804-3	2008	We now demonstrate that treatment of acute promyelocytic leukemia (APL)-derived NB4 cells with ATRA results in dissociation of the translational repressor 4E-BP1 from the eukaryotic initiation factor eIF4E, and subsequent formation of eIF4G-eIF4E complexes.	Tretinoin	95-99	eukaryotic translation initiation factor 4E	Homo sapiens	241-246
18220364-4	2008	We have investigated conformational changes of eIF4E induced by interaction with two cap analogues, 7-methyl-GTP and N (2), N (2),7-trimethyl-GTP.	n (2), n (2),7-trimethyl-gtp	117-145	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
18220364-7	2008	Formation of the complex with 7-methyl-GTP makes the eIF4E structure more compact, while binding of N (2), N (2),7-trimethyl-GTP leads to higher solvent accessibility of the protein backbone in comparison with the apo form.	7-methylguanosine triphosphate	30-42	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
18220364-7	2008	Formation of the complex with 7-methyl-GTP makes the eIF4E structure more compact, while binding of N (2), N (2),7-trimethyl-GTP leads to higher solvent accessibility of the protein backbone in comparison with the apo form.	Nitrogen	100-105	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
18164262-4	2008	Our results show that etoposide treatment caused a rapid increase in eIF-4E phosphorylation.	Etoposide	22-31	eukaryotic translation initiation factor 4E	Homo sapiens	69-75
18164262-5	2008	The addition of CGP57380, a specific inhibitor of the eIF-4E kinase Mnk, not only inhibited eIF-4E phosphorylation but also resulted in reduced interaction between eIF-4E and eIF-4G.	CGP 57380	16-24	eukaryotic translation initiation factor 4E	Homo sapiens	54-60
18164262-5	2008	The addition of CGP57380, a specific inhibitor of the eIF-4E kinase Mnk, not only inhibited eIF-4E phosphorylation but also resulted in reduced interaction between eIF-4E and eIF-4G.	CGP 57380	16-24	eukaryotic translation initiation factor 4E	Homo sapiens	92-98
18164262-5	2008	The addition of CGP57380, a specific inhibitor of the eIF-4E kinase Mnk, not only inhibited eIF-4E phosphorylation but also resulted in reduced interaction between eIF-4E and eIF-4G.	CGP 57380	16-24	eukaryotic translation initiation factor 4E	Homo sapiens	92-98
18164262-7	2008	However, a JNK-specific inhibitor, SP600125, strongly suppressed etoposide-induced eIF-4E phosphorylation.	pyrazolanthrone	35-43	eukaryotic translation initiation factor 4E	Homo sapiens	83-89
18164262-7	2008	However, a JNK-specific inhibitor, SP600125, strongly suppressed etoposide-induced eIF-4E phosphorylation.	Etoposide	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	83-89
17971516-9	2008	PD-98059 pretreatment abolished TNF-alpha-induced phosphorylation of ERK1/2 and eIF4E, whereas PS was only partially inhibited.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	80-85
19111193-4	2008	PBs also contain mRNA and eIF4E but lack other preinitiation factors and contain instead a number of proteins associated with mRNA decay such as DCP1a, DCP2, hedls/GE-1, p54/RCK.	pbs	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	26-31
17601486-0	2007	Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells.	perillyl alcohol	0-16	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
18082048-1	2007	OBJECTIVE: This study examined the effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), on eukaryotic initiation factor (eIF- 4E) expression in rat myocardial fibroblasts infected by Coxsackievirus B3 (CVB3) in order to identify the drug target for treatment of viral myocarditis.	Sirolimus	45-54	eukaryotic translation initiation factor 4E	Homo sapiens	143-150
17671235-6	2007	Moreover, CDDO increases the ratio of transcriptionally active p42 and the inactive p30 CEBPA isoform, which, in turn, leads to transcriptional activation of CEBPA-regulated genes (eg, GSCFR) and is associated with dephosphorylation of eIF2alpha and phosphorylation of eIF4E.	2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid	10-14	eukaryotic translation initiation factor 4E	Homo sapiens	269-274
17707924-4	2007	Preincubation with glutathione also prevented 4E-BP1, eIF4E and Mnk-1 phosphorylation induced by leucine, as well as enhancement of procollagen alpha1(I) protein levels.	Glutathione	19-30	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
17707924-4	2007	Preincubation with glutathione also prevented 4E-BP1, eIF4E and Mnk-1 phosphorylation induced by leucine, as well as enhancement of procollagen alpha1(I) protein levels.	Leucine	97-104	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
17556672-0	2007	Steroid and oxygen effects on eIF4F complex, mTOR, and ENaC translation in fetal lung epithelia.	Steroids	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
17556672-0	2007	Steroid and oxygen effects on eIF4F complex, mTOR, and ENaC translation in fetal lung epithelia.	Oxygen	12-18	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
17556672-4	2007	We now show, by Western blotting and m(7)GTP-Sepharose pull-down experiments, that in FDLE cultured under 3% O(2), DEX decreases formation of eIF4F and increases association of eIF4E with its inhibitor 4E-BP by changing 4E-BP phosphorylation.	Dexamethasone	115-118	eukaryotic translation initiation factor 4E	Homo sapiens	142-147
17556672-4	2007	We now show, by Western blotting and m(7)GTP-Sepharose pull-down experiments, that in FDLE cultured under 3% O(2), DEX decreases formation of eIF4F and increases association of eIF4E with its inhibitor 4E-BP by changing 4E-BP phosphorylation.	Dexamethasone	115-118	eukaryotic translation initiation factor 4E	Homo sapiens	177-182
17556672-5	2007	Conversely, FDLE cultured at 21% O(2) expressed lower levels of 4E-BP and maintained eIF4E-eIF4G association independent of DEX.	Oxygen	33-37	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
17606765-7	2007	Taken together, SAHA caused a rapid decrease of cyclin D1 in MCL by blocking the translation of cyclin D1 by inhibiting the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR/eIF4E-BP pathway, probably by PI3K inhibition.	Vorinostat	16-20	eukaryotic translation initiation factor 4E	Homo sapiens	170-175
17909059-9	2007	Sorafenib also down-regulated cFLIP(L), most likely through a translational mechanism, in association with diminished eIF4E phosphorylation, whereas ectopic expression of cFLIP(L) significantly reduced sorafenib/TRAIL lethality.	Sorafenib	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	118-123
17601486-0	2007	Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells.	Genistein	21-30	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
17601486-9	2007	Importantly, perillyl alcohol disrupted interactions between eIF4E and eIF4G, key components of eIF4F (m(7)GpppX) cap binding complex.	perillyl alcohol	13-29	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
17786234-3	2007	In this issue of the JCI, Graff and colleagues describe potent antitumor effects using second-generation antisense oligonucleotides for eIF4E (see the related article beginning on page 2638).	Oligonucleotides	115-131	eukaryotic translation initiation factor 4E	Homo sapiens	136-141
17786246-4	2007	Herein we report development of eIF4E-specific antisense oligonucleotides (ASOs) designed to have the necessary tissue stability and nuclease resistance required for systemic anticancer therapy.	Oligonucleotides	57-73	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
17786246-4	2007	Herein we report development of eIF4E-specific antisense oligonucleotides (ASOs) designed to have the necessary tissue stability and nuclease resistance required for systemic anticancer therapy.	Oligonucleotides, Antisense	75-79	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
17786246-6	2007	Most importantly, intravenous ASO administration selectively and significantly reduced eIF4E expression in human tumor xenografts, significantly suppressing tumor growth.	Oligonucleotides, Antisense	30-33	eukaryotic translation initiation factor 4E	Homo sapiens	87-92
17786246-9	2007	These data have prompted eIF4E-specific ASO clinical trials for the treatment of human cancers.	Oligonucleotides, Antisense	40-43	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
17823871-5	2007	Immunoblots showed that matrine inhibited the activity of eIF4E through dephosphorylation of 4E-BP1 in a dose- and time-dependent manner.	matrine	24-31	eukaryotic translation initiation factor 4E	Homo sapiens	58-63
17823871-8	2007	These findings suggested that matrine inhibits the activity of eIF4E by dephosphorylating 4E-BP1, which partly counts for the growth inhibition in gastric MKN45 cells.	matrine	30-37	eukaryotic translation initiation factor 4E	Homo sapiens	63-68
17524464-3	2007	Here we identify a motif (MC) within the Mid domain of Ago proteins, which bears significant similarity to the m(7)G cap-binding domain of eIF4E, an essential translation initiation factor.	Methylcholanthrene	26-28	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
17638893-1	2007	Pathologic redirection of translational control by constitutive activation of eukaryotic translation initiation factor 4F (eIF4F), the cap-dependent translation initiation apparatus, is an obligatory step in oncogenesis; however, its mechanism remains undefined.	cap	135-138	eukaryotic translation initiation factor 4E	Homo sapiens	78-121
17638893-1	2007	Pathologic redirection of translational control by constitutive activation of eukaryotic translation initiation factor 4F (eIF4F), the cap-dependent translation initiation apparatus, is an obligatory step in oncogenesis; however, its mechanism remains undefined.	cap	135-138	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
17584618-1	2007	Central to cap-dependent eukaryotic translation initiation is the eIF4F complex, which is composed of the three eukaryotic initiation factors eIF4E, eIF4G, and eIF4A.	cap	11-14	eukaryotic translation initiation factor 4E	Homo sapiens	142-147
17802829-2	2007	METHOD: Thiosthorothioate 10-23DNAzyme specific to eIF4E gene mRNA 1059 was designed and synthesized, and its inhibition effects on the expression of eIF4E gene in Hep-2 cells were observed.	thiosthorothioate	8-25	eukaryotic translation initiation factor 4E	Homo sapiens	51-56
17368478-0	2007	Structures of the human eIF4E homologous protein, h4EHP, in its m7GTP-bound and unliganded forms.	7-methylguanosine triphosphate	64-69	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
17368478-7	2007	m(7)GTP binds to 4EHP 200-fold more weakly than it does to eIF4E with the guanine base sandwiched by a tyrosine and a tryptophan instead of two tryptophan residues as seen in eIF4E.	(7)gtp	1-7	eukaryotic translation initiation factor 4E	Homo sapiens	59-64
17368478-7	2007	m(7)GTP binds to 4EHP 200-fold more weakly than it does to eIF4E with the guanine base sandwiched by a tyrosine and a tryptophan instead of two tryptophan residues as seen in eIF4E.	(7)gtp	1-7	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
17368478-7	2007	m(7)GTP binds to 4EHP 200-fold more weakly than it does to eIF4E with the guanine base sandwiched by a tyrosine and a tryptophan instead of two tryptophan residues as seen in eIF4E.	Guanine	74-81	eukaryotic translation initiation factor 4E	Homo sapiens	59-64
17368478-7	2007	m(7)GTP binds to 4EHP 200-fold more weakly than it does to eIF4E with the guanine base sandwiched by a tyrosine and a tryptophan instead of two tryptophan residues as seen in eIF4E.	Guanine	74-81	eukaryotic translation initiation factor 4E	Homo sapiens	175-180
17368478-8	2007	The tyrosine resides on a loop that is longer in h4EHP than in eIF4E.	Tyrosine	4-12	eukaryotic translation initiation factor 4E	Homo sapiens	63-68
17368478-9	2007	The consequent conformational difference between the proteins allows the tyrosine to mimic the six-membered ring of the tryptophan in eIF4E and adopt an orientation that is similar to that seen for equivalent residues in other non-homologous cap-binding proteins.	Tyrosine	73-81	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
17368478-9	2007	The consequent conformational difference between the proteins allows the tyrosine to mimic the six-membered ring of the tryptophan in eIF4E and adopt an orientation that is similar to that seen for equivalent residues in other non-homologous cap-binding proteins.	Tryptophan	120-130	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
17368478-11	2007	A peptide derived from the eIF4E inhibitory protein, 4E-BP1 binds h4EHP 100-fold less strongly than eIF4E but in a similar manner.	h4ehp	66-71	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
17802829-2	2007	METHOD: Thiosthorothioate 10-23DNAzyme specific to eIF4E gene mRNA 1059 was designed and synthesized, and its inhibition effects on the expression of eIF4E gene in Hep-2 cells were observed.	thiosthorothioate	8-25	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
17802829-4	2007	The level of inhibiting eIF4E in hep-2 cells transfected by DNAzyme was lower than that by only lipofectamine 2000 transfected and Hep-2.	Lipofectamine	96-114	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
17369309-5	2007	We show that 4EHP binds cap analogs m(7)GpppG and m(7)GTP with 30 and 100 lower affinity than eIF4E.	cap	24-27	eukaryotic translation initiation factor 4E	Homo sapiens	94-99
17440067-3	2007	Treatment of human colorectal cancer HCT-116 cells and human prostate cancer PC-3 cells, but not a normal prostate epithelial cell line (PrEC), with PEITC caused an increase in expression of the eukaryotic translation initiation factor 4E (eIF4E) binding protein (4E-BP1) and inhibition of 4E-BP1 phosphorylation.	phenethyl isothiocyanate	149-154	eukaryotic translation initiation factor 4E	Homo sapiens	195-238
17440067-4	2007	Results from pull-down assay using 7-methyl-GTP Sepharose 4B beads indicated that PEITC treatment reduced cap-bound eIF4E, confirming that increased 4E-BP1 expression and inhibition of 4E-BP1 phosphorylation indeed reduced the availability of eIF4E for translation initiation.	phenethyl isothiocyanate	82-87	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
17440067-4	2007	Results from pull-down assay using 7-methyl-GTP Sepharose 4B beads indicated that PEITC treatment reduced cap-bound eIF4E, confirming that increased 4E-BP1 expression and inhibition of 4E-BP1 phosphorylation indeed reduced the availability of eIF4E for translation initiation.	phenethyl isothiocyanate	82-87	eukaryotic translation initiation factor 4E	Homo sapiens	243-248
17440067-6	2007	Ectopic expression of eIF4E prevented PEITC-induced translation inhibition and conferred significant protection against PEITC-induced apoptosis.	phenethyl isothiocyanate	38-43	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
17440067-6	2007	Ectopic expression of eIF4E prevented PEITC-induced translation inhibition and conferred significant protection against PEITC-induced apoptosis.	phenethyl isothiocyanate	120-125	eukaryotic translation initiation factor 4E	Homo sapiens	22-27
17440067-7	2007	These results indicate that PEITC modulates availability of eIF4E for translation initiation leading to inhibition of cap-dependent translation.	phenethyl isothiocyanate	28-33	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
17440067-7	2007	These results indicate that PEITC modulates availability of eIF4E for translation initiation leading to inhibition of cap-dependent translation.	cap	118-121	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
17220299-7	2007	Trx1 facilitated synthesis of HIF-1alpha by activating Akt, p70S6K, and eIF-4E, known to control cap-dependent translation.	cap	97-100	eukaryotic translation initiation factor 4E	Homo sapiens	72-78
17481512-0	2007	Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression.	Doxorubicin	52-63	eukaryotic translation initiation factor 4E	Homo sapiens	105-110
17481512-4	2007	We hypothesized that the degree of TLK1B elevation is correlated with eIF4E overexpression and translates clinically to an increased risk for recurrence in breast cancer patients treated with doxorubicin-based adjuvant chemotherapy.	Doxorubicin	192-203	eukaryotic translation initiation factor 4E	Homo sapiens	70-75
17385562-6	2007	Whereas beta-ZOL mainly had an impact on the biological activity of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), protein kinase B (Akt), eukaryotic initiation factor 4E (eIF4E) and its repressor 4E binding protein 1 (4E-BP1), DON reduced the abundance of p38 MAPk, Akt and specific 4E-BP1 bands.	zearalenol	8-16	eukaryotic translation initiation factor 4E	Homo sapiens	161-192
17385562-6	2007	Whereas beta-ZOL mainly had an impact on the biological activity of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), protein kinase B (Akt), eukaryotic initiation factor 4E (eIF4E) and its repressor 4E binding protein 1 (4E-BP1), DON reduced the abundance of p38 MAPk, Akt and specific 4E-BP1 bands.	zearalenol	8-16	eukaryotic translation initiation factor 4E	Homo sapiens	194-199
17332346-4	2007	CCI-779, an mTOR inhibitor, arrested growth of a phosphatase and tensin homologue deleted on chromosome 10 (PTEN) abnormal HNSCC cell line FaDu, inhibiting phosphorylation of 4E-binding protein 1, resulting in increased association with eIF4E and inhibition of basic fibroblast growth factor and vascular endothelial growth factor.	temsirolimus	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	237-242
17178882-5	2006	Sorafenib also reduced the phosphorylation level of eIF4E and down-regulated the antiapoptotic protein Mcl-1 in a MEK/ERK-independent manner.	Sorafenib	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
17425063-2	2007	The effect of leucine on protein synthesis appears to be closely associated with eIF4G phosphorylation and its association with eIF4E, but whether eIF4G phosphorylation actually mediates the effects of leucine or is merely associated with these events has not been elucidated.	Leucine	14-21	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
17382186-8	2007	Although eIF4E overexpression has been suggested to make cells resistant to rapamycin, we observed marked growth inhibition with rapamycin as a single agent in SKRC39, which has marked overexpression of eIF4E.	Sirolimus	76-85	eukaryotic translation initiation factor 4E	Homo sapiens	9-14
17382186-8	2007	Although eIF4E overexpression has been suggested to make cells resistant to rapamycin, we observed marked growth inhibition with rapamycin as a single agent in SKRC39, which has marked overexpression of eIF4E.	Sirolimus	129-138	eukaryotic translation initiation factor 4E	Homo sapiens	203-208
16936779-4	2007	Experiments with rapamycin and the Bcr-Abl inhibitor, imatinib mesylate, in Bcr-Abl-expressing cell lines and primary CML cells indicated that Bcr-Abl and mTORC1 induced formation of the translation initiation complex, eIF4F.	Imatinib Mesylate	54-71	eukaryotic translation initiation factor 4E	Homo sapiens	219-224
17259394-5	2007	High glucose, high insulin, and high glucose+high insulin stimulated phosphorylation of 4E-BP1, a repressor binding protein for eukaryotic initiation factor 4E (eIF4E), that was dependent on activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin.	Glucose	5-12	eukaryotic translation initiation factor 4E	Homo sapiens	128-159
17259394-5	2007	High glucose, high insulin, and high glucose+high insulin stimulated phosphorylation of 4E-BP1, a repressor binding protein for eukaryotic initiation factor 4E (eIF4E), that was dependent on activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin.	Glucose	5-12	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
17259394-5	2007	High glucose, high insulin, and high glucose+high insulin stimulated phosphorylation of 4E-BP1, a repressor binding protein for eukaryotic initiation factor 4E (eIF4E), that was dependent on activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin.	Glucose	37-44	eukaryotic translation initiation factor 4E	Homo sapiens	128-159
17259394-5	2007	High glucose, high insulin, and high glucose+high insulin stimulated phosphorylation of 4E-BP1, a repressor binding protein for eukaryotic initiation factor 4E (eIF4E), that was dependent on activation of phosphatidylinositol 3-kinase, Akt, and mammalian target of rapamycin.	Glucose	37-44	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
17259394-6	2007	High glucose, high insulin, and high glucose+high insulin also promoted release of eIF4E from 4E-BP1, phosphorylation of eIF4E, and increase in eIF4E association with eIF4G, critical events in the initiation phase of mRNA translation.	Glucose	5-12	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
17259394-6	2007	High glucose, high insulin, and high glucose+high insulin also promoted release of eIF4E from 4E-BP1, phosphorylation of eIF4E, and increase in eIF4E association with eIF4G, critical events in the initiation phase of mRNA translation.	Glucose	5-12	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
17259394-6	2007	High glucose, high insulin, and high glucose+high insulin also promoted release of eIF4E from 4E-BP1, phosphorylation of eIF4E, and increase in eIF4E association with eIF4G, critical events in the initiation phase of mRNA translation.	Glucose	5-12	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
17259394-6	2007	High glucose, high insulin, and high glucose+high insulin also promoted release of eIF4E from 4E-BP1, phosphorylation of eIF4E, and increase in eIF4E association with eIF4G, critical events in the initiation phase of mRNA translation.	Glucose	37-44	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
17259394-6	2007	High glucose, high insulin, and high glucose+high insulin also promoted release of eIF4E from 4E-BP1, phosphorylation of eIF4E, and increase in eIF4E association with eIF4G, critical events in the initiation phase of mRNA translation.	Glucose	37-44	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
17259394-6	2007	High glucose, high insulin, and high glucose+high insulin also promoted release of eIF4E from 4E-BP1, phosphorylation of eIF4E, and increase in eIF4E association with eIF4G, critical events in the initiation phase of mRNA translation.	Glucose	37-44	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
17259394-7	2007	High glucose, high insulin, and high glucose+high insulin increased Erk phosphorylation, which is an upstream regulator of eIF4E phosphorylation, and PD098059, which is a MEK inhibitor that blocks Erk activation, abolished laminin-beta1 synthesis.	Glucose	37-44	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
17237311-6	2007	Likewise, compared with EC, both ES and EW increased formation of the mRNA cap binding complex eIF4F and stimulated phosphorylation of the translational repressor, 4E-BP1, the 70kD ribosomal protein S6 kinase (S6K1), and the mammalian target of rapamycin (mTOR) kinase at serine 2448.	Einsteinium	33-35	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
17237311-6	2007	Likewise, compared with EC, both ES and EW increased formation of the mRNA cap binding complex eIF4F and stimulated phosphorylation of the translational repressor, 4E-BP1, the 70kD ribosomal protein S6 kinase (S6K1), and the mammalian target of rapamycin (mTOR) kinase at serine 2448.	NSC334073	40-42	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
17210710-0	2007	Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.	Nitric Oxide	0-12	eukaryotic translation initiation factor 4E	Homo sapiens	184-189
17091471-5	2007	Cells expressing variant eIF4E did not form foci in culture and produced smaller colonies in soft agar compared to cells expressing wild-type eIF4E.	Agar	98-102	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
17178882-10	2006	In mechanism of action studies, sorafenib inhibited the phosphorylation of both ERK and eIF4E, reduced the microvessel area (assessed by CD34 immunohistochemistry), and induced tumor cell apoptosis (assessed by terminal deoxynucleotidyl transferase-mediated nick end labeling) in PLC/PRF/5 tumor xenografts.	Sorafenib	32-41	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
16982703-6	2006	Preincubation of KMCH cells with pifithrin-alpha enhanced gemcitabine-induced cytotoxicity in an eIF-4E-dependent manner.	pifithrin	33-42	eukaryotic translation initiation factor 4E	Homo sapiens	97-103
16715128-13	2006	Rapamycin inhibits IGF-I-stimulated cell motility, through suppression of both S6K1 and 4E-BP1/eIF4E-signaling pathways, as a consequence of inhibition of mTOR kinase activity.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
17036047-2	2006	For example, eIF4G and eIF4E-binding proteins (4E-BPs) modulate cap affinity, and thus physiological activity of eIF4E, by binding a site distal to the 7-methylguanosine cap-binding site.	7-methylguanosine	152-169	eukaryotic translation initiation factor 4E	Homo sapiens	23-28
17036047-2	2006	For example, eIF4G and eIF4E-binding proteins (4E-BPs) modulate cap affinity, and thus physiological activity of eIF4E, by binding a site distal to the 7-methylguanosine cap-binding site.	7-methylguanosine	152-169	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
17036047-3	2006	Further, cap binding substantially modulates eIF4E"s affinity for eIF4G and the 4E-BPs.	cap	9-12	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
16550606-5	2006	At physiological concentrations (2.5 microM), curcumin rapidly inhibited phosphorylation of the mammalian target of rapamycin (mTOR) and its downstream effector molecules, p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1), in a panel of cell lines (Rh1, Rh30, DU145, MCF-7 and Hela).	Curcumin	46-54	eukaryotic translation initiation factor 4E	Homo sapiens	199-230
16982703-5	2006	Modulation of eIF-4E expression by RNA interference enhanced the efficacy of gemcitabine in KMCH cholangiocarcinoma cells.	gemcitabine	77-88	eukaryotic translation initiation factor 4E	Homo sapiens	14-20
16982703-6	2006	Preincubation of KMCH cells with pifithrin-alpha enhanced gemcitabine-induced cytotoxicity in an eIF-4E-dependent manner.	gemcitabine	58-69	eukaryotic translation initiation factor 4E	Homo sapiens	97-103
16982703-7	2006	Furthermore, pifithrin-alpha increased eIF-4E phosphorylation at serine 209 via activation of p38 mitogen-activated protein kinase (MAPK).	Serine	65-71	eukaryotic translation initiation factor 4E	Homo sapiens	39-45
16982703-10	2006	Pifithrin-alpha enhanced chemosensitivity by a mechanism independent of p53 and involving AhR and p38 MAPK deregulation of eIF-4E phosphorylation.	pifithrin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	123-129
16897753-4	2006	Treatment of HSC with 5 mM leucine did not alter half-life or steady state levels of procollagen alpha1(I) mRNA, but caused an increase in procollagen alpha1(I) protein that correlated with changes of components involved in translational regulation, like enhanced 4E-BP1, Mnk-1, and eIF4E phosphorylation.	Leucine	27-34	eukaryotic translation initiation factor 4E	Homo sapiens	283-288
16835235-7	2006	We also demonstrate that both FCV and MNV RNA translation require the RNA helicase component of the eIF4F complex, namely eIF4A, because translation was sensitive (albeit to different degrees) to a dominant negative form and to a small molecule inhibitor of eIF4A (hippuristanol).	hippuristanol	265-278	eukaryotic translation initiation factor 4E	Homo sapiens	100-105
16777406-7	2006	The mTOR pathway regulates mRNA translation; exposure of MCF-7 cells to Gemini-23-yne-26,27-hexafluoro-D3 decreased their rate of protein synthesis and increased the association of 4EBP-1 with the translation initiation factor, eIF4E.	1,25-dihydroxy-20S-21(3-hydroxy-3-methyl-butyl)-23-yne-26,27-hexafluoro-vitamin D3	72-105	eukaryotic translation initiation factor 4E	Homo sapiens	228-233
16720573-2	2006	Here, we have shown that eIF4E is ubiquitinated primarily at Lys-159 and incubation of cells with a proteasome inhibitor leads to increased eIF4E levels, suggesting the proteasome-dependent proteolysis of ubiquitinated eIF4E.	Lysine	61-64	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
16626853-4	2006	VPg/eIF4E interaction results in the inhibition of cell-free protein synthesis, and we show that it stems from the liberation of the cap moiety from the complex with eIF4E.	cap	133-136	eukaryotic translation initiation factor 4E	Homo sapiens	4-9
16626853-4	2006	VPg/eIF4E interaction results in the inhibition of cell-free protein synthesis, and we show that it stems from the liberation of the cap moiety from the complex with eIF4E.	cap	133-136	eukaryotic translation initiation factor 4E	Homo sapiens	166-171
16531451-7	2006	Looking for an upstream determinant of translational deregulation, we found an increase in the hyperphosphorylated form of the 4E-BP1 protein in the metastatic cell line, possibly resulting in an increased activation of cap-dependent translation due to increased activity of the eIF4E protein.	cap	220-223	eukaryotic translation initiation factor 4E	Homo sapiens	279-284
16249273-8	2006	NAC and DPI also inhibited phosphorylation of 4E-BP1 on Thr46 and association of eIF4E with eIF4G, steps that are important in the initiation phase of mRNA translation.	Acetylcysteine	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
16434554-9	2006	After extended exposure to 6% halothane, alterations in two separate responses regulated by the target of rapamycin pathway occur: 1) redistribution of eIF4E from its translation-stimulatory association with eIF4G to its translation-inactive complex with eIF4E-binding protein-1; and 2) decreased phosphorylation of ribosomal protein S6 (rpS6) with a corresponding decrease in active forms of a kinase that phosphorylates rpS6 (p70(S6K1)).	Halothane	30-39	eukaryotic translation initiation factor 4E	Homo sapiens	152-157
16739988-4	2006	Site-specific phosphorylation of eIF4E and eIF4G and elevated levels of eIF4G:eIF4E complexes in phorbol ester treated HEK293 cells, and in serum-starved tumorigenic human mesenchymal stromal cells, attested to their activated translational states.	Phorbol Esters	97-110	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
16739988-4	2006	Site-specific phosphorylation of eIF4E and eIF4G and elevated levels of eIF4G:eIF4E complexes in phorbol ester treated HEK293 cells, and in serum-starved tumorigenic human mesenchymal stromal cells, attested to their activated translational states.	Phorbol Esters	97-110	eukaryotic translation initiation factor 4E	Homo sapiens	78-83
16739988-6	2006	Elevated levels of Gemin5:eIF4E complexes were found in phorbol ester treated HEK293 cells.	Phorbol Esters	56-69	eukaryotic translation initiation factor 4E	Homo sapiens	26-31
16540463-0	2006	Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: evidence for a one-step binding mechanism.	Oligoribonucleotides	98-118	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
16540463-0	2006	Stopped-flow kinetic analysis of eIF4E and phosphorylated eIF4E binding to cap analogs and capped oligoribonucleotides: evidence for a one-step binding mechanism.	Oligoribonucleotides	98-118	eukaryotic translation initiation factor 4E	Homo sapiens	58-63
16540463-3	2006	Mammalian eIF4E is phosphorylated at Ser-209 by Mnk1 and Mnk2 kinases.	Serine	37-40	eukaryotic translation initiation factor 4E	Homo sapiens	10-15
16540463-6	2006	Phosphorylation of eIF4E decreased k(on) by 2.1-2.3-fold at 50-100 mm KCl but had progressively less effect at higher ionic strengths, being negligible at 350 mm.	Potassium Chloride	70-73	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
16540463-10	2006	However, measuring k(off) for dissociation of a pre-formed eIF4E.m(7)GpppG complex suggested that the double-exponential kinetics were caused by dissociation of eIF4E dimers, not a two-step mechanism.	(7)gpppg	66-74	eukaryotic translation initiation factor 4E	Homo sapiens	59-64
16540463-10	2006	However, measuring k(off) for dissociation of a pre-formed eIF4E.m(7)GpppG complex suggested that the double-exponential kinetics were caused by dissociation of eIF4E dimers, not a two-step mechanism.	(7)gpppg	66-74	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
16540463-11	2006	Addition of a 12-nucleotide chain to the cap structure increased affinity at high ionic strength for both eIF4E (24-fold) and eIF4E(P) (7-fold), primarily due to a decrease in k(off).	12-nucleotide	14-27	eukaryotic translation initiation factor 4E	Homo sapiens	106-111
16540463-11	2006	Addition of a 12-nucleotide chain to the cap structure increased affinity at high ionic strength for both eIF4E (24-fold) and eIF4E(P) (7-fold), primarily due to a decrease in k(off).	12-nucleotide	14-27	eukaryotic translation initiation factor 4E	Homo sapiens	126-134
16375881-5	2006	eIF4E was purified by affinity chromatography using m(7)GTP-sepharose, and the levels of 4E-BP1 bound to eIF4E were determined.	(7)gtp	53-59	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
16375881-5	2006	eIF4E was purified by affinity chromatography using m(7)GTP-sepharose, and the levels of 4E-BP1 bound to eIF4E were determined.	Sepharose	60-69	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
16515558-3	2006	As expected, purified Aplysia Mnk phosphorylated Aplysia eIF4E at a conserved carboxy-terminal serine and over-expression of Aplysia Mnk in sensory neurons led to increased phosphorylation of endogenous eIF4E.	Serine	95-101	eukaryotic translation initiation factor 4E	Homo sapiens	57-62
16515558-8	2006	We propose that changes in eIF4E phosphorylation in Aplysia neurons are a consequence of changes in cap-dependent translation that are independent of regulation of Aplysia Mnk.	cap	100-103	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
16249273-8	2006	NAC and DPI also inhibited phosphorylation of 4E-BP1 on Thr46 and association of eIF4E with eIF4G, steps that are important in the initiation phase of mRNA translation.	diphenyleneiodonium	8-11	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
16628088-7	2006	Treatment of mice with the calcineurin inhibitor FK506 totally blocked c-Jun NH2-terminal kinase activation, partially blocked the mammalian target of rapamycin pathway, and had no effect on extracellular signal-regulated kinase activation or the phosphorylation of eukaryotic initiation factor 4E.	Tacrolimus	49-54	eukaryotic translation initiation factor 4E	Homo sapiens	266-297
16495443-7	2006	Our results provide direct evidence that cap-dependent translation is engaged during mGluR-LTD and demonstrate that the MEK-ERK and PI3K-mTOR signaling pathways converge to regulate eIF4E activity after induction of DHPG-LTD.	dhpg	216-220	eukaryotic translation initiation factor 4E	Homo sapiens	182-187
16405910-5	2006	Binding of eIF4G to apo-eIF4E likewise induces folding of the protein into a state that is similar to, but not identical with, that of cap-bound eIF4E.	cap	135-138	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
16405910-5	2006	Binding of eIF4G to apo-eIF4E likewise induces folding of the protein into a state that is similar to, but not identical with, that of cap-bound eIF4E.	cap	135-138	eukaryotic translation initiation factor 4E	Homo sapiens	145-150
16138385-2	2006	cis 5-tert-butyl-L-proline (Cbp) was prepared rapidly and efficiently by the addition of low-valent tert-butyl cuprate to an aminal derived from proline.	4,4'-Bis(N-carbazolyl)-1,1'-biphenyl	28-31	eukaryotic translation initiation factor 4E	Homo sapiens	0-26
16138385-2	2006	cis 5-tert-butyl-L-proline (Cbp) was prepared rapidly and efficiently by the addition of low-valent tert-butyl cuprate to an aminal derived from proline.	tert-butyl cuprate	100-118	eukaryotic translation initiation factor 4E	Homo sapiens	0-26
15907373-1	2006	During the oxidative stress generated by hydrogen peroxide (H2O2) in nerve growth factor (NGF)-differentiated PC12 cells, eIF4E binding protein (4E-BP1) and initiation factor 4E (eIF4E) phosphorylated levels decrease significantly, and an enhancement of the association of 4E-BP1 to eIF4E, which in turn decreases eIF4F formation is observed.	Hydrogen Peroxide	41-58	eukaryotic translation initiation factor 4E	Homo sapiens	122-127
15907373-1	2006	During the oxidative stress generated by hydrogen peroxide (H2O2) in nerve growth factor (NGF)-differentiated PC12 cells, eIF4E binding protein (4E-BP1) and initiation factor 4E (eIF4E) phosphorylated levels decrease significantly, and an enhancement of the association of 4E-BP1 to eIF4E, which in turn decreases eIF4F formation is observed.	Hydrogen Peroxide	60-64	eukaryotic translation initiation factor 4E	Homo sapiens	122-127
15907373-2	2006	The treatment with N-acetyl-cysteine (NAC) completely abolishes the H2O2-induced decrease in eIF4E phosphorylated levels, whereas the decrease in 4E-BP1 phosphorylated levels and eIF4F activity inhibition are significantly but not fully reversed.	Acetylcysteine	19-36	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
15907373-2	2006	The treatment with N-acetyl-cysteine (NAC) completely abolishes the H2O2-induced decrease in eIF4E phosphorylated levels, whereas the decrease in 4E-BP1 phosphorylated levels and eIF4F activity inhibition are significantly but not fully reversed.	Acetylcysteine	38-41	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
15907373-2	2006	The treatment with N-acetyl-cysteine (NAC) completely abolishes the H2O2-induced decrease in eIF4E phosphorylated levels, whereas the decrease in 4E-BP1 phosphorylated levels and eIF4F activity inhibition are significantly but not fully reversed.	Hydrogen Peroxide	68-72	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
16242075-7	2005	Individually, EKI-785 diminishes while rapamycin promotes the binding of the translation inhibitor eukaryotic initiation factor 4E binding protein (4EBP1) to the eukaryotic translation initiation factor 4E (eIF4E).	Sirolimus	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	162-205
16099139-9	2006	In contrast, the eIF4E phosphorylation was strongly reduced in DNV treated cells.	deoxynivalenol	63-66	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
16281055-4	2005	Pak2 binds to and phosphorylates initiation factor (eIF)4G, which inhibits association of eIF4E with m(7)GTP, reducing initiation.	7-methylguanosine triphosphate	101-108	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
16271312-1	2005	Taking advantage of the Trp73 residue located close to the 4E-BP binding site of eIF4E, the interaction between the 4E-BP isoform and eIF4E was investigated by the Trp fluorescence titration method.	Tryptophan	24-27	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
16271312-1	2005	Taking advantage of the Trp73 residue located close to the 4E-BP binding site of eIF4E, the interaction between the 4E-BP isoform and eIF4E was investigated by the Trp fluorescence titration method.	Tryptophan	24-27	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
16271312-6	2005	Crystal structure analysis at 2.1 A resolution revealed that the 4E-BP1 fragment, assigned to the Pro47-Pro66 peptide moiety, adopted a reverse L-shaped conformation involving the beta sheet and alpha-helical structures and was located at the root of the handle of the temple-bell-shaped eIF4E through hydrophilic and hydrophobic interactions.	Peptides	110-117	eukaryotic translation initiation factor 4E	Homo sapiens	288-293
16251386-0	2005	Further evidence that ribavirin interacts with eIF4E.	Ribavirin	22-31	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
16251386-1	2005	This commentary discusses the recent reports in RNA by Yan and colleagues and Westman and colleagues of the apparent failure of ribavirin to bind to recombinant eIF4E and inhibit 7-methyl guanosine cap-dependent exogenous mRNA translation of cell extracts in vitro.	Ribavirin	128-137	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
16251386-3	2005	Possible reasons for the discordant findings of Yan and colleagues and Westman and colleagues are suggested, and direct observation of the specific binding of ribavirin to eIF4E by using mass spectrometry is presented.	Ribavirin	159-168	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
16260273-4	2005	eIF-4E expression was evaluated by immunohistochemistry in 88 formalin-fixed, paraffin-embedded cervical tissues; 10 normal cervical specimens; 19 low-grade cervical intraepithelial neoplasias (CINs); 19 high-grade CINs; and 40 invasive squamous cell carcinomas (ISCCs).	Formaldehyde	62-70	eukaryotic translation initiation factor 4E	Homo sapiens	0-6
16260273-4	2005	eIF-4E expression was evaluated by immunohistochemistry in 88 formalin-fixed, paraffin-embedded cervical tissues; 10 normal cervical specimens; 19 low-grade cervical intraepithelial neoplasias (CINs); 19 high-grade CINs; and 40 invasive squamous cell carcinomas (ISCCs).	Paraffin	78-86	eukaryotic translation initiation factor 4E	Homo sapiens	0-6
16283521-0	2005	Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death.	sodium arsenite	0-15	eukaryotic translation initiation factor 4E	Homo sapiens	38-81
16283521-0	2005	Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death.	sodium arsenite	0-15	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
16283521-3	2005	Currently, we have investigated whether the eukaryotic translation initiation factor 4E (eIF4E), the mRNA cap binding and rate limiting factor required for translation, is a target for As-induced cytotoxicity and cell death.	Arsenic	185-187	eukaryotic translation initiation factor 4E	Homo sapiens	44-87
16283521-3	2005	Currently, we have investigated whether the eukaryotic translation initiation factor 4E (eIF4E), the mRNA cap binding and rate limiting factor required for translation, is a target for As-induced cytotoxicity and cell death.	Arsenic	185-187	eukaryotic translation initiation factor 4E	Homo sapiens	89-94
16283521-4	2005	We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.	Arsenic	75-77	eukaryotic translation initiation factor 4E	Homo sapiens	117-122
16283521-4	2005	We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.	Arsenic	203-205	eukaryotic translation initiation factor 4E	Homo sapiens	117-122
16283521-6	2005	All the NaAsO2-treated cells exhibited significant inhibition of eIF4E gene (protein).	sodium arsenite	8-14	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
16283521-7	2005	The potential involvement of eIF4E gene expression in the NaAsO2-induced cytotoxicity and cell death was investigated by silencing the cellular expression of the eIF4E gene by employing a small interfering RNA (SiRNA) specifically targeting the eIF4E gene"s expression.	sodium arsenite	58-64	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
16283521-7	2005	The potential involvement of eIF4E gene expression in the NaAsO2-induced cytotoxicity and cell death was investigated by silencing the cellular expression of the eIF4E gene by employing a small interfering RNA (SiRNA) specifically targeting the eIF4E gene"s expression.	sodium arsenite	58-64	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
16283521-7	2005	The potential involvement of eIF4E gene expression in the NaAsO2-induced cytotoxicity and cell death was investigated by silencing the cellular expression of the eIF4E gene by employing a small interfering RNA (SiRNA) specifically targeting the eIF4E gene"s expression.	sodium arsenite	58-64	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
16283521-8	2005	The SiRNA-mediated silencing of eIF4E gene expression also resulted in significant cytotoxicity and cell death suggesting that the toxicity noticed among the NaAsO2-treated cells was probably due to the chemically induced inhibition of eIF4E gene expression.	sodium arsenite	158-164	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
16283521-8	2005	The SiRNA-mediated silencing of eIF4E gene expression also resulted in significant cytotoxicity and cell death suggesting that the toxicity noticed among the NaAsO2-treated cells was probably due to the chemically induced inhibition of eIF4E gene expression.	sodium arsenite	158-164	eukaryotic translation initiation factor 4E	Homo sapiens	236-241
16283521-9	2005	The potential involvement of inhibition of eIF4E gene expression in the NaAsO2-induced cytotoxicity and cell death was further investigated by employing transgenic cell lines overexpressing the eIF4E gene.	sodium arsenite	72-78	eukaryotic translation initiation factor 4E	Homo sapiens	43-48
16283521-9	2005	The potential involvement of inhibition of eIF4E gene expression in the NaAsO2-induced cytotoxicity and cell death was further investigated by employing transgenic cell lines overexpressing the eIF4E gene.	sodium arsenite	72-78	eukaryotic translation initiation factor 4E	Homo sapiens	194-199
16283521-11	2005	Additional studies conducted to understand the potential mechanisms responsible for NaAsO2-induced inhibition of eIF4E gene expression demonstrated that exposure to NaAsO2 resulted in transcriptional down-regulation of the eIF4E gene only in HCT-15 and HeLa cells, while in the NaAsO2-treated and PLC/PR/5 and Chang cells, the eIF4E mRNA expression level was comparable to those of the corresponding control cells.	sodium arsenite	84-90	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
16283521-11	2005	Additional studies conducted to understand the potential mechanisms responsible for NaAsO2-induced inhibition of eIF4E gene expression demonstrated that exposure to NaAsO2 resulted in transcriptional down-regulation of the eIF4E gene only in HCT-15 and HeLa cells, while in the NaAsO2-treated and PLC/PR/5 and Chang cells, the eIF4E mRNA expression level was comparable to those of the corresponding control cells.	sodium arsenite	84-90	eukaryotic translation initiation factor 4E	Homo sapiens	223-228
16283521-11	2005	Additional studies conducted to understand the potential mechanisms responsible for NaAsO2-induced inhibition of eIF4E gene expression demonstrated that exposure to NaAsO2 resulted in transcriptional down-regulation of the eIF4E gene only in HCT-15 and HeLa cells, while in the NaAsO2-treated and PLC/PR/5 and Chang cells, the eIF4E mRNA expression level was comparable to those of the corresponding control cells.	sodium arsenite	165-171	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
16283521-11	2005	Additional studies conducted to understand the potential mechanisms responsible for NaAsO2-induced inhibition of eIF4E gene expression demonstrated that exposure to NaAsO2 resulted in transcriptional down-regulation of the eIF4E gene only in HCT-15 and HeLa cells, while in the NaAsO2-treated and PLC/PR/5 and Chang cells, the eIF4E mRNA expression level was comparable to those of the corresponding control cells.	sodium arsenite	165-171	eukaryotic translation initiation factor 4E	Homo sapiens	223-228
16283521-11	2005	Additional studies conducted to understand the potential mechanisms responsible for NaAsO2-induced inhibition of eIF4E gene expression demonstrated that exposure to NaAsO2 resulted in transcriptional down-regulation of the eIF4E gene only in HCT-15 and HeLa cells, while in the NaAsO2-treated and PLC/PR/5 and Chang cells, the eIF4E mRNA expression level was comparable to those of the corresponding control cells.	sodium arsenite	165-171	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
16283521-11	2005	Additional studies conducted to understand the potential mechanisms responsible for NaAsO2-induced inhibition of eIF4E gene expression demonstrated that exposure to NaAsO2 resulted in transcriptional down-regulation of the eIF4E gene only in HCT-15 and HeLa cells, while in the NaAsO2-treated and PLC/PR/5 and Chang cells, the eIF4E mRNA expression level was comparable to those of the corresponding control cells.	sodium arsenite	165-171	eukaryotic translation initiation factor 4E	Homo sapiens	223-228
16283521-13	2005	Immunoprecipitation of lysates obtained from the NaAsO2-treated cells and the subsequent western blot analysis of the immunoprecipitated protein(s) using the eIF4E antibody detected the presence of eIF4E protein in the immunoprecipitate suggesting possible ubiquitination of eIF4E protein in the NaAsO2-treated cells.	sodium arsenite	49-55	eukaryotic translation initiation factor 4E	Homo sapiens	158-163
16283521-13	2005	Immunoprecipitation of lysates obtained from the NaAsO2-treated cells and the subsequent western blot analysis of the immunoprecipitated protein(s) using the eIF4E antibody detected the presence of eIF4E protein in the immunoprecipitate suggesting possible ubiquitination of eIF4E protein in the NaAsO2-treated cells.	sodium arsenite	49-55	eukaryotic translation initiation factor 4E	Homo sapiens	198-203
16283521-13	2005	Immunoprecipitation of lysates obtained from the NaAsO2-treated cells and the subsequent western blot analysis of the immunoprecipitated protein(s) using the eIF4E antibody detected the presence of eIF4E protein in the immunoprecipitate suggesting possible ubiquitination of eIF4E protein in the NaAsO2-treated cells.	sodium arsenite	49-55	eukaryotic translation initiation factor 4E	Homo sapiens	198-203
16283521-13	2005	Immunoprecipitation of lysates obtained from the NaAsO2-treated cells and the subsequent western blot analysis of the immunoprecipitated protein(s) using the eIF4E antibody detected the presence of eIF4E protein in the immunoprecipitate suggesting possible ubiquitination of eIF4E protein in the NaAsO2-treated cells.	sodium arsenite	296-302	eukaryotic translation initiation factor 4E	Homo sapiens	198-203
16283521-13	2005	Immunoprecipitation of lysates obtained from the NaAsO2-treated cells and the subsequent western blot analysis of the immunoprecipitated protein(s) using the eIF4E antibody detected the presence of eIF4E protein in the immunoprecipitate suggesting possible ubiquitination of eIF4E protein in the NaAsO2-treated cells.	sodium arsenite	296-302	eukaryotic translation initiation factor 4E	Homo sapiens	198-203
16283521-14	2005	Pre-exposure of the NaAsO2-treated cells to proteasome inhibitors blocked the inhibition of eIF4E gene expression as well as the resulting cytotoxicity and cell death.	sodium arsenite	20-26	eukaryotic translation initiation factor 4E	Homo sapiens	92-97
16283521-17	2005	Transfection of cells with SiRNA specifically targeting eIF4E gene expression resulted in a significant inhibition of cyclin D1 gene suggesting that the observed inhibition of cyclin D1 gene in the NaAsO2-treated cells is most likely mediated through inhibition of eIF4E gene.	sodium arsenite	198-204	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
16283521-17	2005	Transfection of cells with SiRNA specifically targeting eIF4E gene expression resulted in a significant inhibition of cyclin D1 gene suggesting that the observed inhibition of cyclin D1 gene in the NaAsO2-treated cells is most likely mediated through inhibition of eIF4E gene.	sodium arsenite	198-204	eukaryotic translation initiation factor 4E	Homo sapiens	265-270
16283521-18	2005	Taken together, our results indicate that the exposure of cells to NaAsO2 resulted in cytotoxicity and cell death, at least in part, due to the inhibition of eIF4E gene expression leading to diminished cellular levels of critical genes such as cyclin D1.	sodium arsenite	67-73	eukaryotic translation initiation factor 4E	Homo sapiens	158-163
16408751-9	2005	Compared with control groups the protein expression of eIF4E, eIF4G, bFGF and VEGF were significantly inhibited by elemene (P < 0.05), and the microvessel density in elemene treated groups decreased (P < 0.05).	elemene	115-122	eukaryotic translation initiation factor 4E	Homo sapiens	55-60
16408751-9	2005	Compared with control groups the protein expression of eIF4E, eIF4G, bFGF and VEGF were significantly inhibited by elemene (P < 0.05), and the microvessel density in elemene treated groups decreased (P < 0.05).	elemene	169-176	eukaryotic translation initiation factor 4E	Homo sapiens	55-60
16166632-7	2005	Overexpression of eIF4E rendered polysome recruitment of mRNAs with structured 5" untranslated regions largely independent of growth factor and resistant to the PI3K inhibitor LY294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	176-184	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
16131589-4	2005	2004) presented evidence that the antiviral nucleoside ribavirin and its phosphorylated derivatives were structural mimics of the mRNA cap, high-affinity ligands for eIF4E, and potent repressors of eIF4E-mediated cell transformation and tumor growth.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	166-171
16131589-4	2005	2004) presented evidence that the antiviral nucleoside ribavirin and its phosphorylated derivatives were structural mimics of the mRNA cap, high-affinity ligands for eIF4E, and potent repressors of eIF4E-mediated cell transformation and tumor growth.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	198-203
16131589-7	2005	Using a set of reporter mRNAs that are translated via either cap-dependent or viral internal ribosome entry sites (IRES)-dependent initiation, we found that these ribavirin-containing compounds did inhibit translation at high (millimolar) concentrations, but there was no correlation of this inhibition with an eIF4E requirement for translation.	Ribavirin	163-172	eukaryotic translation initiation factor 4E	Homo sapiens	311-316
16191198-3	2005	Three dimensional structures of eIF4Es bound to cap-analogues resemble "cupped-hands" in which the cap-structure is sandwiched between two conserved Trp residues (Trp-56 and Trp-102 of H. sapiens eIF4E).	Tryptophan	149-152	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
16191198-3	2005	Three dimensional structures of eIF4Es bound to cap-analogues resemble "cupped-hands" in which the cap-structure is sandwiched between two conserved Trp residues (Trp-56 and Trp-102 of H. sapiens eIF4E).	Tryptophan	163-166	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
16191198-3	2005	Three dimensional structures of eIF4Es bound to cap-analogues resemble "cupped-hands" in which the cap-structure is sandwiched between two conserved Trp residues (Trp-56 and Trp-102 of H. sapiens eIF4E).	Tryptophan	163-166	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
16191198-4	2005	A third conserved Trp residue (Trp-166 of H. sapiens eIF4E) recognizes the 7-methyl moiety of the cap-structure.	Tryptophan	18-21	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
16191198-4	2005	A third conserved Trp residue (Trp-166 of H. sapiens eIF4E) recognizes the 7-methyl moiety of the cap-structure.	Tryptophan	31-34	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
16191198-10	2005	Class I members carry Trp residues equivalent to Trp-43 and Trp-56 of H. sapiens eIF4E and appear to be present in all eukaryotes.	Tryptophan	22-25	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
16191198-10	2005	Class I members carry Trp residues equivalent to Trp-43 and Trp-56 of H. sapiens eIF4E and appear to be present in all eukaryotes.	Tryptophan	49-52	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
16191198-10	2005	Class I members carry Trp residues equivalent to Trp-43 and Trp-56 of H. sapiens eIF4E and appear to be present in all eukaryotes.	Tryptophan	49-52	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
16242075-7	2005	Individually, EKI-785 diminishes while rapamycin promotes the binding of the translation inhibitor eukaryotic initiation factor 4E binding protein (4EBP1) to the eukaryotic translation initiation factor 4E (eIF4E).	Sirolimus	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	207-212
16103051-9	2005	The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	124-132	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
15901615-4	2005	In the present study, we hypothesized that phosphorylation of eukaryotic initiation factor-4E (eIF4E)-binding protein (4E-BP), which subsequently releases eIF4E and initiates cap-dependent mRNA translation, was required for airway smooth muscle hypertrophy.	cap	175-178	eukaryotic translation initiation factor 4E	Homo sapiens	62-93
16103051-8	2005	Paradoxically, rapamycin also concurrently increased the phosphorylation of both Akt and eIF4E.	Sirolimus	15-24	eukaryotic translation initiation factor 4E	Homo sapiens	89-94
16103051-9	2005	The rapamycin-induced phosphorylation of Akt and eIF4E was suppressed by the phosphatidylinositol-3 kinase (PI3K) inhibitor LY294002, suggesting the requirement of PI3K in this process.	Sirolimus	4-13	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
15901615-4	2005	In the present study, we hypothesized that phosphorylation of eukaryotic initiation factor-4E (eIF4E)-binding protein (4E-BP), which subsequently releases eIF4E and initiates cap-dependent mRNA translation, was required for airway smooth muscle hypertrophy.	cap	175-178	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
15901615-4	2005	In the present study, we hypothesized that phosphorylation of eukaryotic initiation factor-4E (eIF4E)-binding protein (4E-BP), which subsequently releases eIF4E and initiates cap-dependent mRNA translation, was required for airway smooth muscle hypertrophy.	cap	175-178	eukaryotic translation initiation factor 4E	Homo sapiens	155-160
16043507-3	2005	To obtain supporting functional data for this hypothesis, we assessed the ability of ribavirin triphosphate to interfere with the interaction between eIF4E and 7-methyl guanosine capped mRNA.	ribavirin 5'-triphosphate	85-107	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
16024782-0	2005	hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation.	polypyrimidine	21-35	eukaryotic translation initiation factor 4E	Homo sapiens	51-94
16024782-0	2005	hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation.	polypyrimidine	21-35	eukaryotic translation initiation factor 4E	Homo sapiens	96-101
15701678-5	2005	INS also promoted phosphorylation of ERK1/2, S6K1, and 4E-BP1 and dephosphorylation of eIF4E.	Insulin	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	87-92
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	33-43	eukaryotic translation initiation factor 4E	Homo sapiens	135-166
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	33-43	eukaryotic translation initiation factor 4E	Homo sapiens	168-174
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	33-43	eukaryotic translation initiation factor 4E	Homo sapiens	225-231
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	45-48	eukaryotic translation initiation factor 4E	Homo sapiens	135-166
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	45-48	eukaryotic translation initiation factor 4E	Homo sapiens	168-174
15897904-2	2005	In this study we examine whether paclitaxel (PTX) alters the expression and/or phosphorylation of the translation initiation proteins, eukaryotic initiation factor 4E (eIF-4E) and 4E-binding protein (4E-BP1), a suppressor of eIF-4E in the dephosphorylated state.	Paclitaxel	45-48	eukaryotic translation initiation factor 4E	Homo sapiens	225-231
15897904-3	2005	We found that PTX induced the hyperphosphorylation of 4E-BP1 in the breast cancer cell line, MDA MB 231, which reduced its association with eIF-4E, but did not alter the expression and phosphorylation of eIF-4E.	Paclitaxel	14-17	eukaryotic translation initiation factor 4E	Homo sapiens	140-146
15897904-6	2005	The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells.	Paclitaxel	38-41	eukaryotic translation initiation factor 4E	Homo sapiens	71-77
15897904-6	2005	The hyperphosphorylation of 4E-BP1 by PTX increased the association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association of eIF-4E with eIF-4G in PTX treated cells.	6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine	116-128	eukaryotic translation initiation factor 4E	Homo sapiens	158-164
15897904-7	2005	Taken together, our data suggest that PTX-increases the functional level of eIF-4E by promoting the hyperphosphorylation and release of 4E-BP1 through a cdk1-dependent mechanism.	Paclitaxel	38-41	eukaryotic translation initiation factor 4E	Homo sapiens	76-82
15701678-9	2005	Finally, treatment of myotubes with PD-98059 or dnMEK1 adenovirus before TNF + INS addition resulted in a derepression of protein synthesis and the association of eIF4G with eIF4E.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	36-44	eukaryotic translation initiation factor 4E	Homo sapiens	174-179
15763431-7	2005	Treatment with the p38 inhibitor, SB202190, or either of the ERK1/2 inhibitors, PD98059 and U0126, partially blocked Stx1-induced eIF4E phosphorylation.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	34-42	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
15763431-7	2005	Treatment with the p38 inhibitor, SB202190, or either of the ERK1/2 inhibitors, PD98059 and U0126, partially blocked Stx1-induced eIF4E phosphorylation.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	80-87	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
15763431-7	2005	Treatment with the p38 inhibitor, SB202190, or either of the ERK1/2 inhibitors, PD98059 and U0126, partially blocked Stx1-induced eIF4E phosphorylation.	U 0126	92-97	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
15763431-8	2005	The Mnk1 inhibitor, CGP57380, blocked both basal and Stx-induced eIF4E phosphorylation.	CGP 57380	20-28	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
15878868-0	2005	Eukaryotic translation initiation factor 4E is a cellular target for toxicity and death due to exposure to cadmium chloride.	Cadmium Chloride	107-123	eukaryotic translation initiation factor 4E	Homo sapiens	0-43
15878868-1	2005	Whether translation initiation factor 4E (eIF4E), the mRNA cap binding and rate-limiting factor required for translation, is a target for cytotoxicity and cell death induced by cadmium, a human carcinogen, was investigated.	Cadmium	177-184	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
15878868-2	2005	Exposure of human cell lines, HCT15, PLC/PR/5, HeLa, and Chang, to cadmium chloride resulted in cytotoxicity and cell death, and this was associated with a significant decrease in eIF4E protein levels.	Cadmium Chloride	67-83	eukaryotic translation initiation factor 4E	Homo sapiens	180-185
15878868-4	2005	On the other hand, overexpression of the eIF4E gene was protective against the cadmium-induced cytotoxicity and cell death.	Cadmium	79-86	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
15878868-6	2005	In addition, exposure of cells to cadmium resulted in enhanced ubiquitination of eIF4E protein while inhibitors of proteasome activity reversed the cadmium-induced decrease of eIF4E protein.	Cadmium	34-41	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
15878868-6	2005	In addition, exposure of cells to cadmium resulted in enhanced ubiquitination of eIF4E protein while inhibitors of proteasome activity reversed the cadmium-induced decrease of eIF4E protein.	Cadmium	148-155	eukaryotic translation initiation factor 4E	Homo sapiens	176-181
15878868-7	2005	Exposure of cells to cadmium, as well as the specific silencing of eIF4E gene, also resulted in decreased cellular levels of cyclin D1, a critical cell cycle and growth regulating gene, suggesting that the observed inhibition of cyclin D1 gene expression in the cadmium-treated cells is most likely due to decreased cellular level of eIF4E.	Cadmium	21-28	eukaryotic translation initiation factor 4E	Homo sapiens	334-339
15878868-7	2005	Exposure of cells to cadmium, as well as the specific silencing of eIF4E gene, also resulted in decreased cellular levels of cyclin D1, a critical cell cycle and growth regulating gene, suggesting that the observed inhibition of cyclin D1 gene expression in the cadmium-treated cells is most likely due to decreased cellular level of eIF4E.	Cadmium	262-269	eukaryotic translation initiation factor 4E	Homo sapiens	67-72
15878868-8	2005	Taken together, our results demonstrate that the exposure of cells to cadmium chloride resulted in cytotoxicity and cell death due to enhanced ubiquitination and consequent proteolysis of eIF4E protein, which in turn diminished cellular levels of critical genes such as cyclin D1.	Cadmium Chloride	70-86	eukaryotic translation initiation factor 4E	Homo sapiens	188-193
15542544-3	2005	In this report, exposure of human lung fibroblasts to 95% O2 decreased the incorporation of thymidine into DNA at 6 h and the incorporation of leucine into protein beginning at 12 h. The reductions in DNA and protein synthesis were accompanied by increased phosphorylation of eIF4E protein and reduced phosphorylation of 4E-BP1.	Oxygen	58-60	eukaryotic translation initiation factor 4E	Homo sapiens	276-281
15757502-11	2005	Inhibition of the MAPK-interacting kinases by CGP57380 decreases the phosphorylation of eIF4E and PE-induced protein synthesis.	CGP 57380	46-54	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
15766285-4	2005	The temperature-dependent K(d) values for cap analogues were markedly lower, indicating tighter binding, with the eIF4E(K119A) mutant compared with wild-type eIF4E.	cap	42-45	eukaryotic translation initiation factor 4E	Homo sapiens	114-119
15766285-4	2005	The temperature-dependent K(d) values for cap analogues were markedly lower, indicating tighter binding, with the eIF4E(K119A) mutant compared with wild-type eIF4E.	cap	42-45	eukaryotic translation initiation factor 4E	Homo sapiens	158-163
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Fluorouracil	276-290	eukaryotic translation initiation factor 4E	Homo sapiens	160-191
15471950-6	2005	RA treatment of leukemia cells also resulted in an mTOR-mediated phosphorylation of the 4E-BP1 repressor of mRNA translation, to induce its deactivation and dissociation from the eukaryotic initiation factor-4E (eIF-4E) complex.	Tretinoin	0-2	eukaryotic translation initiation factor 4E	Homo sapiens	179-210
15471950-6	2005	RA treatment of leukemia cells also resulted in an mTOR-mediated phosphorylation of the 4E-BP1 repressor of mRNA translation, to induce its deactivation and dissociation from the eukaryotic initiation factor-4E (eIF-4E) complex.	Tretinoin	0-2	eukaryotic translation initiation factor 4E	Homo sapiens	212-218
15657436-8	2005	At the biochemical level, HOXA9 mediates these effects by competing with factors that repress eIF4E function, in particular the proline-rich homeodomain PRH/Hex.	Proline	128-135	eukaryotic translation initiation factor 4E	Homo sapiens	94-99
15388509-3	2005	The purpose of the present set of experiments was to determine whether acute alcohol intoxication alters the phosphorylation state of eukaryotic initiation factor (eIF) 4G, eIF4G.eIF4E complex formation, and the mammalian target of rapamycin (mTOR) signaling pathway in the heart.	Alcohols	77-84	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
15388509-7	2005	Alcohol administration lowered formation of the active eIF4G.eIF4E complex by >90%, whereas it increased the abundance of the inactive 4E-binding protein 1 (4E-BP1).eIF4E complex by approximately 160%.	Alcohols	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
15388509-7	2005	Alcohol administration lowered formation of the active eIF4G.eIF4E complex by >90%, whereas it increased the abundance of the inactive 4E-binding protein 1 (4E-BP1).eIF4E complex by approximately 160%.	Alcohols	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
15388509-11	2005	These data suggest that acute alcohol-induced impairments in myocardial mRNA translation initiation result, in part, from marked decreases in eIF4G.eIF4E complex formation, which appear to be independent of changes in phosphorylation of eIF4G but dependent on mTOR.	Alcohols	30-37	eukaryotic translation initiation factor 4E	Homo sapiens	148-153
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Etoposide	292-301	eukaryotic translation initiation factor 4E	Homo sapiens	160-191
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Etoposide	292-301	eukaryotic translation initiation factor 4E	Homo sapiens	235-266
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Quercetin	307-316	eukaryotic translation initiation factor 4E	Homo sapiens	160-191
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Quercetin	307-316	eukaryotic translation initiation factor 4E	Homo sapiens	235-266
15611226-7	2005	Moreover, we demonstrate that chemotherapeutic agents that suppress protein synthesis and reverse the CD40-mediated dissociation of the translational repressor eukaryotic initiation factor 4E-binding protein from the initiation factor eukaryotic initiation factor 4E, such as 5-fluorouracil, etoposide, and quercetin, dramatically increase the susceptibility of cervical carcinoma cells to CD40L-induced apoptosis.	Fluorouracil	276-290	eukaryotic translation initiation factor 4E	Homo sapiens	235-266
15611299-6	2005	Aptamer 1 inhibits the cap binding to eIF4E more efficiently than the cap analog m7GpppN or aptamer 2.	m7gpppn	81-88	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
15601771-0	2004	Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	21-26
15601771-2	2004	Oncogenic properties of eIF4E are directly linked to its ability to bind 7-methyl guanosine of the 5" mRNA.	7-methylguanosine	73-91	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Guanosine	36-45	eukaryotic translation initiation factor 4E	Homo sapiens	74-79
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Guanosine	36-45	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Guanosine	36-45	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Guanosine	36-45	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
15292274-5	2004	Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates.	Sirolimus	23-32	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	74-79
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	Ribavirin	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	179-184
15601771-3	2004	Here, we observe that the antiviral guanosine analogue ribavirin binds to eIF4E with micromolar affinity at the functional site used by 7-methyl guanosine mRNA cap, competes with eIF4E:mRNA binding, and, at low micromolar concentrations, selectively disrupts eIF4E subcellular organization and transport and translation of mRNAs posttranscriptionally regulated by eIF4E, thereby reducing levels of oncogenes such as cyclin D1.	7-methylguanosine	136-154	eukaryotic translation initiation factor 4E	Homo sapiens	74-79
15601771-4	2004	Ribavirin potently suppresses eIF4E-mediated oncogenic transformation of murine cells in vitro, of tumor growth of a mouse model of eIF4E-dependent human squamous cell carcinoma in vivo, and of colony formation of eIF4E-dependent acute myelogenous leukemia cells derived from human patients.	Ribavirin	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
15601771-7	2004	In all, ribavirin"s association with eIF4E may provide a pharmacologic means for the interruption of posttranscriptional networks of oncogenes that maintain and enhance neoplasia and malignancy in human cancer.	Ribavirin	8-17	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
15292274-5	2004	Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates.	Wortmannin	42-52	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
15292274-5	2004	Surprisingly, although rapamycin, RAD001, wortmannin, and LY294002 inhibited the phosphorylation of 4E-BP1 and its release from eIF4E, they did not prevent the recovery of translation rates.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	58-66	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
15491137-4	2004	A nontrivial, statistically important isothermal enthalpy-entropy compensation has been detected (T(c) = 399 +/- 24 K), which points to significant fluctuations of apo-eIF4E and indicates that the cap-binding microstate lies 9.66 +/- 1.7 kJ mol(-1) below the mean energy of all available conformational states.	cap	197-200	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
15491137-8	2004	Thermodynamic coupling of cap-eIF4E association to intramolecular self-stacking of dinucleotide cap analogues strongly influences the enthalpies and entropies of the binding, but has a negligible effect on the resultant DeltaG degrees and DeltaC(p) degrees values.	Dinucleoside Phosphates	83-95	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
15355912-10	2004	Rapamycin analogs can potentially be used as adjuvant therapy for patients with eIF4E-positive margins.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	80-85
15317596-4	2004	Inhibition of eIF4E phosphorylation with CGP57380 failed to prevent translational reprogramming or the moderate decrease in eIF4F complexes at later times.	CGP 57380	41-49	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
15248766-4	2004	Phosphorylation of eIF(iso)4E has effects on m(7)G cap-binding affinity similar to those of phosphorylation of mammalian eIF4E even though eIF(iso)4E lacks an amino acid that can be phosphorylated at the residue corresponding to Ser-209, the phosphorylation site in mammalian eIF4E.	Serine	229-232	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
15273325-6	2004	The interactions between cap analogs and eIF4E, a cap-binding protein that plays a key role in initiation of translation, can be monitored by measuring intrinsic fluorescence quenching of the tryptophan residues.	Tryptophan	192-202	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
15220445-3	2004	Cap-dependent mRNA translation generally correlates with Mnk1 phosphorylation of eIF4E when both are bound to eIF4G.	cap	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	81-86
15194498-10	2004	The p38 MAPK inhibitor, SB203580, inhibited effectively phosphorylation of HSP-27, CREB, and eIF4E in SARS-CoV-infected cells.	SB 203580	24-32	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
15190216-3	2004	Interestingly, lymphomas expressing Akt, but not those expressing Bcl-2 are sensitized to chemotherapy-induced apoptosis by the mTOR inhibitor rapamycin, an effect that is countered by eIF4E.	Sirolimus	143-152	eukaryotic translation initiation factor 4E	Homo sapiens	185-190
15220445-6	2004	The eIF4G-binding site is located in an N-terminal 66-amino-acid peptide of 100K which is sufficient to bind eIF4G, displace Mnk1, block eIF4E phosphorylation, and inhibit eIF4F (cap)-dependent cellular mRNA translation.	cap	179-182	eukaryotic translation initiation factor 4E	Homo sapiens	137-142
15220445-6	2004	The eIF4G-binding site is located in an N-terminal 66-amino-acid peptide of 100K which is sufficient to bind eIF4G, displace Mnk1, block eIF4E phosphorylation, and inhibit eIF4F (cap)-dependent cellular mRNA translation.	cap	179-182	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
15051500-6	2004	In addition to phosphorylation of 40S ribosomal protein, IFNgamma also induces phosphorylation of the 4E-BP1 repressor of mRNA translation on threonines 37/46, threonine 70, and serine 65, sites whose phosphorylation is required for the inactivation of 4E-BP1 and its dissociation from the eukaryotic initiation factor-4E (eIF4E) complex.	Threonine	142-152	eukaryotic translation initiation factor 4E	Homo sapiens	290-321
15354786-5	2004	The protein expression of eIF4E, eIF4G, bFGF and VEGF were significantly inhibited by elemene; and the mRNA expression of bFGF and VEGF were inhibited either.	elemene	86-93	eukaryotic translation initiation factor 4E	Homo sapiens	26-31
15109672-3	2004	This preliminary communication describes the synthesis of a fluorescein labeled 7-methylguanosinemonophosphate, and its dose dependent binding to purified human eIF4E as demonstrated by the fluorescence polarization assay.	Fluorescein	60-71	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
15109672-3	2004	This preliminary communication describes the synthesis of a fluorescein labeled 7-methylguanosinemonophosphate, and its dose dependent binding to purified human eIF4E as demonstrated by the fluorescence polarization assay.	7-methylguanosinemonophosphate	80-110	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
14990584-6	2004	Here we show that eIF4E rescued cells from the ER stressors brefeldin A, tunicamycin, thapsigargin, and the Ca(2+) ionophore A23187.	Brefeldin A	60-71	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
14990584-6	2004	Here we show that eIF4E rescued cells from the ER stressors brefeldin A, tunicamycin, thapsigargin, and the Ca(2+) ionophore A23187.	Tunicamycin	73-84	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
14990584-6	2004	Here we show that eIF4E rescued cells from the ER stressors brefeldin A, tunicamycin, thapsigargin, and the Ca(2+) ionophore A23187.	Thapsigargin	86-98	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
14990584-6	2004	Here we show that eIF4E rescued cells from the ER stressors brefeldin A, tunicamycin, thapsigargin, and the Ca(2+) ionophore A23187.	Calcimycin	125-131	eukaryotic translation initiation factor 4E	Homo sapiens	18-23
15122903-5	2004	To address this problem, we have determined the binding affinities of eIF4E specifically mutated at position 209 or 159 for a series of novel mono- and dinucleotide cap analogues by a fluorometric time-synchronized titration method.	mono- and dinucleotide	142-164	eukaryotic translation initiation factor 4E	Homo sapiens	70-75
15051500-6	2004	In addition to phosphorylation of 40S ribosomal protein, IFNgamma also induces phosphorylation of the 4E-BP1 repressor of mRNA translation on threonines 37/46, threonine 70, and serine 65, sites whose phosphorylation is required for the inactivation of 4E-BP1 and its dissociation from the eukaryotic initiation factor-4E (eIF4E) complex.	Threonine	142-152	eukaryotic translation initiation factor 4E	Homo sapiens	323-328
15051500-6	2004	In addition to phosphorylation of 40S ribosomal protein, IFNgamma also induces phosphorylation of the 4E-BP1 repressor of mRNA translation on threonines 37/46, threonine 70, and serine 65, sites whose phosphorylation is required for the inactivation of 4E-BP1 and its dissociation from the eukaryotic initiation factor-4E (eIF4E) complex.	Threonine	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	290-321
15051500-6	2004	In addition to phosphorylation of 40S ribosomal protein, IFNgamma also induces phosphorylation of the 4E-BP1 repressor of mRNA translation on threonines 37/46, threonine 70, and serine 65, sites whose phosphorylation is required for the inactivation of 4E-BP1 and its dissociation from the eukaryotic initiation factor-4E (eIF4E) complex.	Threonine	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	323-328
14675529-1	2003	The structure of the eukaryotic initiation factor eIF4E bound to a cognate domain of eIF4G and m(7)GDP in this issue of Cell shows that these factors undergo coupled folding to form a stable complex with high cap binding activity that promotes efficient ribosomal attachment to mRNA during translation initiation.	Guanosine Diphosphate	99-102	eukaryotic translation initiation factor 4E	Homo sapiens	50-55
15094766-7	2004	eIF4E controls the translation of various malignancy-associated mRNAs which are involved in polyamine synthesis, cell cycle progression, activation of proto-oncogenes, angiogenesis, autocrine growth stimulation, cell survival, invasion and communication with the extracellular environment.	Polyamines	92-101	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
14701818-13	2004	The ability of these two zebrafish proteins to bind m(7)GTP, eIF4G, and 4E-BP, as well as to complement yeast conditionally deficient in functional eIF4E, show that eIF4E-1A is a functional equivalent of human eIF4E-1.	(7)gtp	53-59	eukaryotic translation initiation factor 4E	Homo sapiens	165-172
14607835-7	2004	To overcome this protective mechanism, we introduced alanine substitutions at four phosphorylation/inactivation sites in 4EBP1 to constitutively activate a 4EBP mu to block eIF4E.	Alanine	53-60	eukaryotic translation initiation factor 4E	Homo sapiens	173-178
12975586-0	2003	Backbone resonance assignment of human eukaryotic translation initiation factor 4E (eIF4E) in complex with 7-methylguanosine diphosphate (m7GDP) and a 17-amino acid peptide derived from human eIF4GII.	7-methylguanosine 5'-diphosphate	107-136	eukaryotic translation initiation factor 4E	Homo sapiens	39-82
12890645-7	2003	Downregulation of proline-rich tyrosine kinase 2 (PYK2) by antisense oligonucleotides led to a near-complete inhibition of PHAS-1 and eIF4E phosphorylation in response to ANG II.	Oligonucleotides	69-85	eukaryotic translation initiation factor 4E	Homo sapiens	134-139
14645512-8	2003	The aberrant nuclear function of eIF4E is due to abnormally large eIF4E bodies and the loss of regulation by the proline-rich homeodomain PRH.	Proline	113-120	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
14507920-1	2003	Insulin stimulates phosphorylation of multiple sites in the eIF4E-binding protein, PHAS-I, leading to dissociation of the PHAS-I.eIF4E complex and to an increase in cap-dependent translation.	cap	165-168	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
14507920-2	2003	The Ser-64 and Ser-111 sites have been proposed to have key roles in controlling the association of PHAS-I and eIF4E.	Serine	4-7	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
14507920-2	2003	The Ser-64 and Ser-111 sites have been proposed to have key roles in controlling the association of PHAS-I and eIF4E.	Serine	15-18	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
14507920-6	2003	Insulin promoted the release of eIF4E from PHAS-II, a PHAS isoform that lacks the Ser-111 site, but it was without effect on the amount of eIF4E bound to the third isoform, PHAS-III.	Serine	82-85	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
12975586-0	2003	Backbone resonance assignment of human eukaryotic translation initiation factor 4E (eIF4E) in complex with 7-methylguanosine diphosphate (m7GDP) and a 17-amino acid peptide derived from human eIF4GII.	7-methylguanosine 5'-diphosphate	107-136	eukaryotic translation initiation factor 4E	Homo sapiens	84-89
14690557-1	2003	OBJECTIVE: To determine whether the eukaryotic initiation factor-4E (eIF-4E) is involved in the cap-dependent translational regulation of heparanase and study the correlation between heparanase expression and metastatic potential of LS-174T cells.	cap	96-99	eukaryotic translation initiation factor 4E	Homo sapiens	36-67
14690557-1	2003	OBJECTIVE: To determine whether the eukaryotic initiation factor-4E (eIF-4E) is involved in the cap-dependent translational regulation of heparanase and study the correlation between heparanase expression and metastatic potential of LS-174T cells.	cap	96-99	eukaryotic translation initiation factor 4E	Homo sapiens	69-75
14690557-5	2003	RESULTS: The 20-mer antisense oligonucleotide (asODN) against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels.	Oligonucleotides	30-45	eukaryotic translation initiation factor 4E	Homo sapiens	62-68
14690557-5	2003	RESULTS: The 20-mer antisense oligonucleotide (asODN) against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels.	Oligonucleotides	30-45	eukaryotic translation initiation factor 4E	Homo sapiens	110-116
14690557-5	2003	RESULTS: The 20-mer antisense oligonucleotide (asODN) against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels.	asodn	47-52	eukaryotic translation initiation factor 4E	Homo sapiens	62-68
14690557-5	2003	RESULTS: The 20-mer antisense oligonucleotide (asODN) against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels.	asodn	47-52	eukaryotic translation initiation factor 4E	Homo sapiens	110-116
13679036-2	2003	Arachidonic acid stimulated phosphorylation of Akt, S6K1, ribosomal protein S6, 4EBP1, and eIF4E in a time-dependent manner in VSMC.	Arachidonic Acid	0-16	eukaryotic translation initiation factor 4E	Homo sapiens	91-96
13679036-2	2003	Arachidonic acid stimulated phosphorylation of Akt, S6K1, ribosomal protein S6, 4EBP1, and eIF4E in a time-dependent manner in VSMC.	vsmc	127-131	eukaryotic translation initiation factor 4E	Homo sapiens	91-96
13679036-6	2003	LY294002, an inhibitor of PI3K, completely blocked AA-induced phosphorylation of Akt, S6K1, ribosomal protein S6, 4EBP1, and eIF4E, suggesting a role for PI3K in these effects.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	125-130
14558943-1	2003	BACKGROUND & OBJECTIVE: Recent studies have revealed that some transcription factors may be translationally regulated by eukaryotic initiation factor-4E (eIF-4E) in human cancer.	Adenosine Monophosphate	12-15	eukaryotic translation initiation factor 4E	Homo sapiens	125-156
14558943-1	2003	BACKGROUND & OBJECTIVE: Recent studies have revealed that some transcription factors may be translationally regulated by eukaryotic initiation factor-4E (eIF-4E) in human cancer.	Adenosine Monophosphate	12-15	eukaryotic translation initiation factor 4E	Homo sapiens	158-164
14558943-4	2003	METHODS: In order to repress the expression of eIF-4E, a 20-mer antisense oligodeoxynucleotide (ASODN) targeted against the translation start site of eIF-4E mRNA was transfected into human colorectal cancer cell line LS-174T via liposome reagent, followed by assessment of the activity and the protein expression of NF-kappaB by an electrophoretic gel mobility shift assay (EMSA) and Western blot analysis respectively.	Oligodeoxyribonucleotides	74-94	eukaryotic translation initiation factor 4E	Homo sapiens	47-53
14558943-4	2003	METHODS: In order to repress the expression of eIF-4E, a 20-mer antisense oligodeoxynucleotide (ASODN) targeted against the translation start site of eIF-4E mRNA was transfected into human colorectal cancer cell line LS-174T via liposome reagent, followed by assessment of the activity and the protein expression of NF-kappaB by an electrophoretic gel mobility shift assay (EMSA) and Western blot analysis respectively.	Oligodeoxyribonucleotides	74-94	eukaryotic translation initiation factor 4E	Homo sapiens	150-156
14558943-4	2003	METHODS: In order to repress the expression of eIF-4E, a 20-mer antisense oligodeoxynucleotide (ASODN) targeted against the translation start site of eIF-4E mRNA was transfected into human colorectal cancer cell line LS-174T via liposome reagent, followed by assessment of the activity and the protein expression of NF-kappaB by an electrophoretic gel mobility shift assay (EMSA) and Western blot analysis respectively.	asodn	96-101	eukaryotic translation initiation factor 4E	Homo sapiens	47-53
14558943-4	2003	METHODS: In order to repress the expression of eIF-4E, a 20-mer antisense oligodeoxynucleotide (ASODN) targeted against the translation start site of eIF-4E mRNA was transfected into human colorectal cancer cell line LS-174T via liposome reagent, followed by assessment of the activity and the protein expression of NF-kappaB by an electrophoretic gel mobility shift assay (EMSA) and Western blot analysis respectively.	asodn	96-101	eukaryotic translation initiation factor 4E	Homo sapiens	150-156
14558943-6	2003	RESULTS: The 20-mer ASODN against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels, and the repression of eIF-4E gene expression was correlated with decreased expression levels and activity of NF-kappaB protein.	asodn	20-25	eukaryotic translation initiation factor 4E	Homo sapiens	34-40
14558943-6	2003	RESULTS: The 20-mer ASODN against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels, and the repression of eIF-4E gene expression was correlated with decreased expression levels and activity of NF-kappaB protein.	asodn	20-25	eukaryotic translation initiation factor 4E	Homo sapiens	82-88
14558943-6	2003	RESULTS: The 20-mer ASODN against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels, and the repression of eIF-4E gene expression was correlated with decreased expression levels and activity of NF-kappaB protein.	asodn	20-25	eukaryotic translation initiation factor 4E	Homo sapiens	82-88
12860993-4	2003	Here, we investigated the role of ROS in the regulation of PHAS-I phosphorylation on Thr-70 and Ser-65, an event required for the release of eIF4E from PHAS-I.	Reactive Oxygen Species	34-37	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
12860993-4	2003	Here, we investigated the role of ROS in the regulation of PHAS-I phosphorylation on Thr-70 and Ser-65, an event required for the release of eIF4E from PHAS-I.	Threonine	85-88	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
12860993-4	2003	Here, we investigated the role of ROS in the regulation of PHAS-I phosphorylation on Thr-70 and Ser-65, an event required for the release of eIF4E from PHAS-I.	Serine	96-99	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
12944262-0	2003	Charge distribution in 7-methylguanine regarding cation-pi interaction with protein factor eIF4E.	7-methylguanine	23-38	eukaryotic translation initiation factor 4E	Homo sapiens	91-96
12944262-2	2003	Formation of the stacked configuration of positively charged 7-methylguanine in between two aromatic amino acid rings, known as sandwich cation-pi stacking, is thought to be prerequisite for the specific recognition of the cap by eukaryotic initiation factor eIF4E; i.e., discrimination between the cap and nucleotides without the methyl group at N(7).	7-methylguanine	61-76	eukaryotic translation initiation factor 4E	Homo sapiens	259-264
12944262-2	2003	Formation of the stacked configuration of positively charged 7-methylguanine in between two aromatic amino acid rings, known as sandwich cation-pi stacking, is thought to be prerequisite for the specific recognition of the cap by eukaryotic initiation factor eIF4E; i.e., discrimination between the cap and nucleotides without the methyl group at N(7).	Amino Acids, Aromatic	92-111	eukaryotic translation initiation factor 4E	Homo sapiens	259-264
12781867-4	2003	These data show that while the arsenite-induced increase in the phosphorylation of eIF4E and hsp25 was sensitive to SB203580 in cells expressing WT-SAPK2a, these responses to SB203580 were abrogated in cells expressing DR-SAPK2a.	arsenite	31-39	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
12781867-4	2003	These data show that while the arsenite-induced increase in the phosphorylation of eIF4E and hsp25 was sensitive to SB203580 in cells expressing WT-SAPK2a, these responses to SB203580 were abrogated in cells expressing DR-SAPK2a.	SB 203580	116-124	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
12781867-6	2003	However, a cell-permeable, specific inhibitor of Mnk1, CGP57380 and the phosphatidylinositol-3-kinase (PI3-K) inhibitor, LY294002, prevented eIF4E phosphorylation in 293 cells irrespective of SAPK2a expression.	CGP 57380	55-63	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
12781867-6	2003	However, a cell-permeable, specific inhibitor of Mnk1, CGP57380 and the phosphatidylinositol-3-kinase (PI3-K) inhibitor, LY294002, prevented eIF4E phosphorylation in 293 cells irrespective of SAPK2a expression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	121-129	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
12781867-7	2003	Therefore, this study validates the use of SB203580 for investigating signalling pathways modulating the phosphorylation of eIF4E in cultured cells.	SB 203580	43-51	eukaryotic translation initiation factor 4E	Homo sapiens	124-129
12918105-5	2003	METHODS: A 20-mer antisense s-oligodeoxynucleotide (asODN) targeted against the translation start site of eIF-4E mRNA was introduced into LS-174T cells by lipid-mediated DNA-transfection.	Oligodeoxyribonucleotides	28-50	eukaryotic translation initiation factor 4E	Homo sapiens	106-112
12918105-5	2003	METHODS: A 20-mer antisense s-oligodeoxynucleotide (asODN) targeted against the translation start site of eIF-4E mRNA was introduced into LS-174T cells by lipid-mediated DNA-transfection.	asodn	52-57	eukaryotic translation initiation factor 4E	Homo sapiens	106-112
12918105-9	2003	RESULTS: The 20-mer asODN against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels.	asodn	20-25	eukaryotic translation initiation factor 4E	Homo sapiens	34-40
12918105-9	2003	RESULTS: The 20-mer asODN against eIF-4E specifically and significantly inhibited eIF-4E expression at both transcriptional and translational levels.	asodn	20-25	eukaryotic translation initiation factor 4E	Homo sapiens	82-88
12865212-2	2003	METHODS: A 20-mer antisense s-oligodeoxynucleotide (asODN) targeted against the translation start site of eIF-4E mRNA was introduced into LS-174T cells by means of lipid-mediated DNA-transfection, followed by Western blotting analysis and reverse transcription-PCR to determine eIF-4E protein and mRNA levels, respectively.	Oligodeoxyribonucleotides	28-50	eukaryotic translation initiation factor 4E	Homo sapiens	106-112
12865212-2	2003	METHODS: A 20-mer antisense s-oligodeoxynucleotide (asODN) targeted against the translation start site of eIF-4E mRNA was introduced into LS-174T cells by means of lipid-mediated DNA-transfection, followed by Western blotting analysis and reverse transcription-PCR to determine eIF-4E protein and mRNA levels, respectively.	Oligodeoxyribonucleotides	28-50	eukaryotic translation initiation factor 4E	Homo sapiens	278-284
12865212-2	2003	METHODS: A 20-mer antisense s-oligodeoxynucleotide (asODN) targeted against the translation start site of eIF-4E mRNA was introduced into LS-174T cells by means of lipid-mediated DNA-transfection, followed by Western blotting analysis and reverse transcription-PCR to determine eIF-4E protein and mRNA levels, respectively.	asodn	52-57	eukaryotic translation initiation factor 4E	Homo sapiens	106-112
12865212-2	2003	METHODS: A 20-mer antisense s-oligodeoxynucleotide (asODN) targeted against the translation start site of eIF-4E mRNA was introduced into LS-174T cells by means of lipid-mediated DNA-transfection, followed by Western blotting analysis and reverse transcription-PCR to determine eIF-4E protein and mRNA levels, respectively.	asodn	52-57	eukaryotic translation initiation factor 4E	Homo sapiens	278-284
12865212-4	2003	RESULTS: The 20-mer asODN against eIF-4E specifically and significantly inhibited eIF-4E protein expression, and as a result, a significant reduction in heparanase mRNA level was observed by Northern blotting in conjunction with significantly decreased heparanase protein expression.	asodn	20-25	eukaryotic translation initiation factor 4E	Homo sapiens	34-40
12865212-4	2003	RESULTS: The 20-mer asODN against eIF-4E specifically and significantly inhibited eIF-4E protein expression, and as a result, a significant reduction in heparanase mRNA level was observed by Northern blotting in conjunction with significantly decreased heparanase protein expression.	asodn	20-25	eukaryotic translation initiation factor 4E	Homo sapiens	82-88
12838026-6	2003	RESULTS: The overexpression of eIF4E was observed in all 37 paraffin-embedded samples of laryngeal squamous cell carcinoma, whereas no staining was noticed in vocal cords polyps samples.	Paraffin	60-68	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
12777618-3	2003	To circumvent this limitation, we have developed a procedure for the purification of eukaryotic mRNAs using a mutant version of the mRNA 5" cap-binding protein (eIF4E) with increased affinity for the m7GTP moiety of the cap.	7-methylguanosine triphosphate	200-205	eukaryotic translation initiation factor 4E	Homo sapiens	161-166
12641566-6	2003	Here, we demonstrate that these BrdU-treated lung cells express elevated levels of eIF4E protein and enhanced phosphorylation of eIF4E.	Bromodeoxyuridine	32-36	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
12921974-6	2003	Finally, our studies showed that high concentrations of troglitazone inhibited the translation initiation factor 4E (eIF4E), but not eIF4G.	Troglitazone	56-68	eukaryotic translation initiation factor 4E	Homo sapiens	117-122
12755627-9	2003	A similar mode of interaction with 7-methyl-GTP was found for human cap binding protein eIF4E.	7-methylguanosine triphosphate	35-47	eukaryotic translation initiation factor 4E	Homo sapiens	88-93
12755627-10	2003	However, the potency of 7-methyl-GTP for cap binding inhibition was 200-fold stronger with eIF4E and had a higher contribution from the triphosphate moiety as compared to influenza RNP.	7-methylguanosine triphosphate	24-36	eukaryotic translation initiation factor 4E	Homo sapiens	91-96
12747827-7	2003	CONCLUSIONS: Our data demonstrate that the TOS motif functions as a docking site for the mTOR/raptor complex, which is required for multisite phosphorylation of 4E-BP1, eIF4E release from 4E-BP1, and cell growth.	tos	43-46	eukaryotic translation initiation factor 4E	Homo sapiens	169-174
14565465-0	2003	Thermodynamics of 7-methylguanosine cation stacking with tryptophan upon mRNA 5" cap binding to translation factor eIF4E.	7-methylguanosine	18-35	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
14565465-0	2003	Thermodynamics of 7-methylguanosine cation stacking with tryptophan upon mRNA 5" cap binding to translation factor eIF4E.	Tryptophan	57-67	eukaryotic translation initiation factor 4E	Homo sapiens	115-120
14565465-2	2003	The goal of the present study is to dissect the enthalpy and entropy changes of association of the mRNA 5" cap with eIF4E into contributions originating from the interaction of 7-methylguanosine with tryptophan.	7-methylguanosine	177-194	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
14565465-2	2003	The goal of the present study is to dissect the enthalpy and entropy changes of association of the mRNA 5" cap with eIF4E into contributions originating from the interaction of 7-methylguanosine with tryptophan.	Tryptophan	200-210	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
14565501-2	2003	In the present study we have shown two opposing roles of the cap phosphate chain in the specific eIF4E-cap interaction.	Phosphates	65-74	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
14565501-3	2003	The extension of the phosphate chain enhances the binding of the cap to the unphosphorylated eIF4E but destabilises the eIF4E-cap complex in case of the phosphorylated protein.	Phosphates	21-30	eukaryotic translation initiation factor 4E	Homo sapiens	93-98
14565501-3	2003	The extension of the phosphate chain enhances the binding of the cap to the unphosphorylated eIF4E but destabilises the eIF4E-cap complex in case of the phosphorylated protein.	Phosphates	21-30	eukaryotic translation initiation factor 4E	Homo sapiens	120-125
12691746-1	2003	The structural features of human eIF4E were investigated by X-ray crystal analyses of its cap analog (m(7)GTP and m(7)GpppA) complexes and molecular dynamics (MD) simulations of cap-free and cap-bound eIF4Es, as well as the cap-bound Ser209-phosphorylated eIF4E.	(7)gtp	103-109	eukaryotic translation initiation factor 4E	Homo sapiens	33-38
12691746-9	2003	SDS-PAGE analyses showed that this structural instability is highly related to the fast degradation of cap-free eIF4E, compared with cap-bound or 4E-BP/cap-bound eIF4E, indicating the conferment of structural stability of eIF4E by the binary or ternary complex formation.	Sodium Dodecyl Sulfate	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	112-117
12691746-9	2003	SDS-PAGE analyses showed that this structural instability is highly related to the fast degradation of cap-free eIF4E, compared with cap-bound or 4E-BP/cap-bound eIF4E, indicating the conferment of structural stability of eIF4E by the binary or ternary complex formation.	cap	103-106	eukaryotic translation initiation factor 4E	Homo sapiens	112-117
12641566-6	2003	Here, we demonstrate that these BrdU-treated lung cells express elevated levels of eIF4E protein and enhanced phosphorylation of eIF4E.	Bromodeoxyuridine	32-36	eukaryotic translation initiation factor 4E	Homo sapiens	129-134
12554669-3	2003	Surprisingly, we found that a trans cription factor, the proline-rich homeodomain protein PRH, is a negative regulator of eIF4E in myeloid cells, interacting with eIF4E through a conserved binding site typically found in translational regulators.	Proline	57-64	eukaryotic translation initiation factor 4E	Homo sapiens	122-127
12554669-3	2003	Surprisingly, we found that a trans cription factor, the proline-rich homeodomain protein PRH, is a negative regulator of eIF4E in myeloid cells, interacting with eIF4E through a conserved binding site typically found in translational regulators.	Proline	57-64	eukaryotic translation initiation factor 4E	Homo sapiens	163-168
12193593-5	2002	In addition, 5(S)-HETE stimulated phosphatidylinositol 3-kinase (PI3-kinase) activity and phosphorylation of its downstream targets Akt, p70S6K, and 4E-BP1 and their effector molecules ribosomal protein S6 and eIF4E.	5-hydroxy-6,8,11,14-eicosatetraenoic acid	13-22	eukaryotic translation initiation factor 4E	Homo sapiens	210-215
12554876-3	2003	To address this problem, we applied a unique technique in protein engineering, intein-mediated protein ligation, to synthesize eIF4E, which is selectively phosphorylated at Ser 209.	Serine	173-176	eukaryotic translation initiation factor 4E	Homo sapiens	127-132
12554876-5	2003	A 1.5- to 4.5-fold reduction of the cap affinity for phosphorylated eIF4E was observed, depending on the negative charge of the 5"-to-5" phosphate chains as well as the presence of a longer tetraribonucleotide strand.	Phosphates	137-146	eukaryotic translation initiation factor 4E	Homo sapiens	68-73
12554876-5	2003	A 1.5- to 4.5-fold reduction of the cap affinity for phosphorylated eIF4E was observed, depending on the negative charge of the 5"-to-5" phosphate chains as well as the presence of a longer tetraribonucleotide strand.	tetraribonucleotide	190-209	eukaryotic translation initiation factor 4E	Homo sapiens	68-73
12171932-6	2002	On the other hand, LY294002 and wortmannin, specific inhibitors of PI3K, prevented PDGF-BB-induced phosphorylation of Akt and its downstream effector molecules, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	19-27	eukaryotic translation initiation factor 4E	Homo sapiens	203-208
12171932-6	2002	On the other hand, LY294002 and wortmannin, specific inhibitors of PI3K, prevented PDGF-BB-induced phosphorylation of Akt and its downstream effector molecules, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E.	Wortmannin	32-42	eukaryotic translation initiation factor 4E	Homo sapiens	203-208
12171932-7	2002	NEM also abrogated the phosphorylation of p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E induced by PDGF-BB, suggesting that thiol alkylation interferes with the PI3K/Akt pathway at the level of Akt.	Sulfhydryl Compounds	126-131	eukaryotic translation initiation factor 4E	Homo sapiens	84-89
12374755-5	2002	Although the structure is very different from that of other known cap-binding proteins, such as the cytoplasmic cap-binding protein eIF4E, specificity for the methylated guanosine again is achieved by sandwiching the base between two aromatic residues, in this case two conserved tyrosines.	Guanosine	170-179	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
12374755-5	2002	Although the structure is very different from that of other known cap-binding proteins, such as the cytoplasmic cap-binding protein eIF4E, specificity for the methylated guanosine again is achieved by sandwiching the base between two aromatic residues, in this case two conserved tyrosines.	Tyrosine	280-289	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
12167712-0	2002	Gamma interferon and cadmium treatments modulate eukaryotic initiation factor 4E-dependent mRNA transport of cyclin D1 in a PML-dependent manner.	Cadmium	21-28	eukaryotic translation initiation factor 4E	Homo sapiens	49-80
12356315-7	2002	Intramolecular self-stacking of the dinucleotide cap-analogue was analyzed to reveal the influence of this coupled process on the thermodynamic parameters of the eIF4E-mRNA 5" cap interaction.	Dinucleoside Phosphates	36-48	eukaryotic translation initiation factor 4E	Homo sapiens	162-167
12239292-7	2002	VSV infection of HeLa cells resulted in the dephosphorylation of eIF4E at serine 209 between 3 and 6 h postinfection.	Serine	74-80	eukaryotic translation initiation factor 4E	Homo sapiens	65-70
12138083-1	2002	Previous work has suggested that increased phosphorylation of eukaryotic initiation factor (eIF) 4E at Ser-209 in the C-terminal loop of the protein often correlates with increased translation rates.	Serine	103-106	eukaryotic translation initiation factor 4E	Homo sapiens	62-99
12167712-6	2002	Here we report that cadmium treatment, which disperses PML nuclear bodies, leaves eIF4E bodies intact, leading to increased transport of cyclin D1 mRNA and increased cyclin D1 protein levels.	Cadmium	20-27	eukaryotic translation initiation factor 4E	Homo sapiens	82-87
12167712-7	2002	Removal of cadmium allows PML to reassociate with eIF4E nuclear bodies, leading to decreased cyclin D1 transport and reduced cyclin D1 protein levels.	Cadmium	11-18	eukaryotic translation initiation factor 4E	Homo sapiens	50-55
12167712-10	2002	Consistently, overexpression of a series of PML and eIF4E mutant proteins established that PML eIF4E interaction is required for the observed effects of cadmium and interferon treatment.	Cadmium	153-160	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
12167712-10	2002	Consistently, overexpression of a series of PML and eIF4E mutant proteins established that PML eIF4E interaction is required for the observed effects of cadmium and interferon treatment.	Cadmium	153-160	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
12151318-5	2002	Although time had little effect on eIF4E and 4E-BP1 expression and phosphorylation state of control cells, H2O2 induced a 2- to 3-fold increase in eIF4E and 4E-BP1 expression, a 5-fold increase in eIF4E phosphorylation, and a shift in the distribution of 4E-BP1 phosphorylation favoring lesser phosphorylated forms.	Hydrogen Peroxide	107-111	eukaryotic translation initiation factor 4E	Homo sapiens	147-163
12082457-6	2002	By altering the expression of eIF4E, it was possible to modulate the sensitivity of various cell lines to ganciclovir.	Ganciclovir	106-117	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
12054859-2	2002	The association constant values of recombinant eIF4E for 20 different cap analogues cover six orders of magnitude; with the highest affinity observed for m(7)GTP (approximately 1.1 x 10(8) M(-1)).	(7)gtp	155-161	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
12151318-4	2002	Cells were exposed to 200 or 400 microM H2O2 for 4 h and then assessed for changes in proliferation, protein synthesis, and eIF4E and 4E-BP1 status over 72 h. We found that both concentrations of H2O2 inhibited [3H]thymidine incorporation and cell division while inducing a G2/M-predominant growth arrest within 24 h. In addition, H2O2 increased cell size, [3H]leucine incorporation/cell, and total cell protein.	Hydrogen Peroxide	196-200	eukaryotic translation initiation factor 4E	Homo sapiens	124-140
12151318-4	2002	Cells were exposed to 200 or 400 microM H2O2 for 4 h and then assessed for changes in proliferation, protein synthesis, and eIF4E and 4E-BP1 status over 72 h. We found that both concentrations of H2O2 inhibited [3H]thymidine incorporation and cell division while inducing a G2/M-predominant growth arrest within 24 h. In addition, H2O2 increased cell size, [3H]leucine incorporation/cell, and total cell protein.	Hydrogen Peroxide	196-200	eukaryotic translation initiation factor 4E	Homo sapiens	124-140
12056899-4	2002	Whereas eIF4E employs two tryptophans, VP39 uses a tyrosine and a phenylalanine.	Tryptophan	26-37	eukaryotic translation initiation factor 4E	Homo sapiens	8-13
12054859-8	2002	Electrostatically steered eIF4E-cap association is accompanied by additional hydration of the complex by approximately 65 water molecules, and by ionic equilibria shift.	Water	122-127	eukaryotic translation initiation factor 4E	Homo sapiens	26-31
12054859-9	2002	Temperature dependence reveals the enthalpy-driven and entropy-opposed character of the m(7)GTP-eIF4E binding, which results from dominant charge-related interactions (DeltaH degrees =-17.8 kcal/mol, DeltaS degrees= -23.6 cal/mol K).	(7)gtp	89-95	eukaryotic translation initiation factor 4E	Homo sapiens	96-101
11847216-0	2002	4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin.	Sirolimus	142-151	eukaryotic translation initiation factor 4E	Homo sapiens	40-71
11956083-8	2002	Surprisingly, the ability of etoposide to cause increased association of eIF4E with 4E-BP1 does require PKR activity.	Etoposide	29-38	eukaryotic translation initiation factor 4E	Homo sapiens	73-78
11959093-0	2002	Mutations in the S4-H2 loop of eIF4E which increase the affinity for m7GTP.	7-methylguanosine triphosphate	69-74	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
11959093-2	2002	Photolabeling of eIF4E with [gamma-32P]8-azidoguanosine 5"-triphosphate (8-N3GTP) demonstrated cross-linking at Lys-119 in the S4-H2 loop which is distant from the m7GTP binding site [Marcotrigiano et al.	[gamma-32p]8-azidoguanosine 5"-triphosphate	28-71	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
11959093-2	2002	Photolabeling of eIF4E with [gamma-32P]8-azidoguanosine 5"-triphosphate (8-N3GTP) demonstrated cross-linking at Lys-119 in the S4-H2 loop which is distant from the m7GTP binding site [Marcotrigiano et al.	8-azidoguanosine triphosphate	73-80	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
11959093-2	2002	Photolabeling of eIF4E with [gamma-32P]8-azidoguanosine 5"-triphosphate (8-N3GTP) demonstrated cross-linking at Lys-119 in the S4-H2 loop which is distant from the m7GTP binding site [Marcotrigiano et al.	Lysine	112-115	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
11723111-3	2002	Mitogens and cytokines stimulate the phosphorylation of eIF4E at Ser(209), but the functional consequences of this modification have remained a major unresolved question.	Serine	65-68	eukaryotic translation initiation factor 4E	Homo sapiens	56-61
11799119-1	2002	The phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA), a potent stimulator of Erk, leads to the phosphorylation of 4E-BP1 and its dissociation from eIF4E.	Phorbol Esters	4-17	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
11799119-1	2002	The phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA), a potent stimulator of Erk, leads to the phosphorylation of 4E-BP1 and its dissociation from eIF4E.	Tetradecanoylphorbol Acetate	19-55	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
11799119-1	2002	The phorbol ester, 12-O-tetradecanoylphorbol 13-acetate (TPA), a potent stimulator of Erk, leads to the phosphorylation of 4E-BP1 and its dissociation from eIF4E.	Tetradecanoylphorbol Acetate	57-60	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
11879179-0	2002	Crystal structures of 7-methylguanosine 5"-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)-adenosine-5",5"-triphosphate (m(7)GpppA)-bound human full-length eukaryotic initiation factor 4E: biological importance of the C-terminal flexible region.	7-methylguanosine triphosphate	22-55	eukaryotic translation initiation factor 4E	Homo sapiens	164-195
11879179-0	2002	Crystal structures of 7-methylguanosine 5"-triphosphate (m(7)GTP)- and P(1)-7-methylguanosine-P(3)-adenosine-5",5"-triphosphate (m(7)GpppA)-bound human full-length eukaryotic initiation factor 4E: biological importance of the C-terminal flexible region.	m7GpppA	71-127	eukaryotic translation initiation factor 4E	Homo sapiens	164-195
11879179-1	2002	The crystal structures of the full-length human eukaryotic initiation factor (eIF) 4E complexed with two mRNA cap analogues [7-methylguanosine 5"-triphosphate (m(7)GTP) and P(1)-7-methylguanosine-P(3)-adenosine-5",5"-triphosphate (m(7)GpppA)] were determined at 2.0 A resolution (where 1 A=0.1 nm).	7-methylguanosine triphosphate	125-158	eukaryotic translation initiation factor 4E	Homo sapiens	48-85
11879179-1	2002	The crystal structures of the full-length human eukaryotic initiation factor (eIF) 4E complexed with two mRNA cap analogues [7-methylguanosine 5"-triphosphate (m(7)GTP) and P(1)-7-methylguanosine-P(3)-adenosine-5",5"-triphosphate (m(7)GpppA)] were determined at 2.0 A resolution (where 1 A=0.1 nm).	(7)gtp	161-167	eukaryotic translation initiation factor 4E	Homo sapiens	48-85
11879179-1	2002	The crystal structures of the full-length human eukaryotic initiation factor (eIF) 4E complexed with two mRNA cap analogues [7-methylguanosine 5"-triphosphate (m(7)GTP) and P(1)-7-methylguanosine-P(3)-adenosine-5",5"-triphosphate (m(7)GpppA)] were determined at 2.0 A resolution (where 1 A=0.1 nm).	)-7-methylguanosine-p(3)-adenosine-5",5"-triphosphate	176-229	eukaryotic translation initiation factor 4E	Homo sapiens	48-85
11879179-2	2002	The flexibility of the C-terminal loop region of eIF4E complexed with m(7)GTP was significantly reduced when complexed with m(7)GpppA, suggesting the importance of the second nucleotide in the mRNA cap structure for the biological function of eIF4E, especially the fixation and orientation of the C-terminal loop region, including the eIF4E phosphorylation residue.	(7)gtp	71-77	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
11879179-2	2002	The flexibility of the C-terminal loop region of eIF4E complexed with m(7)GTP was significantly reduced when complexed with m(7)GpppA, suggesting the importance of the second nucleotide in the mRNA cap structure for the biological function of eIF4E, especially the fixation and orientation of the C-terminal loop region, including the eIF4E phosphorylation residue.	(7)gtp	71-77	eukaryotic translation initiation factor 4E	Homo sapiens	243-248
11879179-2	2002	The flexibility of the C-terminal loop region of eIF4E complexed with m(7)GTP was significantly reduced when complexed with m(7)GpppA, suggesting the importance of the second nucleotide in the mRNA cap structure for the biological function of eIF4E, especially the fixation and orientation of the C-terminal loop region, including the eIF4E phosphorylation residue.	(7)gtp	71-77	eukaryotic translation initiation factor 4E	Homo sapiens	243-248
11278829-6	2001	We find that modifications at the two sites immediately flanking the eIF4E-binding domain, Thr(46) and Ser(65), consistently have the most significant effects, and that phosphorylation of Ser(65) causes the greatest reduction in binding affinity.	Threonine	91-94	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
11606200-1	2001	Eukaryotic translation initiation factor 4E (eIF4E) is essential for efficient translation of the vast majority of capped cellular mRNAs; it binds the 5"-methylated guanosine cap of mRNA and serves as a nucleation point for the assembly of the 48S preinitiation complex.	Guanosine	165-174	eukaryotic translation initiation factor 4E	Homo sapiens	0-43
11606200-1	2001	Eukaryotic translation initiation factor 4E (eIF4E) is essential for efficient translation of the vast majority of capped cellular mRNAs; it binds the 5"-methylated guanosine cap of mRNA and serves as a nucleation point for the assembly of the 48S preinitiation complex.	Guanosine	165-174	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
11606200-6	2001	eIF4E that is modified such that it cannot be phosphorylated (Ser209-->Ala), is unimpaired in its ability to restore translation to an eIF4E-dependent in vitro translation system.	Alanine	74-77	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
11514293-6	2001	Chronic ethanol administration decreased the abundance of eukaryotic initiation factor (eIF)4G associated with eIF4E in the myocardium by 36% and increased the abundance of the translation response protein (4E-BP1) associated with eIF4E.	Ethanol	8-15	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
11514293-6	2001	Chronic ethanol administration decreased the abundance of eukaryotic initiation factor (eIF)4G associated with eIF4E in the myocardium by 36% and increased the abundance of the translation response protein (4E-BP1) associated with eIF4E.	Ethanol	8-15	eukaryotic translation initiation factor 4E	Homo sapiens	231-236
11514293-9	2001	These data suggest that a chronic alcohol-induced impairment in myocardial protein synthesis results in part from inhibition in peptide chain initiation secondary to marked changes in eIF4E availability and p70(S6K) phosphorylation.	Alcohols	34-41	eukaryotic translation initiation factor 4E	Homo sapiens	184-189
11513750-1	2001	The eukaryotic initiation factor 4E (eIF4E) binding protein (4E-BP1) interacts directly with eIF4E and prevents it from forming initiation factor (eIF4F) complexes required for the initiation of cap-dependent mRNA translation.	cap	195-198	eukaryotic translation initiation factor 4E	Homo sapiens	4-35
11513750-1	2001	The eukaryotic initiation factor 4E (eIF4E) binding protein (4E-BP1) interacts directly with eIF4E and prevents it from forming initiation factor (eIF4F) complexes required for the initiation of cap-dependent mRNA translation.	cap	195-198	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
11513750-1	2001	The eukaryotic initiation factor 4E (eIF4E) binding protein (4E-BP1) interacts directly with eIF4E and prevents it from forming initiation factor (eIF4F) complexes required for the initiation of cap-dependent mRNA translation.	cap	195-198	eukaryotic translation initiation factor 4E	Homo sapiens	147-152
11513750-3	2001	Here we show that D-glucose promotes the ability of insulin to bring about the phosphorylation of 4E-BP1 and the formation of eIF4F complexes.	Glucose	18-27	eukaryotic translation initiation factor 4E	Homo sapiens	126-131
11483729-5	2001	Thus, initiation on the HAV IRES requires that eIF4E be associated with eIF4G and that the cap-binding pocket of eIF4E be empty and unoccupied.	cap	91-94	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
11498025-9	2001	In contrast, insulin-stimulation of the formation of eIF4F complexes requires glucose but not amino acids.	Glucose	78-85	eukaryotic translation initiation factor 4E	Homo sapiens	53-58
11463832-9	2001	Instead, we propose that the kinase activity of MNKs, eventually through phosphorylation of eIF4E, may serve to limit cap-dependent translation under physiological conditions.	cap	118-121	eukaryotic translation initiation factor 4E	Homo sapiens	92-97
11278829-6	2001	We find that modifications at the two sites immediately flanking the eIF4E-binding domain, Thr(46) and Ser(65), consistently have the most significant effects, and that phosphorylation of Ser(65) causes the greatest reduction in binding affinity.	Serine	103-106	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
11278829-6	2001	We find that modifications at the two sites immediately flanking the eIF4E-binding domain, Thr(46) and Ser(65), consistently have the most significant effects, and that phosphorylation of Ser(65) causes the greatest reduction in binding affinity.	Serine	188-191	eukaryotic translation initiation factor 4E	Homo sapiens	69-74
11368785-2	2001	Adenoviral gene transfer was employed to increase either eIF4F complex formation or the phosphorylation of eIF4E on Ser-209.	Serine	116-119	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
11368785-9	2001	We conclude the following: (1) eIF4F assembly is increased by raising eIF4E levels via adenoviral gene transfer; (2) the capbinding affinity of eIF4F is a rate-limiting determinant for total protein synthesis rates; and (3) increases in the quantity of eIF4Falone or in eIF4E phosphorylation are not sufficient to accelerate total protein synthesis rates.	eif4falone	253-263	eukaryotic translation initiation factor 4E	Homo sapiens	31-36
11368785-9	2001	We conclude the following: (1) eIF4F assembly is increased by raising eIF4E levels via adenoviral gene transfer; (2) the capbinding affinity of eIF4F is a rate-limiting determinant for total protein synthesis rates; and (3) increases in the quantity of eIF4Falone or in eIF4E phosphorylation are not sufficient to accelerate total protein synthesis rates.	eif4falone	253-263	eukaryotic translation initiation factor 4E	Homo sapiens	144-149
11437917-2	2001	Eight tryptophan residues, typical for eIF4E, are strictly conserved in the encoded 210 amino acid protein.	Tryptophan	6-16	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
11230136-3	2001	Decapping is activated in extracts by the addition of (7me)GpppG, which specifically sequesters cap-binding proteins such as eIF4E and the deadenylase DAN/PARN.	(7me)gpppg	54-64	eukaryotic translation initiation factor 4E	Homo sapiens	125-130
11331201-6	2001	Moreover, this alcohol-induced impairment in initiation is associated with a decreased availability of eukaryotic initiation factor (eIF) 4E in striated muscle, as evidenced by an increase in the amount of the inactive eIF4E.4E-BP1 complex and decrease in the active eIF4E.eIF4G complex.	Alcohols	15-22	eukaryotic translation initiation factor 4E	Homo sapiens	103-140
11238774-2	2001	Oral administration of leucine stimulates protein synthesis in association with hyperphosphorylation of the translational repressor, eukaryotic initiation factor (eIF) 4E binding protein 1 (4E-BP1), resulting in enhanced availability of the mRNA cap-binding protein eIF4E, for binding eIF4G and forming the active eIF4F complex.	Leucine	23-30	eukaryotic translation initiation factor 4E	Homo sapiens	266-271
10898981-7	2000	Single alanine substitutions at key positions in the peptides impair their binding to eIF4E and markedly reduce their ability to induce apoptosis.	Alanine	7-14	eukaryotic translation initiation factor 4E	Homo sapiens	86-91
11204566-6	2001	We confirm that expression of eIF-4E and eIF-2alpha is biologically relevant in that platelets continue protein synthesis, albeit at a 16 times lower rate than WBC (as determined by 35S-labeled amino acid incorporation, SDS-PAGE and scintillation counting).	Sulfur-35	182-185	eukaryotic translation initiation factor 4E	Homo sapiens	30-36
11204566-6	2001	We confirm that expression of eIF-4E and eIF-2alpha is biologically relevant in that platelets continue protein synthesis, albeit at a 16 times lower rate than WBC (as determined by 35S-labeled amino acid incorporation, SDS-PAGE and scintillation counting).	Sodium Dodecyl Sulfate	220-223	eukaryotic translation initiation factor 4E	Homo sapiens	30-36
11112322-6	2000	A 3.5-kb eIF4E clone isolated from starfish cDNA is 57% identical to human eIF4E and contains the putative phosphorylation site serine-209.	Serine	128-134	eukaryotic translation initiation factor 4E	Homo sapiens	9-14
11112322-8	2000	A starfish eIF4E fusion protein (GST-4E) was phosphorylated in vitro by PRK2 in the presence of 1,2-diolyl-sn-glycerol 3-phosphate.	1,2-diolyl-sn-glycerol 3-phosphate	96-130	eukaryotic translation initiation factor 4E	Homo sapiens	11-16
11112322-12	2000	Thus, PRK2 may regulate translation initiation during oocyte maturation by phosphorylating the serine-209 residue of eIF4E in starfish.	Serine	95-101	eukaryotic translation initiation factor 4E	Homo sapiens	117-122
11112322-13	2000	We also demonstrate that high levels of cAMP inhibit the activation of PRK2, eIF4E, and the eIF4E binding protein during starfish oocyte maturation, while PI3 kinase activates these proteins.	Cyclic AMP	40-44	eukaryotic translation initiation factor 4E	Homo sapiens	77-82
11114520-1	2000	A rate-limiting step during translation initiation in eukaryotic cells involves binding of the initiation factor eIF4E to the 7-methylguanosine-containing cap of mRNAs.	7-methylguanosine	126-143	eukaryotic translation initiation factor 4E	Homo sapiens	113-118
11114520-12	2000	Our findings suggest that Eap1p carries out an eIF4E-independent function to maintain genetic stability, most likely involving SPBs.	sleep-promoting factor B	127-131	eukaryotic translation initiation factor 4E	Homo sapiens	47-52
11076512-5	2000	To further understand the structural requirements for the specific recognition of an m(7)G mRNA cap, we determined the effects of amino acid substitutions in eIF4E and VP39 cap-binding sites on their affinity for m(7)GDP.	Guanosine Diphosphate	217-220	eukaryotic translation initiation factor 4E	Homo sapiens	158-163
11076512-7	2000	The results suggest that both eIF4E and VP39 require a complicated pattern of both orientation and identity of the stacking aromatic residues to permit the selective binding of m(7)GDP.	Guanosine Diphosphate	181-184	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
10942774-4	2000	A portion of PHAS-I that copurified with eIF4E reacted with Thr(P)-36/45 and Thr(P)-69 antibodies but not with Ser(P)-64 antibodies.	Threonine	60-63	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
10942774-4	2000	A portion of PHAS-I that copurified with eIF4E reacted with Thr(P)-36/45 and Thr(P)-69 antibodies but not with Ser(P)-64 antibodies.	Threonine	77-80	eukaryotic translation initiation factor 4E	Homo sapiens	41-46
10898981-8	2000	A triple alanine substitution, which abolishes binding to eIF4E, renders the peptide unable to induce apoptosis.	Alanine	9-16	eukaryotic translation initiation factor 4E	Homo sapiens	58-63
10856257-7	2000	Overexpression of wild-type 4E-T, but not of a mutant defective for eIF4E binding, causes the nuclear accumulation of HA-eIF4E in cells treated with leptomycin B.	leptomycin B	149-161	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
10820006-2	2000	eIF4E is a 25 kDa translation initiation protein, whose solution structure was previously solved in a 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS) micelle of total molecular mass approximately 45-50 kDa.	3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate	102-167	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
10828072-4	2000	To gain insight into molecular mechanisms by which ROS influence the pathogenesis of these diseases, I have studied the effect of H(2)O(2), a ROS, on eIF4E phosphorylation.	Reactive Oxygen Species	142-145	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
10828072-5	2000	H(2)O(2) induced eIF4E phosphorylation in a dose- and time-dependent manner in growth-arrested smooth muscle cells (SMC).	Hydrogen Peroxide	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
10828072-6	2000	H(2)O(2)-induced eIF4E phosphorylation occurred on serine residues.	Hydrogen Peroxide	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
10828072-6	2000	H(2)O(2)-induced eIF4E phosphorylation occurred on serine residues.	Serine	51-57	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
10828072-10	2000	In contrast, trifluoperazine, an antagonist of calcium/calmodulin kinases, completely blocked H(2)O(2)-induced eIF4E phosphorylation.	Trifluoperazine	13-28	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
10828072-10	2000	In contrast, trifluoperazine, an antagonist of calcium/calmodulin kinases, completely blocked H(2)O(2)-induced eIF4E phosphorylation.	Hydrogen Peroxide	94-102	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
10828072-11	2000	In addition, intracellular and extracellular Ca(2+) chelators significantly inhibited H(2)O(2)-induced eIF4E phosphorylation.	Hydrogen Peroxide	86-94	eukaryotic translation initiation factor 4E	Homo sapiens	103-108
10753934-1	2000	Stimulation of serum-starved human embryonic kidney (HEK) 293 cells with either the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), or insulin resulted in increases in the phosphorylation of 4E-BP1 and p70 S6 kinase, eIF4F assembly, and protein synthesis.	Phorbol Esters	84-97	eukaryotic translation initiation factor 4E	Homo sapiens	228-233
10753934-1	2000	Stimulation of serum-starved human embryonic kidney (HEK) 293 cells with either the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), or insulin resulted in increases in the phosphorylation of 4E-BP1 and p70 S6 kinase, eIF4F assembly, and protein synthesis.	Tetradecanoylphorbol Acetate	99-135	eukaryotic translation initiation factor 4E	Homo sapiens	228-233
10753934-1	2000	Stimulation of serum-starved human embryonic kidney (HEK) 293 cells with either the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA), or insulin resulted in increases in the phosphorylation of 4E-BP1 and p70 S6 kinase, eIF4F assembly, and protein synthesis.	Tetradecanoylphorbol Acetate	137-140	eukaryotic translation initiation factor 4E	Homo sapiens	228-233
10753934-6	2000	Transient transfection of constitutively active mitogen-activated protein kinase interacting kinase 1 (the eIF4E kinase) indicated that inhibition of protein synthesis and eIF4F assembly by PD098059 is not through inhibition of eIF4E phosphorylation but of other signals emanating from MEK.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	190-198	eukaryotic translation initiation factor 4E	Homo sapiens	107-112
10753934-6	2000	Transient transfection of constitutively active mitogen-activated protein kinase interacting kinase 1 (the eIF4E kinase) indicated that inhibition of protein synthesis and eIF4F assembly by PD098059 is not through inhibition of eIF4E phosphorylation but of other signals emanating from MEK.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	190-198	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
10744754-6	2000	IFE-3, the most closely related to mammalian eIF4E-1, binds only 7-methylguanosine caps and is essential for viability.	7-methylguanosine	65-82	eukaryotic translation initiation factor 4E	Homo sapiens	45-52
10820006-2	2000	eIF4E is a 25 kDa translation initiation protein, whose solution structure was previously solved in a 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS) micelle of total molecular mass approximately 45-50 kDa.	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	169-174	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
10891393-0	2000	Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies.	Serine	29-32	eukaryotic translation initiation factor 4E	Homo sapiens	19-25
10891393-1	2000	Phosphorylation of Ser 209 is thought to modulate the activity of the cap-binding factor eIF-4E which is a crucial component in the initiation complex for cap-dependent translation of mRNA.	Serine	19-22	eukaryotic translation initiation factor 4E	Homo sapiens	89-95
10891393-2	2000	We report here the full reconstitution of the p38 Map kinase cascade leading to phosphorylation of eIF-4E in vitro and the generation of antibodies specific for phospho-serine 209 in eIF-4E.	Serine	169-175	eukaryotic translation initiation factor 4E	Homo sapiens	99-105
10891393-2	2000	We report here the full reconstitution of the p38 Map kinase cascade leading to phosphorylation of eIF-4E in vitro and the generation of antibodies specific for phospho-serine 209 in eIF-4E.	Serine	169-175	eukaryotic translation initiation factor 4E	Homo sapiens	183-189
10891393-5	2000	By using a potent small molecular weight inhibitor of Mnk1, the upstream kinase for eIF-4E, we observed a rapid dephosphorylation of eIF-4E within 45 min after addition of the inhibitor, suggesting a high turnover of phosphate on eIF-4E mediated by Mnk1 and a yet unidentified phosphatase.	Phosphates	217-226	eukaryotic translation initiation factor 4E	Homo sapiens	84-90
10891393-5	2000	By using a potent small molecular weight inhibitor of Mnk1, the upstream kinase for eIF-4E, we observed a rapid dephosphorylation of eIF-4E within 45 min after addition of the inhibitor, suggesting a high turnover of phosphate on eIF-4E mediated by Mnk1 and a yet unidentified phosphatase.	Phosphates	217-226	eukaryotic translation initiation factor 4E	Homo sapiens	133-139
10891393-5	2000	By using a potent small molecular weight inhibitor of Mnk1, the upstream kinase for eIF-4E, we observed a rapid dephosphorylation of eIF-4E within 45 min after addition of the inhibitor, suggesting a high turnover of phosphate on eIF-4E mediated by Mnk1 and a yet unidentified phosphatase.	Phosphates	217-226	eukaryotic translation initiation factor 4E	Homo sapiens	133-139
10454551-6	1999	Moreover, despite rapamycin-induced dephosphorylation of 4BP-1, eIF-4E-eIF-4G complexes (eIF-4F) were still detected.	Sirolimus	18-27	eukaryotic translation initiation factor 4E	Homo sapiens	64-70
10882133-6	2000	Third, the addition of cap binding protein eIF4E inhibits deadenylation in vitro.	cap	23-26	eukaryotic translation initiation factor 4E	Homo sapiens	43-48
10648556-13	2000	We also demonstrate that eIF4E is specifically released from the speckles by the cap analogue m(7)GpppG in a cell permeabilization assay.	(7)gpppg	95-103	eukaryotic translation initiation factor 4E	Homo sapiens	25-30
10648556-15	2000	5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole (DRB) treatment of cells causes the condensation of eIF4E nuclear speckles.	Dichlororibofuranosylbenzimidazole	0-48	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
10648556-15	2000	5,6-dichloro-1-beta-d-ribofuranosylbenzimidazole (DRB) treatment of cells causes the condensation of eIF4E nuclear speckles.	Dichlororibofuranosylbenzimidazole	50-53	eukaryotic translation initiation factor 4E	Homo sapiens	101-106
11156290-0	2000	Stopped-flow and Brownian dynamics studies of electrostatic effects in the kinetics of binding of 7-methyl-GpppG to the protein eIF4E.	7-methyl-diguanosine triphosphate	98-112	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
11156290-1	2000	The kinetics of binding 7-methyl-GpppG, an analogue of the 5"-mRNA cap, to the cap-binding protein eIF4E, at 20 degrees C, in 50 mM Hepes-KOH buffer, pH 7.2, and 50, 150 and 350 mM KCl, was measured using a stopped-flow spectrofluorometer, and was simulated by means of a Brownian dynamics method.	7-methyl-diguanosine triphosphate	24-38	eukaryotic translation initiation factor 4E	Homo sapiens	99-104
10772338-2	2000	The association rate of 4E-BP1 with eIF4E increased by about two orders of magnitude in the presence of m7GTP (a model compound of mRNA cap structure), but the dissociation rate was scarcely affected, indicating the cap-dependent binding of 4E-BP1 to eIF4E.	7-methylguanosine triphosphate	104-109	eukaryotic translation initiation factor 4E	Homo sapiens	36-41
10772338-3	2000	On the other hand, phosphorylation of 4E-BP1 weakened its interaction with eIF4E whether m7GTP was present or not.	7-methylguanosine triphosphate	89-94	eukaryotic translation initiation factor 4E	Homo sapiens	75-80
10611225-0	2000	Eukaryotic translation initiation factor 4E (eIF4E) binding site and the middle one-third of eIF4GI constitute the core domain for cap-dependent translation, and the C-terminal one-third functions as a modulatory region.	cap	131-134	eukaryotic translation initiation factor 4E	Homo sapiens	0-43
10611225-0	2000	Eukaryotic translation initiation factor 4E (eIF4E) binding site and the middle one-third of eIF4GI constitute the core domain for cap-dependent translation, and the C-terminal one-third functions as a modulatory region.	cap	131-134	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
10504405-8	1999	However, eIF4E-BP1 and eIF4E kinases remain highly active during heat shock, as okadaic acid treatment restores phosphorylation of both factors in heat shocked cells.	Okadaic Acid	80-92	eukaryotic translation initiation factor 4E	Homo sapiens	9-14
10477262-5	1999	The stress-induced changes in eIF4E phosphorylation were totally abrogated by the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580, and were partly inhibited by the phosphoinositide 3-kinase inhibitor LY294002 and the mammalian target of rapamycin (mTOR) inhibitor rapamycin.	SB 203580	135-143	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
10477262-5	1999	The stress-induced changes in eIF4E phosphorylation were totally abrogated by the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580, and were partly inhibited by the phosphoinositide 3-kinase inhibitor LY294002 and the mammalian target of rapamycin (mTOR) inhibitor rapamycin.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	214-222	eukaryotic translation initiation factor 4E	Homo sapiens	30-35
10454551-6	1999	Moreover, despite rapamycin-induced dephosphorylation of 4BP-1, eIF-4E-eIF-4G complexes (eIF-4F) were still detected.	Sirolimus	18-27	eukaryotic translation initiation factor 4E	Homo sapiens	89-95
10439040-5	1999	In cells overexpressing eIF4E, c-myc is overexpressed and particularly the larger, CUG-initiated form (Myc1).	3-Carboxyumbelliferyl beta-D-galactopyranoside	83-86	eukaryotic translation initiation factor 4E	Homo sapiens	24-29
10364159-12	1999	Thr-37 and Thr-46 are efficiently phosphorylated in vitro by FRAP/mTOR when 4E-BP1 is bound to eIF4E.	Threonine	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
10364159-12	1999	Thr-37 and Thr-46 are efficiently phosphorylated in vitro by FRAP/mTOR when 4E-BP1 is bound to eIF4E.	Threonine	11-14	eukaryotic translation initiation factor 4E	Homo sapiens	95-100
10364159-14	1999	Phosphorylated Thr-37 and Thr-46 are detected in all phosphorylated in vivo 4E-BP1 isoforms, including those that interact with eIF4E.	Threonine	15-18	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
10364159-14	1999	Phosphorylated Thr-37 and Thr-46 are detected in all phosphorylated in vivo 4E-BP1 isoforms, including those that interact with eIF4E.	Threonine	26-29	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
10330171-8	1999	To test this model, we have employed the tetracycline-inducible system to increase eIF4E expression.	Tetracycline	41-53	eukaryotic translation initiation factor 4E	Homo sapiens	83-88
10330171-9	1999	Removal of tetracycline induced eIF4E expression up to fivefold over endogenous levels.	Tetracycline	11-23	eukaryotic translation initiation factor 4E	Homo sapiens	32-37
10216941-1	1999	Translation initiation factor 4E (eIF4E) binds the 7-methylguanosine cap structure of mRNA and mediates recruitment of mRNA to ribosomes, with the potential of regulating the overall rate of translation and discriminating between different RNAs.	7-methylguanosine	51-68	eukaryotic translation initiation factor 4E	Homo sapiens	34-39
10394359-1	1999	eIF4G uses a conserved Tyr-X-X-X-X-Leu-phi segment (where X is variable and phi is hydrophobic) to recognize eIF4E during cap-dependent translation initiation in eukaryotes.	Tyrosine	23-26	eukaryotic translation initiation factor 4E	Homo sapiens	109-114
10212283-1	1999	To understand the mechanisms of prostaglandin F2alpha (PGF2alpha)-induced protein synthesis in vascular smooth muscle cells (VSMC), we have studied its effect on two major signal transduction pathways: mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI3-kinase) and their downstream targets ribosomal protein S6 kinase (p70(S6k)) and eukaryotic initiation factor eIF4E and its regulator 4E-BP1.	Dinoprost	32-53	eukaryotic translation initiation factor 4E	Homo sapiens	384-389
10212283-1	1999	To understand the mechanisms of prostaglandin F2alpha (PGF2alpha)-induced protein synthesis in vascular smooth muscle cells (VSMC), we have studied its effect on two major signal transduction pathways: mitogen-activated protein kinases and phosphatidylinositol 3-kinase (PI3-kinase) and their downstream targets ribosomal protein S6 kinase (p70(S6k)) and eukaryotic initiation factor eIF4E and its regulator 4E-BP1.	Dinoprost	55-64	eukaryotic translation initiation factor 4E	Homo sapiens	384-389
10212283-3	1999	PGF2alpha also induced eIF4E and 4E-BP1 phosphorylation, global protein synthesis, and basic fibroblast growth factor-2 (bFGF-2) expression in VSMC.	Dinoprost	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	23-39
10212283-7	1999	PGF2alpha-induced phosphorylation of eIF4E and 4E-BP1 was also found to be sensitive to inhibition by both wortmannin and rapamycin.	Dinoprost	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	37-53
10212283-7	1999	PGF2alpha-induced phosphorylation of eIF4E and 4E-BP1 was also found to be sensitive to inhibition by both wortmannin and rapamycin.	Wortmannin	107-117	eukaryotic translation initiation factor 4E	Homo sapiens	37-53
10212283-7	1999	PGF2alpha-induced phosphorylation of eIF4E and 4E-BP1 was also found to be sensitive to inhibition by both wortmannin and rapamycin.	Sirolimus	122-131	eukaryotic translation initiation factor 4E	Homo sapiens	37-53
10206976-5	1999	In the present study, leucine stimulated phosphorylation of the eIF4E-binding protein, 4E-BP1, in L6 myoblasts, resulting in dissociation of eIF4E from the inactive eIF4E.4E-BP1 complex.	Leucine	22-29	eukaryotic translation initiation factor 4E	Homo sapiens	64-69
10206976-5	1999	In the present study, leucine stimulated phosphorylation of the eIF4E-binding protein, 4E-BP1, in L6 myoblasts, resulting in dissociation of eIF4E from the inactive eIF4E.4E-BP1 complex.	Leucine	22-29	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
10206976-5	1999	In the present study, leucine stimulated phosphorylation of the eIF4E-binding protein, 4E-BP1, in L6 myoblasts, resulting in dissociation of eIF4E from the inactive eIF4E.4E-BP1 complex.	Leucine	22-29	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
10022874-5	1999	Second, mitogens and stresses induce the phosphorylation of eIF4E at Ser 209, increasing the affinity of eIF4E for capped mRNA and for an associated scaffolding protein, eIF4G.	Serine	69-72	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
10022874-5	1999	Second, mitogens and stresses induce the phosphorylation of eIF4E at Ser 209, increasing the affinity of eIF4E for capped mRNA and for an associated scaffolding protein, eIF4G.	Serine	69-72	eukaryotic translation initiation factor 4E	Homo sapiens	105-110
10349744-1	1999	Binding of a long series of mono- and dinucleotide analogues of the 7-methylguanosine containing 5"-mRNA-cap to human protein translation initiation factor eIF4E has been investigated by means of fluorescence.	mono- and dinucleotide	28-50	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
10349744-1	1999	Binding of a long series of mono- and dinucleotide analogues of the 7-methylguanosine containing 5"-mRNA-cap to human protein translation initiation factor eIF4E has been investigated by means of fluorescence.	7-methylguanosine	68-85	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
10349744-3	1999	The results confirm participation of at least two conserved tryptophan residues of eIF4E in interaction with 7-methylguanine, as has been described recently for murine eIF4E, complexed with 7-methyl-GDP in crystal (Marcotrigiano et al., 1997, Cell 89, 951), and for yeast eIF4E, complexed with the same ligand in solution (Matsuo et al., 1997, Nature Struct.	Tryptophan	60-70	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
10349744-3	1999	The results confirm participation of at least two conserved tryptophan residues of eIF4E in interaction with 7-methylguanine, as has been described recently for murine eIF4E, complexed with 7-methyl-GDP in crystal (Marcotrigiano et al., 1997, Cell 89, 951), and for yeast eIF4E, complexed with the same ligand in solution (Matsuo et al., 1997, Nature Struct.	7-methylguanine	109-124	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
10349744-3	1999	The results confirm participation of at least two conserved tryptophan residues of eIF4E in interaction with 7-methylguanine, as has been described recently for murine eIF4E, complexed with 7-methyl-GDP in crystal (Marcotrigiano et al., 1997, Cell 89, 951), and for yeast eIF4E, complexed with the same ligand in solution (Matsuo et al., 1997, Nature Struct.	7-methylguanosine 5'-diphosphate	190-202	eukaryotic translation initiation factor 4E	Homo sapiens	168-173
10349744-6	1999	On the other hand binding by eIF4E of unmethylated guanine nucleotides and N2,N2,7-trimethylguanine containing nucleotides differ substantially from the way of binding of the regular mRNA-cap.	Guanine Nucleotides	51-70	eukaryotic translation initiation factor 4E	Homo sapiens	29-34
10349744-7	1999	Influence of the structural features of the cap-analogues, especially the type of the second nucleoside in the dinucleotide caps, on their association with eIF4E and biological activities in in vitro protein translation systems has been discussed in light of the known structures of the eIF4E-7-methyl-GDP complexes in crystal and solution.	Nucleosides	93-103	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
10349744-7	1999	Influence of the structural features of the cap-analogues, especially the type of the second nucleoside in the dinucleotide caps, on their association with eIF4E and biological activities in in vitro protein translation systems has been discussed in light of the known structures of the eIF4E-7-methyl-GDP complexes in crystal and solution.	Dinucleoside Phosphates	111-123	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
10349744-7	1999	Influence of the structural features of the cap-analogues, especially the type of the second nucleoside in the dinucleotide caps, on their association with eIF4E and biological activities in in vitro protein translation systems has been discussed in light of the known structures of the eIF4E-7-methyl-GDP complexes in crystal and solution.	Guanosine Diphosphate	302-305	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
10037284-5	1999	Immunohistochemical analysis was used to detect eIF4E on paraffin embedded sections of the tumor and the histologically negative surgical margins.	Paraffin	57-65	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
10216947-8	1999	However, an increase in active eIF-4E may allow for the synthesis of ODC even in the presence of polyamine levels that repress ODC translation in cells with lower levels of the initiation factor.	Polyamines	97-106	eukaryotic translation initiation factor 4E	Homo sapiens	31-37
9812990-5	1998	Leucine, but not histidine, additionally caused a redistribution of eIF4E from the inactive eIF4E.4E-BP1 complex to the active eIF4E.eIF4G complex.	Leucine	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	68-73
9812990-5	1998	Leucine, but not histidine, additionally caused a redistribution of eIF4E from the inactive eIF4E.4E-BP1 complex to the active eIF4E.eIF4G complex.	Leucine	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	92-97
9812990-5	1998	Leucine, but not histidine, additionally caused a redistribution of eIF4E from the inactive eIF4E.4E-BP1 complex to the active eIF4E.eIF4G complex.	Leucine	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	92-97
9812990-7	1998	The changes in 4E-BP1 phosphorylation and eIF4E redistribution associated with leucine deprivation were not observed in the presence of insulin.	Leucine	79-86	eukaryotic translation initiation factor 4E	Homo sapiens	42-47
9605667-6	1998	Quantification for eIF4E protein level was accomplished using a rabbit anti-eIF4E antibody and colorimetric development of Western blots using nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.	Nitroblue Tetrazolium	143-165	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
9722592-10	1998	Consistent with these findings, DAMGO-stimulated phosphorylation of 4E-BP1 impairs its ability to bind the translation initiation factor eIF-4E.	Enkephalin, Ala(2)-MePhe(4)-Gly(5)-	32-37	eukaryotic translation initiation factor 4E	Homo sapiens	137-143
9729789-2	1998	15N relaxation studies have been used to characterize the backbone dynamics of deuterated eIF4E in a CHAPS micelle for the apoprotein, the m7GDP-bound form, and the dinucleotide (m7GpppA)-bound form, as well as for CHAPS-free eIF4E.	15n	0-3	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
9729789-2	1998	15N relaxation studies have been used to characterize the backbone dynamics of deuterated eIF4E in a CHAPS micelle for the apoprotein, the m7GDP-bound form, and the dinucleotide (m7GpppA)-bound form, as well as for CHAPS-free eIF4E.	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	101-106	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
9729789-2	1998	15N relaxation studies have been used to characterize the backbone dynamics of deuterated eIF4E in a CHAPS micelle for the apoprotein, the m7GDP-bound form, and the dinucleotide (m7GpppA)-bound form, as well as for CHAPS-free eIF4E.	Dinucleoside Phosphates	165-177	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
9729789-2	1998	15N relaxation studies have been used to characterize the backbone dynamics of deuterated eIF4E in a CHAPS micelle for the apoprotein, the m7GDP-bound form, and the dinucleotide (m7GpppA)-bound form, as well as for CHAPS-free eIF4E.	m7GpppA	179-186	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
9729789-2	1998	15N relaxation studies have been used to characterize the backbone dynamics of deuterated eIF4E in a CHAPS micelle for the apoprotein, the m7GDP-bound form, and the dinucleotide (m7GpppA)-bound form, as well as for CHAPS-free eIF4E.	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	215-220	eukaryotic translation initiation factor 4E	Homo sapiens	90-95
9729789-3	1998	Large differences in overall correlation time between the CHAPS-free form (11.8 ns) and samples containing different concentrations of CHAPS (15.9-19.4 ns) indicate that eIF4E is embedded in a large micelle in the presence of CHAPS, with a total molecular weight in the range of 40-60 kDa.	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	58-63	eukaryotic translation initiation factor 4E	Homo sapiens	170-175
9729789-3	1998	Large differences in overall correlation time between the CHAPS-free form (11.8 ns) and samples containing different concentrations of CHAPS (15.9-19.4 ns) indicate that eIF4E is embedded in a large micelle in the presence of CHAPS, with a total molecular weight in the range of 40-60 kDa.	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	135-140	eukaryotic translation initiation factor 4E	Homo sapiens	170-175
9729789-3	1998	Large differences in overall correlation time between the CHAPS-free form (11.8 ns) and samples containing different concentrations of CHAPS (15.9-19.4 ns) indicate that eIF4E is embedded in a large micelle in the presence of CHAPS, with a total molecular weight in the range of 40-60 kDa.	3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate	135-140	eukaryotic translation initiation factor 4E	Homo sapiens	170-175
9582349-6	1998	The three-dimensional structure of 4EHP, as predicted by homology modeling, closely resembles that of eIF4E and site-directed mutagenesis analysis of 4EHP strongly suggests that it shares with eIF4E a common mechanism for cap binding.	cap	222-225	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
9582349-6	1998	The three-dimensional structure of 4EHP, as predicted by homology modeling, closely resembles that of eIF4E and site-directed mutagenesis analysis of 4EHP strongly suggests that it shares with eIF4E a common mechanism for cap binding.	cap	222-225	eukaryotic translation initiation factor 4E	Homo sapiens	193-198
9605667-6	1998	Quantification for eIF4E protein level was accomplished using a rabbit anti-eIF4E antibody and colorimetric development of Western blots using nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate.	5-bromo-4-chloro-3-indoxyl phosphate	170-206	eukaryotic translation initiation factor 4E	Homo sapiens	19-24
9545260-0	1998	The phosphorylation of eukaryotic initiation factor eIF4E in response to phorbol esters, cell stresses, and cytokines is mediated by distinct MAP kinase pathways.	Phorbol Esters	73-87	eukaryotic translation initiation factor 4E	Homo sapiens	52-57
9545260-3	1998	eIF4E phosphorylation is enhanced by phorbol esters.	Phorbol Esters	37-51	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
9545260-5	1998	Cell stresses such as arsenite and anisomycin and the cytokines tumor necrosis factor-alpha and interleukin-1beta also cause increased phosphorylation of eIF4E, which is abolished by the specific p38 MAP kinase inhibitor, SB203580.	arsenite	22-30	eukaryotic translation initiation factor 4E	Homo sapiens	154-159
9545260-5	1998	Cell stresses such as arsenite and anisomycin and the cytokines tumor necrosis factor-alpha and interleukin-1beta also cause increased phosphorylation of eIF4E, which is abolished by the specific p38 MAP kinase inhibitor, SB203580.	Anisomycin	35-45	eukaryotic translation initiation factor 4E	Homo sapiens	154-159
9545260-5	1998	Cell stresses such as arsenite and anisomycin and the cytokines tumor necrosis factor-alpha and interleukin-1beta also cause increased phosphorylation of eIF4E, which is abolished by the specific p38 MAP kinase inhibitor, SB203580.	SB 203580	222-230	eukaryotic translation initiation factor 4E	Homo sapiens	154-159
9548260-2	1998	eIF4F is itself a three-subunit complex comprising the cap-binding protein eIF4E, eIF4A, an ATP-dependent RNA helicase, and eIF4G, which interacts with both eIF4A and eIF4E and enhances cap binding by eIF4E.	Adenosine Triphosphate	92-95	eukaryotic translation initiation factor 4E	Homo sapiens	75-80
9548260-2	1998	eIF4F is itself a three-subunit complex comprising the cap-binding protein eIF4E, eIF4A, an ATP-dependent RNA helicase, and eIF4G, which interacts with both eIF4A and eIF4E and enhances cap binding by eIF4E.	Adenosine Triphosphate	92-95	eukaryotic translation initiation factor 4E	Homo sapiens	167-172
9548260-2	1998	eIF4F is itself a three-subunit complex comprising the cap-binding protein eIF4E, eIF4A, an ATP-dependent RNA helicase, and eIF4G, which interacts with both eIF4A and eIF4E and enhances cap binding by eIF4E.	Adenosine Triphosphate	92-95	eukaryotic translation initiation factor 4E	Homo sapiens	167-172
9531283-8	1998	The expression of 4E-BP2, a specific repressor of eIF4E function, is high in DP cells but decreases during maturation, raising the possibility of a role for 4E-BP2 in repressing eIF4E phosphorylation.	dp	77-79	eukaryotic translation initiation factor 4E	Homo sapiens	50-55
9468502-3	1998	We demonstrate that incubation of pancreatic islets with elevated glucose levels results in rapid and concentration-dependent phosphorylation of PHAS-I, an inhibitor of mRNA cap-binding protein, eukaryotic initiation factor (eIF)-4E.	Glucose	66-73	eukaryotic translation initiation factor 4E	Homo sapiens	195-232
9465032-5	1998	RAFT1 phosphorylation of 4E-BP1 on Thr-36 and Thr-45 blocks its association with the cap-binding protein, eIF-4E, in vitro, and phosphorylation of Thr-45 seems to be the major regulator of the 4E-BP1-eIF-4E interaction in vivo.	Threonine	46-49	eukaryotic translation initiation factor 4E	Homo sapiens	200-206
9465032-5	1998	RAFT1 phosphorylation of 4E-BP1 on Thr-36 and Thr-45 blocks its association with the cap-binding protein, eIF-4E, in vitro, and phosphorylation of Thr-45 seems to be the major regulator of the 4E-BP1-eIF-4E interaction in vivo.	Threonine	35-38	eukaryotic translation initiation factor 4E	Homo sapiens	106-112
9465032-5	1998	RAFT1 phosphorylation of 4E-BP1 on Thr-36 and Thr-45 blocks its association with the cap-binding protein, eIF-4E, in vitro, and phosphorylation of Thr-45 seems to be the major regulator of the 4E-BP1-eIF-4E interaction in vivo.	Threonine	35-38	eukaryotic translation initiation factor 4E	Homo sapiens	200-206
9465032-5	1998	RAFT1 phosphorylation of 4E-BP1 on Thr-36 and Thr-45 blocks its association with the cap-binding protein, eIF-4E, in vitro, and phosphorylation of Thr-45 seems to be the major regulator of the 4E-BP1-eIF-4E interaction in vivo.	Threonine	46-49	eukaryotic translation initiation factor 4E	Homo sapiens	106-112
9465032-5	1998	RAFT1 phosphorylation of 4E-BP1 on Thr-36 and Thr-45 blocks its association with the cap-binding protein, eIF-4E, in vitro, and phosphorylation of Thr-45 seems to be the major regulator of the 4E-BP1-eIF-4E interaction in vivo.	Threonine	46-49	eukaryotic translation initiation factor 4E	Homo sapiens	106-112
9465032-5	1998	RAFT1 phosphorylation of 4E-BP1 on Thr-36 and Thr-45 blocks its association with the cap-binding protein, eIF-4E, in vitro, and phosphorylation of Thr-45 seems to be the major regulator of the 4E-BP1-eIF-4E interaction in vivo.	Threonine	46-49	eukaryotic translation initiation factor 4E	Homo sapiens	200-206
9428738-0	1997	Signalling through either the p38 or ERK mitogen-activated protein (MAP) kinase pathway is obligatory for phorbol ester and T cell receptor complex (TCR-CD3)-stimulated phosphorylation of initiation factor (eIF) 4E in Jurkat T cells.	Phorbol Esters	106-119	eukaryotic translation initiation factor 4E	Homo sapiens	207-214
9458731-6	1998	Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter.	Sirolimus	5-14	eukaryotic translation initiation factor 4E	Homo sapiens	133-139
9458731-6	1998	Both rapamycin and wortmannin completely blocked the insulin-induced changes in 4E-BP1 phosphorylation and association of 4E-BP1 and eIF-4E; PD-98059 had no effect on either parameter.	Wortmannin	19-29	eukaryotic translation initiation factor 4E	Homo sapiens	133-139
9405468-1	1997	The eukaryotic initiation factor 4E (eIF4E)-binding protein, PHAS-I, was phosphorylated rapidly and stoichiometrically when incubated with [gamma-32P]ATP and the mammalian target of rapamycin (mTOR) that had been immunoprecipitated with an antibody, mTAb1, directed against a region near the COOH terminus of mTOR.	Phosphorus-32	146-149	eukaryotic translation initiation factor 4E	Homo sapiens	4-35
9405468-1	1997	The eukaryotic initiation factor 4E (eIF4E)-binding protein, PHAS-I, was phosphorylated rapidly and stoichiometrically when incubated with [gamma-32P]ATP and the mammalian target of rapamycin (mTOR) that had been immunoprecipitated with an antibody, mTAb1, directed against a region near the COOH terminus of mTOR.	Adenosine Triphosphate	150-153	eukaryotic translation initiation factor 4E	Homo sapiens	4-35
9428738-5	1997	In these studies, I show that activation of protein kinase C with phorbol ester, stimulation via the T cell receptor complex with the monoclonal antibody OKT3 and cellular stresses increase the phosphorylation of eIF4E in Jurkat T cells.	Phorbol Esters	66-79	eukaryotic translation initiation factor 4E	Homo sapiens	213-218
9160663-6	1997	Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059.	Sirolimus	121-130	eukaryotic translation initiation factor 4E	Homo sapiens	80-86
9160663-6	1997	Growth factor-induced phosphorylation of 4E-BP1 and dissociation of 4E-BP1 from eIF-4E was blocked in cells treated with rapamycin, wortmannin, or PD098059.	Wortmannin	132-142	eukaryotic translation initiation factor 4E	Homo sapiens	80-86
8774702-2	1996	By the direct expression of a synthetic gene encoding human eIF-4E as the soluble form in Escherichia coli and the application on a 7-methylguanosine-5"-triphosphate-Sepharose 4B cap affinity column, pure recombinant eIF-4E was prepared; the optimum pH for the binding of the mRNA cap was 7.5.	7-methylguanosine triphosphate	132-165	eukaryotic translation initiation factor 4E	Homo sapiens	60-66
9020107-4	1997	Results from affinity chromatography on m7GTP-agarose demonstrated that AII-induced phosphorylation of 4E-BP1 promotes its dissociation from eIF4E in target cells.	Sepharose	46-53	eukaryotic translation initiation factor 4E	Homo sapiens	141-146
9116502-9	1997	To isolate eIF-4E binding proteins, recombinant eIF-4E was linked to agarose beads and incubated with cell lysates.	Sepharose	69-76	eukaryotic translation initiation factor 4E	Homo sapiens	48-54
9007984-2	1997	In order to investigate the molecular basis for this recognition, photoaffinity labeling with [gamma-32P]8-N3GTP was used in binding site studies of human recombinant cap binding protein eIF-4E.	[gamma-32p]8-n3gtp	94-112	eukaryotic translation initiation factor 4E	Homo sapiens	187-193
9007984-5	1997	Aluminum (III)-chelate chromatography and reverse-phase HPLC were used to isolate the binding site peptide resulting from digestion of photolabeled eIF-4E with modified trypsin.	aluminum (iii)	0-14	eukaryotic translation initiation factor 4E	Homo sapiens	148-154
8971030-3	1996	This inhibition is causally related to reduced phosphorylation and consequent activation of 4E-BP1, a repressor of the function of the cap-binding protein, eIF4E.	cap	135-138	eukaryotic translation initiation factor 4E	Homo sapiens	156-161
8774702-2	1996	By the direct expression of a synthetic gene encoding human eIF-4E as the soluble form in Escherichia coli and the application on a 7-methylguanosine-5"-triphosphate-Sepharose 4B cap affinity column, pure recombinant eIF-4E was prepared; the optimum pH for the binding of the mRNA cap was 7.5.	7-methylguanosine triphosphate	132-165	eukaryotic translation initiation factor 4E	Homo sapiens	217-223
8774702-2	1996	By the direct expression of a synthetic gene encoding human eIF-4E as the soluble form in Escherichia coli and the application on a 7-methylguanosine-5"-triphosphate-Sepharose 4B cap affinity column, pure recombinant eIF-4E was prepared; the optimum pH for the binding of the mRNA cap was 7.5.	Sepharose	166-178	eukaryotic translation initiation factor 4E	Homo sapiens	60-66
8774702-3	1996	Among the amino acid residues conserved among various eIF-4E species, each of 14 functional residues was replaced with a nonpolar amino acid (alanine or leucine).	Alanine	142-149	eukaryotic translation initiation factor 4E	Homo sapiens	54-60
8774702-3	1996	Among the amino acid residues conserved among various eIF-4E species, each of 14 functional residues was replaced with a nonpolar amino acid (alanine or leucine).	Leucine	153-160	eukaryotic translation initiation factor 4E	Homo sapiens	54-60
8774702-6	1996	Glu103, and two histidine residues at positions 37 and 200 in human recombinant eIF-4E were suggested to be important for the recognition of the mRNA cap structure through direct interaction and/or indirect contributions.	Histidine	16-25	eukaryotic translation initiation factor 4E	Homo sapiens	80-86
8766822-3	1996	Since PD098059, an inhibitor of MAP kinase activation, also blocks insulin-induced phosphorylation of eIF4E, the MAP kinase pathway seems to mediate this effect.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	6-14	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
8662663-0	1996	Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins.	Serine	29-35	eukaryotic translation initiation factor 4E	Homo sapiens	19-25
8610440-6	1996	An artificial increase of the level of phosphorylated eIF4E by treating the cells with the phosphatase inhibitor okadaic acid changed neither the kinetics of EMCV and poliovirus infection, nor that of host shut-off.	Okadaic Acid	113-125	eukaryotic translation initiation factor 4E	Homo sapiens	54-59
8610440-8	1996	Besides this entry-induced eIF4E dephosphorylation, dephosphorylation was also induced by blocking protein synthesis with the initiation inhibitor pactamycin, or with the elongation inhibitor cycloheximide.	Pactamycin	147-157	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
8610440-8	1996	Besides this entry-induced eIF4E dephosphorylation, dephosphorylation was also induced by blocking protein synthesis with the initiation inhibitor pactamycin, or with the elongation inhibitor cycloheximide.	Cycloheximide	192-205	eukaryotic translation initiation factor 4E	Homo sapiens	27-32
8610440-9	1996	We conclude that eIF4E is dephosphorylated by entry of EMCV, and the effect is strengthened by the decrease in cap-dependent translation.	cap	111-114	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
7590282-0	1995	Role of Ser-53 phosphorylation in the activity of human translation initiation factor eIF-4E in mammalian and yeast cells.	Serine	8-11	eukaryotic translation initiation factor 4E	Homo sapiens	86-92
8652634-1	1996	1H-NMR spectroscopy was applied to a study of the mode of interaction, in aqueous medium in the pH range 5.2-8.5 and at low and high temperatures, between several mono- and dinucleotide analogues of the mRNA cap m7GpppG and a selected tripeptide Trp-Leu-Glu, and a tetrapeptide Trp-Glu-Asp-Glu, the sequence of which corresponds to one of the suspected binding sites in the mRNA cap-binding protein (CBP).	Hydrogen	0-2	eukaryotic translation initiation factor 4E	Homo sapiens	400-403
8599949-7	1996	Thus, inactivation of eIF-4E is, at least in part, responsible for inhibition of cap-dependent translation in rapamycin-treated cells.	Sirolimus	110-119	eukaryotic translation initiation factor 4E	Homo sapiens	22-28
8882708-1	1996	Recombinant human eukaryotic initiation factor-4E (eIF-4E), purified by m7GTP-Sepharose 4B affinity chromatography, was used for crystallization.	Sepharose	78-87	eukaryotic translation initiation factor 4E	Homo sapiens	18-49
8882708-1	1996	Recombinant human eukaryotic initiation factor-4E (eIF-4E), purified by m7GTP-Sepharose 4B affinity chromatography, was used for crystallization.	Sepharose	78-87	eukaryotic translation initiation factor 4E	Homo sapiens	51-57
8749714-4	1995	However, the phosphorylation state, as well as the turnover of phosphate on eIF-4E, remained unchanged.	Phosphates	63-72	eukaryotic translation initiation factor 4E	Homo sapiens	76-82
8749714-5	1995	Apparently, the change in protein synthesis after RA addition is regulated by another mechanism than eIF-4E phosphorylation.	Radium	50-52	eukaryotic translation initiation factor 4E	Homo sapiens	101-107
7782349-1	1995	Insulin-stimulated protamine kinase (cPK) and protein kinase C (PKC) phosphorylated eukaryotic protein synthesis initiation factor 4E (eIF-4E) on serine and threonine residues located on an identical tryptic fragment as judged by two-dimensional phosphopeptide mapping.	Serine	146-152	eukaryotic translation initiation factor 4E	Homo sapiens	84-133
7629182-7	1995	Moreover, rapamycin attenuated the stimulation of PHAS-I phosphorylation by insulin and markedly inhibited dissociation of PHAS-I.eIF-4E, without decreasing MAP kinase activity.	Sirolimus	10-19	eukaryotic translation initiation factor 4E	Homo sapiens	130-136
7629182-11	1995	Rapamycin may inhibit translation initiation by increasing PHAS-I binding to eIF-4E.	Sirolimus	0-9	eukaryotic translation initiation factor 4E	Homo sapiens	77-83
7782349-1	1995	Insulin-stimulated protamine kinase (cPK) and protein kinase C (PKC) phosphorylated eukaryotic protein synthesis initiation factor 4E (eIF-4E) on serine and threonine residues located on an identical tryptic fragment as judged by two-dimensional phosphopeptide mapping.	Serine	146-152	eukaryotic translation initiation factor 4E	Homo sapiens	135-141
7782349-1	1995	Insulin-stimulated protamine kinase (cPK) and protein kinase C (PKC) phosphorylated eukaryotic protein synthesis initiation factor 4E (eIF-4E) on serine and threonine residues located on an identical tryptic fragment as judged by two-dimensional phosphopeptide mapping.	Threonine	157-166	eukaryotic translation initiation factor 4E	Homo sapiens	135-141
7782349-6	1995	Compared to the dephosphorylation of the cPK-modified serine on eIF-4E, reticulocyte lysates and highly purified protein phosphatase 2A exhibited marked preference for the cPK-modified threonine.	Serine	54-60	eukaryotic translation initiation factor 4E	Homo sapiens	64-70
7782349-6	1995	Compared to the dephosphorylation of the cPK-modified serine on eIF-4E, reticulocyte lysates and highly purified protein phosphatase 2A exhibited marked preference for the cPK-modified threonine.	Threonine	185-194	eukaryotic translation initiation factor 4E	Homo sapiens	64-70
7883007-0	1995	Inhibition of protein synthesis by the heme-controlled eIF-2 alpha kinase leads to the appearance of mRNA-containing 48S complexes that contain eIF-4E but lack methionyl-tRNA(f).	Heme	39-43	eukaryotic translation initiation factor 4E	Homo sapiens	144-150
7666354-4	1995	The isolation of eIF-4E and its purification procedure using the m7GTP affinity chromatography were accomplished.	7-methylguanosine triphosphate	65-70	eukaryotic translation initiation factor 4E	Homo sapiens	17-23
7742816-4	1995	The soluble human eIF-4E digested from the fusion protein showed binding specificity for the m7GTP affinity column.	7-methylguanosine triphosphate	93-98	eukaryotic translation initiation factor 4E	Homo sapiens	18-24
8505316-1	1993	Eukaryotic translation initiation factor 4E (eIF-4E) is one component of the m7G-cap-binding protein complex eIF-4F and is required for cap-dependent translation initiation.	cap	81-84	eukaryotic translation initiation factor 4E	Homo sapiens	0-43
7933086-4	1994	First it is shown that adenovirus blocks the addition of phosphate to eIF-4E rather than enhancing its removal, establishing that the virus impairs a signalling pathway or protein kinase activity involved in eIF-4E phosphorylation.	Phosphates	57-66	eukaryotic translation initiation factor 4E	Homo sapiens	70-76
8125929-3	1994	Angiotensin II induced a 2-3-fold increase in the phosphorylation of eIF-4E in VSMC.	vsmc	79-83	eukaryotic translation initiation factor 4E	Homo sapiens	69-75
8125929-4	1994	The stimulation of phosphorylation was apparent at 20 min and persisted for at least 12 h. Phosphoamino acid analysis revealed that serine is the major residue of eIF-4E phosphorylated by angiotensin II.	Phosphoamino Acids	91-108	eukaryotic translation initiation factor 4E	Homo sapiens	163-169
8125929-4	1994	The stimulation of phosphorylation was apparent at 20 min and persisted for at least 12 h. Phosphoamino acid analysis revealed that serine is the major residue of eIF-4E phosphorylated by angiotensin II.	Serine	132-138	eukaryotic translation initiation factor 4E	Homo sapiens	163-169
8125929-5	1994	Staurosporine and calphostin C, two potent inhibitors of the serine/threonine protein kinase, protein kinase C, significantly attenuated the angiotensin II-induced eIF-4E phosphorylation.	Staurosporine	0-13	eukaryotic translation initiation factor 4E	Homo sapiens	164-170
8125929-5	1994	Staurosporine and calphostin C, two potent inhibitors of the serine/threonine protein kinase, protein kinase C, significantly attenuated the angiotensin II-induced eIF-4E phosphorylation.	calphostin C	18-30	eukaryotic translation initiation factor 4E	Homo sapiens	164-170
8125929-7	1994	Together, these observations indicate that angiotensin II induces phosphorylation of eIF-4E in a protein kinase C-dependent manner and suggest that this pathway may play an important role in the mechanism by which angiotensin II causes hypertrophy of VSMC.	vsmc	251-255	eukaryotic translation initiation factor 4E	Homo sapiens	85-91
8294456-6	1994	The in vitro product also formed a complex with eIF-4E, as judged by its ability to bind to m7GTP-Sepharose.	7-methylguanosine triphosphate	92-97	eukaryotic translation initiation factor 4E	Homo sapiens	48-54
8294456-6	1994	The in vitro product also formed a complex with eIF-4E, as judged by its ability to bind to m7GTP-Sepharose.	Sepharose	98-107	eukaryotic translation initiation factor 4E	Homo sapiens	48-54
8505316-1	1993	Eukaryotic translation initiation factor 4E (eIF-4E) is one component of the m7G-cap-binding protein complex eIF-4F and is required for cap-dependent translation initiation.	cap	81-84	eukaryotic translation initiation factor 4E	Homo sapiens	45-51
8505316-1	1993	Eukaryotic translation initiation factor 4E (eIF-4E) is one component of the m7G-cap-binding protein complex eIF-4F and is required for cap-dependent translation initiation.	cap	81-84	eukaryotic translation initiation factor 4E	Homo sapiens	109-115
8505316-2	1993	The phosphorylation state of eIF-4E correlates with increased activity and a major phosphorylation site resides at serine 53.	Serine	115-121	eukaryotic translation initiation factor 4E	Homo sapiens	29-35
8111971-9	1993	Treatment of oocytes with phorbol 12-myristate 13-acetate, an activator of protein kinase C, for 30 min prior to the addition of 1-MA resulted in the inhibition of 1-MA-induced phosphorylation of eIF-4E, translational activation, and germinal vesicle breakdown.	Tetradecanoylphorbol Acetate	26-57	eukaryotic translation initiation factor 4E	Homo sapiens	196-202
8444875-1	1993	Only serine phosphorylation of eukaryotic initiation factor-4E (eIF-4E) has been previously reported in intact cells.	Serine	5-11	eukaryotic translation initiation factor 4E	Homo sapiens	31-62
8444875-1	1993	Only serine phosphorylation of eukaryotic initiation factor-4E (eIF-4E) has been previously reported in intact cells.	Serine	5-11	eukaryotic translation initiation factor 4E	Homo sapiens	64-70
8444875-2	1993	We found that treatment of HepG2 cells with okadaic acid resulted in as much as 20% of eukaryotic initiation factor (eIF)-4E phosphorylation occurring on threonine residues and that tryptic phosphopeptide maps showed several previously unrecognized phosphopeptides.	Okadaic Acid	44-56	eukaryotic translation initiation factor 4E	Homo sapiens	87-124
8444875-2	1993	We found that treatment of HepG2 cells with okadaic acid resulted in as much as 20% of eukaryotic initiation factor (eIF)-4E phosphorylation occurring on threonine residues and that tryptic phosphopeptide maps showed several previously unrecognized phosphopeptides.	Threonine	154-163	eukaryotic translation initiation factor 4E	Homo sapiens	87-124
8444875-5	1993	The most notable finding was that hyperphosphorylation of eIF-4E and p220 increased binding of p220 but not eIF-4E to the m7GTP cap structure.	7-methylguanosine triphosphate	122-127	eukaryotic translation initiation factor 4E	Homo sapiens	58-64
8111971-9	1993	Treatment of oocytes with phorbol 12-myristate 13-acetate, an activator of protein kinase C, for 30 min prior to the addition of 1-MA resulted in the inhibition of 1-MA-induced phosphorylation of eIF-4E, translational activation, and germinal vesicle breakdown.	1-methyladenine	129-133	eukaryotic translation initiation factor 4E	Homo sapiens	196-202
8111971-9	1993	Treatment of oocytes with phorbol 12-myristate 13-acetate, an activator of protein kinase C, for 30 min prior to the addition of 1-MA resulted in the inhibition of 1-MA-induced phosphorylation of eIF-4E, translational activation, and germinal vesicle breakdown.	1-methyladenine	164-168	eukaryotic translation initiation factor 4E	Homo sapiens	196-202
8111971-11	1993	Another possibility is that eIF-4E is phosphorylated by an unknown kinase that is activated by the cascade of reactions stimulated by 1-MA.	1-methyladenine	134-138	eukaryotic translation initiation factor 4E	Homo sapiens	28-34
1587843-7	1992	Phosphopeptide mapping of eIF-4E from transformed cells indicated a single site of phosphorylation at Ser-53, which is the same as that identified previously in eIF-4E from reticulocytes and HeLa cells.	Serine	102-105	eukaryotic translation initiation factor 4E	Homo sapiens	26-32
1587843-7	1992	Phosphopeptide mapping of eIF-4E from transformed cells indicated a single site of phosphorylation at Ser-53, which is the same as that identified previously in eIF-4E from reticulocytes and HeLa cells.	Serine	102-105	eukaryotic translation initiation factor 4E	Homo sapiens	161-167
1333409-2	1992	We have found that okadaic acid is much more effective in increasing the phosphorylated fraction of eIF-4E than phorbol 12-myristate 13-acetate in Hep G2 cells.	Okadaic Acid	19-31	eukaryotic translation initiation factor 4E	Homo sapiens	100-106
1333409-3	1992	Phosphoprotein phosphatase 2A dephosphorylated eIF-4E isolated from both phorbol 12-myristate 13-acetate- or okadaic acid-treated cells, whereas alkaline and acid phosphatase were relatively ineffective.	Tetradecanoylphorbol Acetate	73-104	eukaryotic translation initiation factor 4E	Homo sapiens	47-53
1333409-3	1992	Phosphoprotein phosphatase 2A dephosphorylated eIF-4E isolated from both phorbol 12-myristate 13-acetate- or okadaic acid-treated cells, whereas alkaline and acid phosphatase were relatively ineffective.	Okadaic Acid	109-121	eukaryotic translation initiation factor 4E	Homo sapiens	47-53
1333409-4	1992	The ability of purified [35S]eIF-4E isolated from okadaic acid-treated cells to bind mRNA caps was compared to phosphoprotein phosphatase 2A-treated [35S]eIF-4E and found to be no different.	Sulfur-35	25-28	eukaryotic translation initiation factor 4E	Homo sapiens	29-35
1333409-4	1992	The ability of purified [35S]eIF-4E isolated from okadaic acid-treated cells to bind mRNA caps was compared to phosphoprotein phosphatase 2A-treated [35S]eIF-4E and found to be no different.	Okadaic Acid	50-62	eukaryotic translation initiation factor 4E	Homo sapiens	29-35
1403850-0	1992	Protein kinase C phosphorylates both serine and threonine residues of the mRNA cap binding protein eIF-4E.	Serine	37-43	eukaryotic translation initiation factor 4E	Homo sapiens	99-105
1403850-0	1992	Protein kinase C phosphorylates both serine and threonine residues of the mRNA cap binding protein eIF-4E.	Threonine	48-57	eukaryotic translation initiation factor 4E	Homo sapiens	99-105
1403850-2	1992	While the protein kinases which catalyze this reaction in intact cells have not been completely identified, evidence suggests that protein kinase C phosphorylates serine residues of eIF-4E in intact cells.	Serine	163-169	eukaryotic translation initiation factor 4E	Homo sapiens	182-188
1403850-3	1992	In this study we demonstrate that protein kinase C also phosphorylates threonine residues of recombinant human eIF-4E in vitro.	Threonine	71-80	eukaryotic translation initiation factor 4E	Homo sapiens	111-117
1403850-4	1992	Phosphorylation of threonine and serine was observed over a range of eIF-4E and salt concentrations.	Threonine	19-28	eukaryotic translation initiation factor 4E	Homo sapiens	69-75
1403850-4	1992	Phosphorylation of threonine and serine was observed over a range of eIF-4E and salt concentrations.	Serine	33-39	eukaryotic translation initiation factor 4E	Homo sapiens	69-75
1403850-7	1992	These findings demonstrate that protein kinase C can phosphorylate both serine and threonine residues of eIF-4E in vitro, but suggest that protein kinase C may not be the primary enzyme that phosphorylates eIF-4E in vivo.	Serine	72-78	eukaryotic translation initiation factor 4E	Homo sapiens	105-111
1403850-7	1992	These findings demonstrate that protein kinase C can phosphorylate both serine and threonine residues of eIF-4E in vitro, but suggest that protein kinase C may not be the primary enzyme that phosphorylates eIF-4E in vivo.	Threonine	83-92	eukaryotic translation initiation factor 4E	Homo sapiens	105-111
2207140-6	1990	Furthermore, the relative affinities of mRNA analogs (capped oligonucleotides) for these initiation factors indicate that the cap is the predominant feature recognized for binding, but other features also contribute to the eIF-4E:mRNA interaction.	Oligonucleotides	61-77	eukaryotic translation initiation factor 4E	Homo sapiens	223-229
2122455-1	1990	Eukaryotic protein synthesis initiation factor 4E (eIF-4E) is a 25-kDa polypeptide that binds to the 7-methylguanosine-containing cap of mRNA and participates in the transfer of mRNA to the 40S ribosomal subunit, a step that is rate-limiting for protein synthesis under most cellular conditions.	7-methylguanosine	101-118	eukaryotic translation initiation factor 4E	Homo sapiens	0-49
2122455-1	1990	Eukaryotic protein synthesis initiation factor 4E (eIF-4E) is a 25-kDa polypeptide that binds to the 7-methylguanosine-containing cap of mRNA and participates in the transfer of mRNA to the 40S ribosomal subunit, a step that is rate-limiting for protein synthesis under most cellular conditions.	7-methylguanosine	101-118	eukaryotic translation initiation factor 4E	Homo sapiens	51-57
2122455-3	1990	Previous studies have indicated that phosphorylation of eIF-4E at Ser-53 is correlated with an increased rate of protein synthesis in a variety of systems in vivo and is required for eIF-4E to become bound to the 48S initiation complex.	Serine	66-69	eukaryotic translation initiation factor 4E	Homo sapiens	56-62
2122455-3	1990	Previous studies have indicated that phosphorylation of eIF-4E at Ser-53 is correlated with an increased rate of protein synthesis in a variety of systems in vivo and is required for eIF-4E to become bound to the 48S initiation complex.	Serine	66-69	eukaryotic translation initiation factor 4E	Homo sapiens	183-189
2122455-7	1990	Cells transfected with the identical vector expressing a variant of eIF-4E, which contains alanine at position 53 and thus cannot be phosphorylated at the major in vivo site, grow normally.	Alanine	91-98	eukaryotic translation initiation factor 4E	Homo sapiens	68-74
2122455-8	1990	Estimations using the Ala-53 variant or a bacterial chloramphenicol acetyltransferase reporter gene in the same vector indicate that the degree of eIF-4E overexpression is 3- to 9-fold more than the endogenous level.	Alanine	22-25	eukaryotic translation initiation factor 4E	Homo sapiens	147-153
2355012-1	1990	Significant phosphorylation (up to 1 mol of phosphate/mol of p25 subunit) occurs only when the protein is part of the eIF-4F complex.	Phosphates	44-53	eukaryotic translation initiation factor 4E	Homo sapiens	118-124
2355012-2	1990	With purified eIF-4E, using the same conditions, up to 0.1 mol of phosphate can be incorporated.	Phosphates	66-75	eukaryotic translation initiation factor 4E	Homo sapiens	14-20
2386781-0	1990	Phenyl azide substituted and benzophenone-substituted phosphonamides of 7-methylguanosine 5"-triphosphate as photoaffinity probes for protein synthesis initiation factor eIF-4E and a proteolytic fragment containing the cap-binding site.	phenylazide	0-12	eukaryotic translation initiation factor 4E	Homo sapiens	170-176
2386781-0	1990	Phenyl azide substituted and benzophenone-substituted phosphonamides of 7-methylguanosine 5"-triphosphate as photoaffinity probes for protein synthesis initiation factor eIF-4E and a proteolytic fragment containing the cap-binding site.	benzophenone	29-41	eukaryotic translation initiation factor 4E	Homo sapiens	170-176
2386781-0	1990	Phenyl azide substituted and benzophenone-substituted phosphonamides of 7-methylguanosine 5"-triphosphate as photoaffinity probes for protein synthesis initiation factor eIF-4E and a proteolytic fragment containing the cap-binding site.	phosphonamides	54-68	eukaryotic translation initiation factor 4E	Homo sapiens	170-176
2386781-0	1990	Phenyl azide substituted and benzophenone-substituted phosphonamides of 7-methylguanosine 5"-triphosphate as photoaffinity probes for protein synthesis initiation factor eIF-4E and a proteolytic fragment containing the cap-binding site.	7-methylguanosine triphosphate	72-105	eukaryotic translation initiation factor 4E	Homo sapiens	170-176
2386781-1	1990	Three photoactive derivatives of the 7-methylguanosine-containing cap of eukaryotic mRNA were used to investigate protein synthesis initiation factor eIF-4E from human erythrocytes and rabbit reticulocytes.	7-methylguanosine	37-54	eukaryotic translation initiation factor 4E	Homo sapiens	150-156
2386781-2	1990	Sensitive and specific labeling of eIF-4E was observed with the previously described probe, [gamma-32P]-gamma-[[(4-benzoylphenyl)methyl]amido]-7-methyl-GTP [Blaas et al.	[gamma-32p]-gamma-[[(4-benzoylphenyl)methyl]amido]-7-methyl-gtp	92-155	eukaryotic translation initiation factor 4E	Homo sapiens	35-41
2386781-9	1990	A third probe, an azidophenylglycine derivative of m7GTP [( 32P]APGM), the monoanhydride of m7GDP with [32P]-N-(4-azidophenyl)-2-(phosphoramido)acetamide, was also synthesized and shown to label eIF-4E specifically.	azidophenylglycine	18-36	eukaryotic translation initiation factor 4E	Homo sapiens	195-201
2386781-9	1990	A third probe, an azidophenylglycine derivative of m7GTP [( 32P]APGM), the monoanhydride of m7GDP with [32P]-N-(4-azidophenyl)-2-(phosphoramido)acetamide, was also synthesized and shown to label eIF-4E specifically.	7-methylguanosine triphosphate	51-56	eukaryotic translation initiation factor 4E	Homo sapiens	195-201
2386781-9	1990	A third probe, an azidophenylglycine derivative of m7GTP [( 32P]APGM), the monoanhydride of m7GDP with [32P]-N-(4-azidophenyl)-2-(phosphoramido)acetamide, was also synthesized and shown to label eIF-4E specifically.	( 32p]apgm	58-68	eukaryotic translation initiation factor 4E	Homo sapiens	195-201
2386781-9	1990	A third probe, an azidophenylglycine derivative of m7GTP [( 32P]APGM), the monoanhydride of m7GDP with [32P]-N-(4-azidophenyl)-2-(phosphoramido)acetamide, was also synthesized and shown to label eIF-4E specifically.	monoanhydride	75-88	eukaryotic translation initiation factor 4E	Homo sapiens	195-201
2386781-9	1990	A third probe, an azidophenylglycine derivative of m7GTP [( 32P]APGM), the monoanhydride of m7GDP with [32P]-N-(4-azidophenyl)-2-(phosphoramido)acetamide, was also synthesized and shown to label eIF-4E specifically.	[32p]-n-(4-azidophenyl)-2-(phosphoramido)acetamide	103-153	eukaryotic translation initiation factor 4E	Homo sapiens	195-201
2386781-10	1990	Unlike [32P]BPM and [125I]APTM, however, [32P]APGM labeled eIF-4E* approximately 4-fold more readily than intact eIF-4E.	Phosphorus-32	42-45	eukaryotic translation initiation factor 4E	Homo sapiens	59-65
2386781-11	1990	Tryptic and CNBr cleavage suggested that eIF-4E* consists of a protease-resistant core of eIF-4E that retains the cap-binding site and consists of approximately residues 47-182.	cap	114-117	eukaryotic translation initiation factor 4E	Homo sapiens	41-47
2386781-11	1990	Tryptic and CNBr cleavage suggested that eIF-4E* consists of a protease-resistant core of eIF-4E that retains the cap-binding site and consists of approximately residues 47-182.	cap	114-117	eukaryotic translation initiation factor 4E	Homo sapiens	90-96
2334695-1	1990	The binding of N-7-substituted cap analogues to eIF-4E from human erythrocytes is described.	4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride	15-18	eukaryotic translation initiation factor 4E	Homo sapiens	48-54
2334695-4	1990	The pH dependence of binding of the cap analogues to eIF-4E indicates that the enolate form of the cap is preferred, as originally postulated by Rhoads et al.	enolate	79-86	eukaryotic translation initiation factor 4E	Homo sapiens	53-59
2334695-6	1990	Data indicate that there are differences in the mode of binding of alkyl-substituted and aryl-substituted cap analogues to eIF-4E arising from favorable interactions of the phenyl ring with the guanosine moiety.	Guanosine	194-203	eukaryotic translation initiation factor 4E	Homo sapiens	123-129
2303467-5	1990	eIF-4E phosphorylation was elevated by 1 h following serum activation and reached a peak by 3-5 h. Treatment of resting cells with phorbol ester also simultaneously stimulated eIF-4E phosphorylation and the movement of L32 mRNA into polysomes.	Phorbol Esters	131-144	eukaryotic translation initiation factor 4E	Homo sapiens	0-6
2105935-1	1990	Site-directed mutagenesis was used to replace the serine residue at the primary phosphorylation site of human eukaryotic initiation factor (eIF) 4E with an alanine residue.	Serine	50-56	eukaryotic translation initiation factor 4E	Homo sapiens	110-147
2105935-1	1990	Site-directed mutagenesis was used to replace the serine residue at the primary phosphorylation site of human eukaryotic initiation factor (eIF) 4E with an alanine residue.	Alanine	156-163	eukaryotic translation initiation factor 4E	Homo sapiens	110-147
2105935-8	1990	When translation reaction mixtures were resolved on sucrose density gradients, the 35S-labeled eIF-4ESer was found on the 48 S initiation complex in the presence of guanylyl imidodiphosphate, as reported earlier (Hiremath, L.S., Hiremath, S.T., Rychlik, W., Joshi, S., Domier, L.L., and Rhoads, R.E.	Sucrose	52-59	eukaryotic translation initiation factor 4E	Homo sapiens	95-104
2105935-8	1990	When translation reaction mixtures were resolved on sucrose density gradients, the 35S-labeled eIF-4ESer was found on the 48 S initiation complex in the presence of guanylyl imidodiphosphate, as reported earlier (Hiremath, L.S., Hiremath, S.T., Rychlik, W., Joshi, S., Domier, L.L., and Rhoads, R.E.	Sulfur-35	83-86	eukaryotic translation initiation factor 4E	Homo sapiens	95-104
2105935-8	1990	When translation reaction mixtures were resolved on sucrose density gradients, the 35S-labeled eIF-4ESer was found on the 48 S initiation complex in the presence of guanylyl imidodiphosphate, as reported earlier (Hiremath, L.S., Hiremath, S.T., Rychlik, W., Joshi, S., Domier, L.L., and Rhoads, R.E.	Guanylyl Imidodiphosphate	165-190	eukaryotic translation initiation factor 4E	Homo sapiens	95-104
17631896-1	2007	Structural complexes of the eukaryotic translation initiation factor 4E (eIF4E) with a series of N(7)-alkylated guanosine derivative mRNA cap analogue structures have been characterised.	4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride	97-101	eukaryotic translation initiation factor 4E	Homo sapiens	28-71
33971490-1	2021	Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are located at the meeting-point of ERK and p38 MAPK signaling pathways, which can phosphorylate eukaryotic translation initiation factor 4E (eIF4E) at the conserved serine 209 exclusively.	Serine	233-239	eukaryotic translation initiation factor 4E	Homo sapiens	164-207
33971490-1	2021	Mitogen-activated protein kinase (MAPK)-interacting kinases (MNKs) are located at the meeting-point of ERK and p38 MAPK signaling pathways, which can phosphorylate eukaryotic translation initiation factor 4E (eIF4E) at the conserved serine 209 exclusively.	Serine	233-239	eukaryotic translation initiation factor 4E	Homo sapiens	209-214
33812053-0	2021	Propofol inhibits tumor angiogenesis through targeting VEGF/VEGFR and mTOR/eIF4E signaling.	Propofol	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	75-80
33812053-8	2021	Propofol also inhibited VEGF/VEGFR2-and mTOR/eIF4E-mediated signaling pathways in endothelial cells.	Propofol	0-8	eukaryotic translation initiation factor 4E	Homo sapiens	45-50
28766096-4	2018	RESULTS: Increased phosphorylation levels of ERK, Mnk1, and eIF4E were observed in ovarian cancer cell exposed to chemotherapeutic agents, and paclitaxel-resistant SK-OV-3-r cells, and is a common response of ovarian cancer patients undergoing chemotherapy.	Paclitaxel	143-153	eukaryotic translation initiation factor 4E	Homo sapiens	60-65
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	eukaryotic translation initiation factor 4E	Homo sapiens	100-105
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
28766096-5	2018	MEK inhibitor U0126 inhibits basal and chemodrug-induced phosphorylation of ERK as well as Mnk1 and eIF4E, suggesting that Mnk1/eIF4E are the downstream signaling of ERK pathway and chemotherapy agents activate ERK/MNK/eIF4E in a MEK-dependent manner.	U 0126	14-19	eukaryotic translation initiation factor 4E	Homo sapiens	128-133
17631896-1	2007	Structural complexes of the eukaryotic translation initiation factor 4E (eIF4E) with a series of N(7)-alkylated guanosine derivative mRNA cap analogue structures have been characterised.	4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride	97-101	eukaryotic translation initiation factor 4E	Homo sapiens	73-78
17631896-1	2007	Structural complexes of the eukaryotic translation initiation factor 4E (eIF4E) with a series of N(7)-alkylated guanosine derivative mRNA cap analogue structures have been characterised.	Guanosine	112-121	eukaryotic translation initiation factor 4E	Homo sapiens	28-71
17631896-1	2007	Structural complexes of the eukaryotic translation initiation factor 4E (eIF4E) with a series of N(7)-alkylated guanosine derivative mRNA cap analogue structures have been characterised.	Guanosine	112-121	eukaryotic translation initiation factor 4E	Homo sapiens	73-78
17631896-2	2007	Mass spectrometry was used to determine apparent gas-phase equilibrium dissociation constants (K(d)) values of 0.15 microM, 13.6 microM, and 55.7 microM for eIF4E with 7-methyl-GTP (m(7)GTP), GTP, and GMP, respectively.	7-methylguanosine triphosphate	168-180	eukaryotic translation initiation factor 4E	Homo sapiens	157-162
17631896-2	2007	Mass spectrometry was used to determine apparent gas-phase equilibrium dissociation constants (K(d)) values of 0.15 microM, 13.6 microM, and 55.7 microM for eIF4E with 7-methyl-GTP (m(7)GTP), GTP, and GMP, respectively.	(7)gtp	183-189	eukaryotic translation initiation factor 4E	Homo sapiens	157-162
17631896-2	2007	Mass spectrometry was used to determine apparent gas-phase equilibrium dissociation constants (K(d)) values of 0.15 microM, 13.6 microM, and 55.7 microM for eIF4E with 7-methyl-GTP (m(7)GTP), GTP, and GMP, respectively.	Guanosine Triphosphate	177-180	eukaryotic translation initiation factor 4E	Homo sapiens	157-162
17631896-3	2007	For tight and specific binding to the eIF4E mononucleotide binding site, there seems to be a clear requirement for guanosine derivatives to possess both the delocalised positive charge of the N(7)-methylated guanine system and at least one phosphate group.	mononucleotide	44-58	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
17631896-3	2007	For tight and specific binding to the eIF4E mononucleotide binding site, there seems to be a clear requirement for guanosine derivatives to possess both the delocalised positive charge of the N(7)-methylated guanine system and at least one phosphate group.	Guanosine	115-124	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
17631896-3	2007	For tight and specific binding to the eIF4E mononucleotide binding site, there seems to be a clear requirement for guanosine derivatives to possess both the delocalised positive charge of the N(7)-methylated guanine system and at least one phosphate group.	4-(4-fluorophenyl)-2-methyl-6-(5-piperidinopentyloxy)pyrimidine hydrochloride	192-196	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
17631896-3	2007	For tight and specific binding to the eIF4E mononucleotide binding site, there seems to be a clear requirement for guanosine derivatives to possess both the delocalised positive charge of the N(7)-methylated guanine system and at least one phosphate group.	Guanine	208-215	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
17631896-3	2007	For tight and specific binding to the eIF4E mononucleotide binding site, there seems to be a clear requirement for guanosine derivatives to possess both the delocalised positive charge of the N(7)-methylated guanine system and at least one phosphate group.	Phosphates	240-249	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
17631896-4	2007	We show that the N(7)-benzylated monophosphates 7-benzyl-GMP (Bn(7)GMP) and 7-(p-fluorobenzyl)-GMP (FBn(7)GMP) bind eIF4E substantially more tightly than non-N(7)-alkylated guanosine derivatives (K(d) values of 7.0 microM and 2.0 microM, respectively).	n(7)-benzylated monophosphates	17-47	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
17631896-4	2007	We show that the N(7)-benzylated monophosphates 7-benzyl-GMP (Bn(7)GMP) and 7-(p-fluorobenzyl)-GMP (FBn(7)GMP) bind eIF4E substantially more tightly than non-N(7)-alkylated guanosine derivatives (K(d) values of 7.0 microM and 2.0 microM, respectively).	-n(7)-alkylated guanosine	157-182	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
17631896-5	2007	The eIF4E complex crystal structures with Bn(7)GMP and FBn(7)GMP show that additional favourable contacts of the benzyl groups with eIF4E contribute binding energy that compensates for loss of the beta and gamma-phosphates.	(2-benzoylethyl)trimethylammonium	197-201	eukaryotic translation initiation factor 4E	Homo sapiens	4-9
17631896-5	2007	The eIF4E complex crystal structures with Bn(7)GMP and FBn(7)GMP show that additional favourable contacts of the benzyl groups with eIF4E contribute binding energy that compensates for loss of the beta and gamma-phosphates.	(2-benzoylethyl)trimethylammonium	197-201	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
17631896-5	2007	The eIF4E complex crystal structures with Bn(7)GMP and FBn(7)GMP show that additional favourable contacts of the benzyl groups with eIF4E contribute binding energy that compensates for loss of the beta and gamma-phosphates.	gamma-phosphates	206-222	eukaryotic translation initiation factor 4E	Homo sapiens	4-9
17631896-5	2007	The eIF4E complex crystal structures with Bn(7)GMP and FBn(7)GMP show that additional favourable contacts of the benzyl groups with eIF4E contribute binding energy that compensates for loss of the beta and gamma-phosphates.	gamma-phosphates	206-222	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
17631896-6	2007	The N(7)-benzyl groups pack into a hydrophobic pocket behind the two tryptophan side-chains that are involved in the cation-pi stacking interaction between the cap and the eIF4E mononucleotide binding site.	Tryptophan	69-79	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
17631896-6	2007	The N(7)-benzyl groups pack into a hydrophobic pocket behind the two tryptophan side-chains that are involved in the cation-pi stacking interaction between the cap and the eIF4E mononucleotide binding site.	mononucleotide	178-192	eukaryotic translation initiation factor 4E	Homo sapiens	172-177
34965440-5	2021	Thus, KSHV regulation of the oxygen-sensing machinery allows virally infected cells to initiate translation via the mTOR-dependent eIF4E1 or the HIF2alpha-dependent, mTOR-independent, eIF4E2.	Oxygen	29-35	eukaryotic translation initiation factor 4E	Homo sapiens	131-137
34944712-9	2021	GSEA indicated that individuals with the increased levels of miR-154 had upregulated AKT-MTOR, CYCLIN D1, KRAS, EIF4E, RB, ATM, and EMT gene sets.	gsea	0-4	eukaryotic translation initiation factor 4E	Homo sapiens	112-117
34944630-8	2021	The metabolic shift by steviol was mediated through the repression of the phosphorylation of mTOR and translation initiation proteins (4E-BP1, eIF4e, eIF4B, and eIF4G).	steviol	23-30	eukaryotic translation initiation factor 4E	Homo sapiens	143-148
34214017-0	2021	Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.	cryptotanshinone	0-16	eukaryotic translation initiation factor 4E	Homo sapiens	102-107
34214017-9	2021	Furthermore, CPT and imatinib increased the apoptotic rates and markedly decreased the phosphorylation levels of STAT3 and eIF4E.	Imatinib Mesylate	21-29	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
34917504-6	2021	And the combination of borneol and radiation exposure significantly decreased the expression levels of HIF-1alpha, mTORC1 and eIF4E.	isoborneol	23-30	eukaryotic translation initiation factor 4E	Homo sapiens	126-131
34841476-5	2021	Exportin-1 is known to regulate nuclear to cytoplasmic trafficking of 5"-7-methylguanosine (m7G)-modified microRNAs and mRNAs that interact with its cargo protein EIF4E.	5"-7-methylguanosine	70-90	eukaryotic translation initiation factor 4E	Homo sapiens	163-168
34869595-7	2021	Subsequently, the upstream signal of autophagy was analyzed and it was found that Ad-VT reduced the resistance of cells to doxorubicin by reducing the level of mTOR, and then the analysis of the upstream and downstream proteins of mTOR found that Ad-VT increased the sensitivity of MCF-7/ADR cells to adriamycin by activating AMPK-mTOR-eIF4F signaling axis.	Doxorubicin	301-311	eukaryotic translation initiation factor 4E	Homo sapiens	336-341
34812269-0	2021	Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E.	mir-15a-5p	14-24	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
34812269-0	2021	Inhibition of miR-15a-5p Promotes the Chemoresistance to Pirarubicin in Hepatocellular Carcinoma via Targeting eIF4E.	pirarubicin	57-68	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
34812269-3	2021	Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP).	pirarubicin	181-192	eukaryotic translation initiation factor 4E	Homo sapiens	87-130
34812269-3	2021	Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP).	pirarubicin	181-192	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
34812269-3	2021	Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP).	pirarubicin	194-197	eukaryotic translation initiation factor 4E	Homo sapiens	87-130
34812269-3	2021	Our investigation is aimed at testifying the influence of microRNA-15a-5p (miR-15a-5p)/eukaryotic translation initiation factor 4E (eIF4E) on hepatocellular carcinoma resistance to pirarubicin (THP).	pirarubicin	194-197	eukaryotic translation initiation factor 4E	Homo sapiens	132-137
34812269-6	2021	Moreover, eIF4E was verified as a direct target of miR-15a-5p by binding its 3"-UTR, which was confirmed by luciferase report experiment.	mir-15a-5p	51-61	eukaryotic translation initiation factor 4E	Homo sapiens	10-15
34812269-8	2021	Mechanically, eIF4E was proven as a specific downstream of miR-15a-5p and mediated the effects of miR-15a-5p on cell viability and apoptosis of HepG2 cells treated with THP.	mir-15a-5p	59-69	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
34812269-8	2021	Mechanically, eIF4E was proven as a specific downstream of miR-15a-5p and mediated the effects of miR-15a-5p on cell viability and apoptosis of HepG2 cells treated with THP.	mir-15a-5p	98-108	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
34812269-8	2021	Mechanically, eIF4E was proven as a specific downstream of miR-15a-5p and mediated the effects of miR-15a-5p on cell viability and apoptosis of HepG2 cells treated with THP.	pirarubicin	169-172	eukaryotic translation initiation factor 4E	Homo sapiens	14-19
34812269-9	2021	These findings supported that miR-15a-5p facilitated THP resistance of hepatocellular carcinoma cells by modulating eIF4E, thus providing an experimental basis that miR-15a-5p might act as a novel diagnostic target in hepatocellular carcinoma resistance to THP.	pirarubicin	53-56	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
34812269-9	2021	These findings supported that miR-15a-5p facilitated THP resistance of hepatocellular carcinoma cells by modulating eIF4E, thus providing an experimental basis that miR-15a-5p might act as a novel diagnostic target in hepatocellular carcinoma resistance to THP.	pirarubicin	257-260	eukaryotic translation initiation factor 4E	Homo sapiens	116-121
34255842-3	2021	First, we use capCLIP to identify the eIF4E cap-omes in human cells with/without the mTORC1 (mechanistic target of rapamycin, complex 1) inhibitor rapamycin, there being an emerging consensus that rapamycin inhibits translation of TOP (terminal oligopyrimidine) mRNAs by displacing eIF4E from their caps.	Sirolimus	197-206	eukaryotic translation initiation factor 4E	Homo sapiens	282-287
34255842-3	2021	First, we use capCLIP to identify the eIF4E cap-omes in human cells with/without the mTORC1 (mechanistic target of rapamycin, complex 1) inhibitor rapamycin, there being an emerging consensus that rapamycin inhibits translation of TOP (terminal oligopyrimidine) mRNAs by displacing eIF4E from their caps.	oligopyrimidine	245-260	eukaryotic translation initiation factor 4E	Homo sapiens	38-43
34255842-3	2021	First, we use capCLIP to identify the eIF4E cap-omes in human cells with/without the mTORC1 (mechanistic target of rapamycin, complex 1) inhibitor rapamycin, there being an emerging consensus that rapamycin inhibits translation of TOP (terminal oligopyrimidine) mRNAs by displacing eIF4E from their caps.	oligopyrimidine	245-260	eukaryotic translation initiation factor 4E	Homo sapiens	282-287
34565342-12	2021	Mechanistically, the co-treatment of JQ1 or OTX-015 with temsirolimus significantly downregulated the expression levels of phosphorylated 4EBP1/p70-S6K/eIF4E (mTOR components) and BRD4 (BET protein)/MYCN proteins.	temsirolimus	57-69	eukaryotic translation initiation factor 4E	Homo sapiens	152-157
34344911-4	2021	Using this strategy we obtained AuNPs decorated with 7-methylguanosine mRNA 5" cap analogs and showed that they bind cap-specific protein, eIF4E.	7-methylguanosine	53-70	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
34565316-7	2021	Based on the VPg, eIF4E1, and eIF4E2 models and data on the natural polymorphism of VPg amino acid sequence, we suggested that the key role in the recognition of potato cap-binding factors belongs to the R104 residue of VPg.	vpg	220-223	eukaryotic translation initiation factor 4E	Homo sapiens	18-24
34344911-7	2021	Tris-Lipo-diluted cap-AuNPs conjugates interacted with eIF4E in fully specific manner, enabling design of functional tools.	Tromethamine	0-4	eukaryotic translation initiation factor 4E	Homo sapiens	55-60
34122630-13	2021	In addition, eukaryotic translation initiation factor 4E (eIF4E) was the target gene of miR-768-3p in breast cancer.	mir-768-3p	88-98	eukaryotic translation initiation factor 4E	Homo sapiens	13-56
34122630-13	2021	In addition, eukaryotic translation initiation factor 4E (eIF4E) was the target gene of miR-768-3p in breast cancer.	mir-768-3p	88-98	eukaryotic translation initiation factor 4E	Homo sapiens	58-63
34122630-14	2021	All experiments confirmed that miR-768-3p, a tumor suppressor, inhibited the viability, migration and invasion of breast cancer cells through eIF4E.	mir-768-3p	31-41	eukaryotic translation initiation factor 4E	Homo sapiens	142-147
34277430-8	2021	Furthermore, we found that ouabain inhibited protein synthesis through regulation of the eukaryotic initiation factor 4E (eIF4E) and eIF4E binding protein 1 (4EBP1).	Ouabain	27-34	eukaryotic translation initiation factor 4E	Homo sapiens	89-120
34277430-8	2021	Furthermore, we found that ouabain inhibited protein synthesis through regulation of the eukaryotic initiation factor 4E (eIF4E) and eIF4E binding protein 1 (4EBP1).	Ouabain	27-34	eukaryotic translation initiation factor 4E	Homo sapiens	122-127
34188131-6	2021	Caf20 binding to eIF4E is entirely dependent on a canonical motif shared with other 4E-BPs.	caf20	0-5	eukaryotic translation initiation factor 4E	Homo sapiens	17-22
35628412-5	2022	Although mammalian NaN3-induced SGs are very small, they still contain the canonical SG proteins Caprin 1, eIF4A, eIF4E, eIF4G and eIF3B.	Sodium Azide	19-23	eukaryotic translation initiation factor 4E	Homo sapiens	114-119
35136028-0	2022	Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.	Everolimus	69-79	eukaryotic translation initiation factor 4E	Homo sapiens	97-102
35339025-1	2022	OBJECTIVES: Ribavirin inhibits eukaryotic translation initiation factor 4E (eIF4E), thereby decreasing cap-dependent translation.	Ribavirin	12-21	eukaryotic translation initiation factor 4E	Homo sapiens	31-74
35339025-1	2022	OBJECTIVES: Ribavirin inhibits eukaryotic translation initiation factor 4E (eIF4E), thereby decreasing cap-dependent translation.	Ribavirin	12-21	eukaryotic translation initiation factor 4E	Homo sapiens	76-81
35339025-3	2022	METHODS: In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) >= 30%.	Ribavirin	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	174-179
35339025-3	2022	METHODS: In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) >= 30%.	Ribavirin	39-48	eukaryotic translation initiation factor 4E	Homo sapiens	183-188
35339025-8	2022	RESULTS: Six patients were evaluable in the pharmacodynamic study: 4 had decreased p-eIF4E after 14 days of ribavirin.	Ribavirin	108-117	eukaryotic translation initiation factor 4E	Homo sapiens	85-90
35339025-14	2022	CONCLUSION: Oral ribavirin decreases p-eIF4E levels and is well-tolerated.	Ribavirin	17-26	eukaryotic translation initiation factor 4E	Homo sapiens	39-44
35574389-6	2022	We found that peptide cyclization enhances Pep8 affinity for eIF4E, induction of p53 and tumor cell growth suppression.	pep8	43-47	eukaryotic translation initiation factor 4E	Homo sapiens	61-66
35349401-11	2022	Also, it is demonstrated that Vpg interacts with eIF4E and that rapamycin treatment partially diminishes the viral protein synthesis.	Sirolimus	64-73	eukaryotic translation initiation factor 4E	Homo sapiens	49-54
35267559-7	2022	c-MYC overexpression can induce the expression of eIF4E that favours the translation of structured mRNA to produce oncogenic factors that promote cell proliferation and confer tamoxifen resistance.	Tamoxifen	176-185	eukaryotic translation initiation factor 4E	Homo sapiens	50-55
35104872-6	2022	PKs found in both subclasses of PTE assume a specific conformation with a hyperreactive guanylate (G*) in SHAPE structure probing, previously found critical for binding eIF4E.	guanosine 5'-monophosphorothioate	88-97	eukaryotic translation initiation factor 4E	Homo sapiens	169-174
35136028-2	2022	Activated mitogen-activated protein kinase interacting kinases/eukaryotic translation initiation factor 4E (MNK/eIF4E) axis plays a crucial role in resistance to Everolimus in non-small cell lung cancer (NSCLC).	Everolimus	162-172	eukaryotic translation initiation factor 4E	Homo sapiens	112-117
35136028-13	2022	The combination of miR-7-5p with Everolimus induced apoptosis to exhibit a synergistic anticancer therapeutic efficacy through dual abrogation of MNK/eIF4E and mTOR in NSCLC.	Everolimus	33-43	eukaryotic translation initiation factor 4E	Homo sapiens	150-155
35136028-15	2022	Either endogenous miR-7-5p or exo-miR-7-5p combined with Everolimus can enhance the anticancer efficacy by targeting MNK/eIF4E axis and mTOR.	exo-mir-7-5p	30-42	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
35136028-15	2022	Either endogenous miR-7-5p or exo-miR-7-5p combined with Everolimus can enhance the anticancer efficacy by targeting MNK/eIF4E axis and mTOR.	Everolimus	57-67	eukaryotic translation initiation factor 4E	Homo sapiens	121-126
2605173-1	1989	The binding of analogues of the 7-methylguanosine-containing cap, m7GTP and m7GpppG, to eIF-4E from human erythrocytes as a function of pH, temperature, and ionic strength is described.	7-methylguanosine	32-49	eukaryotic translation initiation factor 4E	Homo sapiens	88-94
34949712-5	2022	Down-regulation of RHA or the anomalous shape of the PBS segment abrogated hypermethylated caps and derepressed eIF4E binding for virion protein translation during global down-regulation of host translation.	pbs	53-56	eukaryotic translation initiation factor 4E	Homo sapiens	112-117
2605173-1	1989	The binding of analogues of the 7-methylguanosine-containing cap, m7GTP and m7GpppG, to eIF-4E from human erythrocytes as a function of pH, temperature, and ionic strength is described.	7-methylguanosine triphosphate	66-71	eukaryotic translation initiation factor 4E	Homo sapiens	88-94
2605173-1	1989	The binding of analogues of the 7-methylguanosine-containing cap, m7GTP and m7GpppG, to eIF-4E from human erythrocytes as a function of pH, temperature, and ionic strength is described.	7-methyl-diguanosine triphosphate	76-83	eukaryotic translation initiation factor 4E	Homo sapiens	88-94
2605173-2	1989	From the pH-dependent binding of m7GTP and m7GpppG to eIF-4E, a new model describing the nature of the cap.eIF-4E interaction is proposed.	7-methylguanosine triphosphate	33-38	eukaryotic translation initiation factor 4E	Homo sapiens	54-60
2605173-2	1989	From the pH-dependent binding of m7GTP and m7GpppG to eIF-4E, a new model describing the nature of the cap.eIF-4E interaction is proposed.	7-methylguanosine triphosphate	33-38	eukaryotic translation initiation factor 4E	Homo sapiens	107-113
3038908-6	1987	In addition, we found that the 24-kDa CBP from mitotic cells was metabolically labeled with 32P to a lesser extent than the protein purified from interphase cells.	Phosphorus-32	92-95	eukaryotic translation initiation factor 4E	Homo sapiens	38-41
2910847-5	1989	When translation reactions were resolved on sucrose density gradients, the 35S-labeled eIF-4E sedimented predominantly at 3-4 S. However, in the presence of edeine or guanylyl imidodiphosphate, both of which cause accumulation of 48 S initiation complexes, eIF-4E was detected in the 48 S region.	Sucrose	44-51	eukaryotic translation initiation factor 4E	Homo sapiens	87-93
2910847-5	1989	When translation reactions were resolved on sucrose density gradients, the 35S-labeled eIF-4E sedimented predominantly at 3-4 S. However, in the presence of edeine or guanylyl imidodiphosphate, both of which cause accumulation of 48 S initiation complexes, eIF-4E was detected in the 48 S region.	Sulfur-35	75-78	eukaryotic translation initiation factor 4E	Homo sapiens	87-93
2910847-5	1989	When translation reactions were resolved on sucrose density gradients, the 35S-labeled eIF-4E sedimented predominantly at 3-4 S. However, in the presence of edeine or guanylyl imidodiphosphate, both of which cause accumulation of 48 S initiation complexes, eIF-4E was detected in the 48 S region.	Sulfur-35	75-78	eukaryotic translation initiation factor 4E	Homo sapiens	257-263
2910847-5	1989	When translation reactions were resolved on sucrose density gradients, the 35S-labeled eIF-4E sedimented predominantly at 3-4 S. However, in the presence of edeine or guanylyl imidodiphosphate, both of which cause accumulation of 48 S initiation complexes, eIF-4E was detected in the 48 S region.	Edeine	157-163	eukaryotic translation initiation factor 4E	Homo sapiens	87-93
2910847-5	1989	When translation reactions were resolved on sucrose density gradients, the 35S-labeled eIF-4E sedimented predominantly at 3-4 S. However, in the presence of edeine or guanylyl imidodiphosphate, both of which cause accumulation of 48 S initiation complexes, eIF-4E was detected in the 48 S region.	Edeine	157-163	eukaryotic translation initiation factor 4E	Homo sapiens	257-263
2910847-5	1989	When translation reactions were resolved on sucrose density gradients, the 35S-labeled eIF-4E sedimented predominantly at 3-4 S. However, in the presence of edeine or guanylyl imidodiphosphate, both of which cause accumulation of 48 S initiation complexes, eIF-4E was detected in the 48 S region.	Guanylyl Imidodiphosphate	167-192	eukaryotic translation initiation factor 4E	Homo sapiens	87-93
2910847-5	1989	When translation reactions were resolved on sucrose density gradients, the 35S-labeled eIF-4E sedimented predominantly at 3-4 S. However, in the presence of edeine or guanylyl imidodiphosphate, both of which cause accumulation of 48 S initiation complexes, eIF-4E was detected in the 48 S region.	Guanylyl Imidodiphosphate	167-192	eukaryotic translation initiation factor 4E	Homo sapiens	257-263
3941087-2	1986	The messenger RNA cap-binding protein (CBP) was isolated from human erythrocyte, rabbit erythrocyte, and rabbit reticulocyte lysate by affinity chromatography on 7-methylguanosine 5"-triphosphate-Sepharose.	7-methylguanosine triphosphate	162-195	eukaryotic translation initiation factor 4E	Homo sapiens	18-37
3112145-1	1987	Eukaryotic protein synthesis initiation factor 4E (eIF-4E) was labeled in situ with [32P]orthophosphate in cultured HeLa cells and rabbit reticulocytes and purified by affinity chromatography.	Phosphate-32P	84-103	eukaryotic translation initiation factor 4E	Homo sapiens	0-49
3112145-1	1987	Eukaryotic protein synthesis initiation factor 4E (eIF-4E) was labeled in situ with [32P]orthophosphate in cultured HeLa cells and rabbit reticulocytes and purified by affinity chromatography.	Phosphate-32P	84-103	eukaryotic translation initiation factor 4E	Homo sapiens	51-57
3112145-3	1987	After treatment of the protein with citraconic anhydride to block epsilon-amino groups of lysyl residues, tryptic digestion yielded a labeled peptide whose composition was consistent with the structure Trp-Ala-Leu-Trp-Phe-Phe-Lys-Asn-Asp-Lys-Ser(P)-Lys-Thr-Trp-Gln-Ala-Asn-L eu-Arg, one of the arginyl peptides predicted from the human eIF-4E cDNA sequence.	citraconic anhydride	36-56	eukaryotic translation initiation factor 4E	Homo sapiens	336-342
3112145-3	1987	After treatment of the protein with citraconic anhydride to block epsilon-amino groups of lysyl residues, tryptic digestion yielded a labeled peptide whose composition was consistent with the structure Trp-Ala-Leu-Trp-Phe-Phe-Lys-Asn-Asp-Lys-Ser(P)-Lys-Thr-Trp-Gln-Ala-Asn-L eu-Arg, one of the arginyl peptides predicted from the human eIF-4E cDNA sequence.	Tryptophan	214-217	eukaryotic translation initiation factor 4E	Homo sapiens	336-342
3112145-4	1987	The only serine in this peptide is located at position 53 of eIF-4E.	Serine	9-15	eukaryotic translation initiation factor 4E	Homo sapiens	61-67
3112145-5	1987	Thus, it is concluded that eIF-4E contains a single site of phosphorylation for an endogenous protein kinase, which is Ser-53 in the human eIF-4E sequence.	Serine	119-122	eukaryotic translation initiation factor 4E	Homo sapiens	27-33
3112145-5	1987	Thus, it is concluded that eIF-4E contains a single site of phosphorylation for an endogenous protein kinase, which is Ser-53 in the human eIF-4E sequence.	Serine	119-122	eukaryotic translation initiation factor 4E	Homo sapiens	139-145
3793730-2	1987	Initiation factor eIF-4F, a multiprotein cap binding protein complex, was purified from HeLa cells by m7G affinity chromatography and independently by phosphocellulose column chromatography.	phosphocellulose	151-167	eukaryotic translation initiation factor 4E	Homo sapiens	18-24
3793730-5	1987	Two-dimensional isoelectric focusing/sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the eIF-4F samples shows that p28 comprises two isoelectric variants, one of which labels with phosphate and disappears when samples are treated with alkaline phosphatase.	Phosphates	193-202	eukaryotic translation initiation factor 4E	Homo sapiens	102-108
3793730-8	1987	eIF-4F fractionated by phosphocellulose chromatography separates into forms containing either phosphorylated or unphosphorylated p28.	phosphocellulose	23-39	eukaryotic translation initiation factor 4E	Homo sapiens	0-6
3941087-2	1986	The messenger RNA cap-binding protein (CBP) was isolated from human erythrocyte, rabbit erythrocyte, and rabbit reticulocyte lysate by affinity chromatography on 7-methylguanosine 5"-triphosphate-Sepharose.	7-methylguanosine triphosphate	162-195	eukaryotic translation initiation factor 4E	Homo sapiens	39-42
3941087-2	1986	The messenger RNA cap-binding protein (CBP) was isolated from human erythrocyte, rabbit erythrocyte, and rabbit reticulocyte lysate by affinity chromatography on 7-methylguanosine 5"-triphosphate-Sepharose.	Sepharose	196-205	eukaryotic translation initiation factor 4E	Homo sapiens	18-37
3941087-2	1986	The messenger RNA cap-binding protein (CBP) was isolated from human erythrocyte, rabbit erythrocyte, and rabbit reticulocyte lysate by affinity chromatography on 7-methylguanosine 5"-triphosphate-Sepharose.	Sepharose	196-205	eukaryotic translation initiation factor 4E	Homo sapiens	39-42
3941087-12	1986	Species of CBP with faster or slower electrophoretic mobilities could be generated by treatment of the protein either with O2 in the presence of a catalyst or with dithiothreitol.	Oxygen	123-125	eukaryotic translation initiation factor 4E	Homo sapiens	11-14
3941087-12	1986	Species of CBP with faster or slower electrophoretic mobilities could be generated by treatment of the protein either with O2 in the presence of a catalyst or with dithiothreitol.	Dithiothreitol	164-178	eukaryotic translation initiation factor 4E	Homo sapiens	11-14
3910088-1	1985	A 24 000-dalton protein [yeast eukaryotic initiation factor 4E (eIF-4E)] was purified from yeast Saccharomyces cerevisiae postribosomal supernatant by m7GDP-agarose affinity chromatography.	Sepharose	157-164	eukaryotic translation initiation factor 4E	Homo sapiens	64-70
3910088-2	1985	The protein behaves very similarly to mammalian protein synthesis initiation factor eIF-4E with respect to binding to and elution from m7GDP-agarose columns and cross-linking to oxidized reovirus mRNA cap structures.	Sepharose	141-148	eukaryotic translation initiation factor 4E	Homo sapiens	84-90
6088805-4	1984	eIF3 activity, when determined in the presence of purified CBP complex, is present in sucrose gradients of factors from both infected and uninfected cells.	Sucrose	86-93	eukaryotic translation initiation factor 4E	Homo sapiens	59-62
3891747-1	1985	The 24-kilodalton messenger RNA cap-binding protein (CBP) was purified from the rabbit reticulocyte postribosomal supernatant fraction using an affinity resin consisting of the p-aminophenyl gamma-ester of m7GTP coupled to Sepharose.	p-aminophenyl gamma-ester	177-202	eukaryotic translation initiation factor 4E	Homo sapiens	32-51
3891747-1	1985	The 24-kilodalton messenger RNA cap-binding protein (CBP) was purified from the rabbit reticulocyte postribosomal supernatant fraction using an affinity resin consisting of the p-aminophenyl gamma-ester of m7GTP coupled to Sepharose.	p-aminophenyl gamma-ester	177-202	eukaryotic translation initiation factor 4E	Homo sapiens	53-56
3891747-1	1985	The 24-kilodalton messenger RNA cap-binding protein (CBP) was purified from the rabbit reticulocyte postribosomal supernatant fraction using an affinity resin consisting of the p-aminophenyl gamma-ester of m7GTP coupled to Sepharose.	7-methylguanosine triphosphate	206-211	eukaryotic translation initiation factor 4E	Homo sapiens	32-51
3891747-1	1985	The 24-kilodalton messenger RNA cap-binding protein (CBP) was purified from the rabbit reticulocyte postribosomal supernatant fraction using an affinity resin consisting of the p-aminophenyl gamma-ester of m7GTP coupled to Sepharose.	7-methylguanosine triphosphate	206-211	eukaryotic translation initiation factor 4E	Homo sapiens	53-56
3891747-1	1985	The 24-kilodalton messenger RNA cap-binding protein (CBP) was purified from the rabbit reticulocyte postribosomal supernatant fraction using an affinity resin consisting of the p-aminophenyl gamma-ester of m7GTP coupled to Sepharose.	Sepharose	223-232	eukaryotic translation initiation factor 4E	Homo sapiens	32-51
3891747-1	1985	The 24-kilodalton messenger RNA cap-binding protein (CBP) was purified from the rabbit reticulocyte postribosomal supernatant fraction using an affinity resin consisting of the p-aminophenyl gamma-ester of m7GTP coupled to Sepharose.	Sepharose	223-232	eukaryotic translation initiation factor 4E	Homo sapiens	53-56
3891747-5	1985	During a conventional (nonaffinity) purification of CBP from a high salt extract of the ribosomal pellet, immunological reactivity paralleled the ability to reverse cap analogue inhibition of translation, indicating that the 24-kilodalton polypeptide present in the postribosomal supernatant fraction is immunologically cross-reactive with the CBP purified from ribosomes.	Salts	68-72	eukaryotic translation initiation factor 4E	Homo sapiens	52-55
3891747-6	1985	Fractionation of whole reticulocyte lysate by sucrose gradient sedimentation followed by immunoblotting revealed that CBP was present in the supernatant fraction and the region of the gradient corresponding to ribosomal subunits but not in mono- or polysomes.	Sucrose	46-53	eukaryotic translation initiation factor 4E	Homo sapiens	118-121
3891747-7	1985	The CBP to ribosome ratio was found to be approximately 0.02, assuming that the m7GTP-Sepharose retains all of the protein.	7-methylguanosine triphosphate	80-85	eukaryotic translation initiation factor 4E	Homo sapiens	4-7
3891747-7	1985	The CBP to ribosome ratio was found to be approximately 0.02, assuming that the m7GTP-Sepharose retains all of the protein.	Sepharose	86-95	eukaryotic translation initiation factor 4E	Homo sapiens	4-7
6088805-5	1984	CBP complex activity, determined in the presence of eIF3 from poliovirus-infected cells, is present in uninfected cells only and comigrates on sucrose gradient with an activity which restores the ability of crude initiation factors from infected cells to translate capped globin mRNA.	Sucrose	143-150	eukaryotic translation initiation factor 4E	Homo sapiens	0-3
6283140-5	1982	The 0 to 40% ammonium sulfate precipitates from both uninfected and infected cells contain eucaryotic initiation factor 3 (eIF-3), eIf-4B, and the cap-binding protein (CBP), which is detected by means of a cross-linking assay, as well as other proteins.	Ammonium Sulfate	13-29	eukaryotic translation initiation factor 4E	Homo sapiens	147-166
6089873-9	1984	Furthermore, the CBP complex reverses the high salt induced inhibition of translation of the former mRNAs.	Salts	47-51	eukaryotic translation initiation factor 4E	Homo sapiens	17-20
6283140-5	1982	The 0 to 40% ammonium sulfate precipitates from both uninfected and infected cells contain eucaryotic initiation factor 3 (eIF-3), eIf-4B, and the cap-binding protein (CBP), which is detected by means of a cross-linking assay, as well as other proteins.	Ammonium Sulfate	13-29	eukaryotic translation initiation factor 4E	Homo sapiens	168-171
33975880-9	2021	These findings implicate the involvement of the MNK1/2-eIF4E axis during PPBC metastasis and suggest a promising immunomodulatory route to enhance the efficacy of immunotherapy by blocking phospho-eIF4E.	ppbc	73-77	eukaryotic translation initiation factor 4E	Homo sapiens	55-60
7306524-4	1981	The 24K CBPs released from both columns were found to be active, both as judged by a cross-linking assay that utilized 10(4)-oxidized methyl-3H-labeled reovirus mRNA as a substrate for the protein and also by the ability of the isolated 24K CBP to stimulate the translocation of capped Sindbis virus mRNA in HeLa cell extracts.	Tritium	141-143	eukaryotic translation initiation factor 4E	Homo sapiens	8-11
33647641-8	2021	Once this loop is activated by BaP or BPDE exposure, both pathways in this loop would be up-regulated, promote EIF4E transcription, inhibit trophoblast cell proliferation, and further induce miscarriage.	Benzo(a)pyrene	31-34	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
33647641-8	2021	Once this loop is activated by BaP or BPDE exposure, both pathways in this loop would be up-regulated, promote EIF4E transcription, inhibit trophoblast cell proliferation, and further induce miscarriage.	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	38-42	eukaryotic translation initiation factor 4E	Homo sapiens	111-116
33230623-2	2021	4Ei-10 is a member of the class of ProTide compounds and has elevated membrane permeability and is a strong active chemical antagonist for eIF4E.	4ei-10	0-6	eukaryotic translation initiation factor 4E	Homo sapiens	139-144
33783376-0	2021	eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma.	Sorafenib	70-79	eukaryotic translation initiation factor 4E	Homo sapiens	0-5
33783376-3	2021	Herein, we aimed to demonstrate that eIF4E-eIF4G complex inhibition enhanced the effect of sorafenib.	Sorafenib	91-100	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
33783376-9	2021	Besides, the coadministration of sorafenib and 4E1RCat or 4EGI-1 synergistically inhibited the expressions of eIF4E, eIF4G and phospho-4E-BP1 in HCC cells while blocking the phosphorylation of 4E-BP1 with lentiviral transfection failed to increase the sensitivity of HCC cells to sorafenib treatment.	Sorafenib	33-42	eukaryotic translation initiation factor 4E	Homo sapiens	110-115
33783376-11	2021	CONCLUSION: In a word, eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in HCC treatment.	Sorafenib	93-102	eukaryotic translation initiation factor 4E	Homo sapiens	23-28
34012509-3	2021	Tomivosertib was highly effective at blocking eIF4E phosphorylation on serine 209 in AML cells.	Serine	71-77	eukaryotic translation initiation factor 4E	Homo sapiens	46-51
33837631-8	2021	ISRIB restores partly, inhibition in eIF4E-BP1 phosphorylation, promotes eIF2alpha phosphorylation, albeit slowly, and mitigates suppression of translation accordingly, in CCCP-treated cells.	Carbonyl Cyanide m-Chlorophenyl Hydrazone	172-176	eukaryotic translation initiation factor 4E	Homo sapiens	37-42
33711336-0	2021	Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.	Emetine	0-7	eukaryotic translation initiation factor 4E	Homo sapiens	87-92
33711336-6	2021	In a chromatin immunoprecipitation (CHIP) assay, emetine was shown to disrupt the binding of SARS-CoV-2 mRNA with eIF4E (eukaryotic translation initiation factor 4E, a cellular cap-binding protein required for initiation of protein translation).	Emetine	49-56	eukaryotic translation initiation factor 4E	Homo sapiens	114-119
33711336-6	2021	In a chromatin immunoprecipitation (CHIP) assay, emetine was shown to disrupt the binding of SARS-CoV-2 mRNA with eIF4E (eukaryotic translation initiation factor 4E, a cellular cap-binding protein required for initiation of protein translation).	Emetine	49-56	eukaryotic translation initiation factor 4E	Homo sapiens	121-164
33711336-7	2021	Further, molecular docking and molecular dynamics simulation studies suggested that emetine may bind to the cap-binding pocket of eIF4E, in a similar conformation as m7-GTP binds.	Emetine	84-91	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
33711336-7	2021	Further, molecular docking and molecular dynamics simulation studies suggested that emetine may bind to the cap-binding pocket of eIF4E, in a similar conformation as m7-GTP binds.	7-methylguanosine triphosphate	166-172	eukaryotic translation initiation factor 4E	Homo sapiens	130-135
33417999-7	2021	In vivo, RNAi-mediated dip3 silencing decreased eIF4E levels and was accompanied by an immunosuppressive phenotype in S. litura.	dip3	23-27	eukaryotic translation initiation factor 4E	Homo sapiens	48-53
33837631-9	2021	These findings are consistent with the idea that CCCP-induced oxidative stress leading to eIF2alpha phosphorylation and ATF4 expression, which is known to stimulate genes involved in autophagy, play a pro-survival role together with AKT activation and regulate mTOR-mediated eIF4E-BP1 phosphorylation.	Carbonyl Cyanide m-Chlorophenyl Hydrazone	49-53	eukaryotic translation initiation factor 4E	Homo sapiens	275-280
33165737-5	2021	Beyond early findings on induced activation of PI3K/Akt, MEK/ERK, and Mnk/eIF4E survival signaling pathways that compromise the efficacy of rapalog-based cancer therapy, recent findings on the essential role of GSK3 in mediating cancer cell response to mTOR inhibitors and mTORC1 inhibition-induced upregulation of PD-L1 in cancer cells may provide some explanations.	rapalog	140-147	eukaryotic translation initiation factor 4E	Homo sapiens	74-79